Biological properties of the x-gene product of hepatitis B virus by Rossner, Michael T.
BIOLOGICAL PROPERTIES OF THE X-GENE PRODUCT 
OF HEPATITIS B VIRUS 
MICHAEL T. ROSSNER 
Thesis submitted for the degree of Doctor of Philosophy 
Department of Molecular Biology 
Faculty of Science 







CHAPTER 1: Introduction I 
1.1 Hepatitis B Disease Characteristics 2 
1.2 Virion and Genome Structure 4 
1.3 (3enome/ Organisation 
Id 
 Viral Polypeptides 6 
1.3.1 HBsAg 7 
1.3.2 HBcAg 13 
1.3.3 Polymerase 20 
1.3.4 HBxAg 21 
1.4 Viral Transcription 28 
1.4.1 The subgenomic mRNAs 29 
1.4.2 Genomic mRNAs B 
1.4.3 HBV enhancers  35 
1.4.3a The HBV enhancer 35 
1.4.3b HBV enhancer II 41 
1.4.4 Glucocorticoid receptor binding 41 
1.5 Virus Reproduction 42 
1.5.1 Attachment to hepatocyte 42 
1.5.2 Genome replication 43 
1.5.3 Virus assembly 46 
1.6 HBV Infection and Hepatoma 46 
1.7 Aims of this Thesis 49 
CHAFFER 2: Materials and Methods 51 
2A MATERIALS 52 
241 Suppliers of Laboratory Reagents 52 
242 Mammalian Cell Culture 53 
2A.2.1 Mammalian cell lines 53 
2A.2.2 Mammalian cell culture media 53 
243 Microbiological Materials 54 
2A.3.1 Bacterial strains 54 
2A.3.2 Bacteriophage and plasmids 55 
2A.3.3 Microbiological media 57 
244 Solutions 58 
245 Antisera 59 
2B METHODS 61 
2B.1 Mammalian Cell Culture 61 
2B.1.1 Cell culture 61 
2B.1.2 Transient transfection of hepatoma cells 61 
20.2 Preparation of Nucleic Acids 61 
2B.2.1 Phenol extraction of nucleic acid solutions 61 
2B.2.2 Precipitation of nucleic acids with ethanol 62 
2B.2.3 Preparation of RNA from mammalian cells in culture 62 
2B.2.4 Preparation of plasmid DNA and bacteriophage M13 replicative 
form (RF) DNA 64 
2B.2.5 Quantification of nucleic acids 67 
2B.2.6 Transformation of E. coli with bacteriophage M13 DNA or plasmid 
DNA 67 
2B.3 Enzymatic Manipulation of DNA 69 
2B.3.1 Digestion of DNA with restriction endonucleases 69 
213.3.2 Filling-in 3' recessed termini of DNA 69 
2R3.3 In vitro recombination of DNA fragments 70 
213.4 Electrophoresis of Nucleic Acids 70 
213.4.1 Electrophoresis of DNA in agarose gels 70 
213.4.1a Gel photography 71 
213.4.2 Recovery of DNA  from low-melting-temperature agarose gels 71 
2B.4.3 Electrophoresis of RNA in agarose gels 72 
2135 Radio-Labelling DNA 73 
213.5.1 Labelling DNA by random priming with hexadeoxyribonucleotide 
primers 73 
2B.5.2 Sephadex gel filtration of DNA (Spun columns) 74 
2B6 Nucleic Acid Hybridisation 75 
213.6.1 Transfer of DNA from E. coli colonies to membranes (colony 
lifts) 75 
2B.6.2 Transfer of DNA from bacteriophage M13 plaques to 
membranes 76 
213.6.3 Transfer of DNA from agarose gels to membranes (Southern 
blotting) 76 
213.6.4 Transfer of RNA from agarose gels to membranes (Northern 
blotting) 77 
213.6.5 Hybridisation of radio-labelled DNA probes to single stranded 
nucleic acids immobilised on nitrocelluose or nylon membranes 78 
213.6.6 Rehybridisation 79 
213.7 DNA Sequencing 80 
213.7.1 Preparation of single-stranded template DNA 80.  
213.7.2 Dideoxynucleotide chain-termination sequencing reactions 83 
2133.3 Resolution of sequencing reaction products by electrophoresis in 
urea-polyacrylamide gels 85 
2K8 Amplification of mRNA Using the Polymerase Chain Reaction (PCR) 86 
213.9 Site Directed Mutagenesis (SDM) 89 
213.9. 1 Phosphorylation of 5 '  end of oligodeoxynucleotide with 14 
plynuc1eotide kinase 90 
213.9.2 Synthesis of mutant strand DNA and recovery of mutant clones 90 
213.10 Techniques for Analysis of Proteins. 92 
213.10.1 Radio-immunoassay for detection of HBsAg 92 
213.10.2 Lowry protein assay 93 
213.10.3 Electrophoresis of proteins in polyacrylamide gels 93 
213.10.4 Staining of proteins separated in polyacrylamide gels 95 
213.10.5 Transfer of proteins separated in polyacrylamide gels to 
membranes (Western blotting) 95 
213.10.6 Spotting of proteins onto nitrocellulose membranes 96 
213.10.7 Purification of rabbit antiserum 96 
213.10.8 Immunological detection of proteins immobilised on nitrocellulose 
filters  97 
213.10.9 Preparation of -ga1actosidase fusion proteins from E. co/i 98 
213.10.10 Purification of HBcX produced in El coli 99 
a) Small-scale preparation 100 
b) Large-scale preparation 1. 101 
c) Large-scale preparation 2. 103 
213.10.11 Preparation of crude protein extract from mammalian cells in 
culture 105 
213.10.12 Immunoprecipitation of soluble protein 105 
213.10.13 Assay for protein kinase activity 106 
213.10.14 Electron microscopy of HBcAgI}{BxAg fusion protein 107 
CHAPTER 3: The Immunological Response to }{BxAg 108 
3.1 Introduction 109 
3.2 Results 112 
3.2.1 Plasmid constructions 112 
3.2.2 Antigenicity of HBxAg fragments fused to fl-galactosidase 117 
3.3 Discussion 120 
CHAPTER 4: HBxAz Modulates Expression of HBsAa 124 
4.1 Introduction: General Features of Transactivation by HBxAg 125 
4.2 Results 134 
4.2.1 Plasmid constructions 134 
4.2.2 Transient expression of HBsAg 139 
4.2.3 Frameshift mutation in the X gene reduces transient expression of 
HBsAg 140 
4.2.4 Detection of different forms of HBAg 142 
4.2.5 Complementation of the mutation in the X-gene 144 
4.2.6 HBxAg modulates the level of preS2/S mRNAs 146 
4.2.7 Detection of an X-specific transcript 146 
4.2.8 HBxAg activates expression of the large-S polypeptide 149 
4.2.9 Investigation of the HBxAg response element of HBV 153 
4.3 Discussion 155 
CHAPTER 5: Is HBxAg a protein kinase? 166 
5.1 Introduction 167 
5.2 Results 168 
5.2.1 Plasmid constructions 168 
5.2.2 Purification of fusion protein encoded by pHBcX 169 
5.2.3 Production of antiserum to HBcX 179 
5.2.4 HBcX has no kinase activity 179 
5.2.5 Protein kinase activity in extracts of human hepatoma cells 
transiently expressing HBxAg 180 
5.3 Discussion 184 
CHAPTER 6: Mechanism of Transactivation by HBxAg and Potential Role for 
HBxAg in the Aetiology of HCC 191 
6A Mechanism of Transactivation by HBxAg 192 
6A.1 Some features of transcriptional control in eukaiyotes 192 
6A.2 Cellular factors mediate transactivation by HBxAg 193 
6A.3 Identification of factor binding sites that mediate transactivation by 
HBxAg 194 
6A.4 Mechanisms for alteration of the activity of cellular transcription 
factors 200 
6A.4.1 Post-translational modification 201 
6A.4.2 Protein-protein interactions 204 
6B Potential Mechanisms for the involvement of HBxAg in the Development of 
HCC 206 
6C Concluding Remarks 209 
References 210 
Appendix I: Nucleotide sequence of HBV subtype a4yw 245 
Appendix H: References for transactivation by HBxAg 257 
Appendix ifi: Rossner, M.T., Jackson, R.J. and Murray, K. (1990). Modulation of 
expression of the hepatitis B virus surface antigen gene by the viral X-gene 
product. Proceedings of the Royal Society B (London) 241:51-58. 258 
Abstract 
Several biological properties of the X-gene product of hepatitis B virus (HBV) were 
investigated to begin to elucidate its function in the viral life-cycle and its contribution to 
the physiological consequences of HBV infection. One of these consequences is a 
humoral immune response mounted by the host that is directed against the X-gene 
product (HBxAg). The antigenicity of segments of HBxAg was investigated by expressing 
them as fusion proteins in E. co/i. Cross-reactivity of these products was determined with 
antisera from an .HBV infected chimpanzee and from a rabbit inoculated with HBxAg 
produced in E. coli. These polyclonal antisera contained antibodies to all segments of 
HBxAg, although much weaker reactivity with a fusion protein containing only the middle 
third of the antigen was observed with both antisera. 
A striking serological feature of HBV infection is the vast amount of viral surface 
antigen (HBsAg) secreted from infected cells, and the contribution of HBxAg to this high 
level of HBsAg expression was investigated. Human hepatoma cells transfected with a 
plasmid construction containing the transcription units for the preS2 and surface (preS2/S) 
mRNAs and the X mRNA secreted HBsAg into the culture medium. A frameshift 
mutation in the X gene greatly reduced the production of HBsAg. The mutation could 
be complemented by cotransfection with a plasmid containing the X'structural gene under 
control of the SV40 early promoter. Levels of HBsAg production were directly related 
to the amount of preS2/S mRNA produced showing that HBxAg can modulate expression 
of this gene. HBsAg polypeptides containing preS domains are secreted by HBV infected 
hepatocytes at a low level relative to the major-S polypeptides which contain only the 
surface domain. HBxAg did not influence the relative levels of the various forms of 
HBsAg polypeptide produced by hepatoma cells transfected with a plasmid encoding both 
preS domains. HBsAg production was reduced upon cotransfection of cells with a plasmid 
construction containing the HBV enhancer indicating that expression of HBsAg is 
influenced by proteins binding to this region. However, HBxAg could still exert its 
transactivating effect in the presence of the competitor plasmid, indicating that this effect 
can be mediated through DNA sequences outwith the enhancer region. 
The ability of HBxAg to function as a protein serine/threonine kinase was investigated 
to determine whether this polypeptide may be the source of the endogenous kinase 
activity associated with HBV particles. In addition, this enzymatic function could account 
for the ability of HBxAg to modulate transcription. No protein kinase activity was 
detected for HBxAg expressed in E. co/i as a fusion protein with HBcAg or for HBxAg 
expressed in hepatoma cells. 
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CHAPTER 1: Introduction 
1.1 Hepatitis B Disease Characteristics 
Hepatitis B is an infectious liver disease of man. The serological source of infection 
was affirmed by the discovery of a novel antigen in patient sera (Blumberg et at. 1965: 
Prince, 1968) eventually shown to be a viral gene-product. The causative agent, the 
hepatitis B virus (HBV), was discovered by Dane et at (1970) who observed the virion, 
subsequently referred to as the Dane particle, in electron micrographs of serum from 
patients with hepatitis B. The virus can be transmitted vertically from mother to newborn 
baby or horizontally through sexual contact or blood contact. The disease is also referred 
to as serum hepatitis due to the blood to blood aspect of its transmission. 
HBV exhibits narrow host range, infecting only humans and higher primates (Maynard 
et at,. 1972, Barker et at, 1973). In the infected host, the virus shows strong tissue 
tropism primarily infecting liver cells (Berquist et at, 1975). HBV DNA has been 
detected in low copy number in cells other than hepatocytes, most commonly blood 
leukocytes and bone marrow, indicating limited non-hepatic infection (Elfassi et at, 1984; 
Laure et at, 1985; Korba et at, 1986). However, the biological consequences of this 
observation are unclear. 
The disease state induced by HBV infection is manifested in several ways characterised 
by the extent of liver inflammation and damage and viral persistence. Variations in the 
pathogenic effects of HBV infection are attributed to differences in the host's immune 
system (reviewed by Dienstag. 1984). The majority of individuals infected with HBV 
experience acute infection associated with varying amounts of hepatocyte necrosis which 
is manifest by increased serum transaminase activity and patient jaundice. The host 
mounts an immune attack on the infection, producing antibodies to the viral antigens 
(figure 1.1). Evidence that HBV is not directly cytopathic (reviewed by Ferrari et at, 
1988) supports the hypothesis that hepatocyte necrosis results from the effects of the 
cytotoxic T-lymphocytes (CTLs) specific for proteolytic fragments of HBV antigens 
expressed on the surface of infected cells in association with major histocompatibility 
complex.(MHC) class I antigens (Mondelli a' at, 1982; reviewed by Dienstag, 1984). 
While in the majority of cases, acute infection is resolved by complete clearance of the 
virus and the development of immune memory to counter reinfection, a small percentage 
of hosts develop a fulminant disease state resulting in severe liver dysfunction and leading 
to high mortality (O'Grady et at, 1986). 5-10% of infected adults develop chronic HBV 
infection (Hoofnagle and Alter, 1984) characterised by the persistence of viral antigens 
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FIGURE 1.1 Serological profile of HBV infection. 
Temporal appearance of HBV antigens and antibodies to them during acute and chronic 
infection. Variations in the time at which the various markers appear in individual cases 
are indicated by dashed lines. Adapted from Murray, 1987. 
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in patient serum (figure 1.1). This disease state may continue after integration of HBV 
DNA into the host-cell chromatin where transcription of viral antigens may continue in 
the absence of virion production. Chronic infection can give rise to substantial liver 
cirrhosis but may also lead to the development of a carrier state in which viral antigens 
are present in the serum in the absence of other pathological features of the disease. 
Chronically infected patients are predisposed to developing hepatocellular carcinoma 
(HCC) (Szmuness,1978) with more than 100-fold greater chance of developing this 
neoplasia than non-infected individuals (Beasley, 1981). Hepatitis B is a worldwide health 
problem because of the number of chronically infected people in the world estimated at 
2 x 108 (Szmuness,1978). 
1.2 Virion and Genome Structure 
HBV is the prototype member of the hepadnavirus family which includes hepatitis 
viruses isolated from the woodchuck (WI-TV) (Summers et at, 1978), ground squirrel 
(GSHV) (Marion et aL, 1980). Pekin duck (DHBV) (Mason et at, 1980) and grey heron 
(HHV) (Sprengel et at, 1988). This taxonomy is derived from the relative hepatropism 
of virus family members, their common virion morphology, common genome size, structure 
and organization, and common mechanism of genome replication which proceeds through 
reverse transcription of an RNA intermediate in a manner analogous to retroviruses. 
In 1970, Dane et at observed the 42 nm hepatitis B virion in electron micrographs of 
serum from infected patients. The virion has an outer envelope of 7 nm thickness which 
is lipid bilayer derived from the .endoplasmic reticulum (ER) membrane of the host 
hepatocyte (Patzer a at, 1986). Embedded in this envelope are molecules of surface 
antigen (HBsAg) encoded by the viral genome (figure 1.2a). Within the envelope of the 
virus particle is the nucleocapsid. This 27 nm protein core houses the viral genome and 
is composed of 180 sübunits  of the virally encoded core antigen (HBcAg) arranged 
in icosahedral conformation with T=3 symmetry (Onodera et at, 1982). A protein-kinase 
activity is associated with the nucleocapsid with the capacity to phosphorylate HBcAg 
(Albin and Robinson, 1980, Feitelson et at, 1982; Gerlich a at, 1982; see Chapter 5 for 
further discussion). The viral genome was first detected as the endogenous template of 
a DNA polymerase activity displayed by immunoprecipitated virion core particles 
(Robinson and Greenman, 1974). 
A large body of work led to the elucidation of the structure of the HBV genome 
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FIGURE 12 Structure of the HBV virion, HBsAg particles and the viral genome. 
The HBV virion (Dane particle). The viral genome and virion associated enzymatic 
activities are located within the 27 nm nucleocapsid composed of HBcAg. The 
nucleocapsid is enveloped in host derived lipid into which HBsAg is embedded 
forming a virus particle with a diameter of 42 run. 
Secreted forms of HBsAg. Filaments and spherical particles that are composed of 
HBsAg and host-derived lipid are secreted from HBV infected cells. Both forms have 
a diameter of 22 run. 
The HBV genome. The viral genome is a partially double-stranded, circular molecule 
with a protein covalently attached to the 5' end of the minus strand and an 
oligoribonucleotide linked to the 5 '  end of the plus strand. 
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(reviewed by Robinson, 1977; figure 1.2c). The circular, partially double stranded, DNA 
genome contains two strands of unequal length. The long strand serves as template for 
viral mRNA transcription and, by convention, is termed the minus strand. This strand is 
3190 bases long in the HBV isolate used in these studies (Burrell et at, 1979; Pasek et at. 
1979; Pugh et at, 1986). The numbering system employed in this thesis fixes nucleotide 
number 1 at the start of the coding sequence for HBcAg (Pasek et at, 1979; see Appendix 
I). The minus strand of HBV DNA is not a covalently closed circle as it contains a nick 
yielding 5' and 3' termini which have been mapped to nucleotide positions 3100 and 3108 
respectively (Will et at, 1987). The eight nucleotide terminal redundancy forms a single-
stranded tail at the 5' end of the strand to which a protein is covalently attached (Gerlich 
and Robinson, 1980). The minus strand contains a 10 bp sequence repeated at two places 
(direct repeat (DR) 1: 3106-3116 and DR2: 2872.2882). These repeats and the protein 
attached to the 5' end are significant features in replication of the viral genome (see 
section 1.5.2). 
The plus strand of DNA in the HBV virion is incomplete with a variable 3' end 
leaving a single-stranded gap in the genome. The size of the gap averages one kilobase 
(kb), with all HBV DNA molecules in a given population being double stranded 5' to 
nucleotide position 1420 on the plus strand (Delius ci at, 1983). The endogenous DNA 
polymerase uses the 3' hydroxyl-group of the plus strand as a primer to close the single 
stranded gap and make fully double stranded DNA molecules. The 5' end of the plus 
strand has been mapped to position 2882 (Will et at, 1987), and the HBV genome is held 
in circular conformation because the 5' end of the plus strand does not correspond with 
the 3' end of the minus strand but overlaps and pairs with approximately 220 bases at the 
5 end of the minus strand (Sattler and Robinson, 1979). Covalently attached to the 5' 
end of the plus strand is a capped oligoribonucleotide of abouf17 bases in length (Will 
et at, 1987) which primes synthesis of the plus strand during viral replication (see section 
1.5.2). 
1.3 Gefloine07an1sat1onand Viral Polypeptides 
The genome of several HBV isolates has been cloned in E. coli and the nucleotide 
sequence determined (Galibert et at, 1979; Pasek et at. 1979; Valenzuela et at, 1980; 
Fujiyama et at, 1983; Ono et at, 1983; Kobayashi and Koike, 1984; Okamoto ci at, 1987). 
Productive infection was established in chimpanzees by inoculation with cloned HBV 
DNA intrahepatically or by intrahepatic injection of autologous hepatocytes transfected 
with cloned HBV DNA (Will et at, 1985). This demonstrated that no essential viral 
sequences had been altered during cloning and that the viral genome structural features 
were not necessary for infectivity. The HBV sequence revealed 4 major open reading 
frames (ORFs) in the 3.2 kb minus strand using all three translational frames (figure 1.3). 
The ORFs include preS/surface, preC/core, polymerase and X. These four genes are 
conserved in all of the mammalian hepadnaviruses, while the avian viral genomes lack an 
ORF with homology to the X-gene (Mandart et at, 1984; Sprengel et at, 1988). The 
hepadnaviruses provide a superlative example of the genetic economy of viruses, as each 
nucleotide in the genome is part of at least one ORF. 
In the past, the molecular analysis of HBV has been limited to the animal models and 
to the expression of viral antigens encoded by cloned HBV DNA in a variety of systems. 
Recently, several laboratories have demonstrated that certain hepatoma cell lines are 
competent for the expression of all of the HBV genes from their native transcriptional 
control elements and for the production of virus particles (Sureau et at, 1986; Chang et 
at, 1987; Sells et at, 1987; Tsurimoio et at, 1987; Yaginuma et at, 1987b; Shih et at, 
1989). 
1.3.1 HBsAg 
In addition to 42 nm virus particles, electron micrographs of patient serum reveal an 
abundance of 22 nm spherical particles and rod shaped filaments with the same 22 nm 
diameter and variable length (figure 1.2b). These particles, which are present in vast 
excess over the 42 nm virions (Dan&et at. 1970), are composed exclusively of HBsAg and 
host derived lipid, and they may serve as "decoy virions" to bind virus neutralising, 
anti-HBsAg antibodies produced during infection (Murray, 1987). The characterisation 
of anti-HBsAg antibodies has defined distinct epitopes on HBsAg including a major 
antigenic determinant (a) common to all HBV isolates and two sets of mutually exclusive 
subtype determinants (d/y) and (nw) giving rise to four major antigenic subtypes of HBV: 
ac/n, adw, ayr and ayw (LeBouvier, 1971; and Bancroft, 1972). The cloned HBV DNA used 
in these studies was isolated from a virus subtype designated adyw. The donor serum from 
which virus was isolated displayed this compound virus subtype (Burrell et at, 1979), which 
may be due to infection by more than one virus subtype. 
The common and subtype-specific antigenic determinants are located within the 
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FIGURE 13 HBV genome organisation and viral transcripts. 
A linear representation of the HBV genome is shown. Nucleotide positions of ORFs in 
three translational reading frames (a,b,c) are shown. Numbers indicate the first and last 
coding nucleotides. Transcriptional control regions are shown as boxes and are 
abbreviated as follows: spi = preSi promoter; spIT = preS2IS promoter; enhlXp = 
enhancer/X promoter; Cp = core promoter. 'V Indicates HBV polyadenylation signal at 
nucleotide position 16. Viral transcripts are represented by dashed lines with arrows 
highlighting transcription initiation sites. 
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principle forms of HBsAg (major-S), which are a protein of 24 kilodaltons (p24) and its 
glycosylated derivative, gp27 (Peterson et aL, 1977; Peterson, 1981), referred to henceforth 
as the major-S polypeptides. These two proteins are present in nearly equal quantities 
in the virion envelope and in subviral HBsAg forms (Heerman ci aL, 1984). Partial 
amino- and carboxy-terminal sequence of the major-S polypeptides (Peterson, 1977) 
revealed that they are encoded by nucleotide positions 1437-2114 (the surface ORF) 
yielding polypeptides of 226 amino acids in length with gp27 glycosylated at asparagine 
residue 146 (figure 1.4). Larger polypeptides are present in all morphological forms of 
HBsAg. All of the polypeptides cross-reacted with antiserum raised against p24 indicating 
that they are coterminal at the carboxyl-ends with the major-S proteins (Heerman ci aL, 
1984). The middle-S polypeptides (gp33 and gp36) contain an additional 55 residues at 
their amino-terminus, which are encoded by the preS2 ORF. Both forms of middle-S 
polypeptide are glycosylated at amino acid residue number 4 of the preS2 domain; while 
the size difference between the two forms is due to the differential glycosylation at the 
site within the surface domain (Stibbe and Gerlich, 1983). The large-S polypeptides (p39 
and gp42) are encoded by the preSi, preS2 and surface ORFs, fusing 163 residues to the 
amino-terminus of the major-S proteins. The coding capacity of the preSl ORF varies 
among HBV subtypes with the adw, adr, and ay), subtypes containing an additional 11 
codons at the 5 end. The size difference between the large-S polypeptides is again due 
to differential glycosylation at the site within the surface domain. As the two forms of 
major-, middle-, or large-S arise from differential glycosylation of the same site it is likely 
that whatever dictates the relative amounts of p24 and gp27 also carries over to middle-
and large-S proteins. 
In addition to potential modification by glycosylation, both forms of large-S 
polypeptide re acylated, with myristic acid covalently bound to the amino-terminal glycine 
residue (Persing ci aL, 1987). All hepadnaviral large-S proteins contain the sequence 
methionine-glycine at the amino-terminus, and it is proposed that the amide linkage to 
myristate is formed with the exposed amino-group of the glycine residue following 
cleavage of the initiator methionine. 
Monoclonal antibodies that react exclusively with either middle- or large-S 
polypeptides in immunoblot analysis, have been produced by inoculation of mice with 
HBV virion (Heerman et aL, 1984; Heerman ci aL, 1987). This demonstrated that the 
minor forms of HBsAg are present in the virion and that preSi and preS2 domains are 
exposed on the surface of the envelope where they are capable of eliciting an antibody 
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FIGURE 1.4 HBsAg forms. 
Surface antigen domains contained in major-, middle-, and large-S polypeptides are 
indicated. The filled circle represents the glycosylated amino acid residue in the preS2. 
domain, while an open circle represents the residue in the surface domain that is variably 
glycosylated. The filled square indicates the rnyristoylated residue in the preSi domain. 
Transcriptional start sites are represented by arrows, and the numbers indicate the 
nucleotide positions mapped by Yaginuma et aL (1987b). Adapted from Neurath (1989). 
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response. Using antiserum raised against p24, the polypeptide composition of all three 
morphological forms of HBsAg was determined by immunoblotting (Heerman et at, 1984). 
The large-S polypeptides comprise 1-2% of the total envelope proteins in 22 nm spherical 
particles, while HBsAg filaments and the virion envelope contain up to 20% of these 
species. The middle-S polypeptides comprise 5-10% of total HBsAg polypeptides in all 
three forms. The relative amounts of HBsAg polypeptides are controlled at the 
transcriptional level and by the differential use of start codons within a particular 
transcript (see section 1.4.1). 
HBsAg has been expressed in high yield in yeast (reviewed by Murray, 1987) and in 
a variety of mammalian cell lines under control of native or heterologous transcriptional 
control elements (reviewed by Acs and Price, 1990). Studies in both systems indicated 
that the major-S polypeptide alone contains all of the information necessary for correct 
assembly and secretion of 22 nm spherical particles (Valenzuela et at, 1982; Persing et at, 
1985). Examination of HBV infected hepatocytes (Gerber et at, 1974) or of stably 
transfected cells producing HBsAg (Patzer et at, 1986) by electron microscopy revealed 
that 22 nm particles are assembled in the ER and secreted via the constitutive secretory 
pathway through which virion is also secreted (Yamada et at, 1982; see section 1.5.3). 
Particle assembly initiates with the translocation of HBsAg monomers into the ER 
membrane (Eble et at, 1986). Transmembrane molecules aggregate in the plane of the 
membrane and bud off into the lumen of the ER. Secretion of HBsAg particles appears 
to be less efficient than that of host-cell proteins with the rate limiting step being the 
transfer from the ER to the Golgi apparatus (Patzer et at, 1984). 
Transfer of HBsAg from the ER through the rest of the secretory pathway is 
influenced by the presence of large-S forms. Large-S polypeptides, overexpressed in 
mammalian cells under control of a heterologous promoter, are not secreted but are 
retained in the ER. In addition, overexpression of large-S proteins can inhibit secretion 
of middle- and major-S polypeptides when the different forms are expressed from the 
same plasmid construction or from cotransfected plasmids (Laub et at, 1983: Persing et 
at, 1986; McLachlan et at, 1987; Ou and Rutter, 1987; Molnar-Kimber et at, 1988): The 
extent of inhibition in stably transfected cells correlated with the proportion of total 
HBsAg constituted by large-S polypeptides (Ou and Rutter, 1987). This correlation was 
also observed in Xenopus oocytes injected with a constant amount of mRNA encoding 
middle- and major-S polypeptides and varying amounts of mRNA encoding large-S forms 
(Standring et at, 1986). Large-S polypeptides are expressed at a relatively low level 
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during infection compared to the heterologous systems representing only 1-5% of the total 
pool of HBsAg (Fleerman a at, 1984). Inhibition of HBsAg secretion was not observed 
upon expression of preSi sequences under control of the native promoter in COS 
(monkey kidney) cells (Siddiqui et at, 1986), and there is an abundance of HBsAg 
secreted during natural infection. However, the preferential location of large-S 
polypeptides in the virion envelope and HBsAg filaments suggests that their retention in 
the ER may contribute to the formation of more complicated structures. 
The sequences required for ER retention have been investigated by deletion analysis 
of the large-S polypeptides (Kuroki et at, 1989; Yu, 1991). A mutant in which only the 
first 19 amino acid residues of the preSi domain were fused to the preS2 and surface 
domains was retained in the ER, whereas further deletion of amino acids 949 resulted 
in efficient secretion of the product (Kuroki a at, 1989). This indicated that 
myristoylation at amino acid residue 2 (glycine) was not involved in ER retention, which 
was confirmed by mutating this particular residue to alanine in the full length large-S 
polypeptide thereby abolishing acylation but not affecting ER retention. The presence 
of an ER retention signal within the first 19 amino acid residues of the preSi domain was 
confirmed by Yu (1991), who noted, however, that an additional deletion of residues 66-
117 of the preSi domain restored wild-type characteristics to the mutant protein. The 
mechanism of ER retention of both the wild type and double-mutant large-S polypeptides 
remains to be elucidated. 
Vaccine development against HBV has focused on priming the immune system to 
produce antibodies against HBsAg. The serum derived vaccine consists of purified 22 nm 
particles (Hilleman a at, 1978), and has proven safe and effective (Szmuness et at, 1980). 
Production of the serum derived vaccine is costly due to the necessary purification and 
testing procedures, and its use carries the perceived risk of contamination with the human 
immunodeficiency virus (HIV). Genetically engineered vaccines utilise HBsAg particles 
consisting of major-S polypeptide (p24) produced in yeast (S. cerevisiae). The recombinant. 
antigen was shown to protect chimpanzees upon subsequent challenge with HBV (Murray 
et at, 1984), and is now in general use for vaccination of human populations. 
Studies with the various surface antigen species have revealed the importance of the 
preS regions in the immune response to HBV infection. Antibodies against both the 
preSi and preS2 regions are produced during acute infection (Neurath a at, 1985; 
Klinkert et at, 1986). While the antigenic determinants (or epitopes) within the major-S 
polypeptide are dependent on conformation, the preS regions contain continuous epitopes 
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whose binding to antibody is independent of disulphide linkages (Neurath et at, 1985). 
Immunisation of mice with genetically engineered 22 nm particles composed of middle-
and major-S polypeptides has shown that the preS2 region is significantly more 
immunogenic than the S region (Milich a at, 1985). In this system, the antibody 
responses to the preS2 epitopes regularly exceeded the anti-S response. In the same 
study, the immune response to HBsAg particles containing middle- and major-S 
polypeptides was investigated in mice from a strain that does not produce a significant 
antibody response when inoculated with particles consisting of only major-S protein. 
Immunisation with the mixed particles elicited antibody production to .both preS and S 
epitopes. This phenomenon can be explained by efficient stimulation of T-helper cells by 
the preS2 region. (See below, section 1.3.2, for a more detailed discussion of T-help 
specific for one component of a polypeptide or particle stimulating antibody production 
against another.) In support of this hypothesis, T-helper cell recognition sites have been 
identified within the preS2 domain (Milich a at, 1986b, 1990). T-helper cell recognition 
sites have also been identified in the preSi region, and synthetic peptides representing the 
amino acid sequence at these sites can stimulate T-helper cells for antibody production 
to epitopes within the preSl, preS2 and S regions of HBsAg (Milich et at, 1986a,1987a). 
The preS domains of HBsAg are important for viral uptake into hepatocytes (see 
section 1.5.1), and synthetic peptides representing amino acid sequence from the preS2 
region can elicit an HBV-neutralising antibody response in chimpanzees (Itoh et at, 1986: 
Neurath ci at, 1986a). The growing evidence for the importance of the preS regions in 
viral function and host immune response argues for their inclusion in FIBV vaccines. 
1.3.2 HBcAg 
The sequence of the core ORF spans nucleotide positions 1 to 549 capable of 
encoding a protein of 183 amino acids and approximately 21 kilodaltons (kD). HBcAg 
itself is not detectable in the serum of infected individuals, although, during recovery from 
acute infection, an antibody response is mounted against this antigen. The reactivity of 
antibodies raised against HBcAg is conformation dependent, as denaturation of core 
changes 
I 
specificity to HBeAg (Ohori ci at, 1980). HBeAg is found in large 
quantities in the serum of HBV infected individuals and the appearance of antibodies 
specific for this antigenic form of HBcAg indicates low infectivity of serum and is 
prognostic of viral clearance (Overby ci at, 1983). Evidence that HBeAg may be a 
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proteolytic cleavage product of HBcAg was supplied by MacKay et at (1981), who 
converted HBcAg synthesized in E. I  coli to HBeAg by treatment with pronase and 
P-mercaptoethanol. Amino acid sequence analysis of serum derived HBeAg showed that 
it is coterminal with HBcAg at the amino-terminus while 34 amino acid residues from the 
carboxyl-terminus of HBcAg were missing in HBeAg (Takahashi ci at. 1983). 
HBcAg encoded by cloned HBV DNA has been produced in a variety of expression 
systems, initially in E. coli (Pasek ci at, 1979; Stahl ci at, 1982) and subsequently in 
mammalian cells (Gough and Murray, 1982; Will ci at, 1984; Roossinck ci at, 1986; 
McLachlan ci at, 1987; Ou ci at, 1986; Roossinck and Siddiqui, 1987; Jean-Jean ci at, 
1989a), yeast (Kniskern ci at, 1986; Miyanohara ci at, 1986), Xcii opus oocytes (Standring 
ci at, 1988), insect cells (Lanford and Notvall, 1990) and in vitro (Weimer ci at, 1987; 
Garcia ci at, 1988). The core ORF in the HBV genome is proceeded by an initiation 
codon in the same translational reading frame, 86 nucleotides upstream of the HBcAg 
start site. This region, from nucleotide position 3096-3182, is termed pre-core (preC) and 
encodes a highly hydrophobic domain. Expression of the core gene with or without the 
preC region in a variety of eukaryotic system's has revealed that secreted HBeAg is 
produced from a polypeptide precursor initiating at the preC start codon (McLachlan et 
at, 1987; Ou ci at, 1986; Weimer ci at, 1987; Standring ci at, 1988). The 29 residue 
preC signal sequence directs translocation of the preC/core polypeptide across the ER 
membrane and is cleaved after residue 19 (Garcia ci at, 1988). Proteolytic processing of 
the carboxyl-terminus results in secretion of the mature 17 kD HBeAg polypeptide. The 
preC region is required for cell-surface expression of a preC/core gene-product in cultured 
human hepatoma cells (HepG2) infected with a vaccinia virus recombinant carrying this 
gene (Schlicht and Schaller, 1989). 
Comparison of the predicted amino acid sequence of HBcAg to a protein sequence 
database revealed a sequence homologous to the active site of aspartyl-proteases which 
could potentially carry out self-cleavage during biosynthesis of HBeAg (Miller, 1987). 
However, in HepG2 cells transiently transfected with the complete HBV genome, 
mutation of the essential aspartate residue within the protease-like sequence did not affect 
secretion of HBeAg indicating that this function can be carried out by a cellular enzyme 
(Nassal ci at, 1989). 
Examination of the predicted amino-acid sequence of HBcAg revealed a highly-
charged, protamine-like sequence at the carboxyl-terminus consisting of four clusters of 
arginine residues. Petit and Pillot (1985) demonstrated that HBcAg isolated from infected 
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hepatocytes and transferred to nitrocellulose membrane after polyacrylamide gel 
electrophoresis in the presence of sodium_dodecylLsulfate (SDS-PAGE), bound non-
specific DNA but showed stronger affinity for HBV DNA. There are conflicting reports, 
however, about the importance of the protamine-like region in mediating nucleic acid 
binding. Both recombinant HBcAg produced in El co/i and serum derived HBeAg, 
immobilised on nitrocellulose membrane, bound HBV DNA (Matsuda ci at, 1988), while 
recombinant HBeAg did not (Gallina a at. 1989). The two HBeAg preparations differed 
in the 10 amino acid residues of the preC region and amino acids 143-149 that are present 
in serum derived HBeAg but were absent in the recombinant antigen, and it is possible 
that those differences account for the discrepancy in results. 
The highly basic carboxyl-terminus of HBcAg also resembles the signals that direct 
nuclear localisation for several viral and cellular proteins, for example, adenovirus Ela 
(Lyons ci at, 1987), SV40 T-antigen. (Kalderon ci at, 1984) and glucocorticoid receptor 
(Picard and Yamamoto, 1987). Viral nucleocapsids can be detected in the nucleus of 
HBV infected hepatocytes (Ray ci at, 1976: Chu and Liaw, 1987). However, expression 
of the core gene in cultured mammalian cells has yielded disparate results, with 
observations of nuclear localisation (McLachlan ci at, 1987: Eckhardt ci at, 1991), 
cytoplasmic localisation (Jean-Jean ci at, 1989a; Ou ci at, 1989; Yeh ci at, 1990), or both 
(Roossinck ci at, 1987). In expression systems where HBcAg itself was cytoplasmic, 
nuclear localisation has been observed for a protein representing the precursor of HBeAg 
in which the 19 amino acid residues of the signal sequence have been cleaved off, but the 
protamine-like domain remains (Ou ci at, 1989; Yeh ci at, 1990). These forms have been 
observed from in vitro translation of preC/core mRNA in the presence of pancreas 
microsomal vesicles (Garcia ci at, 1988), and presumably represent aborted membrane 
translocation events. Eckhardt ci at (1991) observed nuclear localisation of HBcAg itself 
and demonstrated the importance of the arginine clusters in mediating nuclear 
translocation; the importance of this region was also shown for nuclear localisation of the 
HBeAg precursor (Yeh ci at, 1990). However, Yeh and his colleagues argue that the 10 
amino terminal-residues remaining after cleavage of the preC signal peptide are also 
required, as HBcAg itself is not localised to the nucleus in their expression system. 
Several lines of evidence have led to the investigation of HBcAg as a candidate 
component of HBV vaccines. The humoral response to the viral surface antigen can vary 
considerably from patient to patient during infection or after vaccination ranging from 
high- to non-responder phenotypes (Hoofnagle et at, 1978). In contrast, high titres of 
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anti-HBcAg antibodies are produced in virtually 100% of chronic HBV infections 
(Floofnagle, 1973) indicating that a non-responder phenotype may not exist for this 
antigen. Vento ci' a/l (1985) showed that HBsAg-positive, chronic liver disease patients 
who have not mounted an anti-HBsAg antibody response, have T-helper cell sensitisation 
to HBcAg but not to HBsAg (12/12 patients tested). Studies on the T-helper cell 
response to HBcAg by Milich and his colleagues were preceded by the report that 
vaccination of chimpanzees with HBcAg produced in K coil could protect them against 
subsequent challenge with HBV (Murray ci a/I, 1984). 
Following immunisation of mice with HBcAg, proliferation of T-helper cells isolated 
from the immunised mouse could be stimulated by the antigen in vitro (Milich and 
McLachlan, 1986). The degree of T-helper cell immunogenicity displayed by HBcAg 
along with its ability to function as a 1-cell independent antigen (Milich and McLachlan, 
1986) could explain the enhanced humoral response that it elicits compared with HBsAg. 
In the mouse, 1-helper cell epitopes of HBcAg have been mapped to specific peptide 
stretches, and it has been shown that different inbred strains of mice produce a T-cell 
response to different epitopes (Milich ci a/I, 1987b). This may be due to the differential 
interaction of peptides with the variable MHC class II antigens expressed by the different 
strains, as T-helper cells only recognise antigen in association with these antigens. 
Milich ci' a/I (1987c) went on to investigate the possibility that T-helper cells specific 
for HBcAg could help B-cells produce antibodies specific for HBsAg. Mice were primed 
by immunisation with a synthetic peptide sequence of HBcAg known to contain a T-cell 
epitope. Upon challenge with HBV, the primed mice produced antibodies to HBsAg in 
much higher titre than unprimed mice (Milich et A, 1987c). This result is consistent with 
that of Lanzavecchia (1985) who showed that B-cells could function as antigen presenting 
cells to 1-helper cells. The events in vivo may be envisioned as follows (figure 1.5): 
Immunisation with the HBcAg peptide causes clonal expansion of T-helper cells with 
receptors specific for this peptide in association with MHC class II antigen. Upon 
challenge with virus, a B-cell specific for HBsAg binds to the virion via cell surface 
immunoglobulin molecules. Endocytosis brings the virion into the B-cell where its 
constituent parts undergo proteolytic processing, and a proteolytic fragment of HBcAg is 
expressed on the surface of the B-cell in association with MHC class II antigen. This 
complex is recognised by a T-helper cell with a receptor specific for the complex of 
HBcAg and MHC class II antigen, and the T-helper cell secretes lymphokines onto the 
B-cell causing its clonal expansion. That is, a T-helper cell specific for HBcAg stimulates 
if' 
FIGURE 1.5 Model for the production of antibodies to HBsAg by priming T-helper cells 
specific for HBcAg 
Immunisation with HBcAg or with a peptide representing part of the HBcAg primary 
sequence causes clonal expansion of T-helper cells with receptors specific for a proteolytic 
fragment of HBcAg in association with MHC class II antigen. Upon challenge of the 
immune system with intact virus (A), a B-cell present in the host's immune repertoire and 
expressing surface immunoglobulin specific for HBsAg (a-HBsAg) binds to the envelope 
of the virus particle. B) Endocytosis brings the virion into the B-cell where its constituent 
proteins are subjected to proteolytic processing. C) A proteolytic fragment of HBcAg is 
expressed on the surface of the B-cell in association with MHC class II antigen. D) The 
HBcAg/MHC complex is recognised by a T-helper cell with an HBcAg-specific receptor 
that is present in the blood at a higher concentration than normal due to priming with 
HBcAg. The T-cell secretes lymphokines onto the B-cell causing its clonal expansion and 
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the clonal expansion of a.B-cell producing antibodies specific for HBsAg. 
Because protcolytic processing of internalised antigen is a key step in stimulation of 
B-cells specific for one component of a particle by T-helper cells specific for another 
component, the same principle should hold for separate components of the same 
polypeptide. This hypothesis was confirmed by Milich et at (1988).  who showed that a 
synthetic HBsAg peptide, which did not elicit an antibody response in mice was rendered 
immunogenic upon linkage to a synthetic T-helper cell epitope from HBcAg. 
Understanding this system has prompted the expression of chimeric HBcAg particles in 
E. co/i in which the HBcAg coding sequence (or part of it) is fused to a heterologous 
sequence in order to enhance the antibody response against the heterologous polypeptide 
segment (Clarke et at, 1987; Borisova et at, 1989; Stahl and Murray. 1989; Francis et at, 
1990). 
HBcAg produced in E. co/i spontaneously forms particles whose structure appears 
identical to HBcAg purified from HBV infected liver when observed by electron 
microscopy (Cohen and Richmond, 1982). The E. co/i derived HBcAg particles are 
immunogenic, eliciting an antibody response cross-reactive with HBcAg derived from 
human liver (Pasek et at, 1979) and antigenic, reacting with anti-HBcAg antibodies in 
serum from HBV infected individuals (Stahl et at, 1982). Several studies have begun to 
decipher the features of HBcAg primary sequence required for particle formation. 
Stahl et at (1982) synthesised HBcAg in E. co/i as a fusion protein with the first eight 
amino acid residues of -galactosidase fused in frame to HBcAg containing short deletions 
of amino-terminal residues. Extracts from cells expressing a fusion protein in which the 
first two amino-terminal residues of HBcAg were deleted, were 100 times more reactive 
with anti-HBcAg serum (as assayed by radio-immunoassay) than extracts from cells 
expressing a fusion protein in which the first four amino-terminal residues were deleted. 
It has been confirmed that the same amount of fusion protein was expressed by cells 
harbouring the different plasmids (F. Stewart, personal communication); therefore, the 
difference in cross-reactivity with anti-HBcAg was most likely due to an altered secondary 
structure, although the ability of the fusion proteins to form particles has not been 
assessed. 
HBcAg mutants, deleted at the carboxyl-terminus, were expressed in E. co/i and 
assessed for the capacity to form particles by their sedimentation profile in sucrose 
gradient and by electrdn microscopy (Birnbaum and Nassal, 1990). HBcAg deleted to 
amino acid residue 164, 149 or 144 was able to form particles, while deletion to residue 
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139 or 138 abolished this capacity. Birnbaum and his colleagues note that deletion to 
residue 149, completely removing the protamine-like sequence, dramatically reduced the 
non-specific RNA content of the particles as well as the stability of the particles to SDS 
or acid treatment. The authors speculate that nucleic acid may contribute to the stability 
of HBcAg particles. 
The carboxy-terminal deletion of HBcAg to residue 149 mimics the carboxyl-terminus 
of e antigen, which is secreted from HBV infected cells as soluble dimer (Neurath et aL. 
1979). HBeAg that formed particles when expressed in E. coli lacked the 10 amino-
terminal residues remaining in serum HBeAg after cleavage of 19 amino acid residues 
from the 29 residue signal sequence encoded by the preC region. This structural feature 
may account for the lack of particle formation by native HBeAg, although it is more likely 
that this attribute is due to the different biosynthetic pathways of HBeAg and HBcAg 
(Birnbaum and Nassal, 1990). 
Petit and Pillot (1985) noted that core particles isolated from the cytoplasm of HBV 
infected hepatocytes contained HBcAg in different oxidation states. A doublet of HBcAg 
observed by SDS-PAGE under non-reducing conditions was reduced to a single band 
upon treatment with -mercaptoethanol suggesting intramolecular disulphide bonds in the 
HBcAg molecule. The oxidation state of HBcAg and HBeAg (amino acid residues 1-144) 
produced in E. co/i was investigated by Gallina et aL (1989). Both antigens formed 
particles as observed by electron microscopy; SDS-PAGE under non-reducing conditions 
revealed that HBeAg formed a 32 kD dimer while HBcAg did not even enter the gel 
indicating that additional disulphide bonds in the carboxy-terminal 34 amino acid residues 
link HBcAg dimers together in the particle structure. Additional evidence for the 
importance of intermolecular disulphide bonds in the HBcAg particle structure was the 
inability to dissociate the particles in SM urea (although F[BeNg antigenic determinants 
were revealed) while HBeAg particles were completely dissociated by this treatment as 
assessed by sedimentation properties in sucrose gradients. 
The ability of sequences located within HBcAg amino acid residues 3-144 to direct 
particle formation has been exploited for the construction of fusion proteins containing 
heterologous sequences expressed in particulate form (Stahl and Murray, 1989). Because 
of their particulate nature, the chimeric proteins were easy to purify, and an antibody 
response was elicited against the heterologous epitopes when injected into rabbits. The 




The polymerase (p01) gene of HBV covers 801 'c of a translational reading frame in the 
HBV genome from ndcleotide positions 407-2902. This ORF is capable of encoding a 
protein of 832 amino acids or about 93 kD. The endogenous polymerase function of 
HBV was originally assigned to this ORF due to the similarity in the size of its coding 
capacity to the DNA polymerase enzymes of bacteria and viruses (Galibert a' at, 1979: 
Pasek a' at, 1979). Sequence homology studies comparing the predicted amino acid 
sequence from the polymerase ORF with reverse transcriptase sequences from 
retroviruses and cauliflower mosaic virus showed tracts of strong homology indicating 
functional relatedness (Toh et at, 1983). 
The detection of antibodies directed against a product of the polymerase ORF in 
serum from HBV infected chimpanzees (McGlynn and Murray, 1988) and humans 
(Stemler a' at. 1988) indicates that it is expressed during the viral life-cycle. The 
requirement of the pol-gene product for replication of the HBV genome was 
demonstrated in one of the first reports of virus production from transiently transfected 
hepatoma cells in culture (Yaginuma et at, 1987b). Transfection of cells with a mutant 
HBV genome carrying a premature termination codon in the polymerase ORF resulted 
in production of core particles that did not contain viral DNA. 
Antisera prepared against fragments of the polymerase protein expressed in E. co/i 
(Mack et at. 1988) or against synthetic peptides representing the deduced amino acid 
sequence of a segment of the pot-gene product (Bavand a' at, 1989) have detected cross-
reacting proteins present in HBV particles produced by cultured hepatoma cells. This 
protein displays reverse transcriptase activity when immobilised within a polyacrylamide 
gel following PAGE (Bavand and Laub, 1988; Bavand et at, 1989). 
Several domains have been identified within the po/-gene product. 
Immunoprecipitation of DHBV DNA by antibodies directed against the amino-terminus 
of the polymerase polypeptide indicates that the genome-linked protein of DHBV (and. 
by inference, HBV) is encoded by this region of the p0/-gene product (Bartenschlager and 
Schaller, 1988; Bosch et at, 1988). A model for replication of the HBV genome indicates 
that the genome-linked protein remains covalently attached to the minus strand DNA 
after priming reverse transcription of this strand from the viral pregenome mRNA (sec 
section 1.5.2). Sequence comparisons originally identified other domains within the 
polymerase ORF which displayed homology to the DNA polymerase and reverse 
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transcriptase domain and to the RNase H domain of retroviralpo/-genes (Toh et at, 1983; 
Radziwill et at. 1990). 
Mutational analysis of the polymerase ORF was carried out in the context of the 
complete HBV genome, by assessing the endogenous DNA polymerase activity of core 
particles isolated from the cytoplasm of transiently transfected cells (Radziwill et at. 1990). 
Mutations in all three domains within this ORF dramatically reduced endogenous 
polymerase activity. Mutations in the RNase H domain blocked degradation of the RNA 
component in the hybrid molecule of viral pregenome RNA and minus strand DNA 
confirming RNase H activity for this domain and indicating that the other domains can 
function independently for priming and carrying out DNA synthesis. pol-gene mutations 
could be complemented by supplying a wild-type pol-gene product in trans from an HBV 
genome with a mutated core ORF indicating that the polymerase polypeptide exists in a 
diffusible state. Specificity for reverse transcription of the viral pregenome RNA could 
arise if this activity of the polymerase is activated after the terminal protein domain binds 
to a specific target sequence in the viral RNA. 
The viral pregenome RNA is packaged into the nucleocapsid where reverse 
transcription occurs (Enders ci at. 1987):  Indirect evidence for a specific interaction 
between the po/-gene product and the pregenome RNA has been provided by the 
observation in both the DHBV model system (Hirsch cx' at. 1990) and HBV 
(Bartenschlager et at, 1990) that the p0/-gene product is required for encapsidation of the 
pregenome RNA. M 85 nucleotide encapsidation signal within the pregenome RNA 
(nucleotide positions 3134-3182/1-36) is necessary and sufficient for mediating this 
function (Bartenschlager a at, 1990; Junker-Niepmann et at, 1990). 
1.3.4 HBxM 
The X-gene was first described as an ORF in the DNA sequence of the HBV genome 
covering nucleotide positions 2656-3117 (Galibert ci at, 1979). This ORF has a coding 
capacity of 154 amino acid residues to produce a protein of 17 kD. Based on this size, 
it was initially proposed that the e antigen was the product of this ORF (Galibert ci at, 
1981), but this hypothesis was disproved by the discovery that HBeAg can be derived from 
HBcAg (MacKay ci at, 1981). The function of the X-gene product (HBxAg) in the viral 
life-cycle is still under intensive investigation. 
There is strong evidence that HBxAg is expressed during viral infection and is 
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immunogenic. Expression of a —1 kb X-specific mRNA has been detected in mammalian 
cells transfected with the complete HBV genome (Gough, 1983; Zelent ci at, 1987; Koike 
ci at, 1989) or with a fragment of the HBV genome containing the surface and X ORFs 
(Simonsen and Levinson, 1983; Saito ci at, 1986: Siddiqui ci at, 1986: Bulla and Siddiqui. 
1988. 1989). While X-gene specific transcripts have not been detected in HBV infected 
liver (Cattaneo ci al, 1984: Will ci at, 1987: Suet at, 1989), a predominantly nuclear, non-
polyadenylated RNA of 0.65 kb has been observed in WHV infected liver that hybridised 
specifically to the X region of the WHV genome (Kaneko and Miller, 1988). In support 
of evidence for expression of an X-specific mRNA, an X promoter has been identified 
within 200 nucleotides 5' to the X ORF which can direct transcription of a heterologous 
reporter gene (Treinin and Laub, 1987; Siddiqui ci at, 1987: Wollersheim ci at, 1988). 
Direct evidence for the ability of the X-gene to encode a protein product has been 
provided by its expression in both prokaryotic (Kay ci at, 1985; Elfassi ci at, 1986: Meyers 
ci at, 1986; Pugh ci at, 1986: Chisaka ci at, 1987: Pfaff ci at, 1987: Chen ci at, 1988; 
Jameel ci at, 1990: Katayama et at. 1989: Stemler ci at, 1990: Wu ci at, 1990) and 
eukaryotic (Moriarty ci at. 1985; Siddiqui ci at, 1987: Koike ci at, 1988; Levrero ci at, 
1990b) systems and by in vitro transcription and translation (Pfaff ci at. 1987; Lin and Lo, 
1989: Wu ci at, 1990). These synthetic antigens as well as synthetic peptides representing 
segments of HBxAg have served as reagents to detect antibodies to HBxAg in the sera 
of HBV infected individuals (Kay ci at, 1985: Moriarty ci at. 1985; Elfassi ci at, 1986: 
Meyers ci at, 1986; Pfaff ci at, 1987; Koike ci at, 1988; Weber ci at, 1988; Katayama ci 
at, 1989: Levrero ci at, 1990b; Stemler ci at, 1990). The immunological response to 
HBxAg is considered in detail in Chapter 3. 
Antisera raised against HBxAg expressed in E. co/i or against synthetic peptides 
representing segments of HBxAg have been used to detect cross-reacting proteins in 
several preparations. HBxAg could not be detected in the serum of HBV infected 
chimpanzees (Weber et at, 1988), either because it is not manifested in the serum during 
infection or the quantity present is too low to be detected. Pfaff ci at (1987) were unable 
to detect a polypeptide encoded by the X ORF in liver specimens from 24 HBV infected 
patients. In contrast, analysis by immunoblotting of proteins extracted from the liver of 
a patient with chronic HBV infection or fromLa human hepatoma cell line (PLC/PRF/S) 
containing integrated HBV DNA resulted in the detection of a 28 kD protein that cross-
reacted with antiserum raised against a synthetic peptide fragment of HBxAg (Moriarty 
ci at, 1985). This size was larger than predicted from the deduced amino acid sequence 
22 
and could not be due to glycosylation of the polypeptide, as the amino acid sequence 
reveals no available sites (asparagine-X-serine/threonine). The possibility of a fusion 
protein containing HBxAg fused to a segment of HBcAg or HBsAg was ruled out by the 
failure of anti-sera specific for HBcAg or HBsAg to cross-react with the 28 kD species. 
In addition, the protein did not appear to be bound to DNA as treatment of the protein 
extracts with DNase did not effect its mobility. Moriarty and her colleagues speculate that 
the 28 kD protein could represent a fusion of HBxAg with cellular sequences encoded at 
the junction of one of the HBV integration sites in the host chromosomes. The 
identification of fusion proteins of this sort is discussed further in section 1.6. 
Proteins that cross-reacted with anti-.HBxAg serum were immunoprecipitated from the 
medium of human hepatoma cells (HuH7) transiently transfected with the complete HBV 
genome (Chang et at, 1987). Proteins of 17 kD, corresponding to the predicted size of 
HBxAg, and 22 kD were detected by this procedure. Chang and his colleagues speculate 
that the larger polypeptide could be a cellular protein complexed to HBxAg and co-
precipitated with it, or, as above, it could be a fusion protein of HBxAg and cellular 
sequences. The metabolic labelling of cells and immunoprecipitation procedure were 
carried out 10-14 days post-transfection by which time input DNA may have integrated 
into the chromosomes of transfected cells potentially fusing the X ORF to cellular 
sequences. 
HBxAg has been detected by indirect immunofluorescence analysis or 
immunohistochemical staining of hepatocytes from HBV infected liver (Vitvitski et at, 
1988; Katayama et at, 1989), hepatocytes from transgenic mice harbouring the X ORF in 
their chromatin (Lee et at, 1990), hepatoma cell lines containing integrated HBV DNA 
(Chisaka et at, 1987), cell lines transfected with the X ORF under control of a 
heterologous promoter (Siddiqui ci at, 1987; Hu ci at, 1990; Levrero ci at, 1990b), and 
cell lines transfected with the complete HBV genome (Pugh ci at, 1986; Vitvitski ci at, 
1988). There are conflicting reports about the subcellular location of HBxAg in these 
preparations. While general cytoplasmic staining was observed in HBV infected 
hepatocytes and HBxAg transgenic mice, an association with the nuclear periphery 
(Siddiqui ci at, 1987; Chisäka ci at, 1987; Levrero ci at, 1990b) or more generalised 
nuclear, and cytoplasmic staining (Hu et at, 1990) have been observed in cultured cells. 
The amino acid sequence of HBxAg does not contain a short, highly basic stretch of 
residues that is typical of many nuclear proteins (section 1.3.2; figure 1.6), but this does 
not rule out the capacity to enter the nucleus (Dingwall and Laskey, 1986). 
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FIGURE 1.6 Sequence comparison of HBxAg isolates. 
Alignment of X antigen amino acid sequences in single letter code translated from the 
nucleotide sequence of eight HBV, five WHy, and one GSHV isolates. Numbers 
represent amino acid position in the HBVadyw sequence. Complete identity at a 
particular position is indicated by *, while positions containing amino acid residues of 
homologous structure and charge are indicated by .. Completely conserved cysteine 
residues are indicated above the HBVadyw sequence, and every tenth amino acid residue 
in the HBVadyw sequence is marked with a + above it. Sequence alignment was carried 
out using the program, "Clustal" (Higgins and Sharp, 1988). 
References: HBVadyw, Pugh et al. (1986) 
HBVayw, Galibert et at (1979) 
HBVayw2, Bichko c/ at (1985) 
HBVadw, Ono et at (1983) 
HBVadw2, Valenzuela et at (1980) 
HBVadr, Ono et at (1983) 
HBVadr4, Fujiyama et at (1983) 
HBVayr, Okamoto et at (1986) 
WHV1. Etiemble et at (1986) 
Cohen et at (1988) 
Cohen et at (1988) 
Girones et at (1989) 
WHYS, Galibert a at (1982) 
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HBVadw2  MAARLYCQLDPSRDVLCLRPVGAESRGRPLSGPLGTLSSPSPSAVPADHGAHLSLRGLPV 
HBVadr MARVCCQLDPARDVLCLRPVGAESRGRPVSCPFGALPSPSSSAVPHCMiLSLRGLPV 
HEVadr4 MARVCCQLDPDVLCLRPVG.ESRGRPVSGPFGTLPSPSSSAVPHGJJiLSLRGLFV 






GSHV MAARLCCQLDSSRDVLLLRPLRGQPSGPSVSGTSAGSPSSAJkSJSFSSGHQjU IPVGRLPA 
cons. .*.**. .**** *** .. * * 
61 117 









WHV1 CFASASGPCCLVFTCADLRTMDSTVN ---- FVSWHAKRQLGMPS --- YJJLWTPY IKDQLL 
WHV2 CFASASGPCCLVFTCADLRTMDSTVN ---- FVSWUpIJC2QLGMPS --- KDLWTPYIJçEQLL 
WHv3 CFASASGPCCLVFTCAELRTMSTVN ---- FVSWHA1qRQLG?4J'S --- 1cDLWTPYIFJQLL 
WHV4 CFASASGPCCLVFTCADLRTMDSTVN ---- FVSWHTQLGMPS --- YjLWTpY IKDQLL 
WHyS CFASASGPCCLVVTCAELRTHDSTVN ---- FVSWIThJIRQLGMPS---JQLWTPY IRDQLL 
GSHV CFYSSAGPCCLGFTCADLRTMWSTVN ---- FVPWHAj1,RQLG1Q --- jQFWTAY IRDQLL 
cons.  
118 154 
+ + C + + 
HEVadyw KDWEELGEEIRLKVFVLGGCRIUCLVCAPAPCNFFTSA 











WHyS TICWEEGSIDPRLS IFVLGGCRHK--CMRLP------- 
GSHV TLWEEGI IDPRLXLFVLGGCRHK--fll---------- 
cons. • • ** 
Recently, HBxAg has been detected as a component of the HBV virion (Wu et at. 
1990). Virus particles were incubated with [y-32P]ATP and subsequently dissociated with 
SDS. A 16.5 kD labelled polpeptide was immunoprecipitated specifically with anti-
HBxAg serum. The significance of phosphorylation of HBxAg in the endogenous kinase 
reaction will be considered in Chapter 5. 
The presence of proteins in various HBV preparations that cross-react with antisera 
specific for HBxAg and the mounting of an humoral immune response against HBxAg 
during HBV infection indicate that an immunogenic protein is expressed from the X ORF 
of the HBV genome. This ORF is conserved in all mammalian hepadnaviruses and amino 
acid sequence comparisons show two strong regions of similarity in all species (Colgrove 
et at, 1989; personal observations, figure 1.6, amino acid positions 1-20 and 132-140) 
suggesting a conserved function for the X-gene products. In their review, Ganem and 
Varmus (1987) cite their own unpublished results suggesting that the X-gene product is 
necessary for viral growth in the GSHV system. 0/9 animals exposed to viral genomes 
bearing a frameshift mutation in the X ORF caused by oligonucleotide insertion 
developed infection, while 1/3 recipients of a genome containing an insertion in the X 
ORF that maintained its reading frame became viraemic. The effect of a frameshift 
mutation at the 3 - end of the X ORF (following amino acid 117) was investigated upon 
transient transfection of HUH 7 cells with the mutant HBV genome (Yaginuma et at. 
1987b). No effect was observed on the production of core particles containing viral DNA. 
However, from the mutant plasmid construction used in this study it was possible that a 
biologically active X-gene product was expressed from a second, intact copy of the X 
ORF. Subsequent studies with a plasmid construction derived from the one described 
above, but lacking the intact copy of the X ORF, revealed that the mutation in the X 
ORF reduced viral transcription in a different hepatoma cell line (HepG2) although it was 
not essential for production of core particles containing viral DNA (Koike et at. 1989). 
The effect of the HBxAg mutation on HBV transcription is consistent with numerous 
reports that have now emerged concerning the transactivating function of HBxAg (see 
appendix II for references). 
Three lines of reasoning led to the hypothesis that HBxAg encodes a transcriptional 
transactivator. 1) HBV replicates in a manner analogous to retroviruses, and all human 
retroviruses characterised to date encode polypeptides that activate transcription from the 
viral long terminal repeat (LTR). 2) HBV infection is correlated with the development 
of HCC (see section 1.6) and many isolated HCC tissues contain HBV DNA integrated 
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into the host cell chromosomes. However, no specific integration site has been observed 
in human HCC suggesting that HBV may play a role in the development of neoplasia 
through the action of one of its gene products in trans. 3) One of the mysteries in the 
search for the function of the X gene is the absence of a homologous ORF in the avian 
hepadnaviruses (Mandart et at, 1984; Sprengel et at, 1988). It is possible that these 
species have a cellular gene performing the function served by the X-gene product of the 
mammalian hepadnaviruses. Investigation of the nucleotide sequence of the X ORF 
indicated that, like retroviral oncogenes, it has a codon usage preference favoured by 
eukaryotic cellular genes and not by the genes of viruses that infect eukaryotic cells 
(Miller and Robinson, 1986). Miller and Robinson (1986) speculate that, like retroviral 
oncogenes, the X-gene may be. "recently acquired from cellular sequences. However, 
unlike the retroviral sequences, a cellular gene has not been detected that contains 
enough sequence homology to cross-hybridise with X-specific DNA probes. In addition, 
HBxAg does not function like retroviral oncogenes that can transform cells in vitro and 
rapidly produce tumours in vivo. Miller and Robinson (1986) speculated that HBxAg may 
have a transactivating function like that encoded by the pX genes of human T-cell 
lymphotropic virus (HTLV) I and II which also have cellular codon usage, do not have 
a cellular homologue, and do not behave as oncogenes, yet infection with these viruses 
is linked to neoplasia. 
The potential of HBxAg to activate transcription from a variety of transcriptional 
control elements has come under rigorous investigation, and the targets that have been 
described are listed in table 4.1. HBV transcriptional control regions, as well as those 
from heterologous viruses and certain cellular genes are susceptible to transactivation by 
this promiscuous HBV gene-product. A detailed consideration of the features of 
transactivation by HBxAg is given in Chapter 4, while the mechanism by which it may 
carry out this function is discussed in Chapter 6. Here, I will examine the primary 
structure of HBxAg for features that have been described as integral to the function of 
various cellular and viral transcriptional activating proteins. 
Transcription factors are polypeptides that bind to specific sequence motifs (-8 bp 
in length) proximal or distal to a gene and influence its transcription, (see section 6A.1 
for more detailed discussion; for reviews see Maniatis et at, 1987; Ptashne, 1988; Johnson 
and McKnight, 1989; Mitchell and Tjian, 1989). Distinct domains that mediate DNA-
binding and trans-acting functions have been identified within transcriptional activating 
polypeptides. 
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Several different types of DNA-binding domains have been identified for eukaryotic 
transcription factors. Although DNA-binding capacity has not been observed for HBxAg 
(Faktor and Shaul, 1990; Jameel et at., 1990; Twu et aL, 1990; Unger and Shaul. 1990; Wu 
a aL, 1990), two reports have noted features in the amino acid sequence of HBxAg that 
appear similar to two well defined DNA-binding motifs (Lo et at.. 1988; Lin and Lo, 
1989). Zinc fingers' are formed by tetrahedral coordination of a Zn+ + ion to the 
polypeptide with looping out of intervening amino acid residues, and are encoded by a 
segment of —30 residues within the protein (reviewed by Evans and Hollenberg. 1988). 
Two possible sequence motifs comprise zinc fingers: the C2H2 motif, which takes the 
genera! form C-X24-C-X3-F-X5-L-X2-H-X34-H, is part of the transcription factors Spi 
and TFIIIA (among others). The Cx motif is composed of 4-6 cysteine residues separated 
by variable numbers of amino acid residues, but in each case, two non-adjacent pairs are 
separated by not more than five residues. The primary sequence of the HBxAg isolate 
used in these studies contains ten cysteine residues, eight of which are completely 
conserved among the HBV isolates, and four of which are completely conserved among 
all mammalian hepadnaviral isolates considered in figure 1.6 (residue numbers 7, 61, 69, 
137 in the numbering of the FlBVadyw isolate). Lo a aL (1988) speculate that the 
cysteine residues of HBxAg may form a zinc finger, however, they are not in the proper 
consensus configuration for zinc-binding in any of the X antigen sequences in figure 1.6. 
Even proteins that do contain cysteine residues in the proper configuration may not bind 
DNA, for example, the adenovirus Ela protein (reviewed by Evans and J4ollenberg, 1988). 
HBxAg produced by in vitro transcription and translation may form dimers, which can 
be detected by SDS-PAGE under non-reducing conditions, indicating a disulphide linkage 
(Lin and Lo, 1989). Several eukaryotic transcription factors bind DNA  only in dimer 
conformation, for example C/EBP (CCAAT/enhancer binding protein), CREB (cyclic 
AMP response element binding protein) and Fos/Jun (components of the transcription 
factor API). Dimerisation of these proteins is not dependent on disulphide bonds, but 
is mediated by an a-helical array of four leucine residues each separated by six intervening 
residues, the "leucine zipper" (reviewed by Landschu!z et aL, 1988b). Lin and Lo (1989) 
speculate that a potential leucine zipper motif in HBxAg could contribute to dimer 
formation (leu-9, leu-16, ala-23, leu-30 and leu-37 in the amino acid sequence of the 
HBVadyw isolate). Two observations argue against dimer formation mediated by these 
residues. 1) ct-Helical secondary structure is not predicted for this region (figure 3.5). 2) 
The motif is not conserved when the sequence of several X antigen isolates is considered 
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(figure 1.6). While the central alanine residue is conserved in all human X antigen 
isolates, it is not present in the rodent isolates in which a proline is found in this position. 
Similarly, the leucine residue at position 37 is present in all human isolates but is replaced 
by serine in the rodent polypeptides. The leucine residue at position 30 is found in only 
three of fourteen isolates and is not replaced by a similar residue in the others. Primary 
sequence homologies to other types of DNA-binding domains that have been defined, for 
example the basic domain of nuclear factor 1 (NF-1) or the homeodomains, are not 
observed in HBxAg. Nor is a helix-turn-helix secondary structure, predicted or actually 
observed for many transcriptional control proteins, strongly predicted for HBxAg (see 
figure 3.5). 
The activator domains of eukaryotic transcription factors are distinct from the DNA-
binding domain, but are required for transactivating or transrepressing function. An 
activator domain can be linked to a heterologous DNA-binding domain creating a 
chimeric transcription factor with the specificity of the DNA-binding domain (reviewed 
by Ptashne, 1988; Mitchell and Tjian, 1989). Several types of activator domains have been 
described: transcription factor Spi has two activator domains consisting of —25% 
glutamine, while that of NFl is proline rich. Neither of these motifs appear in the 
primary sequence of HBxAg. The activator domain of several transcription factors 
including the glucocorticoid receptor and yeast activators GAL4 and GCN4, consist of 
stretches of negatively charged residues with a predicted a-helical secondary structure. 
The region of HBxAg from amino acid positions 107-126 contains eight negatively charged 
residues, has predicted a -helical secondary structure, and could represent an activator 
domain. The requirement of this region for HBxAg activity is subject to debate at 
present, and is discussed in detail in section 4.1. 
1.4 Vita! Transcription 
Upon infection of hepatocytes, cellular enzymes convert the virion DNA into a 
covalently-closed circular molecule that is found only in the nucleus of infected cells 
(reviewed by Ganem and Varmus, 1987; see section 1.5.2). This DNA species serves as 
template for viral transcription which is carried out by host-cell RNA polymerase II and 
regulated by HBxAg and by cellular transcription factors. The hepatropism of HBV is 
influenced in part by the regulatory effect of liver-specific protein factors on viral 
transcription. When considering HBV transcriptional control elements it is important to 
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bear in mind that each one is also part of at least one open reading frame and alterations 
to the sequence of these elements among hepadnaviral isolates is therefore subject to 
evolutionary constraints on their coding capacity as well as on their function in viral 
transcription. 
All transcripts encoding viral proteins are of plus.. strand polarity, are unspliced, and 
coterminate at a common polyadenylation site (figure 1.3). The 3' processing site has 
been mapped to nucleotide position 40±5 (Cattaneo et at, 1983; Simonsen and Levinson, 
1983; Cattaneo et at, 1984). This termination site is —20 nucleotides downstream of the 
conserved hekanucleotide 16-TATAAA-21 which is homologous to the consensus sequence 
located at a similar distance from the 3'  processing site of cellular genes transcribed by 
RNA polymerase II (Proudfoot and Brownlee, 1976). The evidence for production in low 
abundance of an X-specific mRNA has been discussed (section 1.3.4). The major HBV 
transcripts are 3.3 kb mRNAs that are greater than genome-unit length and subgenomic 
mRNAs of 2.0 kb and 2.3 kb (excluding poly A tails). 
1.4.1 The subgenomic mRNAs 
The various HBsAg polypeptides are not produced by processing of a polyprotein but 
by differential transcription of the pre-S and surface ORFs. The 2.3 kb mRNA contains 
the coding sequence for the preSi, preS2, and surface domains of the large-S polypeptides 
as well as for the X gene. Translation of this mRNA in Xenopus oocytes yielded only 
large-S products indicating that internal initiation sites are not used (Standring et at, 
1986), and this mRNA species is referred to henceforth as the preSi mRNA. 
The initiation site of the preSi mRNA has been mapped to nucleotide position 907±4 
in RNAs extracted from HBV infected liver (Will et at, 1987), PLCIPRFI5 cells (Ou and 
Rutter, 1985) or HuH7 cells transfected with HBV DNA and producing virus particles 
(Yaginuma ci at, 1987b). This site is 25 nucleotides downstream of the sequence 876-
TATATAA-882 which corresponds in position and sequence to the 'TATA box' found in 
most eukatyotic promoters. A minimal preSi promoter region (nucleotide positions 816-
941) has been determined by assessment of the promoter activity of DNA fragments 
derived from this region and fused to a reporter gene (Raney et at, 1990). 
The smaller 2.0 kb subgenomic mRNAs have heterogenous 5' termini straddling the 
preS2 initiation codon at position 1272 (Standring ci at, 1984; Ou and Rutter, 1985; 
Siddiqui et at, 1986; Yaginuma et at, 1987b) and are referred to collectively as the 
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pre52/S mRNAs (figure 1.4). Experiments mapping the HBV transcripts from PLC/PRFI5 
cells (Ou and Rutter, 1985) or from HuH7 cells transfected with HBV DNA (Yaginuma 
et at, 1987b) indicated that approximately half of the preS2/S mRNAs initiate upstream 
of the preS2 initiation codon to produce a transcript containing both preS2 and surface 
ORFs, while the other half initiate downstream of this site and encode only the major-S 
polypeptides. However, as noted above, the major-S species are the predominant form 
of HBsAg produced by infected hepatocytes. The expression of major-S polypeptides 
(along with middle-S forms) from mRNA containing the initiation codons of the preS2 
and surface domains has been demonstrated following injection of this mRNA into 
Xen opus oocytes (Standring a at, 1986), or expression of this mRNA from a heterologous 
promoter in mammalian cells (McLachlan et at, 1987; Ou and Rutter, 1987; Molnar-
Kimber a at, 1988) indicating inefficient utilisation of the preS2 initiation codon. 
Consistent with these results is the observation that the nucleotide sequence surrounding 
the preS2 initiation codon has two mismatches with the optimal translation initiation 
sequence described by Kozak (1986), while that surrounding the initiation codon of the 
surface ORF has only one mismatch. 
Examination of the DNA sequence upstream of start sites of the pre52/S mRNAs 
reveals that the promoter does not contain a "TATA" sequence. Detailed mutational 
analysis of another promoter lacking a "TATA box", the 5V40 late promoter, revealed a 
region from -31 to -21 (relative to the transcription initiation site) that was important in 
the control of the level of late mRNA expression and for setting its initiation site. (Brady 
et at, 1982). The DNA sequence upstream of the pre52/S mRNA start sites (nucleotide 
positions 1222.1233) contains homology to this region of the 5V40 late promoter at a 
similar position relative to initiation of transcription (Cattaneo a at, 1983). The 
importance of this region for transcription of the preS/S mRNAs is unclear (figure 1.7). 
Raney a at (1989) showed that a DNA fragment representing nucleotide 1063-1410 could 
direct maximal transcription of the chloramphenicol acetyl transferase (CAT) reporter 
gene relative to the level of CAT transcribed when this gene was inserted into the 
complete HBV genome at position 1310. Deletion of the fragment from the 5' end to 
nucleotide 1153 reduced transcriptional activity two-fold, while deletion to nucleotide 1221 
(leaving the 5V40-homologous region intact) abolished promoter function indicating that 
sequences upstream of the region of homology were important for promoter activity. 
Employing a similar approach. De-Medina et at (1988) defined a region from nucleotide 
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FIGURE 1.7 preS2/S promoter region 
Representation of HBV nucleotide positions 1050-1500 encompassing the preS2/S 
promoter region. The region of homology to the SV40 late promoter and the 
positions of the initiation codons for the preS2 (1272) and surface (1437) ORFs 
- are indicated. The arrow represents the transcriptional initiation sites of the 
preS2!S mRNAs. 
Analysis of promoter activity in human hepatoma cells (HepG2) of fragments of 
the HBV genome fused to CAT (Raney ex aL, 1989). Promoter activity is given 
as a percentage of CAT activity relative to that obtained when the CAT gene was 
inserted into the complete HBV genome at position 1410. 
Analysis of promoter activity in PLC/PRF/5 cells (De-Medina et aL, 1988). 
Promoter activity is given as a percentage of CAT activity relative to that obtained 
from a fragment of the HBV genome representing nucleotide positions 1010-1310 






cells. In this system a promoter region deleted to nucleotide 1232 (removing the SV40-
homologous region) retained transcriptional activity, albeit at a level three-fold lower than 
maximum, while removal of a further 20 nucleotides yielded one-tenth of the original 
promoter activity indicating that sequences downstream of the region of homology are 
important for promoter activity. 
In vitro binding of protein factors extracted from the nuclei of human hepatoma cells 
(I-IepG2) has been identified both within and outwith the SV40-homologous region 
(Raney et at, 1989). One of the factors binding outwith this region has been identified 
as nuclear factor 1 (NF-1) (Nagata et at, 1982) which binds to nucleotide positions 1064-
1084 (Shaul ci at, 1986), although this binding site does not appear to be important for 
preS2/S promoter activity in differentiated hepatoma cells (De-Medina ci at, 1988). 
The relative amounts of the various forms of HBsAg are regulated, in part, by the 
differential activities of the two subgenomic mRNA promoters. The preS2/S promoter 
displays much higher activity than the preSi promoter in various systems including: 1) 
HBV infected liver (Cattaneo ci at, 1984), 2) human hepatoma cells transiently (Chang 
ci at, 1987; Yaginuma ci at, 1987b) or stably (Sureau ci at, 1986) transfected with the 
complete HBV genome and producing virus, 3) human hepatoma cells transiently 
transfected with a plasmid construction containing the complete preSl mRNA 
transcription unit (Bulla and Siddiqui, 1988,1989; Yuh and Ting, 1990), or 4) the HCC cell 
line, PLC/PRF/5 (Ou and Rutter, 1985). In the latter system, mRNAs initiating under 
control of the preS2/S promoter represented 98% of the total surface antigen message. 
In contrast, the two subgenomic mRNA promoters, isolated from one another and fused 
to a reporter gene, display similar transcriptional activity (Siddiqui ci at, 1986; Antonucci 
and Rutter, 1989; Bulla and Siddiqui, 1989; Chang and Ting, 1989). Bulla and Siddiqui 
(1989) have described a negative regulatory region within the preSl coding region 
(nucleotide positions 1219-1280), that, when removed, greatly increases transcription from 
the preSi promoter upon transient expression in HepG2ells. In addition to the systems 
described above, the preSi promoter shows much lower activity than the preS2/S 
promoter upon transient transfection of HepG2 cells with a plasmid construction 
containing a reporter gene inserted into the complete HBV genome immediately 
downstream of one promoter or the other (Raney ci at, 1990). If the negative region 
described by Bulla and Siddiqui (1989) is functioning in this system, it is doing so at a 
distance of —3 kb as opposed to —300 bp in the native configuration. 
The subgenomic mRNA promoters in isolation (De-Medina et at, 1988; Chang and 
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Ting, 1989) or in the context of the complete HBV genome (Chang and Ting, 1989: 
Raney et at, 1990) show preferential activity upon transfection into differentiated 
hepatoma cells, compared to undifferentiated hepatoma cells or other cell types. The 
preferential activity, however, is far more pronounced for the preSi promoter, and this 
observation may be reflected by the capacity of non-hepatic cell lines transfected with 
HBV DNA to secrete spherical HBsAg particles containing middle- and major-S 
polypeptides but not HBsAg filaments composed of higher quantities of large-S 
polypeptides (Dubois et at, 1980; Stratowa et at, 1982; Siddiqui, 1983; Stenlund et at, 
1983; Wang et at, 1983; Zelent et at, 1987). In addition, analysis of HBV transcripts in 
the tissues of transgenic mice containing the complete HBV genome incorporated into 
their chromatin, revealed preSi mRNA exclusively in the liver while preS2/S mRNAs are 
found in many other tissues (Araki et at, 1989; Farza et at, 1989). 
Protein-binding sites in the preSi promoter were analysed by DNase I protection 
(Chang, H.K. et at, 1989; Zhou and Yen, 1991) and by alteration of mobility in acrylamide 
gel (Zhou and Yen, 1991). Binding sites for the ubiquitous transcription factor Oct-1 
(octamer-binding protein 1) and liver-specific factor HNF-1 (hepatocyte nuclear factor 1) 
have been identified at nucleotide positions 846-853 and 818-829 respectively, which 
contain strong sequence homology to other known binding sites for these factors. 
Deletion of either factor binding site yielded reduced transcriptional activity from the 
preSi promoter region (Chang, H.K. et at, 1989; Raney et at, 1990; Zhou and Yen, 
1991). HNF-1 was identified by virtue of its ability to bind to a common sequence motif 
in the promoter regions of several liver-specific genes, for example, albumin, a1-
antitrypsin and a-_fetoprotein i (reviewed by Johnson, 1989). This factor is expressed 
exclusively in liver cells and its requirement for preSl promoter activity may contribute 
to the hepatocyte-specific expression of HBV virion as large-S forms comprise up to 20% 
of the HBsAg polypeptides in the virion envelope. 
1.4.2 Genomic mRNAs 
The genomic mRNAs are greater than one genome-unit in length and are produced 
by read-through of the polyadenylation signal by RNA polymerase II. As with the various 
forms of HBsAg, the production of core and preC/core polypeptides is regulated by 
heterogenous initiation of the genomic mRNAs. The predominant 5 '  end of genomic 
mRNAs isolated from HBV infected liver has been mapped to nucleotide position 3100+2 
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(Will a aL. 1987), which is immediately downstream of the pre-core initiation codon (this 
transcript will be referred to as core mRNA). Minor, heterogenous initiation sites were 
mapped upstream of the pre-core start codon (the preC/core mRNAs). The initiation site 
at nucleotide 3100 was confirmed in mRNA extracted from HuJ47 cells transiently 
transfected with the complete viral genome and producing virus (Yaginuma et aL, 1987b), 
although in this system, the transcripts initiating upstream of the preC start codon 
represented roughly half of the genomic mRNAs. 
As described for the preS2/S mRNAs, no "TATA-box" homology is found within 150 
bp upstream of the core mRNA initiation site. The functional core promoter has been 
identified in the region 2975-3100 by fusion of varying fragments of HBV DNA to 
reporter genes (Honigwachs et aL. 1988; Yaginuma and Koike. 1989; Lopez-Cabrera et 
aL, 1990). The importance of this region for production of virus particles by transiently 
transfected hepatoma cells was confirmed by Yaginuma and Koike (1989). 
The core promoter in isolation (Honigwachs et aL. 1988; Lopez-Cabrera et aL, 1990) 
or in the context of the complete HBV genome (Raney a aL, 1990) fused to a reporter 
gene shows preferential activity upon transfection into differentiated hepatoma cells 
compared to undifferentiated hepatoma cells or other cell types. This may be reflected 
by the low abundance of genomic mRNAs relative to preS2/S mRNAs in rodent cells 
transfected with the complete HBV genome in comparison to the relative levels in 
infected liver tissue (Gough, 1983; Cattaneo et aL, 1984). In addition. HBV virion 
production by transfection of cells with the native HBV genome is limited to 
differentiated hepatoma cells, however, transcription of the genomic mRNAs under 
control of the human metallothionein promoter permitted virion production in HeLa cells 
(Junket et aL, 1987). 
Liver-specific transcription is attributable, in part, to the binding of liver specific 
nuclear factors (along with ubiquitous nuclear factors) to the core promoter region 
described above (Karpen et aL, 1988; Yaginuma and Koike, 1989; Lopez-Cabrera et aL, 
1990). One of these liver-specific factors is C/EBP (discussed in greater detail in Chapter 
4) which binds at up to five places in the core promoter and stimulates transcription from 
this region fused to a reporter gene or in the context of the preC/core coding sequences 
(Lopez-Cabrera et aL, 1990). Stimulation of core promoter activity was only observed 
with low concentrations of C/EBP, and the authors hypothesize that at low concentration, 
C/EBP only interacts with particularly high affinity binding sites, while at higher 
concentrations C/EBP may bind to other sites thereby blocking the binding of other 
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factors that are important for activating transcription. 
The core mRNA encodes the core and polymerase polypeptides, while the preC/core 
mRNAs encode the HBeAg precursor (Jean-Jean et al., 1989a) and the polymerase 
polypeptide, although polymerase is less efficiently translated from this mRNA (Ou et all, 
1990). Genetic analysis in the DHBV model system indicated that the pol-gene product 
is not produced initially as a core/polymerase fusion protein but by internal initiation of 
translation (Chang, L.J. et al., 1989; Schlicht et al., 1989b). A mutant DHBV genome 
containing a stop codon in the core ORF could produce the pol-gene product to 
complement a mutant genome containing a stop codon in the polymerase ORF allowing 
production of core particles with endogenous polymerase activity. Internal initiation of 
translation for the po/-gene product has also been reported in the HBV system (Jean-Jean 
et all, 1989b; Roychoudhury and Shih, 1990). 
1.4.3 HBV enhancers 
Enhancers are segments of DNA that influence the transcriptional activity of a 
promoter region; they can function from a distant position and in either orientation 
relative to the promoter. Two regions of the HBV genome have been identified that 
display enhancer function. The first region that was identified (referred to as the HBV 
enhancer) is located at nucleotide positions 2300-2550, while a second enhancer region 
(referred to as HBV enhancer II) has been described more recently and is located in the 
same region as that identified for the core promoter (nucleotide positions 2950-3100). 
1.4.3a The HBV enhancer 
The HBV enhancer was initially identified by Shaul et all (1985) who observed 
increased transcriptional activity from an HBV DNA segment (nucleotide positions 2683-
2966) fused to a reporter gene when the sequences 2243-2682 were included in a 5 '
position in either orientation. The region of the HBV genome that served as a promoter 
for transcription in these studies may not be relevant to viral transcription in the infected 
hepatocyte as it is upstream of the region defined as the core promoter. However, the 
enhancer region was also able to stimulate transcription when fused to well defined, 
heterologous promoters including the SV40 early promoter (Shaul et al., 1985; Tognoni 
et all, 1985; Elfassi, 1987; Vannice and Levinson. 1988; Chang and Ting, 1989: 
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Honigwachs et at, 1989; Ostapchuk et at, 1989; Patel et aL, 1989), the herpes simplex 
virus thymidine kinase (it) promoter (Antonucci and Rutter, 1989; Yee, 1989), and the 
human -globin promoter (Ben-Levy et at, 1989). Collectively these studies, along with 
others described below, have defined the HBV enhancer within nucleotide positions 2300-
2550. 
Transcription from all of the HBV promoters is influenced by the viral enhancer. An 
HBV DNA fragment encompassing nucleotide positions 2244-2635 fused to the CAT 
reporter gene directed transcription with heterogenous start sites at positions 2605±15 
(Treinin and Laub, 1987) indicating a promoter activity juxtaposed to the X ORF. 
Transcription from this promoter, however, was influenced by sequences greater than 100 
bp upstream from the site of transcription initiation. Deletion of HBV enhancer 
sequences, 2244-2396, greatly reduced transcriptional activity, while further deletion to 
2499 abolished this function indicating that the X promoter is dependent on the presence 
of enhancer sequences. 
Both subgenomic mRNA promoters isolated from one another and fused to a reporter 
gene are influenced by the viral enhancer (Faktor a at, 1988; De-Medina et at, 1988; 
Antonucci and Rutter, 1989; Chang and Ting, 1989). In addition, deletion of the 
enhancer region from a plasmid construction containing the transcription units for both 
subgenomic mRNM yielded reduced HBsAg secretion from transiently transfected 
hepatoma cells compared to that observed with the parent plasmid (Bulla and Siddiqui, 
1988; Faktor a at, 1988). Transcription from the core promoter (as defined above) fused 
to the CAT gene is activated by the presence of the enhancer region (Jamee! and 
Siddiqui, 1986; Antonucci and Rutter, 1989; Honigwachs a at, 1989; Patel et at, 1989). 
As for HBsAg, secretion of HBeAg from hepatoma cells transiently transfected with a 
plasmid construction containing the preC/core ORF was higher when the enhancer was 
present in its native position (Roossinck et at, 1986). The effect of the enhancer on 
production of all viral transcripts has been confirmed in hepatoma cells transiently 
transfected with the complete HBV genome and producing virus (Hu and Siddiqui, 1991). 
Deletion of the enhancer region (2246-2588) reduced initiation of transcription from all 
of the viral promoters. 
The contribution of the enhancer region to the liver-specific expression of viral 
transcripts in under debate. The following investigations were all carried out with 
transcriptional control regions fused to a reporter gene, and, in considering this issue, I 
will only cite studies in which transcription from a plasmid construction containing the 
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enhancer was directly compared to that from a construction in which the enhancer was 
region was not present. Patel et at. 1989 noted that the enhancer functioned to increase 
transcription when fused to the SV40 early promoter upon transfection into differentiated 
hepatoma cells but not into HeLa cells. Activity exclusively in liver cells was also 
observed for the enhancer in association with the tIc promoter (Yee. 1989) or the preSi 
or preS2/S promoters of HBV (Antonucci and Rutter, 1989; Patel ci at. 1989). 
Employing a plasmid construction similar to the HBV enhancer/SV40 early promoter 
construction used above (Patel ci at. 1989), Ostapchuk ci at (1989) have observed 
enhancer activity in HepG2, HeLa and P9 (embryonal carcinoma) cells. This result 
confirmed other observations of activity in many different cell types of the HBV enhancer 
in association with the SV40 early promoter (Elfassi ci at, 1987; Vannice and Levinson, 
1988). Chang and Ting (1989) noted that the enhancer fused to the preSi promoter 
showed preferential activity in differentiated hepatocytes compared to poorly 
differentiated hepatocytes or other cell types. However, this difference was not observed 
when the enhancer was fused to the preS2/S promoter. 
Many factors may contribute to the discrepancy in the results obtained regarding the 
liver-cell specificity of the HBV enhancer. These include, differences in the DNA 
fragments used to encompass the enhancer and the placement of the enhancer relative 
to the initiation site in these manufactured transcriptional control regions. Transient 
transfection of non-hepatoma cells (HeLa) or poorly differentiated hepatocytes (SkHepl) 
with the complete HBV genome resulted in reduced secretion of HBsAg and HBeAg 
compared to differentiated hepatoma cells, HuH7 and HepG2 (Hu and Siddiqui, 1991). 
However, deletion of the enhancer region (nucleotide positions 2246-2585) resulted in 
reduced antigen secretion by all cell types suggesting that the liver-cell specificity of the 
enhancer may be limited. - 
The regions of the HBV enhancer and upstream sequences that bind nuclear proteins 
are shown in figure 1.8. The sites originally identified were UE1 (upstream enhancer 
region 1), UE2, and UE3 which bound liver-specific factors and the E site which bound 
factors extracted from both liver and HeLa cells (Shaul and Ben-Levy, 1987). The binding 
of liver-specific protein factors to the UE2 site has been confirmed in an independent 
study (Patel ci at, 1989) although the particular factors that bind to this site and to UE3 
have not been identified. The IJEl site binds purified, recombinant, liver-specific C/EBP 
(Landschulz ci at, 1988a) and, in addition, binding of proteins to this site could be 
efficiently competed by an oligonucleotide comprising an HNF-1 binding site (Patel ci at, 
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FIGURE 1.8 Nuclear protein binding sites within the HBV enhancer region. 
A linear representation of the HBV enhancer (2300-2550) and upstream flanking 
sequence is shown. Binding regions are indicated by thick lines, and each region is named 
as designated by the authors. * denotes a site bound by the purified factor that is 
indicated, or that binding of nuclear proteins to this site was competed by the authentic 
factor binding site. Sites that bound proteins present only in liver cells are indicated by 
the dashed line. 
References; nucleotide positions of HBV fragments used for binding assays; type of 
binding assay. 
Shaul and Ben-Levy (1987); 2107-2654; DNase I protection. 
Ben-Levy et at (1989); 2395-2654; DNase I protection. 
Patel et at (1989); 2246-2588; DNase I protection. 
Karpen et aL (1988); 2362-2654; methylation interference. 
Ostapchuk et aL (1989); 2397-2503; DNase I protection: 
Dikstein a at (1990b); 2395-2515; DNase I protection. 
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1989). 
The E site was initially identified by its ability to bind protein factors in extracts from 
differentiated hepatocytes (Shaul and Ben-Levy. 1987). Proteins that bind to this site are 
also present in HeLa cells and other cell types (Shaul and Ben-Levy, 1987; Ben-Levy et 
at, 1989: Patel et at. 1989). Purified, recombinant, C/EBP binds to this site (Landschulz, 
et at, 1988a: Dikstein et at, 1990b). The proteins present in other cell types that bind to 
the E site have not been identified, although a polypeptide with DNA-binding properties 
homologous to C/EBP has been isolated from HeLa cells (Clark et at, 1988). In a 
chromatography fraction of liver-cell nuclear extract, which lacked a protein binding to the 
complete E site, a second protein was detected which bound to the DNA sequence 2463-
TGTT1'-2467 (TGT3) within the E element (Ben-Levy et at, 1989). The TGT3-binding 
protein was also observed when DNase I protection assays were carried out with a 
mutated E site that was unable to bind C/EBP (Dikstein etaL, 1990a). This motif, 
together with three 3' flanking nucleotides are completely conserved in the transcriptional 
control regions of three genes expressed exclusively in liver cells, a-fetoprotein, a 1-
antitrypsin and albumin (Shaul and Ben-Levy, 1989). 
The transcription factor AP-1 (activator protein 1) was originally identified as the 
nuclear protein in HeLa-cell extracts that bound to a sequence motif in the human 
metallothionein promoter and SV40 enhancer which was known to confer responsiveness 
to transcriptional activation by tumour promoting phorbol-ester compounds (Lee et at, 
1987). AP-1 is functionally constituted by a homodimer of the c-jun gene product or a 
heterodimerof the c-jun and c-fos gene products. An oligonucleotide comprising an AP-1 
binding site efficiently competed for factors binding to an oligonucleotide representing the 
E-binding site implicating this factor in binding to the E site which contains sequence 
homology to the AP-1 binding consensus (2470-TGACGCA-2476). 
Synthetic multimers of the E site placed downstream of the 3-globin transcription unit 
function to enhance transcription upon transfection of this plasmid construction into 
hepatoma cells. Cotransfection of cells with this plasmid construction and one expressing 
c-Jun resulted in increased transcription under control of the -glohin promoter/E-site 
complex (Faktor et at, 1990). The -g1obin promoter alone was not activated by c-Jun. 
functionally implicating this factor in interacting with the E site. In addition, transcription 
directed by the -globin promoteriE-site complex could be stimulated by treatment of 
transfected cells with phorbol ester (Ben-Levy et at, 1989) providing further evidence for 
the interaction of AP-1 with this site. The multimerised E site also served as a target for 
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transactivation by HBxAg (Faktor and Shaul, 1990; see Chapters 4 and 6 for further 
discussion). - 
When the complete HBV enhancer was placed downstream of the 3-globin 
transcription unit, a mutation within the E site, which blocked binding to C/EBP (Dikstein 
ci at, 1990b), also blocked enhancer activity (Dikstein et at, 1990a) indicating a functional 
consequence of C/EBP binding. Transcription from the parent plasmid construction 
containing an intact enhancer was susceptible to stimulation by C/EBP provided in trans 
at low but not at high concentration (Dikstein ci at, 1990b). At high concentrations. 
recombinant C/EBP binds to additional sites in the enhancer (Dikstein et at, 1990b) 
(nucleotide positions 2430-2451 and 2451-2470). The mechanism proposed by Lopez-
Cabrera • and her colleagues, who observed the same phenomenon for activation of 
transcription by C/EBP from the core promoter could be in effect in this system as well. 
Binding of proteins to nucleotide positions 2432-2444 could be competed by an 
oligonucleotide representing DNA sequence from the polyoma virus enhancer which binds 
the ubiquitous nuclear factor EF-C (Ostapchuk et at, 1989; Ben-Levy et at. 1989). 
Deletion or mutation of this site dramatically reduced transcriptional activity of the 
enhancer in association with a heterologous promoter (Ostapchuk ci at, 1989: Dikstein 
ci at, 1990a). 
The other sites in the HBV enhancer region shown to bind a purified protein are the 
NF-1 binding sites defined by Ben-Levy et at (1989)(figure1.8b). Mutation of the 
downstream NF-1 site reduced transcriptional activity while mutation of the upstream site 
had little effect (Dikstein et at, 1990a). Patel ci at (1989) however, did not detect 
binding of purified NF-1 to the enhancer, casting confusion on the nature of the 
protein(s) mediating transcriptional activation at the downstream NP-i binding site 
defined by Ben-Levy ci' at (1989). 
The HBV enhancer is unusual in that it is transcribed as part of the mature viral 
messages for HBsAg and HBcAg and is contained within the coding region for the viral 
polymerase. Its presence within a mature transcript may be unique to the HBV enhancer 
among all eukat otic enhancer regions although, a sequence within the coding region of 
adenovirus Ela protein shows some enhancer properties (Osborne ci at, 1984). The only 
enhancer property that has been called into question for the HBV enhancer is its 
orientation independence. Vannice and Levinson (1988) showed that the HBV enhancer 
functions in only its native orientation when placed in the transcribed region in association 
with a heterologous promoter. The enhancer is strategically placed between the most 
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active HBV promoters and affects the production of all viral transcripts. Evidence for 
binding of protein factors to the enhancer in vivo is provided by template competition 
experiments in which transcription from a plasmid construction containing the enhancer 
in association with either the core promoter (Karpen et all, 1988) or the preS2!S promoter 
(this study) is inhibited in hepatoma cells upon cotransfection with a plasmid construction 
containing the enhancer region. In addition. DNase I hypersensitive sites have been 
detected in the HBV enhancer region contained in DNA extracted from the liver of HBV 
transgenic mice indicating the presence of proteins bound to this region (El-Ghor and 
Burk, 1989; Pourcel et at, 1990). 
1.4.3b HBV enhancer II 
The core promoter region was defined by Yee (1989) as encompassing nucleotides 
2966-3056. This 88 bp fragment (HBV enhancer II) enhanced the transcriptional activity 
of the tk promoter fused to the CAT gene when placed 5' or 3' to the transcription unit 
and in either orientation. Stimulation of transcription by enhancer II occurred exclusively 
in differentiated hepatoma cells compared to other cell types. Enhancer II also stimulated 
transcription from the SV40 early promoter fused to the CAT gene in an orientation and 
position independent manner, and it could increase transcription from either of the HBV 
subgenomic mRNA promoters fused to the CAT gene when placed downstream Of the 
transcription unit in its native orientation (Yuh and Ting, 1990). As above, the activity 
of enhancer II in these studies was specific to differentiated hepatocytes. In contrast to 
the results obtained with the subgenomic promoters isolated from each other, the 
enhancer II region activated the preS2/S promoter but not the preSl promoter when 
these elements were present in their native configuration (Zhou and Yen, 1990). The 
mechanism governing preferential activation of a particular subgenomic promoter has yet. 
to be investigated. 
1.4.4 Glucocorticoid receptor binding 
The glucocorticoid receptor (GR) functions as a transcription factor after binding 
ligand. GR binding sites have been identified in the transcriptional control regions of a 
variety of eukaryotic genes including the human growth hormone (Moore ci all, 1985) and 
human metallothionein promoters (Karin et at, 1984) and the mouse mammary tumour 
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virus LTR (Scheidereit a' aL, 1983). A binding site for purified rat-liver GR has been 
identified within the surface ORF at nucleotide positions 16214650 (Tur-Kaspa et all, 
1988). This site in isolation did not serve as a target for stimulation of transcription by 
dexamethasone (a glucocorticoid analog), however, a complex of the GR binding site and 
the HBV enhancer conferred susceptibility to dexamethasone treatment. 
1.5 Virus Reproduction 
1.5.1 Attachment to heatocyte 
The tissue- and host-specificity of hepadnaviruses is attributed in part to the preS 
regions of the middle- and large-S polypeptides which can mediate hepatocyte attachment 
by the HBV virion. The species specificity of individual members of the hepadnavirus 
family may result from the low level of homology between pre-S regions relative to the 
other viral ORFs (reviewed by Acs and Price, 1990). 
In 1979, Imai a' aL showed that the gp36 form of HBsAg, which is now known to 
contain preS2 sequences, could bind gluteraldehyde-polymerised human serum albumin 
(Gp-HSA) while the p24 and gp27 forms encoded by the surface gene alone could not. 
A polypeptide fragment of 8 kd can be created by cleavage of gp33 with cyanogen 
bromide. This fragment contains 55 amino acids derived from the preS2 region and could 
bind to Gp-HSA but not to polymerised serum albumin from other species (Machida et 
aL, 1984). Additional evidence that the binding of Gp-HSA was mediated by the preS2 
region was the inability of HBsAg particles composed exclusively of major-S polypeptides 
to do so (Persing a' aL, 1985). Thung and Gerber (1981) showed that only hepatocytes 
from humans and chimpanzees could bind Gp-HSA on their cell surfaces. Since this 
binding specificity parallels the host specificity of HBV, a model was proposed for the 
attachment of HBV to hepatocytes indicating that polymerised serum albumin serves as 
a bridge between polypeptide sequence in the preS2 region of HBsAg on virus particles 
and receptors on the surface of hepatocytes. 
Several observations have cast doubt on this model (reviewed by Ganem and 
Varmus,1987). Firstly, polymerised serum albumin is present in sera from patients with 
liver disease whereas only monomeric forms are present in the circulation of healthy 
individuals. These forms do not bind UBsAg, and thus how could initial infection of 
hepatocytes take place? Secondly, naturally polymerised forms of serum albumin do not 
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bind HBsAg; this property is limited to albumin polymerised with gluteraldehyde (Yu et 
aL, 1985). Thirdly, it has been shown that a 27 amino acid synthetic polypeptide derived 
from residues 10-36 of the preSi region can bind directly to hepatocyte receptors, and 
antiserum raised against this peptide inhibited attachment of hepatoma cells to 
immobilised HBsAg particles purified from human serum (Neurath et at. 1986b). When 
recombinant HBsAg particles produced in yeast were examined for the ability to bind 
liver-cell plasma membranes, only particles containing large-S polypeptides had this 
capacity (Pontisso et at, 1989), supporting the observation that the prçSl domain can 
directly mediate binding to hepatocytes. 
1.5.2 Genome replication 
A model for replication of the HBV genome is based on information collected about 
the replication of HBV itself and of the animal hepadnaviruses. Detailed reviews are 
provided by Seeger et at (1986). Ganem and Varmus (1987) and Robinson (1990), and 
figure 1.9 shows a schematic representation of the replication process. 
Upon entry of the HBV genome into the nucleus of the infected hepatocyte, the first 
step in replication is the transition of the genome to a covalently-closed circular, 
supercoiled DNA molecule. This involves several steps: 1) removal of the 
oligoribonucleotide from the 5' end of the plus strand and removal of the protein 
covalently attached to the 5' end of the minus strand; 2) trimming of the eight terminally-
redundant nucleotides from the 5 '  end of the minus strand; 3) completion of the plus 
strand gap by DNA polymerase; 4) ligation of the 5' and 3' ends of the plus strand and 
of the minus strand: 5) introduction of superhelical turns. The minus strand of the HBV 
DNA molecule Serves as template for transcription of the pregenome RNA, which is 
greater than one genome-unit in length. 
There are several independent pieces of evidence for reverse transcription of the 
minus strand DNA from this pregenome RNA template. 1) Replication is not 
semiconservative; the product of replication (the HBV genome) is asymmetric consisting 
of one long strand and one short strand. 2) Isolated core particles can synthesize minus 
strand DNA in the presence of the DNA polymerase inhibitor, actinomycin D, and the 
product is an RNA-DNA hybrid (Summers and Mason, 1982). 3) The deduced amino 
acid sequence of the polymerase ORF shows homology to known reverse transcriptases 
(Toh et at, 1983), and a polypeptide with this enzymatic activity is encapsidated in the 
43 
FIGURE 1.9 Replication of the HBV genome. 
1). A linear representation of the pregenome RNA. (+) Indicates polarity of the HBV 
sense strand DNA. 2) Protein primed reverse transcription of minus-strand DNA. 3) 
Degradation of the RNA component in the RNA-DNA hybrid by RNase H, leaving an 
oligoribonucleotide hybridised to the DR1 sequence at the 3' end of the minus strand (-). 
4) Translocation of the oligoribonucleotide to DR2 at the 5' end of the minus strand. 
5,6) Synthesis of plus strand DNA primed by the oligoribonucleotide. Key to 
abbreviations and symbols: R = terminal redundancy in the pregenome RNA; DR = 
direct repeat; (A)n = polyadenylated 3' terminus of the pregenome RNAA= genome-
linked protein; r = eight nucleotide terminal redundancy in minus strand DNA; ft' = 
oligoribonucleotide. Adapted from Seeger et at (1986). 
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HBV virion (Bavand and Laub, 1988; Bavand et at, 1989). Pregenome RNA is packaged 
into viral core particles where it serves as template for reverse transcription of minus 
strand DNA (Enders a' at. 1987). Only core mRNAs and not preC/core mRNAs are 
packaged as pregenome RNA although both contain the encapsidation signal described 
above (section 1.3.3). The encapsidation signal is translated in the pteC/core mRNAs and 
•the progress of ribosomes through this region may block recognition of the signal (Nassal 
et at, 1990). 
The 5' end of minus strand DNA has been mapped tdiiudlitdè position .3108 within 
the DR1 sequence (Will a' at, 1987). Viral precedent (reviewed by Wimmer, 1982) 
indicates that the protein found covalently attached to the 5' end of the minus strand 
DNA primes synthesis of that strand. Reverse transcription proceeds along the length of 
the pregenome mRNA from the DR1 sequence at the 3' end of the template through to 
position 3100 which is the 5' nucleotide of the template. This creates the eight nucleotide 
terminal redundancy in the minus strand. 
The 5' end of the plus strand DNA has been mapped to nucleotide position 2882 at 
the 5' side (in the sense of the minus strand) of the DR2 sequence (Will et at, 1987). 
The capped oligoribonucleotide that is attached to this end of the strand contains the 11 
DR nucleotides, but 6 flanking nucleotides are derived from DR1 (Lien et at. 1986). The 
following model has been proposed to explain this phenomenon. The RNA component 
of the RNA-DNA hybrid produced by reverse transcription of the minus strand is 
degraded by RNase H. A capped oligoribonucleotide derived from the 5' end of the 
pregenome mRNA is left hybridised to the 3' DR1 sequence of the minus strand, and it 
is subsequently translocated to hybridise with the DR2 sequence at the 5' end of this 
strand. 
Synthesis of the plus strand is primed by the oligoribonucleotide. The viral DNA• 
polymerase must accomplish a strand transfer at the nick in the minus strand to continue 
synthesis of the plus strand. This may be facilitated by circularisation of the minus strand 
mediated by base-pairing of its terminally-redundant nucleotides. Synthesis of the plus 
strand is constrained in some way as to inhibit its completion which may be due to the 
concentration of nucleotides available within the nucleocapsid where this synthesis takes 
place. 
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1.5.3 Virus assembly 
The initial event in assembly of the virus particle is insertion of HBsAg into the 
membrane of the ER (Patzer et at, 1986; Eble et at, 1987). A model for the 
conformation of the major-S polypeptide indicates that it contains two transmembrane 
domains resulting in a loop on the cytoplasmic side of the ER, while both termini are 
within the lumen of the ER (Eble et at, 1987). Following its association with the ER 
membrane HBsAg does not become associated with any subsequent intracellular organelle 
membrane or the plasma membrane (Patzer et at, 1986) 
HBcAg forms core particles containing pregenome RNA within the cytoplasm, and the 
following model has been proposed for association of core particles with HBsAg for 
formation of the viral envelope (Ou et at, 1986). The pre-C/core polypeptide becomes 
associated with the ER membrane. Most of this antigen is translocated completely across 
the membrane where it is processed to HBeAg and secreted, while a small fraction may 
not get completely translocated but becomes associated with HBsAg that is also embedded 
in the membrane. The highly basic carboxyl-terminus of the membrane associated 
preC/core protein may remain on the cytoplasmic side of the ER where it associates with 
core particles. The core particle then buds into the lumen of the ER, enveloped by the 
ER membrane and associated HBsAg to forma virus particle. Here, the lipid composition 
of the envelope is altered from that of the original ER membrane (Eble et at. 1986). 
Envelope protein is glycosylated in the golgi apparatus, and virus particles are secreted 
from the cells. 
1.6 HBV Infection and Hepatoma 
Several lines of evidence indicate a strong correlation between chronic HBV infection 
and the development of 11CC (reviewed by Ganem and Varmus, 1987). 1) The 
geographical distribution of areas where chronic HBV infection is prevalent coincides with 
that for high incidence of HCC (Szmuness, 1978). 2) Individuals chronically infected with 
HBV are subject to more that 100-fold increase in the risk of developing 11CC (Beasley. 
1981). 3) HBV DNA is found integrated in a high proportion of 11CC tumour tissues and 
in cell lines derived from them. 
The latent period between primary HBV infection and the development of 11CC is 
very long (tens of years), and potential causal links between infection and neoplasia that 
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Were initially investigated were derived from examples of slow-transforming. RNA tumour 
viruses. These viruses, for example avian leukosis viruses and murine leukaemia viruses, 
activate specific cellular oncogenes (proto-oncogenes) by integration of viral DNA in the 
flanking sequence in the host chromosome. Extensive analysis of the integrated 
configuration of HBV DNA in HCC tumour tissues and tumour-derived cell lines has 
revealed no specific integration site in the host chromosome although particular 
integration events in or near known proto-oncogenes (or potential proto-oncogenes) have 
been observed. Dejean et at (1986) described a unique HBV integration event in which 
the pre-S region of HBV was fused in-frame to a cellular sequence with homology to the 
v-erb-A oncogene, however, altered expression of the fusion gene was not established. 
A single HBV integration event within a gene homologous to the cyclin A gene has been 
documented (Wang et at, 1990). Cyclin A is involved in the G2/M transition of the cell-
cycle and the authors speculate that interference with the function of this gene could 
affect the regulation of cell growth. In the woodchuck model-system, integration of WHV 
DNA adjacent to c-myc (Hsu et at, 1988) or N-myc (Fourel et at, 1990) loci, resulting in 
transcriptional activation of the proto-oncogene, has been observed in a relatively high 
proportion of HCC tumours, however a similar event is yet to be reported in humans. 
Integrated viral DNA may contain deletions and rearrangements, however, junctions 
between viral and cellular DNA are commonly located in the single stranded gap region 
of the viral genome (Koshy et at, 1983). While no HBV ORF is universally maintained 
in HCC tissues, a large portion of the X ORF and upstream sequences are maintained in 
many cloned integration sites (Dejean et at, 1984; Miyaki et at, 1986: Nagaya et at, 1987; 
Yaginuma et at, 1987a). This observation led to the hypothesis that HBxAg encoded by 
integrated HBV sequences may contribute to cellular transformation in a proportion of 
HCC cases. To test this hypothesis, NIH3T3 cells were stably transfected with the X-gene 
under control of the SV40 early promoter/enhancer complex (Shirakata et at, 1989). 
Transfected cells that expressed a high amount of X transcript displayed transformed 
growth characteristics in culture and induced tumours in nude mice. Additional evidence 
for the neoplastic potential of HBxAg is cited by Ganem (1990); HCC has been induced 
in two lines of transgenic mice harbouring the X-gene under control of its own 
promoter/enhancer complex, although this effect was not observed for transgenic mice in 
which HBxAg expression was under control of a heterologous promoter (Lee et at, 1990). 
As viral transactivator proteins have oncogenic potential, for example adenovirus Ela. 
SV40 large T (reviewed by Jones et at, 1988) and HTLV1 40tax (reviewed by Varmus. 
1988), the persistence of transactivating function encoded by integrated HBxAg sequences 
was examined. A fusion protein of HBxAg (amino acid residues 1-142) and 78 cellular 
residues encoded by DNA cloned from HCC tissue retained the capacity to transactivate 
the SV40 early promoter/enhancer complex or the HTLV1 LTR fused to the CAT gene 
(Wollersheim ci at, 1988). The cloned HCC DNA produced a transcript initiating within 
the X promoter and terminating within the cellular sequence upon transient transfection 
into hepatoma cells, indicating that the fusion protein could have been expressed in the 
tumour cells. In addition, the potential importance of HBxAg in sustaining neoplasia was 
highlighted by conservation of the integrity of this ORF while the surface and polymerase 
ORFs in the integrated DNA were destroyed by point mutations. The maintenance of 
transactivating capacity has also been demonstrated for a fusion protein of HBxAg (amino 
acid residues 1-149) and five cellular residues encoded by aDNA clone isolated from 
chronic hepatitis tissue (Takada and Koike, 1990). The mechanism by which the 
transactivating function of HBxAg may contribute to the development of neoplasia is 
considered in detail in Chapter 6, however, transactivating capacity of proteins encoded 
by integrated HBV DNA is not limited to the product of the X ORF. HBV DNA and 
flanking sequence, cloned from an integration site in a hepatoma cell line (Kekule ci at, 
1990) or HCC tissue (Caselmann et at, 1990), encoded a transcriptional transactivator 
upon cotransfection into hepatoma cells with a plasmid construction containing the SV40 
early promoter/enhancer complex fused to CAT. The sequence of the DNA cloned from 
the integration sites revealed an ORF encompassing viral sequence fused within the 
surface ORF to cellular DNA. A frameshift mutation in the preS2, region of this ORF 
abolished transactivating capacity, while the preSi region was not essential for this 
function. Truncated middle-S polypeptides containing as few as 21 amino acid residues 
of the surface ORF or as many as 139 functioned as transactivators while the full length 
middle-S polypeptide did not. Interestingly, in the clone derived from HCC tissue, the X 
ORF was disrupted by a frameshift mutation following amino acid residue 117 which 
abolished its transactivating capacity suggesting that the function of the middle-S 
transactivator may be important in maintaining neoplastic growth. 
While cis or trans effects from integrated HBV DNA on transcription of a cellular 
gene may contribute to the development of HCC, it is also possible that the liver 
inflammation associated with chronic HBV infection may be sufficient to explain the 
correlation between HBV infection and hepatoma. The development of HCC has been 
associated with other inflammatory conditions including schistosomiasis and alcoholic 
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cirrhosis. All of these conditions result in regenerative hyperplasia increasing the risk of 
mutation through normal replication processes. An experimental model of this 
phenomenon has been provided by transgenic mice in which overexpression of the large-S 
polypeptide leads to accumulation of HBsAg aggregates in the hepatocyte and eventual 
necrosis (Chisari et aL, 1989). The subsequent regenerative hyperplasia has been shown 
to correlate with the development of 11CC in these mice. 
A current model indicates that cancer arises through a multistep process resulting in 
aberration of more than one cellular process (reviewed by Hunter, 1991). Therefore, it 
is possible that all of the causal associations discussed above can contribute to the cascade 
of events culminating with the development of HCC. 
1.7 Aims of this Thesis 
When this research project was initiated in 1986, serological evidence was just 
emerging for the production of HBxAg during HBV infection. In addition, the 
importance of the immune response to internal antigens of HBV in mediating protection 
from subsequent infection had been demonstrated (Murray et aL. 1984). The humoral 
immune response to HBxAg was investigated by expressing fragments of HBxAg in E. co/i 
fused to the carboxyl-terminus of -galactosidase and assessing their reactivity with anti-
HBxAg antibodies in the serum of an HBV-infected chimpanzee or of a rabbit modulated 
with HBxAg purified from E. coil (Chapter 3). In antisera raised against the native 
antigen, the presence of antibodies directed against particular portions of a molecule can 
give an indication of its structure when presented to the immune system. 
Concurrent with these studies, reports began to emerge that HBxAg could function 
as a transcriptional transactivator. At the time, all of these experiments had been 
conducted using target transcriptional control elements (including the HBV enhancer/core 
promoter or HBV enhancer/X promoter complexes) fused to a heterologous .reporter 
gene. Transactivation of transcription from the preS2/S promoter was suggested by the 
large quantities of HBsAg secreted froth HBV infected cells, and the possibility that this 
effect was mediated in part by HBxAg was investigated. A system had been established 
in our laboratory (Jackson, 1987) for the secretion of HBsAg by cultured mouse 
fibroblasts transiently transfected with a plasmid construction containing the complete 
transcription unit for the preS2IS mRNAs under control of its own promoter. This 
expression system was adapted to human hepatoma cells, and the availability of a sensitive 
radio-immunoassay for the detection of HBsAg made possible an assessment of the effect 
of HBxAg on the production of HBsAg when these polypeptides were expressed from a 
fragment of viral DNA containing these ORFs in their native configuration (Chapter 4). 
This system was exploited to examine the effect of HBxAg on production of all forms of 
HBsAg and for a preliminary investigation of the region of the HBV genome that 
mediates transactivation by HBxAg. 
A consideration of the mechanisms by which HBxAg may modulate transcriptional 
activity (see Chapter 6), and the heretofore unidentified protein kinase activity associated 
with the HBV virion led to the hypothesis that HBxAg may possess a protein kinase 
activity. Therefore, kinase activity was assessed for HBxAg produced in E. co/i as a fusion 
protein with HBcAg (Chapter 5). The results presented in this thesis along with those 
published concurrently have begun to elucidate the role for HBxAg in the viral life-cycle. 
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2A1 Suppliers of Laboratory Reagents 
Restriction endonucleases: 
Boebringer Mannheim plc: Mannheim, Germany 
GIBCO BRL Life Technologies: Paisley, Scotland 
New England Biolabs Inc.; Beverly, Massachusetts, U.S.A. 
Pharmacia LKB Biotechnology; Milton Keynes, U.K. 
E. co/i DNA polymerase I (holoenzyme and Kienow fragment), T4 DNA ligase. DNase 
I (RNase free): 
Boehringer Mannheim plc 
Ther,nus aquadcus (Taq) DNA polymerase: 
International Biotechnologies Inc. (IBI): New Haven, Connecticut, U.S.A. 
Deoxynucleoside triphosphates and dideoxynucleoside triphosphates: 
Boehringer Mannheim plc 
Radioactive nucleoside triphosphates and deoxynucleoside triphosphates: 
Amersham International, plc; Aylesbury, U.K. 
Standard laboratory reagents (various grades): 
BDH Chemicals Ltd.: Poole, U.K 
Fisons Chemicals; Loughborough, U.K. 
Gibco BRL Life Technologies 
Sigma Chemical Co.: Poole, U.K. 
Bacterial media reagents: 
Becton-Dickinson U.K. Limited; Oxford, U.K. 
Difco Laboratories; East Moseley, U.K. 
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Reagents for mammalian cell culture: 
Gibco BRL Life Technologies 
ICN Flow Limited; Rickmansworth. U.K. 
Sera-lab; Sussex, U.K. 
Sigma Chemical Co. 
HBsAg detection kit: 
AUSRIA 11-125 Diagnostic Kit: Antibody to Hepatitis B Surface Antigen 12 1 
(Human). Abbott Laboratories, Chicago, Illinois, U.S.A. 
2A.2 Mammalian Cell Culture 
2A.2.1 Mammalian cell lines 
Name Cell type Source from which cells Reference 
were obtained 
HepG2 human hepatoma European Collection of Knowles et all (1980) 
Animal Cell Cultures, 
Porton Down, U.K 
HuH7 human hepatOma J. Pugh, St. Mary's Nakabayashi et all 
Hospital, London (1982) 
2A.2.2 Mammalian cell culture media 
10 x Glasgow Modification of Eagle's Medium (BHK 21) (McPherson and Stoker. 1962: 
with modifications by House, Medical Research Council, Institute of Virology. University 
of Glasgow, Scotland, 1964) was supplied by Gibco BRL Life Technologies and ICN Flow 
Ltd. 100 x MEM Non-Essential Amino Acids (Eagle. 1959) was supplied by Gibco BRL 
Life Technologies and ICN Flow Ltd. Foetal bovine serum was supplied by ICN Flow 
Ltd. 
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2k3 Microbiological Materials 
2A.3.1 Bacterial strains 




supE44, supF58. hsdR5 14. 
tipR55, lacYl 
F, darn3, dctn6, gal, ara, 
lac, thr, leu., thi, tunA, tsx  
Use 
general host for plasmid 
cloning 
darn methylation minus host 
for preparation of plasmid 
DNA that can be digested 
with restriction 
endonucleases sensitive to 
this type of methylation. 
Strain 
ED8654 
GM48 Marinus (1973) 
MCIO61(X) 
NFl 
araD139, Lt(ara, leu)7697. 
&acX74, gailY, galK, hsK. 
hsm , sn-A, x  
K12AH1Atrp, lacZmm, 
XNarn7, Narn53, cI857AH1  
contitutive repression of 
expression from plasmids 
carrying XPr promoter 
heat-inducible expression 
from plasmids carrying XPr 
promoter 
MC1061: Casadaban 
and Cohen (1980); 
derivative: N.E. 
Murray. unpublished 
Stanley and Luzio 
(1984) 
Gough and Murray 
(1983) 
NM522 hsdA5, z(lac, pro), supE, host for bacteriophage M13 
thi, [F', pro A+B+, vectors and for plasmid 
lacZAM15, lac,] pUC8 vector 
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Strain Relavant Genotype Use Reference 
TG1 hsdA5, A(lac, pro), supE, 
thi, [Fl traD36, proABt 
/acZAM15, 1acI] 
host for bacteriophage Mfl 










mutL::Tn1O, a(lac, pro), 
sttpE, thi, [Fl proABt 
lacZM15, lac,] 
W3110 [F'. lad'!]  
tranformation host for 
heteroduplexes produced by 
SDM using bacteriophage 
M13 
host for expression from a 
plasmid bearing the tac 
promoter 
Kramer ci at (1984) 
Brent and Ptashne 
(1981) 
2A.3.2 Bacteriophage and plasmids 
El coli plasmids and bacteriophage used in these studies are listed below. Construction 
of derivative plasmids and bacteriophage is described in "Results chapters. 
Name Description Reference 
M13mp8! E. coli bacteriophage M13 based vectors used for Messing and Vieira 
M13mp9 generating single stranded DNA for sequence (1982); Norrander et 
M13mp18/ determination and SDM. These vectors contain a al. (1983) 
M13mp19 portion of the lacZ gene (encoding -galactosidase) 
and multiple cloning sites. 
pUC8 Ampr. E. coli cloning vector containing a portion of Vieira and Messing 
the lacZ gene (encoding -galactosidase) and (1982) 
multiple cloning sites. 
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Name Description Reference 
pHBV130 Tetr. This plasmid contains an HBV DNA insert of Gough and Murray 
greater than 1 genome-unit length. approximately (1982) 
3.8kb [ca. nucleotides 850-3182/1-1460] in pBR322. 
pEX2/3 Amp'S These plasmids are -galactosidase fusion Stanley and Luzio 
protein expression vectors. They contain the coding (1984) 
sequence for a fusion protein of the bacteriophage 
X cro protein (amino acids 1-8)/E. co/i lac repressor 
(amino acids 318-357)/ 3-galactosidase (amino acids 
25-1008) under control of the Ur promoter. These 
vectors contain a polylinker at the 3' end of the 
fusion gene which is in a different reading frame in 
each of the plasmids (pEX2 or pEX3) allowing 
fusion of further sequences using in vitro DNA 
recombination techniques. In addition each plasmid 
has the bacteriophage fd transcription termination 
sequences and stop codons engineered in each 
translational reading frame downstream of the 
polylinker. 
pSV2G jj1pr This plasmid contains the rabbit -glohin Gorman et al. (1982) 
coding sequences under control of the SV40 early 
promoter/enhancer complex. - 
pHBcS111 Amp'. This plasmid contains the coding sequence Stahl and Murray 
-156 for a fusion protein of 3-galactosidase (amino acids (1989) 
1-8)/HBcAg (amino acids 3-144)/major-S 
polypeptide (amino acids 111-156) under control of 
the tac promoter. 
Name Description Reference 
pBBX Ampr. This plasmid contains the codingsé4üênce Pugh et aL (1986) 
for a fusion protein of X cr0 protein (amino acids 1-
8)! HBxAg (amino acids 10-154) under control of 
the APr promter. 
2A.3.3 MicrobioIoicaI media 
Luria-broth (L-broth) 
10  Difco.Bacto Tryptone 
5 g Difco Bacto Yeast extract 
10 g NaCI 
Made to 1 litre with H20, and adjusted to pH 7.2. 
L-aczar 
As L-broth, but containing 15 g agar per litre. 
Top-layer a1ar 
10 g trypticase 
5g NaCI 
10 g agar 
Made to 1 litre with H20. 
5 x Spizizen salts 
2 g (NH4)2SO4 
14g K2HPO4 
6 g KH2PO4 
1 g tn-sodium citrate 
200 mg MgSO4 
Made to I litre with H20 
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Minima! agar 
15 g Difco Bacto agar 
200 ml Spizizen salts (5x) 
10 ml 20% (w/v) glucose 
125 /it vitamin Bi (5 mg,/ml) 
Made to 1 litre with H20 
Antibiotics 
ampicillin stock solution: 100 mg/rn! in H20: used at 100 tiglml 
tetracycline stock solution: 100 mg/ml in absolute ethanol: used at 100 AgIml 
2A4 Solutions 
All solutions were prepared in distilled water 
20x SSC 
3M NaCl 
0.3M tn-sodium citrate 
IN TBE 
0.9M Tnis-HCI 
0.9M boric acid 
2mM EDTA 
TE 
10rnM Tnis-HCI pH 8.0 
1mM EDTA 
Sequ encing TE 
10mM Tris-HCl pH 8.0 
0.1mM EDTA 
STE 








Phenol/chloroform/jso-amyl alcohol (PCI) 
25 ml distilled phenol equilibrated with 1M Tris-HCI pH 8.0 
24 ml chloroform 
1 ml iso-amyl alcohol 
2A.3 Antisera 
Rabbit 98 anti-HBxA2 (Pugh et aL, 1986) 
Serum from a rabbit inoculated with denatured fusion protein containing amino acids 1-8 
of Xcro protein fused to the amino terminus of HBxAg (amino acid residues 10-154). The 
fusion protein was produced in E. co/i and purified by SDS-polyacrylamide gel  
electrophoresis as described (Pugh et at. 1986). 30 tg of protein was mixed with 
Freund's complete adjuvant and injected subcutaneously into the rabbit. A second 
inoculation with the same components was given after 28 days and a third inoculation of 
fusion protein without adjuvant was given after a further 28 days. The serum used in 
these studies was from the third test-bleed withdrawn 8 days after the third inoculation. 
Rabbit 87 anti-HBcAg 
Serum from a rabbit inoculated with HBcAg produced in F. ccli (Biogen Inc.). 70g  of 
protein was mixed with an equal volume of adjuvant [0.4% Tween 80, 5.0% pluronic 
L121. 10% squalone, 1 mg/mI muramyl dipeptide in PBS] and injected subcutaneously into 
the rabbit. A second inoculation with the same components was given after 29 days and 
a third inoculation with the same components was given after a further 28 days. The 
serum used in this study was from the third test-bleed withdrawn 9 days after the third 
incoculation. The adjuvant formulation was suggested by A. Alison, Syntex Inc., Palo 
Alto, California, U.S.A., who kindly provided the reagents (Allison and Byars, 1986). 
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Immunoglobulin G (IgG) was purified from this serum by precipitation with ammonium 
sulphate. Ammonium sulphate was added to the serum to 40%, and the mixture was 
incubated for 30 minutes at 4°C with stirring. The precipitate was sedimented by 
centrifugation (12,000 x g) for 10 minutes at 4°C. The pellet was redissolved in a volume 
of PBS equal to the original volume of serum, and ammonium sulphate was added to 
40%. The mixture was incubated for 30 minutes at 4°C with stirring, and the precipitate 
was sedimented by centrifugation (12,000 x g) for 10 minutes at 4°C. The pellet 
containing IgG was redissolved in a volume of PBS equal to the original volume of serum 
and dialyzed against three changes of 1 litre each of PBS. 
Chimpanzee Peter serum (Murray et at. 1984) 
Serum from chimpanzee Peter from a test-bleed withdrawn 184 days after experimental 
infection with HBV subtype ayw. 
Monoclonal antibody MA18/7: anti-preSi (1-Teerman et at, 1984) 
Monoclonal antibody was produced by fusion of myeloma cells with spleen cells of a 
BALB/C mouse inoculated with 42 nm }IBV particles of subtype ayw. This antibody was 
kindly supplied by W. Gerlich, University of Gottingen, Germany. 
Monoclonal antibody 019/10; anti-preS2 (Heerman et at, 1988) 
Monoclonal antibody was produced by fusion of myeloma cells with spleen cells of a 
BALB/C mouse inoculated with 22 nm HBsAg paritcles, subtype adv. This antibody was 
kindly supplied by W. Gerlich, University of Gottingen. Germany. 
2B METHODS 
28.1 Mammalian Cell Culture 
2B.1.1 Cell culture 
Human hepatoma cells devoid of integrated HBV sequences (HepG2 and HuH7) were 
grown in 6% CO2 at 37°C in Glasgow modification of Eagle's medium (GMEM) 
supplemented with 1mM sodium pyruvate, 2mM L-glutamine, 1 x non-essential amino 
acids, 50Mg/mlstreptomycin, 50 U/mI penicillin and 10% (vlv) foetal bovine serum (FCS). 
2B.1.2 Transient transfection of hepatoma cells 
The method used for transient transfection of hepatoma cells with plasmid DNA was the 
DEAE-Dextran/chloroquine method essentially as described by Luthman and Magnusson 
(1983). 4 x 106  cells were seeded onto 9 cm plates 1 day before transfection. Cells were 
washed twice in 2 ml of PBS at 37°C. and plasmid DNA was added in 5 ml of a solution 
containing 200 .tg/ml DEAE-Dextran (molecular weight 5 x 106; Sigma) and 50 mM Tris-
HCI pH 7.3 in serum-free GMEM. DNA was adsorbed for 5 hours (HuH7 cells) or 6 
hours (HepG2 cells) at 37°C at which time 50 M1  of 10mM chloroquine diphosphate was 
added (final concentration, 100 MM). Cells were incubated for a further 2 hours (HepG2) 
or 3 hours (HuH7) after which the transfection solution was removed, cells were washed 
twice in 2 ml of PBS at 37°C and were incubated in 15 ml of GMEM supplemented with 
10% (v/v) FCS for 3.5-4.5 days. 
28.2 Preparation of Nucleic Acids 
2B.2.1 Phenol extraction of nucleic acid solutions 
Proteins present in DNA and RNA solutions were removed by extraction with phenol (re-
distilled and equilibrated with 1M Tris-HCI pH 8.0) or with phenol/chloroform/iso-amyl 
alcohol (PCI). An equal volume (unless otherwise stated) of phenol or PCI, was added 
to the solution containing nucleic acid, and the two liquid phases were mixed by vigourous 
inversion or votexing. The mixture was incubated at room temperature for 5 minutes, and 
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the liquid phases were remixed as above. The phases were separated by centrifugation 
for 5 minutes at room temperature in a microcentrifuge (17,000 x g) or bench-top 
centrifuge (3000 x g) depending on the volume. The upper, aqueous phase containing 
nucleic acid was recovered. 
213.2.2 Precipitation of nucleic acids with ethanol 
Nucleic acids were precipitated from aqueous solutions by addition of one-tenth volume 
(unless otherwise noted) of 3M sodium acetate pH 5.2, and 2.5 volumes of cold absolute 
ethanol (-20°C). The mixture was inverted gently several times and incubated at -20°C 
for several hours or -70°C for 30 minutes. Nucleic acids were sedimented by 
centrifugation (17,000 x g) in a microcentrifuge or Sorvall centrifuge for 15 minutes at 
4°C. The supernatant was discarded, the nucleic acid pellet was dried under vacuum and 
redissolved in H20 or TE [1OmM Tris-HCl pH 8.0, 1mM EDTA] or sequencing TE 
[10mM Tris-HCl pH 8.0, 0.1mM EDTA]. 
2B.2.3 Preparation of RNA from mammalian cells in culture 
In order to remove any trace of RNase, all salt solutions and H20 were treated with 0.1% 
diethyl pyrocarbonate (DEPC), allowed to stand for several hours at room temperature 
and autoclaved. 
a) Preparation of cytoplasmic RNA 
Cell lysis buffer: 




The method used to prepare cytoplasmic RNA was essentially that described by S. 
Heckford (personal communication). The medium was removed from a confluent 
monolayer of mammalian cells in a 90mm plate and the cells were washed twice in 2 ml 
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of ice-cold PBS. 2 ml of ice-cold PBS was added to the cell monolayer, cells were scraped 
with a sterile rubber policeman and removed from the plate with a sterile pasteur pipette. 
The plate was washed with 2 ml of fresh, ice-cold PBS and this was added to the initial 
2 ml suspension. The cells from 2-4 plates of cells transfected with the same amount of 
the same plasmid DNA were harvested as above and combined. The cells were 
sedimented from suspension by centrifugation (300 x g) for 5 minutes at 4°C and washed 
by resuspension in 10 ml of PBS. The cells were sedimented by centrifugation (300 x g) 
for 5 minutes at 4°C and resuspended in 10 cell volumes of lysis buffer. NP40 was added 
to 0.501c (v/v), cells were vortexed for 30 seconds and the nuclei were removed by 
centrifugation (1600 x g) for 15 minutes at 4°C. The supernatant was recovered, SDS was 
added to 0.5% (w/v) and contaminating proteins and DNA were extracted with an equal 
volume of phenol at 60°C. The upper, aqueous phase was recovered, and, in order to 
recover RNA left at the interface of the two liquid phases, an equal volume of TE [10mM 
Tris-I-ICl pH 8.0, 1mM EDTA] was added to the organic phase, the phases were mixed 
by vortexing and separated by centrifugation (17,000 x g) in a microcentrifuge for 5 
minutes at room temperature. The upper, aqueous was recovered and combined with the 
aqueous phase from the original extraction. Contaminating proteins and DNA were 
extracted from the combined RNA solutions with an equal volume of phenol at 60°C. 
The upper, aqueous phase was recovered and remaining traces of phenol were extracted 
with an equal volume of chloroform/isoamyl alcohol (24/1). The upper, aqueous phase 
was recovered, and RNA was precipitated with ethanol. The RNA pellet was redissolved 
in H20. RNA was stored in aliquots of approximately 40 A as an ethanol precipitate at - 
70°C. 
b) Preparation of total cellular RNA 
Guanidine hydrochloride (GnHCl) solution: 




RNA extraction buffer: 
100mM Tris-HCl p1-I 9.0 
100mM NaCl 
1mM EDTA 
1% (w/v) SDS 
The method used to prepare total cellular RNA was a modification of that described by 
MacDonald et aL (1987). Cells were harvested from confluent monolayers as described 
above, and the cell pellet was resuspended in 10 ml of GnHCl solution. The cells were 
lysed by homogenisation and 0.33 ml of 3M potassium acetate pH 5.0 and 5.5 ml of cold 
absolute ethanol (-20°C) were added. The solution was mixed by gentle inversion, and 
RNA was precipitated by incubation of the solution for at least 4 hours at -20°C. RNA 
was sedimented by centrifugation (17,000 x g) for 20 minutes at 0°C, and the RNA pellet 
was redissolved in 7 ml of GnHCl solution. 0.23 ml of 3M potassium acetate pH 5.0 and 
3.6 ml of cold absolute ethanol were added to the solution, and RNA was re-precipitated 
by incubation of the solution for at least 4 hours at -20°C. RNA was sedimented by 
centrifugation as above, and the RNA pellet was redissolved in 5 ml of RNA extraction 
buffer. Contaminating proteins were extracted by adding an equal volume of PCI. The 
phases were mixed vigorously by vortexing for 5 minutes and separated by centrifugation 
(3,000 x g) for 5 minutes at room temperature. The upper, aqueous phase was recovered, 
and RNA was precipitated by adding 0.375 ml of 3M sodium acetate pH 5.2 and 10 ml 
of cold absolute ethanol. • The solution was incubated for at least 4 hours at -20°C and 
RNA was sedimented by centrifugation (17,000 x g) for 20 minutes at 4°C. The RNA 
pellet was redissolved in H20. RNA was stored in aliquots of approximately 40 jg as an 
ethanol precipitate at -70°C. 
2B.2.4 Preparation of plasmid DNA and bacteriophae M13 replicative form (RF) DNA 
a) Small-scale preparation of plasmid DNA 
Lysis buffer: 
50mM glucose 
25mM Tris-HCl pH 8.0 
10mM EDTA 
Lysis solution (freshly prepared): 
200mM NaOH 
1% (w/v) SDS 
The method used for small-scale preparation of plasmid DNA was a modification of that 
described by Jsh-Horowicz and Burke (1981). 5 ml of L-broth containing the appropriate 
antibiotic (100 jig/ml) was inoculated with a single colony of E. coli habouring the desired 
plasmid, and cells were grown to stationary phase at 37°C (or at 30°C for cells containing 
a temperature sensitive mutant gene) with shaking. Cells from 1.5 ml of culture were 
sedimented by centrifugation (17,000 x g) in a microcentrifuge for 1 minute at room 
temperature. The cell pellet was resuspended in 100 j.il of lysis buffer and incubated for 
5 minutes at room temperature. 200 jil of lysis solution was added, the suspension was 
mixed by gentle inversion and incubated for 5 minutes on ice. 150 Al of 5M potassium 
acetate pH 5.0 (3M potassium acetate, 2M acetic acid) was added, mixed by gentle 
inversion and incubated for 5 minutes on ice. Precipitated protein, SDS and chromosomal 
DNA were sedimented by centrifugation (17,000 xg) in amicrocentrifuge for 5 minutes 
at 4°C. Contaminating proteins in the clarified supernatant were extracted with PCI. The 
upper, aqueous phase was recovered and nucleic acids were precipitated with ethanol. 
The nucleic acid pellet was dried under vacuum and redissolved in 50 Al H20. 1 jil of 
RNase A (10 mg/ml; Sigma) was added, and the solution was incubated for 20 minutes at 
37°C. Contaminating proteins in the solution were extracted with PCI, the upper. 
aqueous phase was recovered, and plasmid DNA was precipitated with ethanol. The 
plasmid DNA pellet was dried under vacuum and redissolved in 50 j.il H20 or TE [10mM 
Tris-HCI pH 8.0, 1mM EDTA]. 
b) Large-scale preparation of plasmid DNA 
Lysis buffer: 
25mM Tris-HC1 pH 8.0 
10mM EDTA 
15% (w/v) sucrose 
M. 
Lysis solution (freshly prepared): 
200mM NaOH 
1% (w/v) SDS 
The method used for large-scale preparation of plasmid DNA was a scaled-up 
modification of the method for small-scale plasmid DNA preparation described by 
Birnboim and Doly (1979). 50 ml of L-broth containing the appropriate antibiotic (100 
gIml) was inoculated with a single colony of E. co/i harbouring the desired plasmid and 
cells were grown to stationary phase at 37°C (or at 30°C for cells containing a temperature 
sensitive mutant gene) with shaking. Cells were sedimented from suspension by 
centrifugation (12,000 x g) for 10 minutes at 4°C, and the cell pellet was resuspended in 
3.5 ml of lysis buffer. 8 mg of lysozyme (Sigma) dissolved in 0.5 ml of lysis buffer was 
added, and the suspension was incubated for 30 minutes on ice. 8 ml of lysis solution was 
added, the suspension was mixed by gentle inversion and incubated for 10 minutes on ice. 
5 ml of 3M sodium acetate pH 5.2 was added, mixed by gentle inversion and incubated 
for 10 minutes on ice. Precipitated protein. SDS and chromosomal DNA were 
sedimented by centrifugation (17,000 x g) for 40 minutes at 4°C. One-twentieth volume 
of 3M sodium acetate pH 5.2 was added to the clarified supernatant, and nucleic acids 
were precipitated by adding 2 volumes of absolute ethanol. The nucleic acid pellet was 
dried under vacuum and redissolved in 0.5 ml H2O. 10 Al of RNase A (10 mg/mI: Sigma) 
was added, and the solution was incubated for 30 minutes at 37°C. Contaminating 
proteins in the solution were extracted with phenol (1 extraction) and then PCI (2 
extractions). The upper, aqueous phase was recovered and plasmid DNA was precipitated 
with ethanol. The plasmid DNA pellet was dried under vacuum and redissolved in I ml 
H20. 
c) Preparation of bacteriophage M13 replicative form (RF), double stranded DNA 
A fresh, single plaque of M13 was picked with a sterile wooden toothpick and transferred 
into 2 ml of an L-broth culture of E. co/i NM522 cells (OD650flm  0.2), and the culture 
was grown for 4.5 hours at 37°C with shaking. For small-scale preparation of RF DNA, 
the cells were sedimented from suspension by centrifugation in a microcentrifuge (17,000 
x g) for one minute at room temperature and the procedure used was that for small-scale 
preparation of plasmid DNA. For large-scale preparation. 50 btl of the 2 ml culture 
prepared above was added to 50 ml of an L-broth culture of K coli NM522 cells 
(OD650nm  0.2), and this culture was grown for 4.5 hours at 37°C with shaking. Cells were 
sedimented from suspension by centrifugation (12000 x g) for 10 minutes at 4°C. From 
this point onwards the procedure was that of large-scale preparation of plasmid DNA. 
213.2.5 Quantification of nucleic acids 
The optical density (OD) of nucleic acid solutions at 260nm was measured using a Perkin-
Elmer, Lambda 15, UV/VIS Spectrophotometre. An OD260nm  value of 1.0 represents 
a concentration of 50Mg/ml for DNA and 38 Mg/mI for RNA. 
2B.2.6 Transformation of E. coli with bacteriophajie M13 DNA or plasmid DNA 
a) Calcium chloride method 
This method for transformation of E. coli was a modification of that described by Mandel 
and Higa (1970). 
M13 DNA: E. coli were made competent for uptake of DNA by the following procedure. 
5 ml of L-broth was inoculated with a single colony of E. coli NM522, TO1, or BMH71-18 
mulL and the culture was grown to stationary phase at 37°C with shaking. 100 ml of L-
broth was inoculated with 1 ml of the stationary phase culture and cells were grown to 
OD650nm  0.3 at 37°C with shaking. The cell culture was incubated for 10 minutes on ice, 
and cells were sedimented from 20 ml of culture by centrifugation (3000 x g) for 5 minutes 
at 4°C. The cell pellet was resuspended in 10 ml of ice-cold 100mM CaCl2 and incubated 
for 30 minutes on ice. Cells were sedimented from suspension by centrifugation (3000 x 
g) for 5 minutes at 4°C, and the cell pellet was resuspended in 2 ml of ice-cold 100mM 
CaCl2. 
For transformation of competent cells, approximately 0.1 ng of RF form or 1 ng of single 
stranded bacteriophage DNA was added to 200 M1  of cell suspension in glass tubes, and 
the mixture was incubated for 30 minutes on ice. The cells were heat-shocked by 
incubation for 4 minutes at 42°C and added to 3.5 ml of molten top-layer agar containing: 
67 
200 pA of the L-broth culture at OD650nm  0.3 as plating cells, 30 pA X-gal [20 mg/ml 5-
bromo-4-chloro-3-indolyl- p -D-galactopyranoside in dimethylformamide] and 20 At IPTG 
[20 mglml isopropyl--D-thiogalactopyranaside in dirnethylformamide] for selection of blue 
versus colourless plaques. Transformed cells were plated on minimal agar plates 
supplemented with vitamin BI (final concentration, 0.625 pgjml). Non-recombinant 
bacteriophage produce -galactosidase yielding a blue colour on selective medium while 
recombinant bacteriophage are incapable of producing -galactosidase and yield a clear, 
colourless plaque on selective medium. 
Plasmid DNA: Preparation of transformation competent cells was performed as described 
above except that; 1) cells containing a temperature sensitive mutant gene were grown at 
30°C, 2) following dilution of the stationary phase culture, cells other than E. coli NM522 
or TO1 were grown to OD650nm  0.5 and 3) the final cell suspension in 2 ml 100mM 
CaCl2 was incubated for a further 30 minutes on ice instead of being used immediately. 
For transformation of competent cells, approximately 0.1 ng of plasmid DNA was added 
to 50M1  of cell suspension and the mixture was incubated on ice for 30 minutes. The cells 
were heat-shocked by incubation for 4 minutes at 42°C after which 200 At of fresh L-broth 
was added. The cells were shaken for 1 hour at the appropriate temperature to allow 
expression of the antibiotic gene carried by the plasmid. Transformed cells were plated 
on L-agar plates containing 100 btg/ml of the appropriate antibiotic. Insertion of 
heterologous DNA into the polylinker in plasmid pUC8 was detected by colour selection 
on L-agar plates containing 100 /kgiml ampicillin, 40 jig/ml X-gal and 40 jig/mI IPTG. 
b) DMSO method 
Transformation buffer: 
10% (w/v) polyethylene glycol, molecular weight 3000 (Sigma) 




This method for transformation of E. co/i was essentially that described by Chung and 
Miller (1988). Cells were grown to the same OD650nm  as for the CaCl2 method, 
incubated for 10 minutes on ice, and sedimented from 20 ml of culture by centrifugation 
(3000 x g) for 5 minutes at 4°C. The cell pellet was resuspended in 2 ml of 
transformation buffer, and incubated for 30 minutes on ice. 0.1 ng of plasmid DNA was 
added to 100 Al of cell suspension, and the mixture was incubated for 30 minutes on ice. 
For bacteriophage M13, transformed cells were plated immediately as above. For plasmid 
DNA, 200 M1  of 20mM glucose in transformation buffer was added to the transformed 
cells, cells were shaken for 1 hour at the appropriate temperature and plated as above. 
213.3 Enzymatic Manipulation of DNA 
213.3.1 Digestion of DNA with restriction endonucleases 
DNA was digested with approximately 5U of restriction endonuclease per j.tg of DNA 
using buffer and temperature conditions recommended by the manufacuterer. Digestion 
reactions were terminated by heating for 10 minutes at 65°C. by phenol extraction, or by 
addition of DNA sample buffer for agarose gel electrophoresis (section 2B.4.1). 
213.3.2 Filling-in 3' recessed termini of DNA 
The 3 recessed termini created by digestion of DNA with certain restriction 
endonulceases were rendered blunt by the action of E. co/i DNA polymerase I (Kienow 
fragment). 10 jig of plasmid DNA was digested with the appropriate restriction 
endonuclease, the reaction mixture was extracted with phenol, and cleaved DNA was 
precipitated with ethanol. The DNA pellet was dried under vacuum, redissolved in 33 Jul 
H20, and incubated for 1 hour at 37°C with the following: 
4 Al 100mM Tris-HCI pH 8.0, 100mM MgCl2 
1 pA 10mM each dGTP, dATP, dflP. dCTP 
2 Al E. coli DNA polymerase I (Klenow fragment) (5 UIjil: Boehringer) 
The reaction was terminated either by phenol extraction or by addition of DNA sample 
buffer for agarose gel electrophoresis (section 213.4.1). 
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213.3.3 In vitro recombination of DNA fragments 
10 x ligation buffer (for either blunt or cohesive ends): 




Linear DNA fragments were recombined in vitro by the action of bacteriophage T4 DNA 
ligase (Boehringer). Ligation reactions were carried out for 16 hours at 12°C in the 
following 10 Al reaction mixture: 
7 Al desired insert DNA in H20 (300 ng in total) 
1 Al desired, linearised, plasmid DNA in H20 (100 ngal) 
1 pd 10 x ligation buffer 
1 Al T4 DNA ligase (1 U/pA; Boehringer) 
213.4 Electrophoresis of Nucleic Acids 
2B.4.1 Electrophoresis of DNA in aarose gels 
5 x DNA sample buffer: 
15% (w/v) ficoll, molecular weight 400,000 
50 mM EDTA 
0.125% (w/v) bromophenol blue 
0.125% (w/v) xylene cyanol FF 
DNA was fractionated on the basis of fragment size by electrophoresis in submerged, 
horizontal, agarose, slab gels. Agarose gels consisted of 0.6% to 1.5% (w/v) agarose 
(depending on the size of the DNA fragments to be separated) melted in 1 x TBE buffer 
in a microwave oven. Gels were cast containing 0.5 jig/ml ethidium bromide. Prior to 
loading, 0.2 volumes of 5 x DNA sample buffer were added to each sample. 
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Electrophoresis was carried out in I x TBE buffer, at 5-20 volts(V)/cm. 1 kb ladder 
(Bethesda Research Laboratories) was used for DNA size standards. 
2B.4.la Gel photography 
Nucleic acids stained with ethidium bromide were visualised under short-wave ultraviolet 
light using a Cromato-vue UV-transilluminator (302 nm wavelenght). Photographs of gels 
were taken on a Kodak specialist 3 camera containing a red (Al) filter at £14.5 for 20 
seconds using Ilford HPS film (5 X 4 inch sheet). The exposed film was developed for 
5 minutes at room temperature in Ilford microphen developer. The development reaction 
was stopped by incubation in 3% acetic acid for 30 seconds, and the image was fixed in 
Flypam fixer for 5 minutes. The film was washed in cold water and air dried. 
2B.4.2 Recovery of DNA from low-melting-temperature agarose gels 
The method used to recover DNA from low-melting-temperature agarose gels was 
essentially that of Wieslander (1979). DNA fragments were fractionated as described 
above except that low-melting-temperature agarose (Bethesda Research Labortories) was 
used when casting gels. DNA was visualised under short-wave ultraviolet light, the desired 
band was excised using at sterile scalpel, and the piece of agarose gel was placed in a 1.5 
ml microcentrifuge tube. The gel piece was melted at 65°C for 10 minutes and an equal 
volume of TE pre-warmed to 37°C was added. The solution was mixed by votexing and 
placed at 65°C for an additional 5 minutes. The solution was cooled to 37°C and an equal 
volume of phenol pre-warmed to 37°C was added. The phases were mixed by votexing 
and immediately separated by centrifugation (17,000 x g) in a microcentrifuge for 5 
minutes at room temperature. The upper, aqueous phase was recovered and re-extracted 
with phenol pre-warmed to 37°C. The upper, aqueous phase was again recovered, and 
ethidium bromide and trace amounts of phenol were extracted with an equal volume of 
butan-1-ol. The lower, aqueous phase was recovered and DNA was precipitated with 
ethanol. The DNA pellet was dried under vacuum, redissolved in 10 jfl F120 and stored 
at -20°C. 
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2B.4.3 Electrophoresis of RNA in agarose eels 
10 x MOPS buffer 
200mM 3-(N-morpholino) propane-sulphonic acid (MOPS) 
50mM sodium acetate 
10mM EDTA 
to pH 7.0 with NaOH 
Formamide sample buffer 
100 At 10 x MOPS buffer 
200 At formamide 
120 At formaldehyde (37% (w/v)) 
Ficoll-dye-EDTA (FDE) 
500 At 0.2M EDTA pH 7.0 
0.3 g ficoll, molecular weight 400,000 
10 mg bromophenol blue 
to 1 ml with H2O 
RNA was fractionated on the basis of size by eletrophoresis in submerged, horizontal, 
agarose, slab gels containing formaldehyde. The method used was a modification of that 
described by Lehrach et iiL (1977). 1% (w/v) agarose gels containing 0.27M formaldehyde 
were prepared as follows: 1 g of agarose was melted in 88 ml H20 in a microwave oven. 
The solution was cooled to 60°C and 10 ml of 10 x MOPS buffer, 2m1 of formaldehyde 
(37% (w/v)) and 10 At of ethidium bromide (5 mg/ml) were added. 1% (w/v) agarose gels 
containing 0.675M formaldehyde were prepared as follows: 1 g of agarose was melted in 
85m1 H2O in microwave oven. The solution was cooled to 60°C and 10 ml of 10 x MOPS 
buffer, 5 ml of formaldehyde (37% (w/v)) and 10 At of ethidium bromide (5 mg/ml) were 
added. The gel was cast on a horizontal bed. 
RNA was prepared from monolayers of mammalian cells in culture and stored in aliquots 
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of approximately 40 Ag at -70°C as an ethanol precipitate as described above (section 
2B.2.3). RNA was sedimented by centrifugation (17,000 x g) in a microcentrifuge for 15 
minutes at 4°C, and the superanatant was removed carefully by aspiration with a drawn-
out, glass capillary tube. The RNA pellet was redissolved in 45 Jul H20 and 5M1  of 10 x 
DNasel buffer [1M sodium acetate pH 5.2, 100 mM MgCl2] was added. 1 M1  of DNasel 
(23 U/MI, RNase free; Boehringer) was added to the RNA solution and it was incubated 
for 30 minutes at 37°C. 25 M1  of DNase treated RNA was added to 25 At of FDE and the 
solution was heated to 60°C for 5 minutes. The denatured RNA was snap-cooled on ice. 
and 10 M'  of formamide sample buffer was added. 
Electrophoresis of RNA samples was carried out in 1 x MOPS buffer at 5-20 volts/cm 
until the desired fractionation was achieved. RNA was visualised under short-wave 
ultraviolet light and photographed as described above (section 2B.4.1a). 
2B3 Radio-Labelling DNA 
213.5.1 Labelling DNA by random priming with hexadeoxvribonucleotide primers 
Oligo-labelling buffer (OLB) was prepared as follows: 
Solution 0: 
1.25M Tris-HCi pH 8.0 
125mM MgCl2 
Solution A: 
1.0 ml solution 0 
18 At -mercaptoethanoi (14M) 
S At 100mM dATP 
5 pA 100mM dGTP 
5 Ml  100mM dTTP 
Solution B: 
2.OM HEPES (N-2-hydroxyethylpiperazine-N '-2-ethanesuiphonic acid). 
adjusted to pH 6.6 with 4M NaOH 
Solution C: 
hexadeoxyribonucleotides (Pharmacia) suspended at 90 OD units/ml 
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Solution OLB: 
2 parts solution A 
5 parts solution B 
3 parts solution C 
Stored in lObtl aliquots at -20°C. 
The method used to label DNA was that of Feinberg and Vogelstein (1983). Plasmid 
DNA was digested with the appropriate restriction endonuclease and cleavage products 
were fractionated by electrophoresis in a low-melting-temperature • agarose gel. The 
desired DNA fragment was excised from the gel with a sterile scalpel, and the piece of 
agarose gel was placed into a preweighed, 1.5 ml microcentrifuge tube. H20 was added 
at a ratio of 3 ml H20 per gram of gel. The tube was incubated at 100°C for 10 minutes 
to melt the gel and denature the DNA. The DNA fragment in agarose was stored at - 
20°C. and prior to labelling was re-boiled for 5 minutes and then incubated at 37°C for 
10 minutes. Labelling reactions were carried out for 2 hours at 37°C or for 16 hours at 
room temperature in the following reaction mixture: 
35 Al DNA fragment in melted agarose (approx. 10 ng in total) 
10 Al OLD 
2 1.1 bovine serum albumin (10 mg/ml) 
5 p.1 [a-32P]dCTP (10 p.Ci/jil; Amersham) 
The labelling reaction was stopped and salt concentration was increased for gel filtration 
by adding 50 Al of STE [10mM Tris-HC1 pH 8.0, 1mM EDTA, 150mM NaCI] and 
unincorporated radio-labelled nucleotides were removed from the reaction mixture by gel 
filtration through Sephadex G-50 (Pharmacia) (see below). 
213.5.2 Sephadex eel filtration of DNA (Spun columns 
The method for preparation and use of spun columns was essentially that described by 
Maniatis et aL (1982). Dry Sephadex G-50 beads (Pharmacia) were swollen in an excess 
of TE [10mM Tris-HCI pH 8.0, 1mM EDTA] overnight at 4°C. Columns were prepared 
in 1 ml plastic syringes from which the plunger had been removed and the hole plugged 
with glass wool. Sephadex ci-so was added until the bed filled the whole syringe, and the 
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column was packed by centrifugation (300 x g) for 3 minutes at room temperature yeilding 
a bed volume of approximately 0.9 ml. The column was equilibrated by adding 0.5 ml of 
STE [10mM Tris-HCI pH 8.0, 1mM EDTA, 150mM NaClj followed by centrifugation (300 
x g) for 3 minutes at room temperature. The equilibration step was repeated and the 
sample added to the column. Unincorporated f a-32P]dCTP was trapped in the column, 
and labelled DNA was collected by centrifugation (300 x g) for 5 minutes at room 
temperature. 





1M Tris-HCI pH 8.0 
1.5M NaCl 
213.6.1 Transfer of DNA from E. coli colonies to membranes (colony lifts) 
The method used for colony lifts was essentially that described by Grunstein and Hogness 
(1975). E. coli were transformed with plasmid DNA encoding an antibiotic resistance 
gene and which had been manipulated in vitro to contain inserts of heterologous DNA 
Transformed cells were plated on L-agar plates containing the appropriate antibiotic (100 
LgIml) for selection of transformed cells. Resulting colonies were picked individually using 
sterile wooden toothpicks and transferred in a grid pattern onto a fresh L-agar plate 
containing the appropriate antibiotic (100 jig/mI). Colonies were allowed to grow 
overnight at the appropriate temperature. The plates were cooled to 4°C, and the 
colonies were lifted onto nitrocellulose membrane disks (0.45 jim pore size; Sartorius) by 
carefully laying the disk onto the plate, marking its position and removing it as soon as 
it had become moistened. Cells were lysed and DNA denatured by placing the 
membranes colony side up on blotting paper saturated with denaturation solution for 5 
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minutes at room temperature. The pH of the membranes was neutralised by placing them 
colony side up on blotting paper saturated with neutralisation buffer for 5 minutes at 
room temperature. The neutralisation step was repeated, the membranes were dried on 
blotting paper and baked in a vacuum oven for 2 hours at 80°C. 
213.6.2 Transfer of DNA from bacteriophage M13 plagues to membranes (plague lifts) 
Low-Tris Buffer (LTB): 
20mM Tris-HCl pH 7.9 
20mM NaCl 
1mM EDTA 
The method used for plaque lifts was a modification of that described by Benton and 
Davis (1977). E. coli NM522 were transformed with bacteriophage M13 vectors which 
had been manipulated in vitro to contain inserts of heterologous DNA. Transformed cells 
were plated on minimal agar plates with the appropriate compounds for colour selection 
(section 2B.2.6). Colourless plaques were picked with a sterile wooden toothpick and 
transferred into 50 M1  of LTB. A lawn of NM522 cells was prepared by adding 100 bLI of 
a stationary phase culture in L-broth to 3.5 ml of molten top-layer agar containing 30 Al 
X-gal and 200 IPTG and plating on minimal agar plates supplemented with vitamin BI 
(final concentration 0.625 itg/ml). 1 .tl of M13 bacteriophage in LTB was spotted onto 
the cell lawn in a grid of 50 spots per plate. Bacteriophage were allowed to grow 
overnight and the plates were cooled to 4°C. Bacteriophage plaques were lifted onto 
nitrocellulose membrane disks (0.45 gm pore size; Sartorius) by carefully placing the disk 
on the plate, marking its position and removing it as soon as it had become moistened. 
It was not necessary to denature the DNA on the membranes as single stranded phage 
DNA was present in the plaques. Membranes were baked in a vacuum oven for 2 hours 
at 80°C. 
213.6.3 Transfer of DNA from agarose gels to membranes (Southern blotting) 
The method used for transferring DNA from agarose gels to membranes was essentially 
that described by Southern (1975). DNA was fractionated by electrophoresis in an 
agarose gel containing ethidium bromide, and the separation of DNA fragments Was 
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recorded . by photographing the gel. The gel was soaked in approximately 5 volumes of 
denaturation solution for 20 minutes at room temperature with gentle shaking. The 
denaturation step was repeated, the gel was rinsed in H20 and soaked in approximately 
5 volumes of neutralisation buffer for 20 minutes at room temperature with gentle 
shaking. The neutralisation step was repeated, the gel was rinsed in H20 and placed on 
top of 4 pieces of blotting paper (8" x 8" on a glass plate) saturated with 20 x SSC. Thin 
plastic film (Saran Wrap) was placed over the exposed areas of saturated blotting paper, 
in order to prevent evaporation. A nylon membrane (Nytran. Amersham International) 
cut to the size of the gel was soaked in 2 x SSC for 2 minutes and placed on top of the 
gel. Three pieces of blotting paper cut to the size of the gel were saturated with 2 x SSC 
and placed on top of the nylon membrane, and 20-30 pieces of dry blotting paper cut to 
the size of the gel were placed on top of the saturated ones. A stack of 15-20 paper 
hand-drying towels were placed on top of the dry blotting papers and a weight of 
approximately 1 kg was placed on top of the whole stack. Transfer was allowed to 
proceed for at least 8 hours at which time the membrane was removed from the transfer 
set-up and exposed to ultraviolet light from a Cromato-vue UV-transilluminator (302 nm 
wavelength) for 5 minutes in order to cross link DNA to the membrane. 
213.6.4 Transfer of RNA from agarose gels to membranes (Northern blotting) 
RNA was fractionated by electrophoresis in a formaldehyde, agarose gel containing 
ethidium bromide, and the position of the ribosomal RNA bands was recorded by 
photographing the gel. The gel was soaked in approximately S volumes of 2 x SSC for 20 
minutes at room temperature with gentle shaking in order to remove formaldehyde. The 
soaking step was repeated, the gel was rinsed in H20, and RNA was transferred to a 
nylon membrane (Nytran, Amersham International) using a set-up identical to that used 
for the transfer of denatured DNA from agarose gels to membranes. RNA was 
crosslinked to the membrane using ultraviolet light as described for single stranded DNA. 
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2B.6.5 Hybridisation of radio-labelled DNA probes to single stranded nucleic acids 
immobilised on nitrocelluose or nylon membranes 
100 x Denhardt's solution (Denhardt, 1966): 
2% (w/v) bovine serum albumin 
2% (w/v) ficoll, molecular weight 400,000 
2% (w/v) polyvinyl pyrrolidone, molecular weight 360,000 
Pre-hybridisation solution: 
40% (vAr) formamide 
200 pg/mI sonicated salmon sperm DNA 
6 x SSC 
0.2% SDS 
5 x Denhardt's solution  
For 10 ml: 
4 ml formamide 
200 pA 10mg/mI sonicated salmon sperm DNA 
2.5 ml 20 x SSC 
200 Al 10% (w/v) SDS 
0.5 ml 100 x Denhardt's solution 
2.6 ml H20 
Pre-hybridisation solution was prepared as follows: sonicated salmon sperm DNA 
was added to formamide and the solution heated for 10 minutes at 80°C to 
denature the DNA. The heated solution was then added to a solution of the 
other three components. 
Hybridisation solution: 
For 10 ml: 
40% formamide 4 ml formamide 
200 tg/ml sonicated salmon sperm DNA 200 Al 10mg/mi sonicated salmon sperm DNA 
6xSSC 2.5 ml20xSSC 
0.2% SDS 200 pA 10% (w/v) SDS 
1 x Denhardt's solution 100 jil 100 x Denhardt's solution 
3mlH2O 
Hybridisation solution was prepared in the same manner as pre-hybridisation 
solution. - 
A nitrocellulose or nylon membrane onto which RNA orsingle stranded DNA had been 
transfered was incubated for at least 1 hour in pre-hybridisation solution (approximately 
10 ml per 100 cm2 of membrane) in a plastic bag at 37°C with gentle shaking. The pre-
hybridisation solution was then removed from the plastic hag and replaced with 
hybridisation solution (approximately 7 ml per 100 cm2 of membrane). The radio-labelled 
DNA probe was denatured by incubating for 5 minutes at 100°C and snap-cooled by 
placing immediately in an ice-water bath. The probe was added to the hybridisation 
solution in the platic bag, the bag was resealed and incubated for at least 8 hours at 37°C 
with gentle shaking. 
Following incubation with the radio-labelled probe, the membrane was washed in 
approximately 200 ml of 2 x SSC, 0.1% SDS for 15 minutes at room temperature. This 
wash was repeated, and the membrane was then washed in 200 ml of 0.5 x SSC, 0.1% 
(w/v) SDS for 1 hour at 37°C. Higher stringency could be obtained by increasing the 
temperature of the wash to 65°C and/or washing membranes in 0.1 x SSC, 0.1% SDS 
The washed membrane was placed on blotting paper to remove excess liquid, but was not 
allowed to dry completely. The membrane was then sealed in a plastic bag and X-ray film 
(Cronex 4) was exposed to the membrane in a light-proof cassette with intensifying 
screens (Dupont Cronex Lightning Plus) at -70°C. Exposure times varied according to the 
intensity of the signal obtained. 
213.6.6 Rehybridisation 
The method used to remove radio-labelled DNA probe hybridised to single stranded 
nucleic acid immobilised on a nylon membrane was that described in the protocols manual 
supplied with Gene Screen Plus Membranes (Dupont). 0.1 x SSC, 0.01% SDS at 100°C 
was poured onto the membrane which was washed in the solution for 3 minutes with 
gentle shaking. The solution was decanted from the membrane, and the procedure was 
repeated 4 times. The membrane was incubated in pre-hybridisation solution and 
hybridised to a new radio-labelled DNA probe as described above. 
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2B.7 DNA Sequencing 
The method used for determination of DNA sequence was the dideoxynucleotide chain 
termination method based upon that described by Sanger ci aL (1977, 1980). 
213.7.1 Preparation of sinQle-stranded template DNA 
Low-Tris buffer (LTB): 
20mM Tris-HCl pH 7.9 
20mM NaCl 
1mM EDTA 
PEG 6000 solution: 
2.5M NaCl 
20% (w/v) polyethylene glycol, molecular weight 6000 (Sigma) 
a) Small-scale preparation: 
E. coli NM522 were transformed with bacteriophage M13 vectors that had been 
manipulated in vitro to contain inserts of heterologous DNA. Transformed cells were 
plated on minimal agar plates with the appropriate compounds for colour selection 
(section 213.2.6). Individual colourless plaques were picked with a sterile wooden 
toothpick and transferred into 50 Al of LTB. In order to purify single plaques, serial 
dilutions of LTB phage stocks were made to 10-5 and 10 6 in LTB, and 100 j.tl of the 
dilution was plated in 3.5 ml of molten top-layer agar containing 100 Al of a stationary 
phase culture of E. coli NM522 or TG1 in L-broth, 30 Al X-gal, and 20 pA IPTG on 
minimal plates supplemented with vitamin Bi (final concentration, 0.625 )ug/ml). 
Bacteriophage were allowed to grow for at least 12 hours at 37°C. Individual colourless 
plaques were picked with a sterile toothpick and transferred into 1.5 ml of L-broth 
containing 15 M1  of a stationary phase culture of K coli NM522 or TG1 in L-broth. Cells 
were grown for 5.5 hours at 37°C with vigourous shaking. 
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Bacteriophage particles were isolated as follows: the 1.5 ml culture was transferred to a 
microcentrifuge tube and cells were sedimented by centrifugation (17,000 x g) in a 
microcentrifuge for 5 minutes at room temperature. The supernatant was transferred to 
a fresh microcentrifuge tube and bacteriophage particles were precipitated by adding 200 
M1 of PEG 6000 solution. The contents of the tube were mixed by gentle inversion and 
incubated for 25 minutes at room temperature. The precipitated bacteriophage particles 
were sedimented by centrifugation (17.000 x g) in a microcentrifuge for 5 minutes at room 
temperature. The supernatant was decanted and excess PEG 6000 solution was removed 
from the walls of the tube by brief centrifugation (17.000 x g) in a microcentrifuge for I 
•minute at room temperature. The remaining PEG 6000 solution was removed carefully 
from the microcentrifuge tube by aspiration with a drawn-out, glass capillary tube. The 
bacteriophage pellet was resuspended in 100 pA of sequencing TE [10mM Tris-HCI pH 
8.0, 0.1mM EDTA]. Bacteriophage were lysed and contaminating proteins were extracted 
by adding 50 Al of phenol. The liquid phases were mixed by votexing for 10 seconds, 
allowed to stand for 10 minutes at room temperature and mixed again by vortexing for 10 
seconds. The liquid phases were separated by centrifugation (17,000 x g) in a 
microcentrifuge for 5 minutes at room temperature. and 85 pA of the upper, aqueous 
phase was recovered with care not to remove any phenol. Single stranded DNA was 
precipitated by adding 10 M1  of 3M sodium acetate pH 5.2 and 250 M1  of cold absolute 
ethanol (-20°C), and incubating for at least 12 hours at -20°C. Single stranded DNA was 
sedimented by centrifugation (17,000 x g) in a microcentrifuge for 15 minutes at 4°C, the 
DNA pellet was dried under vacuum and redissolved in 50 pA of sequencing TE. 
b) Large-scale preparation 
Single plaques from a recombinant bacteriophage M13 stock in LTB were isolated as 
described for small-scale preparation. As for small-scale preparation, individual plaques 
were picked with a sterile toothpick and transferred to 1.5 ml of L-broth containing 15 
Al of a stationary phase culture of E. coil TG1 in L-broth. Cells were grown for 5.5 hours 
at 37°C with vigourous shaking, the 1.5 ml culture was transferred to a microcentrifuge 
tube, and cells were sedimented by centrifugation. The supernatant was transferred to a 
fresh microcentrifuge tube. 100 ml of L-broth was inoculated with 1 ml of a stationary 
phase culture of TG1 cells in L-broth, and the cells were grown to OD650nm  0.3 at 37°C 
with shaking. The supernatant from the 1.5 ml bacteriophage culture was used to 
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innoculate the 100 ml culture of TG1 cells, and the culture was grown for 4 hours at 37°C 
with shaking. Cells were sedimented from suspension by centrufugation (12,000 x g) for 
30 minutes at 4°C, and the supernatant was transferred to fresh centrifuge tubes. 
Bacteriophage particles were precipitated by adding 0.2 volumes of PEG 6000 solution, 
the contents of the tubes were mixed by gentle inversion and incubated for 25 minutes 
at room temperature. The precipitated bacteriophage particles were sedimented by 
centrifugation (12.000 x g) for 5 minutes at room temperature. The supernatant was 
decanted, and excess PEG 6000 solution was removed from the walls of the centrifuge 
tube by brief centrifugation (12,000 x g) for 1 minute at room temperature. The 
remaining PEG 6000 solution was removed carefully from the centrifuge tube by 
aspiration with a drawn-out, glass Pasteur pipette. The bacteriophage pellet was 
resuspended in 0.5 ml of sequencing TE [10mM Tris-HCl pH 8.0, 0.1mM EDTA] and 
transferred to a microcentrifuge tube. Bacteriophage particles were re-precipitate4 by 
adding 200 jzl of PEG 6000 solution, the contents of the tube were mixed by gentle 
inversion and incubated for 15 minutes at room temperature. The precipitated 
bacteriophage particles were sedimented by centrifugation (17,000 x g) in a 
microcentrifuge for 5 minutes at room temperature. The supernatant was decanted, and 
excess PEG 6000 solution was removed from the walls of the tube by brief centrifugation 
(17.000 X g) in a microcentrifuge for 1 minute at room temperature. The remaining PEG 
6000 solution was removed from the microcentrifuge tube by aspiration with a drawn-.out, 
glass capillary tube. The bacteriophage pellet was resuspended in 0.5 ml of sequencing 
TE; bacteriophage were lysed and contaminating proteins were extracted by adding 200 
Al of phenol. The liquid phases were mixed by vortexing for 20 seconds, allowed to stand 
for 15 minutes at room temperature and mixed again by vortexing for 20 seconds. The 
phases were separated by centrifugation (17,000 x g) in a microcentrifuge for 5 minutes 
at room temperature, and the upper, aqueous phase was recovered. Contaminating 
proteins were removed by repeated extraction with 200 j.tl of phenol. The upper, aqueous 
layer was recovered and remaining traces of phenol were extracted by adding 0.5 ml of 
diethyl ether. The lower, aqueous phase was recovered and re-extracted with 0.5 ml of 
diethyl ether. The lower, aqueous phase was recovered and extracted with 0.5 ml of 
chloroform. The upper, aqueous phase was recovered, and single stranded bacteriophage 
DNA was precipitated with ethanol. The DNA pellet was dried under vacuum and 
redissolved in 100 Al of sequencing TE. 
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213.7.2 Dideoxvnucleotjde chain-termination sequencing reactions 
10 x TM: 
100mM Tris-HC1 pH 8.5 
50mM MgCl2 
Oligodeoxynucleotide sequencing primers: 
S 'd(GTAAAACGACGGCCAGT)3' Bacteriophage M13 universal sequencing 
primer (20 nucleotides from the polylinker 
site); 17 bases. 
5 'd(CGCCAACflACAAGGCC)3' HBV sense strand, nucleotide positions 2382-
2398; 17 bases. 
5 d(ATGGCTGCTAGGCTGTG)3' HBV sense strand, nucleotide positions 2656-
2672; 17 bases. 
5 d(GCACGTCGCATGGAGA)3' HBV sense-strand, nucleotide positions 2881- 
2896; 16 bases. 
5 'd(GCGGCTAGGAGFI'CCGC)3' HBV anti-sense strand. nucleotide positions 
2571-2555; 17 bases. 
Oligodeoxynucleotide sequencing primers were synthesised by the OSWEL DNA 
service, Department of Chemistry, University of Edinburgh, using an Applied 
Biosystems Inc. 38013, DNA Synthesizer and were diluted in H20 to a 
concentration of 1 pmole/j.tl. 
Primer mixes: 
a) Primer mix for complete sequencing (4 chain termination reactions): 
1.5 jil oligodeoxynucleotide primer (1 pmole/bLl) 
1.5 jxl 10  TM 
10 jzl single stranded template DNA (100 ngIl) 
b) Primer mix for single dideoxynucleotide tracking (per clone): 
0.4 M'  oligodeoxynucleotide primer (1 pmo!e/btl) 
0.4 al 10 x TM 
2.4 Al H20 
3 /LI single stranded template DNA (100 nglpl) 
Chain-termination mixes: 
Chain-Termination Mix 
(numbers are in uI) 
Nucleotide L CO  C  AO 
0.5mM dTTP 10 200 200 200 
0.5mM dCTP 200 10 200 200 
0.5mM dGTP 200 200 10 200 
10mM ddTTP 20 
10mM ddCTP 3.2 
10mM ddGTP . 6.4 
10mM ddATP 0.5 
sequencing TE 400 400 400 200 
Kienow reaction mix (per template; 4 chain termination reactions): 
4 MC [a-35S]dATP (8 MCi/Mi; Amersham) 
1.5 units K coli DNA polymerase I (Kienow fragment) (5 U//,Li: Boehringer) 
0.8 pA 10mM Dfl 
6.5 Al 10mM Tris-HCI pH 8.5 
dNTP chase mix: 
dflP, dCTP, dGTP, dATP each at 0.25mM 
Formamide dye: 
0.1% (w/v) xylene cyanol 
0.1% (w/v) bromophenol blue 
10mM EDTA 
in formamide 
Single stranded bacteriophage M13 DNA containing an insert of heterologous DNA was 
primed for DNA polymerisation by annealing to a synthetic oligodeoxynucleotide 
containing sequence complementary to the lacZ gene of the M13 vector or to the DNA 
insert in the M13 vector. 0.5 pmole of primer DNA was mixed with 1 jug of template 
DNA in 1 x TM, the solution was incubated for 5 minutes at 80°C and slowly cooled to 
room temperature over 20 minutes. Sequencing reactions were carried out in microtitte 
plates. 2 Al of template DNA with annealed primer was dispensed into each of 4 wells 
followed by 2 p1 of one of the chain-termination mixes (G°, A°, 10,  or C°), and the 
solutions were mixed by tapping the plate. 2 p1 of Klenow reaction mix was added to each 
well, the solutions were mixed by tapping the plate and incubated for 25 minutes at room 
temperature. 2 Al of dNTP chase mix was added to each well, the solutions were mixed 
by tapping the plate and incubated for a further 20 minutes at room temperature. For 
single-track sequencing the reaction was carried out for only one of the chain-termination 
mixes per template and the rest of the reactions were performed as described above. 
Sequencing reactions were stopped by adding 2 Al of formamide dye to each well and 
double stranded reaction products were denatured by incubating the solutions for 15 
minutes at 80°C. 
2B.7.3 Resolution of sequencim4 reaction products by electrophoresis in urea-
polyacrylamide gels 
Urea-polyacrylamide solution: 
17 g urea 
6 ml 40% (w/v) acrylamide [38% (w/v) acrylamide, 2% (w/v) NN'-methylene 
bisacrylamide 
4 ml 10 x ThE 
17 ml H20 
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DNA sequencing reaction products were resolved in 6% acrylamide. 7M urea gels on a 
vertical gel apparatus. 240 At of 10% (w/v) ammonium persulphate and 35 At of 
N,N,N,N'-tetramethyl-ethylenediamine (TEMED) were added to the urea-polyacrylamide 
solution, the solution was poured between two glass plates with gel dimensions 380mm x 
200mm x 0.5 mm, and allowed to polymerise with the well comb in place. 
The heated sequencing reactions were snap-cooled on ice and approximately 2 Al of each 
sample was loaded onto the gel using a drawn-out, glass capillary tube. The DNA 
sequencing products were separated by electrophoresis using 1 x TBE running buffer at 
constant power of 25-30 watts (ca. 20-30 mA, 1.1-1.5 kV). Electrophoresis was continued 
until the required fragment separation was achieved (bromophenol blue migrates with 
DNA fragments of about 25 nucleotides in length, xylene cyanol migrates with DNA 
fragments of about 75 nucleotides in length). After electrophoresis the gel was fixed by 
immersion in 10% (v/v) acetic acid, 10% (v/v) methanol for 15 minutes at room 
temperature. The gel was transferred to blotting paper, covered in thin plastic film (Saran 
Wrap) and dried on a gel slab drier. X-ray film was exposed to the dried gel for 16 hours 
or longer in a light-proof cassette at -70°C to prevent the gel from sticking to the film. 
213.8 Amplification of inRNA Using the Polymerase Chain Reaction (PCR) 
10 x Activity Grade Buffer (IBI): 
100mM Tris-HCI pH 83 
0.5M KCI 
15mM MgCl2 
0.1% (w/v) gelatin 
0.1% (v/v) Tween 20 
0.1% (v/v) NP-40 
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Oligodeoxynucleotide primers: 
5 d(GGCTGCAGGGGTCACCATArFCYFGGGAACAA)3 - 
REV sense strand, nucleotide positions 914-937 with eight additional 
nucleotides at the 5 end including a cleavage site for restriction 
endoculease Pstl. Tm = 70°C. 
5 d(GGGAAflCGCGGGGTAGGCTGCCGTCCT)3' 
HBV anti-sense strand, nucleotide positions 1236-1217 with eight 
additional nucleotides at the 5 '  end including a cleavage site for restriction 
endonuclease ffcoRl. Tm  70°C. 
5 d(GCTAflCCAGAAGTAGTGAGGAG)3' 
SV40 nucleotide positions 5228-5206. Tm = 68°C. 
5 'd(GCCCCAAAGCCACCCAAcJGC)3' 
HBV anti-sense strand, nucleotide positions 3182-3163. Tm = 68°C. 
Oligodeoxynucleotides were synthesised by the OSWEL DNA service, Department 
of Chemistry. University of Edinburgh, using an Applied Biosystems Inc., 38013, 
DNA Synthesizer and were diluted in H20 to a concentration of 10 pmoles4tl. 
The reverse transcriptase activity of Thermus aquaticus DNA polymerase (Jones and 
Foulkes. 1989; Tse and Forget 1990) was exploited to amplify sequnces directly from 
RNA. RNA was prepared from monolayers of mammalian cells in culture and stored in 
aliquots of approximately 40 jig at -70°C as an ethanol precipitate as described above 
(section 2B.2.3). RNA was sedimented by centrifugation (17,000 x g) in a microcentrifuge 
for 15 minutes at 4°C, and the superanatant was removed carefully by aspiration with a 
drawn-out, glass capillary tube. The RNA pellet was redissolved in 45 Al H20 and 5 p.l 
of 10 x DNasel buffer [1M sodium acetate, 100 mM MgCI21 was added. 1 jil  of DNasel 
(23 U//-Ll. RNase free: Boehringer) was added to the RNA solution, and it was incubated 
for 30 minutes at 37°C. The DNase treated solution was split into two, 25 jil  parts. 1 Jul 
of RNase A (10 mg/ml; Sigma) was added to one of the parts, and it was incubated for 
a further 30 minutes at 37°C. Contaminating proteins in both parts were extracted with 
FY1 
PCI, and nucleic acid was precipitated with ethanol. The supernatants were carefully 
removed by aspiration with a drawn-out, glass capillary tube and the nucleic acid pellets 
were redissolved in 50 Al H20. 1 j.tl RNase inhibitor (40 U/1i1 RNAsin; Promega) was 
added to each sample. PCR reactions were carried out in the following 50m1 reaction 
mixture: 
5 Ml RNA sample (approx. 2 bLg in total of DNase treated material) or RNase 
treated sample 
5 Al 10 x Activity GradeTM  Buffer (IBI) 
1 M1  10mM each dGTP, cIATP, dflP, dCTP 
1 jsl sense strand primer (10 pmoles/Ml) 
1 Al anti-sense strand primer (10 pmoles/Ml) 
0.5 Al Thermus aquaticus DNA polymerase (4 U/MI;  IBI) 
36.5 jtl H20 
overlayed with 50 Al sterile paraffin oil 
PCR reactions were carried out using a Techne PHC-2 Dri-Block with 30 cycles of the 
following reaction times: 
denaturation: 93°C. 1.5 minutes 
annealing: 59°C, 1.5 minutes 
polymerisation: 70°C, 1 minute. 
The products of PCR reactions were visualised by "Southern" hybridisation. The DNA 
products in 10 M1  of PCR reaction mixture were fractionated by electrophoresis in an 
agarose gel and transferred to a nylon membrane (Nytran. Anersham Interantional). 
DNA fragments were detected by hybridisation to a radio-labelled DNA probe 
representing sequences internal to both oligodeoxynucleotide primers. 
F.Y.I 
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28.9 Site Directed Mutagenesis (SDM) 
The method used for SDM was developed by D. Melton (personal communication). 
10 x polynucleotide kinase buffer: 




0.5 mg/ml BSA 
10 x TM: 
100mM Tris-HCI pH 8.5 
50mM MgC12 
Sequencing TE: 
10mM Tris-HCI pH 8.0 
0.1mM EDTA 
CINTP chase mix: 
dflP, dCTP, dGTP, dATP each at 0.25mM 
Mutant oligodeoxynucleotide primer: 
S 'd(CGGCCAGGTCTGTGCCCTGGCTGGGGC)3' 
HBV sense strand, nucleotide positions 2444.2459/2485-2495 for deletion 
of nucleotides 2460-2484. 
Oligodeoxynucleotide was synthesised by the OSWEL DNA Service. Department 
of Chemistry. University of Edinburgh, using an Applied Biosystems Inc., 380B. 
DNA synthesiser. Oligodeoxynucleotide was supplied at a concentration of 40 
pmoles/jsl in H20 and used undiluted. 
2B.9.1 Phosphorylation of 5' end of oligodeoxvnucleotjde with T4 polvnucleotide kinase 
T4 polynucleotide kinase was prepared by S. Bruce as described by Midgley and Murray 
(1985). Phosphorylation of the 5' end of the mutant oligodeoxynucleotide was carried 
out for 1.5 hours at 37°C in the following reaction mixture: 
6,u1 oligodeoxynucleotide (40 pmoles/pd) 
1 p110 x polynucleotide kinase buffer 
2 Al T4 polynucleotide kinase (0.5 U/pA) 
1 Al H20. 
40 p1. H20 were added after the reaction time, contaminating proteins were extracted with 
PCI and nucleic acid was precipitated with ethanol. The nucleic acid pellet was dried 
under vacuum and redissolved in 12 p1 H20. 
2B.9.2 Synthesis of mutant strand DNA and recovery of mutant clones 
The bacteriophage M13 single stranded DNA template used for mutagenesis was the 
vector M13mp19 with 2.3 kb of HBV DNA (nucleotide positions 1004-3182/1-82) inserted 
at the polylinker site. The phosphorylated, mutant primer and the 17-base universal 
primer for bacteriophage M13 (section 2B.7.2) were annealed to the template DNA by 
incubating the following mixture for 5 minutes at 80°C and cooling slowly over 20 minutes 
to room temperature: 
12 p1 phosporylated mutant primer (20 pmoles/.t1) 
3 p1 universal primer (1 pmole/pl) 
3 Al single stranded template DNA (1 /LgIl) 
2p110xTM 
KE 
DNA polymerisation was carried out for 1.5 hours at room temperature in the following 
reaction mixture: 
20 Al single stranded template DNA with primers annealed 
20 pA dNTP chase mix 
I pA 50mM ATP 
1.5 pA F. coli DNA polymerase I (Kienow fragment) (5 U/pd; Boehringer) 
5 Al T4 DNA ligase (1 U/pd: Boehringer) 
2.5 Al sequencing YE 
After the reaction time, contaminating proteins were extracted with PCI and remaining 
traces of PCI were extracted with an equal volume of butan-1-ol. The lower, aqueous 
phase was recovered, and DNA was precipitated with ethanol. The DNA pellet was dried 
under vacuum and redissolved in 32 M1 H20. The HBV DNA insert was now double 
stranded, and it wasexcised from the bacteriophage M13 vector DNA by digestion with 
EcoRI and Hint/Ill. The cleavage products were fractionated by electrophoresis in a low-
melting-temperature agarose gel and the 2.3 kb HBV insert DNA fragment was purified 
as described above (section 2B.4.2). This DNA fragment was ligated to M13mp19 vector 
DNA that had been linearised by digestion with EcoRI and Hint/Ill. F. co/i BMH71-18 
mutL cells were transformed with ligation mixture and recombinant plaques were isolated. 
M13 clones containing a mutated HBV DNA insert were identified by T-track sequencing. 
I ng of mutant template DNA was used to transform F. co/i strain TG1. A single, 
colourless plaque was isolated for small-scale preparation of RF DNA as described above 
(section 2B.2.4c). The insert of HBV DNA was excised from the bacteriophage M13 
vector DNA by digestion with EcoRI and Hint/Ill, and the resulting 2.3 kb HBV DNA 
fragment was ligated to pUC8 linearised by digestion with EcoRI and Hint/Ill. 
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2B.10 Techniques for Analysis of Proteins. 
213.10.1 Radio-immunoassay for detection of FIBsAp 
The medium was recovered from confluent monolayers of hepatoma cells 3.5-4.5 days 
post-transfection with HBsAg expression vectors. In some cases HBsAg was concentrated 
from the culture medium by ultracentrifugation (150,000 x g for 5 to 16 hours) and 
resuspended in 1/20th or 1/30th volume of PBS for assay. Secreted HBsAg was detected 
by radio-immunoassay using the AUSRIA 11-125 kit (Abbott Laboratories). The method 
used was procedure A or B as recommended by the manufacturer. 200 Al of sample was 
added to each well containing a polystyrene bead coated with guinea pig antibody to 
HBsAg and was incubated for 2 hours at 45°C or for 16 hours at room temperature. The 
sample was removed by aspiration and the beads were washed 10 times by filling the well 
each time with 1 ml H20 and removing it by aspiration. 200 Al of [125I-anti-HBsAg 
(human) (0.74 MCi/mI) was added to each well and incubated with the beads for 1 hour 
at 45°C. The liquid was removed by aspiration and the beads were washed as described 
above. The beads were transferred to counting phials and counted in an LKB Mini-
Gamma counter. 
For detection of HBsAg particles containing middle-S (preS2/surface) polypeptides, 
polystyrene beads were incubated at room temperature for at least 4 hours in a solution 
of 200mM NaHCO3 pH 9.2, containing 60Mg!ml anti-preS2 monoclonal antibody, Q19/10 
(Heerman a al., 1988). Beads were dried on absorbent paper and used in the radio-
immunoassay described above in place of the beads coated with guinea pig anti-HBsAg. 
For detection of HBsAg particles containing large-S (preSl/preS2/surface) polypeptides. 
beads were coated with anti-preSi monoclonal antibody, MAI8/7 (Heerman a aL, 1984), 
and used in the radio-immunoassay as described above. 
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2B.10.2 Lowry protein assay 
Solutions: 
Lowry reagent: 
2% (w/v) Na2CO3  
0.01% (w/v) CuSO4 
0.02% (w/v) tn-sodium citrate 
100mM NaOH 
The method used to determine the concentration of protein in solution was that decribed 
by Lowry et at (1951). Protein sample in 0.4 ml was added to 2m] of Lowry reagent; the 
solution was mixed by inversion and incubated for 10 minutes at room temperature. 200 
pa of 50% (v/v) Folin-Ciocaltea's phenol reagent (Sigma) was added, mixed by inversion, 
and the mixture was incubated for 30 minutes at room temperature. OD650nm  was 
recorded for the sample; the assay was calibrated using BSA at a concentration of Ito 400 
jig/ml. 
2B.10.3 Electrophoresis of proteins in polyacrylamide gels 
Resolving gel solutions (50 ml): 
7% acrvlamide 
11.6 ml 30% (w/v) acrylamide 
11.6 ml 0.2% (w/v) NN -- 
methylene bisacrylamide 
6.25 ml 3M Tris-HCI pH 8.8 







Stacking gel solution (15m1, 3.75% acrylamide):. 
1.88 ml 30% (w/v) acrylamide 
1.88 ml 0.2% (w/v) NN'-methylene bisacrylaniide 
1.88 ml 1M Tris-HCl pH 6.8 
9.36 ml H20 
2 x PAGE loading buffer: 
120mM Tris-HCl pH 6.8 
4% (w/v) SDS 
20% (v/ti) glycerol 
60 mM DTT (added to immediately prior to use) 
10 x PAGE running buffer 
0.25M Tris-HCl 
2M glycine 
1% (w/v) SDS 
Proteins were separated on the basis of their molecular weight by polyacrylamide gel 
electrophoresis (PAGE). The method used was the discontinuous buffer system described 
by Laemmli (1970). 10 ml of resolving gel solution was placed in a separate beaker and 
150 p1 of 10% (w/v) ammonium persulphate and 10 M1  of TEMED were added. The 
solution was poured into a mould into which the bottom of the glass plates for PAGE had 
been placed and was allowed to polymerise for 15 minutes to seal the gap between the 
bottoms of the plates. 0.4 ml of 10% (w/v) SDS, 200 j.il of 10% (w/v) ammonium 
persulphate and 20 Al of TEMED were added to the remaining 40 ml of resolving gel 
solution, and the solution was poured between the sealed glass plates with gel demensions 
170mm x 150mm x 1.5mm. The solution between the glass plates was overlaid with H20 
and left to polymerise for at least 1 hour. 150 jil of 10% (w/v) SDS, 100 pA of 10% (w/v) 
ammonium persulphate and 10 Al of TEMED were added to the stacking gel solution, the 
water was removed from above the polymerised resolving gel, and the stacking gel was 
poured on top of the resolving gel with gel dimensions 50mm x 150mm x 1.5mm. The 
NFJ 
stacking gel was allowed to polymerise with the gel comb in place for at least 30 minutes. 
An equal volume of 2 x PAGE loading buffer was added to protein samples and they were 
incubated for 5 minutes at 100°C before loading onto the gel. Electrophoresis was carried 
out on a vertical apparatus using 1 x PAGE running buffer for 5-6 hours at 25 mA or for 
12-16 hours at 6 mA until the desired separation was achieved. Low molecular weight 
markers (Pharmacia) were: phosphorylase b (94 kD), bovine serum albumin (67 kD), 
ovalbumin (43 kD), carbonic anydrase (30 kD), trypsin inhibitor (20.1 kD) and a-
lactalbumin (14.4 kD). High molecular with markers (Sigma) were: myosin (205 kD), I-
galactosidase (116 kD), phosphorylase B (97.4 kD), bovine albumin (66 kD), egg albumin 
(45 kD) and carbonic anhydrase (29 kD). 
2B.10.4 Staining of proteins separated in polyacrylamide gels 
After electrophoresis, polyacrylamide gels were removed from between glass plates and 
incubated with shaking for 1 hour at room temperature in a solution of 40% (v/v) 
methanol and 10% (v/v) acetic acid containing 0.2% (wlv) Coomassie brilliant blue R 
(Sigma). Gels were destained in 40% (v/v) methanol, 10% (v/v) acetic acid. For storage, 
gels were dried onto blotting paper using a slab gel drier. 





20% (v/v) methanol 
The method used for transfer of proteins separated on polyacrylamide gels to membranes 
was essentially that described by Towbin a aL (1979). After electrophoresis, 
polyacrylamide gels were removed from between glass plates and a cassette was 
constructed containing the following components saturated with transfer buffer and 
layered in the following order: Scotchbrite pad, 3 sheets of blotting paper cut to the size 
of the gel, nitrocellulose membrane (0.45 Am pore size; Schleicher and Schull).cut to the 
size of the gel, 3 sheets of blotting paper cut to the size of the gel. Scotchbrite pad. The 
cassette was closed and placed with the nitrocellulose membrane between the gel and the 
anode in a Bio-Rad electrotransfer apparatus filled with transfer buffer. Proteins were 
transfered at 75 V for 4 hours or 40 V for 16 hours. 
Proteins transferred to the nitrocellose membrane could be stained reversibly by 
incubation of the membrane in a solution of 3% (w/v) trichioro-acetic acid and 0.5% (w/v) 
Ponceau S (Sigma) for 30 seconds at room temperature and destaining with H20. The 
stain was removed by incubation of the membrane in protein blocking solution (TS/Milk. 
section 2B.10.8). Proteins transferred to the nitrocellose membrane could be stained 
permanently by incubation of the membrane in a solution of 40% (v/v) methanol and 10% 
(v/v) acetic acid containing 0.1% (w/v) amido black NB (Sigma) for 30 seconds at room 
temperature. The membrane was destained by washing in several changes of 40% (v/v) 
methanol, 10% (v/v) acetic acid. 
2B.10.6 Spotting of proteins onto nitrocellulose membranes 
50 Al of protein preparation was spotted onto a nitrocellulose membrane using a vacuum 
apparatus (Hybri.DotTM Manifold; Bethesda Research Laboratories) 
2B.10.7 Purification of rabbit antiserum 
Antibodies in rabbit 98 anti-HBxAg serum and rabbit 87 anti-HBcAg IgG preparation that 
cross-reacted with endogenous E. coli RB791 proteins were removed by preadsorbing the 
preparations against a lysate of these cells. 10 ml of L-broth containing ampicillin (100 
jig/mi) was inoculated with a single colony of E. coli RB791, and cells were grown to 
stationary phase at 37°C with shaking. The cells were sedimented from suspension by 
centrifugation (12,000 x g) for 10 minutes at 4°C, and the cell pellet was resuspended in 
I ml of TS [10mM Tris-HCl pH 7.4, 150mM NaCI]. 100 Al of 10% (w/v) SDS was added, 
and the suspension was incubated for 5 minutes at 100°C. This lysate was diluted 10 fold 
in TS. Equal volumes of E. coli cell lysate and either Rabbit 87 IgO preparation or 
Rabbit 98 antiserum were mixed by rotation for 12-16 hours at 4°C. Antibody-antigen 
complexes were removed by centrifugation (17,000 x g) in a microcentrifuge for 15 
gel 
minutes at 4°C. The supernatant was transferred to a fresh microcentrifuge tube and an 
equal volume of cell lysate was added again. The procedure was repeated 4 times and the 
pre-adsorbed antiserum was stored at -20°C. 
Antibodies in rabbit 98 anti-HBxAg serum that cross-reacted with the 1cro/ -galactosidase 
fusion protein encoded by the pEX vector series, and antibodies that cross-reacted with 
endogenous E. coil NFl proteins were removed by pre-adsorbing the antiserum against 
a lysate from E. coli NFl cells producing the pEX vector fusion protein. 5 ml of L-broth 
containing ampicillin (100 jig/ml) was inoculated with a single colony of E. coil NFl 
harbouring plasmid vector pEX2. The cells were grown to stationary phase at 30°C with 
shaking. 10 ml of L-broth containing 100 mg/ml ampicillin was inoculated with 100 Al of 
the stationary phase culture, and cells were grown to OD650flm  0.5 at 30°C with shaking. 
Expression of the fusion protein from the XPr promoter contained in the pEX vector was 
induced by incubation of the culture for 30 minutes at 42°C with shaking. The culture was 
then returned to 30°C for a further 30 minutes with shaking. Cells were sedimented from 
the induced culture by centrifugation (12,000 x g) for 10 minutes at 4°C, and the cell 
pellet was resuspended in 1 ml of TS [10mM Tris-HCI pH 7.4, 150mM MaCI]. The cell 
lysate was prepared as described above for E. coil RB791 and the antiserum was 
preadsorbed as described above. 
2B.10.8 Immunological detection of proteins immobilised on nitrocellulose filters 
10 x Tris-HCi/NaCl (TS): 
100mM Tris-HCi pH 8.1 
150mM NaCl 
0.5% Tween 20 
TS/Milk: 
5% (w/v) non-fat milk powder (Marvel) in 1 x TS 
0.1% (w/v) sodium azide 
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Developing solution: 
100mM Tris-HCI pH 9.5 
100mM NaCl 
50mM MgCl2 
0.33 mg/ml nitro-blue-tetrazolium (NBT) 
0.25 mg/ml 5-bromo-4-chloro-3-indolyl-phosphate (BCIP) 
(NBT and BCIP added immediately prior to use) 
Protein samples were electroblotted or spotted onto a nitrocellulose membrane, and the 
membrane was incubated for at least 1 hour at room temperature with shaking in TS/Milk 
in order to block non-specific binding of protein probes to the membrane. The blocking 
solution was removed, and the membrane was incubated with the appropriate dilution if 
primary antibody in TS/Milk (approximately 10 ml per 100 cm2 of membrane) for 4-16 
hours at room temperature with gentle shaking. The primary antibody solution was 
removed, and the membrane was washed in 5 changes of 1 x TS over a period of 30 
minutes. Depending on the animal source of the primary antibody, the secondary 
antibody was either goat anti-rabbit IgG (Fc)  alkaline phosphatase conjugate or goat anti-
human IgG (Fc)  alkaline phosphatase conjugate (1 mg/ml; Promega Biotec). The washed 
•membrane was incubated with a 1:7500 dilution of secondary antibody in TS/Milk for 2 
hours at room temperature with gentle shaking. The membrane was washed in I x TS as 
before, and the presence of bound alkaline phosphatatase was detected by incubation of 
the membrane in developing solution for 2-15 minutes at room temperature. The reaction 
was stopped by washing the inemebrane in several changes of H20. 
2B.109 Preparation of p-palactosidase fusion proteins from E. co/i 
The method used to prepare P -galactosidase fusion proteins was essentially that described 
by Stanley and Luzio (1984). Portions of the HBxAg coding sequence were fused in-
frame to the 3'  end of the coding sequence for 3-galactosidase contained in the plasmid 
pEX2 or pEX3. A single colony of E. coli NFl harbouring one of the pEX plasmid 
derivatives was used to innoculate 5 ml of L-broth containing ampicillin (100 jig/mI), and 
cells were grown to stationary phase at 30°C with shaking. 1.5 ml of L-broth containing 
ampicillin (100 jig/ml) was inoculated with 30 jil of stationary phase culture and cells were 
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grown to OD650nm  0.5 at 30°C with shaking. Expression of the fusion protein from the 
1Pr contained in the pEX vector was induced by incubation of the culture for 30 minutes 
at 42°C with shaking. The culture was then returned to 30°C for a further 30 minutes 
with shaking. 1 ml of the induced cell culture was transferred to a microcentrifuge tube, 
and cells were sedimented from suspension by centrifugation (17,000 x g) in a 
microcentrifuge for 1 minute at room temperature. The cell pellet was resuspended in 
40 Al PAGE loading buffer, cells were lysed and proteins were denatured by incubation 
at 100°C for 5 minutes, and samples were loaded onto a 7% polyactylamide gel. 
2B.10.10 Purification of HBcX produced in K co/i 
HBcX is a fusion protein of HBcAg and HBxAg encoded by plasmid pHBcX whose 
construction is described in section 5.2.1. The methods used to purify HBcX were 
modifications of those described by Stahl and Murray (1989). 
Lysis Buffer: 
50mM Tris-HCl pH 8.0 
1% (v/v) Triton-X100 
0.1mM phenylmethylsulphonyl fluoride (PMSF) 
Column matrices, sizes and equilibration buffers are listed in table 2.1. All column 
matrices were from Pharmacia. Columns were equilibrated with 400 ml of buffer at a flow 
rate of 20 ml per hour. Proteins were eluted from the columns in the amount of buffer 
indicated in the text at a flow rate of 10 ml per hour. 3.3 ml- fractions of eluate were 
collected and assayed for the presence of HBcX by, a) immunodetection with rabbit 98 
anti-HBxAg serum or rabbit 87 anti-HBcAg IgG preparation of proteins spotted onto 
nitrocellulose membrane, b) immunodetection with rabbit 98 anti-HBxAg serum of 
proteins fractionated by PAGE in 12.5% acrylamide gel and electroblotted to 
nitrocellulose membrane, or c) staining of proteins fractionated by PAGE with Coomassie 
blue, Other methods employed for detection of HBcX are indicated in the text. 










2.5 cm diameter X 11 cm 
2.5 cm diameter X 12.5 cm 
2.5 cm diameter X 12.5 cm 
2.5 cm diameter X 10.5 cm 
1.5 cm diameter X 11 cm 
1.5 cm diameter X 11.5 cm  
Equilibration buffer 
100mM NaHCO3 pH 7.0 
100mM NaHCO3 pH 9.6 
10mM Tris-HCl pH 7.0 
8M Urea in 10mM Tris-HC1 
pH7.0 
10mM Tris-HCl pH 7.0 
10mM Tris-HCl pH 7.0 
a) Small-scale preparation 
10 ml of L-broth containing ampicillin (100 jig/mI) was inoculated with a single colony of 
E. coli RB691 harbouring plasmid pHBcX, and cells were grown to stationary phase at 
37°C with shaking. 500 ml of L-broth containing ampicillin (100 jig/ml) was inoculated 
with 10 ml of stationary phase culture, cells were grown to OD650nm  1.0 at 37°C with 
shaking, and 2.5 ml of 100mM IPTG in dimethylformamide was added (final 
concentration, 0.5mM). The cells were grown for 16 hours at 37°C with shaking and were 
sedimented from suspension by centrifugation (17,000 x g) for 10 minutes at 4°C. The cell 
pellet was resuspended in 100 ml of L-broth, and cells were sedimented from suspension 
again by centrifugation (17,000 x g) for 10 minutes at 4°C. The cell pellet was 
resuspended in 10 ml of lysis buffer, the suspension was transferred to a plastic centrifuge 
tube and sonicated for 8 x 30 seconds (Soniprobe, Dawe Instruments type 7530A) to lyse 
the cells. The cellular debris in the lysate was sedimented by centrifugation (12,000 x g) 
for 10 minutes at 4°C, and the supernatant (designated "crude extract") was recovered. 
4 ml of crude extract was layered onto the column of Sepharose CL-413, and protein was 
eluted in 200 ml of 100mM NaHCO3  pH 7.0. Fractions containing HBcX were combined 
and fusion protein was sedimented by ultracentrifugation (160,000 x g) for 1.5 hours at 
4°C. The protein pellet was resuspended in 0.5 ml of 100mM NaHCO3  pH 7.0 containing 
0.1mM PMSF and stored at -20°C. 
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b) Large-scale preparation 1. 
Purification steps used in this preparation are diagrammed in figure 2.1. 
200 ml of L-broth containing ampicillin (100 j.tg/ml) was inoculated with a single colony 
of E. co/i RB791 harbouring plasmid pHBcX, and cells were grown to stationary phase at 
37°C with shaking. 5 x 2 litres of L-broth containing ampicillin (100 ,uglrn!) was inoculated 
with 40 ml/21 of stationary phase culture, cells were grown to OD650nm  1.0 at 37°C with 
shaking, and lml/21 of 1M TPTG in dimthylformamide was added (final concentration, 
0.5mM). The cells were grown for 16 hours at 37°C with shaking and were sedimented 
from suspension by contiuous-flow centrifugation. The cell paste was resuspended in 
200m1 of lysis buffer, and cells were broken by passing through a French press (5 x 15 
seconds at 8000 psi). The cellular debris in the lysate was sedimented by centrifugation 
(12,000 x g) for 20 minutes at 4°C, and the supernatant was recovered. Fusion protein 
was sedimented from crude extract by ultracentrifugation (160,000 x g) for 1.5 hours at 
4°C, and the protein pellets were resuspended in a total of 6m1 of 100mM NaHCO3 pH 
7.0 containing 0.1mM PMSF. This preparation is designated "crude extract" in figures 2.1 
and 2.2. 
3 ml of crude extract was layered onto the column of Sepharose CL-413, and protein was 
eluted in 100 ml of 100mM NaHCO3 pH 7.0. Fractions containing HBcX were combined. 
and fusion protein was sedimented as above. The protein pellet was resuspended in 1.5 
ml of SM urea in 100mM NaHCO3 pH 9.6. This solution was heated to 37°C for 1 hour. 
and layered onto the column of Sephacryl 5-200 equilibrated in 100mM NaHCO3 pH 9.6. 
Protein was eluted in 200m1 of this buffer; fractions containing HBcX were combined, and 
fusion protein was sedimented as above. The protein pellet was resuspended in 1.5 ml 
of 10mM Tris-HCl pH 7.0 containing 0.1mM PMSF. One third of the HBcX preparation 
(0.5 ml) was layered onto the column of CM-Sepharose, and protein was eluted in 200 ml 
of 10mM Tris-HCI pH 7.0. Fusion protein was located in a single fraction by Lowry 
protein assay and sedimented as above. The protein pellet was resuspended in 100 M1  of 
10mM Tris-HCI pH 7.0 containing 0.1mM PMSF, and the purity of the preparation was 
assayed by PAGE in 12.5% acrylamide gel. The 100 pd preparation was recombined with 
the I ml of preparation remaining after gel-filtration in Sephacryl-S200. 
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FIGURE 2.1 Scheme for purification of HBcX. Large-scale preparation 1. 
Column chromatography stages of purification are indicated in boxes along with the butler 
used for equilibration of each column. Details of the purification procedure are provided 
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DEAE-preparation 1 
The protein preparation was split into three parts of 0.35 ml. 1.7 ml of SM urea in 10mM 
Tris-HCI pH 7.0 was added to one of the parts, the solution was heated to 37°C for I 
hour, and layered onto the column of1 pIcrylS-200 equilibrated in 10mM Tris-HCI pH 
7.0. Protein was eluted in 200 ml of 10mM Tris-HCI pH 7.0. Fusion protein was 
sedimented as above from each HBcX-positive fraction separately, and each protein pellet 
was resuspended in 100 btl of 10mM Tris-HCI pH 7.0 containing 0.1mM PMSF. 
1.7 ml of 8M urea in 10mM Tris-HCI pH 7.0 was added to the second part of the HBcX 
preparation, the solution was heated to 37°C for one hour and layered onto the column 
of Sephacryl S-200 equilibrated in the SM urea solution. Protein was eluted in 200 ml of 
this solution, and fusion protein was sedimented as above from each HBcX-positive 
fraction separately. Each protein pellet was resuspended in 100 At of 10mM Tris-HCI pH 
7.0 containing 0.1mM PMSF. 
The third, part of the HBcX preparation was layered onto the column of DEAE-
Sepharose, and was bound to the column by washing in 20 ml of 10mM Tris-HCI pH 7.0 
at a flow rate of 10 ml/hour. Protein was eluted from the column with a 100 ml 
continuous gradient of NaCl (0 - 0.5M) in 10mM Tris-HCI pH 7.0. Fractions containing 
HBcX were combined, and fusion protein was sedimented as above. The protein pellet 
was resuspended in 200 At of 10mM Tris-HCI pH 7.0 containing 0.1mM PMSF. 
c) Large-scale preparation 2. 
Purification steps used in this preparation are diagrammed in figure 2.2. 
E. coil RB791 harbouring plasmid pHBcX were grown and induced as in large-scale 
preparation 1 (above). Cells were lysed as above except that DYE was added to 10mM 
immediately following crushing of cells in the French press, and DYE was present at that 
concentration in all subsequent solutions. Crude extract was prepared as described above, 
the preparation was split into two equal portions, and each half was fractionated by gel 
filtration through the column of Sepharose CL-4B column as described above. Fractions 
from each half containing HBcX were combined separately and fusion protein was 
sedimented as above. The protein pellets were each resuspended in 1.25 ml of 10mM 
Tris-HCI pH 7.0 containing 0.1mM PMSF, and each half was fractionated by 
103 
FIGURE 2.2 Scheme for purification of HBcX. Large-scale preparation 2. 
Column chromatography stages of purification are indicated in boxes along with the buffer 
used for equilibration of each column. Details of the purification procedure are provided 
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100mM NaHCO3 pH 7.0 
1 
DEAE-Sepharose: 
10mM Tris-HCI pH 7.0 
chromatography through the DEAE-Sepharose column as described above. The positive 
fractions were combined, fusion protein was sedimented as above, and the protein pellet 
was resuspended in 200 pA of 10mM Tris-HCI pH 7.0 containing 0.1mM PMSF 
Additional protein was eluted from the DEAE-Sepharose column with steps of 100 ml of 
IM NaCl, lOOmI of 2M NaCl, and lOOmI of SM urea (all solutions were prepared in 
10mM Tris-HCI pH 7.0). Fractions of eluate from each step containing HBcX were 
combined separately. Pooled fractions containing urea were dialysed against three 
changes of I litre each of 10mM Tris-HCI pH 7.0. Fusion protein was sedimented as 
above and each protein pellet was resuspended in 200.tl of 10mM Tris-HCI pH 7.0 
containing 0.1mM PMSF; 
After analysis by PAGE in 12.5% acrylamide gel, all of the protein preparations eluted 
from the DEAE-Sepharose column were combined, fusion protein was sedimented as 
above, and the protein pellet was resuspended in 150 M1  of 10 mM Tris-HCI pH 7.0 
containing 0.1mM PMSF. 
0.11 Preparation of crude protein extract from mammalian cells in culture 
Confluent monlayers of mammalian cells were washed and scraped from the plate as 
described for RNA preparation (section 2B.2.3a). The cell pellet was resuspended in 1 
ml of PBS containing 0.1mM PMSF and transferred to a microcentrifuge tube. The cell 
suspension was frozen by incubation for 10 seconds in liquid nitrogen and then thawed 
by incubation for 3 minutes at 37°C. The freeze-thaw cycle was repeated 2 more times, 
and cellular debris was removed by centrifugation (17,000 x g) ina microcentrifuge for 10 
minutes at 4°C. The supernatant was recovered and stored at -70°C. 
2B.10.12Jmmunoprecipitation of soluble protein 
Protein A Sepharose beads (Sigma) (10% w/v) wereswollenby  incubation in 1 ml of PBS 
for 1 hour at 37°C. The swollen beads were sedimented from suspension by centrifugation 
(17,000 x g)in a microcentrifuge for 15 seconds at room temperature. Beads were washed 
4 times in several volumes of PBS and finally resuspended (10% (w/v)) in PBS and stored 
at 4°C. 
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The method used to immunoprecipitate soluble protein was that described by Harlow and 
Lane (1988). The appropriate antiserum was added to protein solution at a dilution of 
1:250. the solution was mixed by gentle inversion and incubated for 1 hour on ice. One-
tenth volume of protein A Sepharose bead suspension was added and the mixture was 
incubated for 1 hour at 4°C with rotation. The beads were sedimented from suspension 
by centrifugation (17,000 x g) in a microcentrifuge for 15 seconds and were washed 3 
times in 10 volumes of PBS. The washed beads were used directly in a protein kinase 
assay. 
2B.10.I3 Assay for protein kinase activity 
10 x protein kinase buffer: 




Protein kinase assays were carried out in the following 50 jul reaction mixture. 
5 j.tl 10 x protein kinase buffer 
10 p1 HBcAg (2 tg4tl, E. coli product; Biogen) 
34 b protein sample (either soluble protein, or protein immobilised on protein 
A Sepharose beads) 
1 /Ll {y-32P]ATP (10 ,.LCi/bd; Amersharn) 
As a positive control, the protein sample used was 0.5 jAg of bovine heart protein kinase 
(catlytic subunit of cAMP-dependent protein kinase; Sigma) in 34M1 H20. As a negative 
control, H20 was used in place of HBcAg and protein sample. The kinase reaction was 
carried out for 1 hour at 37°C after which 10 btl of sample was spatted onto each of two 
6.25cm2 DE81 filters. Filters were allowed to dry and were then washed in several 
changes 0.5M Na2HPO4 pH7.0 over a period of 1 hour as described by Maniatis et aL 
(1982). Filters were then washed for 1 minute in H20 and for 1 minute in absolute 
ethanol and allowed to dry at 60°C. The amount of radioactive phosphate incorporated 
106 
into protein was assessed by counting the Cerenkov radiation in the 3H-channel of a 
Beckman LS7000 liquid scintillation counter, and this value was compared to the number 
of counts obtained from an unwashed filter onto which 10 Al of the negative control 
reaction mixture was spotted. 
Labelled proteins in the kinase reaction mixture were separated by PAGE in 12.5% 
acrylamide gel and visualised by autoradiography. 30 At of 2 x PAGE sample buffer 
(section 2B.10.2) was added to the remaining 30 jil of reaction mixture, samples were 
incubated for 5 minutes at 100°C, and protein A Sepharose beads were sedimented by 
centrifugation (17,000 x g) in a microcentrifuge for 15 seconds at room temperature. 
Soluble parts of the samples were loaded onto a 12.5% acrylamide gel, and electrophoresis 
was carried out as described above (section 2B.10.2). Proteins were electroblotted onto 
a nitrocellulose membrane, and visualised by staining with amido black NB (Sigma) as 
described above (section 2B.10.5). X-ray film was exposed to the membrane in a light-
proof cassette with intensifying screens (Dupont Cronex Lightning Plus) at -70°C. 
Exposure times are indicated in figure legends. 
2B.10.14 Electron microscopy of HBcMJHBxAQ fusion protein 
Protein samples were diluted 10-fold in F120 and 1M1  of diluted sample was placed on a 
400 mesh copper electron microscope grid. 3 M1  of 2% (wlv) sodium phospho-tungstate 
pH 7.0 was placed over the protien sample and excess liquid was drained off with blotting 
paper. Samples were viewed and photographed at 40,000 x magnification using a Siemens 
Elmiskop 101 electron microscope. 
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CHAPTER 3: The Immunological Response to liBiAg 
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3.1 Introduction 
Viral infection elicits a humoral (B-cell) and cellular (T-cell) immune response from 
the host directed against the viral antigens. HBxAg itself has not been detected in serum 
from HBV infected individuals (Weber et at, 1988), however, indirect evidence for the 
expression of HBxAg in vivo has been provided by the detection of antibodies specific for 
this antigen in patient sera (Kay et at, 1985; Moriarty et at. 1985; Elfassi et at. 1986: 
Meyers et at. 1986; Pfaff a at, 1987; Koike a at. 1988; Weber a at, 1988; Katayama, 
a at. 1989; Levrero ci at, 1990b: Stemler a at, 1990). Some reports have attempted to 
determine whether the production of antibodies to HBxAg is diagnostic for any of the 
variable clinical features of HBV infection. 
The overall conclusion from the above mentioned studies is that antibodies directed 
against HBxAg are produced during HBV infection in only a fraction of hepatitis B 
patients. Meyers and his colleagues (1986) assayed patient sera for anti-HBxAg by the 
ability to immunoprecipitate a labelled X-gene product produced in E. coli. In a panel of 
49 HBsAg-positive sera, antibodies to HBxAg were detected in only one sample, while in 
a separate panel of sera characterised as containing antibodies to HBeAg, 9/26 were also 
anti-HBxAg positive. The observed correlation between the presence of antibodies 
specific for HBxAg and for HBeAg was consistent with a limited study by Kay a at 
(1985). 
Serum from 254 hepatitis B patients was screened for antibodies directed against 
HBxAg using an ELISA in which a synthetic peptide (representing either amino acid 
residues 100.115 or 144.154 in the deduced HBxAg primary structure) was immobilised 
on the solid phase (Moriarty a at. 1985). Thirty-five sera were found to contain 
antibodies which bound to one or both peptides including sera from asymptomatic carriers 
(4/68), chronic hepatitis patients (20/149), and patients with liver cirrhosis (3/19) or HCC 
(8/11) following chronic HBV infection. The high fraction of sera from HCC patients that 
were positive for anti-HBxAg suggested that this response may be a marker for the 
development of HCC. 
Both of the above correlations were called into question by further investigations of 
the humoral immune response to HBxAg. Several studies have revealed a stronger 
correlation between the chronic active hepatitis (CAH) disease state and production of 
antibodies to HBxAg than that observed in the same studies in sera from patients with 
HCC (table 3.1a). Sera from patients with CAR that were positive for anti-HBxAg were 
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Table 3.1a: Correlation between CAll and anti-HBxAg 
A P C Total 
Disease state 
CAH 4/6 6/31 3/14 13/51 
HCC 11/42 2/49 0/3 13/94 
Results from three studies indicating the ratio of patient sera in which antibodies to 
HBxAg were detected to the total number of sera examined. A: Pfaff et at, 1987; B: 
Levrero a at, 1990b; C: Elfassi ci' at, 1986. Abbreviations: CAT-I = chronic active 
hepatitis; HCC = hepatocellular carcinoma. 
Table 3.1b: Correlation between the presence of HBeAg and anti-HBxAg. 
A P C Total 
Serological 
marker 
HBeAg 3/4 5/6 3/3 11/13 
anti-HBeAg 0/4 1/6 N.T. 1/10 
Results from three studies indicating the ratio of patients that were anti-HBxAg positive 
and also positive for the serological marker indicated to the total number of patients that 
were anti-HBxAg positive. References are the same as for tab1e13.1a. N.T. = not tested. 
predominantly negative for anti-HBeAg, but positive for the presence of HBeAg (table 
3.lb). HBeAg in patient serum is a marker for ongoing viral replication (Overby ci' at. 
1983) suggesting that production of antibodies to HBxAg requires chronic exposure to 
replicating virus. Antibodies to HBxAg in serum from patients with acute infection were 
not detected in any of the studies described thus far. 
The requirement for chronic exposure to HBV replication for seroconversion to anti-
HBxAg positive was called into question by Weber et at (1988). Sera were assayed for 
the presence of antibodies to HBxAg by immunoblot analysis with an X-gene product 
produced in K co/i. From a panel of ten HBsAg-positive sera, cross reacting antibodies 
were detected in patients suffering acute infection (1/3), late acute infection (3/3), and in 
one of two chronic carriers. (The disease state of the patient was undefined for two of the 
serum samples which were both negative for anti-HBxAg antibodies.) Positive sera all 
contained HBeAg but were negative for anti-HBeAg. In the same study, weekly serum 
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samples collected during acute infection of chimpanzees experimentally inoculated with 
HBV were assayed for the presence of anti-HBxAg. All four animals seroconverted to 
anti-HBxAg positive within five months post-infection, but the response was transient. 
lasting at most 70 days. None of the control animals vaccinated with HBsAg or HBcAg 
prior to challenge with HBV developed antibodies to HBxAg. The occurrence of an 
immune response to HBxAg during acute infection has been confirmed by Stemler a al. 
(1990). However, the authors note that they found lower titres of anti-HBxAg antibodies 
in serum from patients experiencing acute infection compared to those with chronic HBV 
infection. 
The detection of antibodies to HBxAg in serum from patients manifesting a number 
of disease states associated with HBV infection in both chimpanzees and humans indicates 
that the viral gene product is expressed and presented in an immunogenic form during 
various clinical manifestations of viral infection. The low proportion of HBV infected 
individuals producing antibodies to HBxAg may be due to the low amount of antigen 
produced by infected cells. X-gene specific transcripts have not been detected in HBV 
infected liver (Cattaneo et at, 1984; Will a at, 1987; Su a at. 1989), and HBxAg has not 
been detected in serum from infected patients (Weber a at, 1988). A consequence of 
intracellular compartmentation of HBxAg may be that it is only presented to the immune 
system upon liver cell necrosis, and higher titres of anti-HBxAg observed in sera from 
chronic hepatitis patients support the hypothesis that ongoing hepatocytolysis is necessary 
for presentation of HBxAg. Mother factor in the low proportion of HBV infected 
individuals who produce antibodies specific for HBxAg may be the cellular codon usage 
demonstrated for this particular antigen of HBV (Miller and Robinson, 1986). If a distant 
cellular homolog is expressed an individual may develop tolerance to the viral antigen of 
similar shape. 
Wu and her colleagues have recently reported that HBxAg is a component of the 
HBV virion. The ability of B cells to function as antigen presenting cells has been 
demonstrated by Lanzavecchia (1985), therefore a B-cell binding to and internalising the 
HBV virion could present peptide fragments of HBxAg in association with MHC class II 
antigens, thereby stimulating T-helper cells with HBxAg-specific receptors. The T-helper 
cell population thus stimulated may enhance the HBxAg specific B-cell response upon 
binding of antigen to the B-cell (see section 1.3.2 for a more detailed outline of this 
mechanism). 
The aim of this part of my investigation was to begin to dissect the antigenic 
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determinants on HBxAg which bind antibodies produced during HBV infection or those 
raised in a rabbit inoculated with a denatured form of HBxAg expressed in E. co/i. 
3.2 Results 
3.2.1 Plasmid constructions 
Pugh et oL (1986) described synthesis in E. co/i of HBxAg encoded by plasmid pBBX 
containing HBV sequences 2682-3182/1-88 inserted at the BarnHl site of plasmid 
pCL19SY (Zabeau and Stanley, 1982). pBBX encodes a fusion protein of 153 amino 
acids in which the 9 amino-terminal residues of HBxAg are replaced with the first 8 
amino-terminal residues of Acro protein. Various segments of the X ORF contained in 
plasmid pBBX were inserted at the polylinker site in plasmid pEX2 or pEX3 (Stanley and 
Luzio, 1984). These two K co/i expression vectors contain a polylinker in a different 
translational reading frame at the 3' end of a Acro//acl/lacZ fusion gene (figure 3.1). 
Transcription is under control of the bacteriophage A right promoter and is heat inducible 
in F. co/i cells (for example. strain NFl) harbouring a A prophage encoding a temperature 
sensitive mutant ci repressor protein. A large proportion of the resulting fusion protein 
is composed of F. co/i polypeptide sequences yielding a stable product accounting for up 
to 30% of protein in crude cell-extracts. In addition, sequences fused to the carboxyl-
terminus of -galactosidase using the pEX system have been shown to maintain their 
antigenicity in immunoblot analysis (Stanley and Luzio. 1984; McGlynn and Murray. 1988). 
HBV DNA inserts in plasmid pEX are shown in figure 3.2, and the corresponding 
fusion proteins encoded by these plasmid constructions are shown in figure 3.3. Plasmid 
pXA was constructed to express in the pEX system all of the HBxAg coding sequence 
(amino acid residues 10-154) contained in plasmid pBBX. Plasmid pEX3 was linearised 
by digestion with Sail, filling in cohesive ends with DNA polymerase I (Kienow fragment), 
and digestion with BamHI. HBV sequences (2683-3158) were isolated from plasmid 
pBBX by digestion with BamHI and A/uI, and the resulting 475 bp DNA fragment was 
ligated to the prepared pEX vector DNA. Recombinant plasmids were selected following 
transformation of E. co/i strain MC1061(A) with DNA in the ligation mixture. These cells 
contain a wild type A prophage and cells harbouring a pEX based plasmid construction 
may be grown at 37°C while maintaining repression of expression from the A right 
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FIGURE 3.1: pEX vector 
Map of plasmid pEX2 showing unique restriction sites 
Organisation of the fusion gene and of translational and transcriptional control elements 
contained in the plasmid. A detailed description is provided in section 2A.3.2. Tfd = 
transcription terminator fragment from bacteriophage fd. 
From Stanley and Luzio, 1984. 
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FIGURE 3.2 
Top: X ORF and 3' flanking sequence in HBV subtype adyw used in this study. 
Restriction endonuclease cleavage sites used for subcloning fragments of the X 
ORF into plasmid pEX are indicated. Numbers under restriction sites represent 
the position of the first nucleotide of the recognition sequence. The positions of 
the first and last nucleotides of HBxAg coding sequence are indicated. 
Below: Fragments of the X ORF contained in plasmids encoding -galactosidase/HBxAg 
fusion proteins. Plasmids are shown in the order in which their products appear 
in figure 3.4. Restriction endonuclease cleavage sites flanking the insert of HBV 
DNA are indicated. The numbers represent the first and last nucleotides of HBV 
sequence contained in the recombinant plasmids. (Construction of plasmids is 
described in detail in section 3.2.1) 
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Top: Open box representing the complete amino acid sequence of HBxAg. 
Below: Predicted amino acid sequences in the single letter code of 3-galactosidase/HBxAg 
fusion proteins. Names of plasmids encoding the proteins are at left in the order 
in which their products appear in figure 3.4. "-gal' represents the protein 
encoded by the Xcro/lacl/lacZ fusion gene contained in the pEX vector with the 
number representing the amino acid position in native f3-galactosidase. Numbers 






pXM3: f3-gal P I HBxAg 
1007 58 154 
pX5M: 3-gaI LIPGDPSTJ HBxAg J RPAAKLAD 
1006 12 104 
-4 
pXA: j3-gal LIPO HBxAg 
1006 10 154 
pXM: J3-gal p HBxAg IGIRRPAAKLD 
1007 58 104 
pX3: I3-gai P HBxAg 
1007 105 154 
-4 
pX5: 3-gaI ILIPGDPS1I HBxAg ILDLQPSLLID 
1006 12 67 
\1%) 
MC1061(A) cells and used to transform E. co/i NFl to allow heat inducible expression of 
the fusion protein encoded by the plasmid. This transformation procedure was used for 
isolation of all the following pEX constructions. DNA sequence determination confirmed 
that the junction of the 3 end of the lacZ gene and the 5' end of the HBV DNA insert 
in plasmid pXA was as expected and the open reading frame was maintained through the 
X-gene stop codon. However, a BamHI site was revealed at the 3' junction of HBV 
sequence and vector sequence. This most likely arose from a failure of the Sail digestion 
of the pEX vector DNA resulting in a linearised plasmid with BamHI cohesive ends. In 
this model, proper ligation of the BamHI cohesive ends at the 3' end of the lacZ gene 
and the 5 'end of the HBV DNA insert occurred in vitro. Upon transformation of E. co/i 
MC1061(A) the 5' overhang of the remaining BamHI cohesive end was repaired by host 
cell DNA polymerase and this blunt end was ligated to the blunt end created by digestion 
of HBV DNA with AM. 
Plasmid pXM3 contains the coding sequence for the carboxy-terminal two thirds of 
HBxAg (amino acid residues 58-154) fused to the 3' end of the IacZ gene and was 
constructed as follows: plasmid pEX2 was linearised by digestion with BamHI and SinaI. 
HBV sequences (2826.3182/1-88) were isolated from plasmid pBBX by digestion with 
Haelll and Sau.IIIa, and the resulting 444 bp DNA fragment was ligated to the prepared 
pEX vector DNA. The integrity of the vector/insert junctions and of the X ORF was 
confirmed by DNA sequence determination. 
Plasmid pX5M contains the coding sequence for the amino-terminal two thirds of 
HBxAg (amino acid residues 12-104) fused to the 3' end of the lacZ gene and was 
constructed as follows: HBV sequences (2683-2966) were isolated from plasmid pBBX by 
digestion with BamHI and HinclL and.the resulting 283 bp DNA fragment was ligated to 
plasmid pEX-3 DNA prepared as described for construction of pXA. DNA sequence 
determination revealed that the vector DNA had only been digested with Sall and this site 
had been rendered blunt by the action of DNA polymerase I (Kienow fragment). It was 
determined that this site had been ligated to the BamHI site at the 5' end of the HBV 
DNA insert whose cohesive end had been repaired. The /acZ ORF was maintained at 
this junction resulting in the loss of only two codons from the 5' end of the desired X 
ORF insert. The integrity of the X ORF and 3' insert/vector junction was confirmed by 
DNA sequence determination. 
Plasmid pXM contains the coding sequence for the middle third of HBxAg (amino 
acid residues 58-104) fused to the 3' end of the lacZ gene and was constructed as follows: 
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plasmid pEX2 was linearised by digestion with EcoRI and Smal. The HBV DNA insert 
in plasmid pXM3 was isolated by digestion with EcoRI and XbaL which cuts 40 
nucleotides downstream of the polylinker site in the pEX vector sequence. The resulting 
502 bp DNA fragment was digested with Hincll, and the resulting 140 bp DNA fragment 
(HBV nucleotide positions 2826-2966) was ligated to the prepared vector DNA. The 
integrity of the vector/insert junctions and of the X ORF was confirmed by DNA 
sequence determination. 
Plasmid pX3 contains the coding sequence for the carboxy-terminal third of HBxAg 
(amino acid residues 105-154) fused to the 3 end of the lacZ gene and was constructed 
as follows: plasmid pEX2 was prepared as described for construction of pXM3. The HBV 
DNA insert in plasmid pXM3 was excised by digestion with EcoRI and Xbal. The 
resulting 502 bp DNA fragment was digested with Hincll and Saulila, and the resulting 
304 bp fragment (HBV nucleotide positions 2966-3182/1-88) was ligated to the prepared 
vector DNA. The integrity of the vector/insert junctions and of the X ORF was 
confirmed by DNA sequence determination. 
Plasmid pX5 contains the coding sequence for the amino-terminal third of HBxAg 
(amino acid residues 12-67) fused to the 3 '  end of the lacZ gene and was constructed as 
follows: plasmid pEX2 was prepared by digestion with Sall, filling in cohesive ends with 
DNA polymerase I (Klenow fragment), and digestion with SstI which cuts following the 
codon for 3-galactosidase residue 650 in the pEX vector sequence. HBV sequences 
(2683-2857) and 1 kb of the lacZ gene were isolated from plasmid pXSM by digestion 
with Avail, filling in cohesive ends with DNA polymerase I (Kienow fragment) and 
digestion with SstI. The resulting 1.2 kb DNA fragment was ligated to the 4.3 kb vector 
DNA fragment. DNA sequence determination confirmed that the X ORF, which had 
been contained in plasmid pX5M, was deleted to codon 67 and the fusion protein coding 
sequence terminated in the vector sequence downstream of the 3' insert/vector junction. 
3.2.2 Antienicity of HBxAg fraQments fused to Q-alactosidase 
I3-galactosidase/}IBxAg fusion proteins were expressed by heat induction of F. co/i 
NFl cells harbouring one of the recombinant plasmids described above. Total protein 
from a panel of induced cells was size fractionated by SDS-PAGE in a 7% aciylamide gel 
and was detected by staining with Coomassie Brilliant Blue (figure 3.4a). The size of the 
fusion proteins was in close agreement with that predicted from the constructions. 
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FIGURE 3.4: Antigenicity of -galactosidase/HBxAg fusion proteins produced in E. co/i 
Extracts of E.co/i cells alone (NFl), cells harbouring the vector plasmid (pEX) and cells 
harbouring plasmids encoding p-galactosidase/HBxAg fusion proteins (pXM3. pX5M, 
pXA, pXM, pX3, pX5) were fractionated by SDS-PAGE in a 7% acrylamide gel. 
Coomassie Blue stain of acrylamide gel. 
Proteins fractionated by SDS-PAGE were transferred to nitrocellulose membrane and 
incubated with serum from chimpanzee Peter (section 2A.5) diluted 1:200. Antibodies 
which bound proteins on the membrane were detected by incubation with goat anti-
human IgG antiserum conjugated to alkaline phosphatase and subsequent incubation 
with a colour producing substrate as described in section 213.10.8. Densitometric 
analysis of the resulting bands was done on the Shimadzu Dual Wavelength Cromato 
Scanner, Model CS-930. The numbers below each lane represent the peak reflective 
intensities obtained. 
Immunoblot analysis as in "B" using a 1:5000 dilution of rabbit 98 anti-HBxAg serum 
(section 2A.5) for the primary incubation and goat anti-rabbit IgG serum for the 
secondary incubation. Rabbit 98 antiserum had been preadsorbed against a lysate of 
E. coli strain NFl producing the pEX vector fusion protein (section 2B.10.7) 
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Coomassie 
NFl pEX pXM3 pX5M pXA pXM pX3 pX5 
Chimpanzee 
NFl pEX pXM3 pX5M pXA pXM pX3 pX5 
owe  
93 .253 .333 .357 .97 .274 .379 
Rabbit 
NFl pEX pXM3 pX5M pXA pXM pX3 pX5 
.17 .246 .140 .310 .62 .309 .141 
The antigenicity of the fusion proteins was assessed by immunological detection of 
proteins transferred to a nitrocellulose membrane after SDS-PAGE. A rabbit antiserum 
was raised by Pugh a aL (1986) against a denatured form of HBxAg produced in E. co/i 
harbouring plasmid pBBX and purified bySDS-PAGE (section 2A.5). The antiserum was 
pre-adsorbed against a lysate from E. co/i NFl cells transformed with plasmid pEX2 in 
which expression of the pEX vector fusion protein had been induced by incubation at 
42°C. This procedure removed antibodies that cross-reacted with endogenous EL co/i NFl 
proteins and with the -galactosidase fusion protein encoded by the pEX vector. (The 
pEX vector protein contained the same eight amino acids of ). cro protein as the HBxAg-
fusion protein with which the rabbit was inoculated.) Serum withdrawn from the rabbit 
prior to inoculation with HBxAg did not react with pEX vector protein or any of the 
fusion proteins (data not shown). The numbers in figure 3.4b,c represent the peak 
reflective intensities obtained by densitometric analysis of the bands on the membrane 
following immunoblotting. The pre-adsorbed rabbit antiserum did not react with pEX 
vector protein: it reacted strongly with antigenic determinants in the carboxy-terminal third 
of HBxAg, less strongly with those in the amino-terminal third of the viral antigen, and 
only minimally with those in the middle third of HBxAg when these sequences were 
presented fused to -galactosidase (figure 3.4c: pX3, pX5 and pXM. respectively). The 
pattern of antigenicity for the carboxy- and amino-terminal thirds of the protein was 
repeated when the middle third of the antigen was included in proteins expressed from 
plasmids pXM3 or pX5M. respectively. Immunological detection revealed breakdown-
products of some of the fusion proteins that retained reactivity with the anti-HBxAg 
antisera. It was not possible to assess the exact constitution of these products, therefor 
they were not included in the densitometric analysis. 
The antigenic determinants recognised by anti-HBxAg antibodies produced during 
acute infection with HBV were determined as above for serum withdrawn from 
chimpanzee Peter 184 days after experimental infection. It had been shown previously 
by immunoblotting that this serum contained antibodies that reacted with HBxAg 
produced in E. co/i encoded by plasmid pBBX (Weber a aL, 1988). Serum withdrawn 
prior to infection did not react with any of the J3-galactosidaselHBxAg fusion proteins 
(data not shown). The anti-HBxAg-positive serum showed virtually no reactivity with the 
pEX vector protein, but reacted strongly with fusion proteins containing either the 
carboxy- or amino-terminal third of HBxAg (figure 3.4b: pX3 or pX5, respectively). As 
observed with the rabbit antiserum, reactivity with the middle third of HBxAg was weak 
119 
(pXM). and when this segment was included with either the carboxy-terminal third 
(pXM3) or amino-terminal third (pX5M) of the antigen it did not alter the pattern of 
reactivity observed when these segments were presented on their own. 
3.3 Discussion 
The presence of antibodies directed against HBxAg in the rabbit anti-serum and the 
chimpanzee serum indicates that both denatured and native HBxAg (respectively) are 
immunogenic. The polyclonal response elicited in both cases contained antibodies that 
reacted with the denatured -galactosidaseIHBxAg fusion proteins immobilised on 
nitrocellulose membrane following SDS-PAGE. The titre of antibodies in the chimpanzee 
serum recognising denatured antigenic determinants on HBxAg was much lower than in 
the rabbit anti-serum raised against a denatured form of the antigen. In order to obtain 
comparable signals the chimpanzee serum was used at a dilution of 1:200 while the rabbit 
anti-serum was used at a dilution of 1:5000. 
Antibodies elicited by a native protein are directed against two classes of antigenic 
determinants (reviewed by Benjamin et at. 1984). Conformational determinants depend 
on the native spatial arrangement of two or more peptide regions in the protein and it is 
improbable that they would be maintained following denaturation of a protein for SDS-
PAGE. Continuous determinants depend only on the amino acid sequence of a peptide 
segment. Antibodies developed against the native antigen will be directed against the 
accessible surface which can combine with appropriate antibodies displayed by the B-cell 
repertoire. Space filling models of globular proteins indicate that very few continuous 
stretches of residues are present at the surface of a protein (Barlow et at. 1986 Van 
Regenmortel, 1989). Therefore, the majority of antibodies raised against a native protein 
will depend on conformation for binding, accounting in part for the low titre of antibodies 
in the chimpanzee serum reacting with the denatured antigens used in the assay in this 
study. Other factors contributing to the low titre of antibodies to HBxAg in the 
chimpanzee are the low level of HBxAg produced during infection and the fact that only 
a fraction of the amount produced is presented to the immune system upon hepatocyte 
necrosis. 
Both chimpanzee and rabbit sera gave differential binding to the various segments of 
HBxAg expressed in the -galactosidase/HBxAg fusion proteins. This differential is most 
likely due to the presence in the serum of a greater number of antibodies directed against 
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a particular antigenic determinant rather than antibodies of greater affinity remaining 
bound to the protein immobilised on the membrane. Immunoblotting does not require 
high affinity antibodies due to the high local concentration of antigen on the  membrane. 
Antibodies can bind through both Fab arms, and, if dislodged, low affinity antibodies have 
the opportunity to bind adjacent sites (Harlow and Lane, 1988). 
Both rabbit and chimpanzee sera reacted weakly with the middle third of HBxAg. In 
the case of the anti-native HBxAg chimpanzee serum, a weak reaction may indicate that 
this segment of HBxAg is buried in its native conformation and is not accessible for 
binding to appropriate antibodies displayed by the B-cell repertoire. That is, an antigenic 
response is not seen because the region is not immunogenic in the animal. The pattern 
of antigenic determinants observed with the chimpanzee serum was in good agreement 
with a computer prediction of antigenic sites in HBxAg (figure 3.5) (Jameson and Wolf, 
1988). The algorithm used in the program calculates an antigenic index which is an 
indication of potentially exposed surface peaks of a native protein based on its amino acid 
sequence. It takes into account parameters that have been shown to correlate with sites 
of antigenic determinants including hydrophilicity (Hopp and Woods, 1981), flexibility 
(Westhof et aL, 1984) and probability of situation at the surface of the protein (Emini et 
aL, 1985). The computer program also considers predictions of secondary structure such 
as a-turns (Chou and Fasman, 1978; Gamier et aL, 1978) which would contribute to 
flexibility. 
It is interesting that the same region of HBxAg that reacted weakly with the 
chimpanzee antiserum also reacted poorly with the rabbit antiserum. Features of 
secondary and tertiary structure of the immunogen should not be a factor in this case, as 
it was denatured by boiling in SDS. Antibody production would have been determined 
by the immune regulatory mechanisms in the host whose response cannot be predicted for 
a protein of unknown form. 
From the single humoral response to native antigen investigated in this study, it is not 
possible to generalise about regions of HBxAg that may be immunodominant. The 
humoral response to particular portions of an antigen vary markedly among individuals of 
a particular species and one needs to evaluate a consensus response from several samples 
before speculating about immunodominance (Geysen et aL, 1987). Such a study has been 
reported recently for HBxAg (Stemler et aL, 1990). 
Stemler and her colleagues investigated the distribution of antibodies directed against 
various segments of HBxAg in 50 sera from HBV patients previously shown to contain 
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FIGURE 3.5: Secondary structure and antigenicity prediction for HBxAg. 
The secondary structure prediction is that of Chou and Fasman (1978) and antigenicity 
was computed using an algorithm developed by Jameson and Wolf (1988). Both 
predictions were plotted using the University of Wisconsin Genetics Computer Group 
(UWQCG) "Peptidestructure" and "Plotstructure" programs (Devereux et aL, 1984). 
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antibodies specific for HBxAg. Antigenicity was determined by immunoblotting for a 
panel of 17 proteins produced in E. coil comprising various segments of HBxAg fused to 
a portion of the replicase gene of bacteriophage MS2. Nearly all of the sera (43/50) 
reacted with 3 of the fusion proteins, indicative of an immunodominant region contained 
within amino acids 90-102. 21 of 50 sera reacted with fusion proteins presenting an 
animo-terminal antigenic determinant (a.a. 33-67), while reactivity with the carboxy-
terminal third of HBxAg was rare with only 2 of 50 sera reacting with an antigenic 
determinant at amino acids 144-154. An immunodominant determinant in the region of 
amino acids 85-110 was confirmed by ELISA. A panel of 38 anti-HBxAg positive sera was 
screened for reactivity with overlapping synthetic peptidés of 15 residues representing the 
entire HBxAg primary structure. Antigenic determinants in peptides comprising both the 
amino- and carboxy-terminal thirds of the antigen (or both) were also detected by this 
analysis in greater than 50% of the sera assayed. The immunoblot presented by Stemler 
et aL for one of the two sera reactive with the carboxy-terminal determinant shows weak 
reactivity with the immunodominant region proposed in their analysis. The pattern of 
reactivity for this serum with amino- and carboxy-terminal determinants is similar to that 
detected with the chimpanzee serum in this study which may have been a rare observation. 
The study of antigenic determinants on a protein molecule provides a database of 
information about the nature of the mammalian humoral immune response. This 
knowledge is invaluable for predicting the immune response to other antigens for vaccine 
development or in the investigation of autoimmune disease. 
123 
CHAPTER 4: HBxM Modulates Expression of HBsAg 
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4.1 Introduction: General Features of Transact ivation by HBxAg 
The ability of HBxAg to transactivate a wide array of targets has been investigated in 
several recent studies (table 4.1; references in Appendix II). Most of these investigations 
have been carried out by transient expression of the bacterial chloramphenicol acetyl 
transferase (CAT) gene in mammalian cells under control of a potential target promoter 
or promoter/enhancer complex. In many studies, HBxAg was supplied in trans by 
cotransfecting a second plasmid containing the HBxAg coding sequence under control of 
its own promoter (Twu and Schloemer, 1987; Seto et at, 1988; Spandau and Lee, 1988; 
Twu and Robinson, 1989; Twu ci al., 1989a,b; Autlero and Schneider, 1990; Hu ci at. 
1990) or under control of a heterologous promoter, most commonly the SV40 early 
promoter/enhancer complex (Twu and Schloemer, 1987; Seto ci al., 1988; Spandau and 
Lee, 1988, Wollersheim ci at, 1988; Koike ci at, 1989; Seto ci at, 1989; Twu and 
Robinson, 1989; Faktor and Shaul, 1990; Rossner ci at, 1990; Seto et at, 1990; Unger and 
Shaul, 1990, Zhou ci at, 1990). 
The transactivating potential of HBxAg is maintained in the context of the whole 
HBV genome either expressed transiently in hepatoma cells (Colgrove ci at, 1989; Koike 
ci at, 1989) or integrated into hepatoma cell chromosomes following stable transfection 
(Zahm ci at, 1988; Siddiqui ci at. 1989; Twu and Robinson, 1989; Zhou ci at, 1990). In 
one example (Twu and Robinson, 1989), transactivation of the HIV1 LTR fused to the 
CAT gene was observed in HepG2 cells stably transfected with HBV DNA and producing 
virus providing further evidence that HBxAg is expressed during HBV replication. 
HBxAg coding sequences isolated from HBV integrates associated with 11CC 
(Wollersheim ci at, 1988) or chronic hepatitis (Takada and Koike, 1990) maintain the 
capacity to transactivate.. The implications of this function on the correlation between 
HBV infection and the development of neoplasia will be considered in Chapter 6. 
HBxAg produced in E. coil and administered to cultured mammalian cells by 
protoplast fusion (Twu ci at, 1990) or by direct application or 'scrape-loading" of the 
purified product (Jameel ci at. 1990) can transactivate an integrated DNA construction 
containing the HIV1 LTR fused to the CAT gene. Purified, EL co/i-derived HBxAg (Wu 
ci at, 1990) and HBxAg produced in hepatoma cells (Aufiero and Schneider, 1990) retain 
their transactivating capacity in transcription assays in vitro. 
The transactivating function of HBxAg is conserved among all the mammalian 
hepadnaviruses (Colgrove ci at, 1989; Seto ci at, 1989). Interestingly, Colgrove and his 
colleagues (1989) note that the DHBV genome does not encode a polypeptide with the 
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Table 4.1: Transactivation by HBxAg 
The targets that have been examined for susceptibility to transactivation by HBxAg are 
shown along with the cell lines in which experiments were conducted. References are 
listed in Appendix II."Low" indicates a low level of transactivation observed compared 
to transactivation of other regulatory regions in the same study, or, when considering a 
mutated regulatory region, compared to transactivation of the parent construction. 
a Tandem NF-KB binding sites derived from the HIV1 LTR were fused to the tk 
promoter fused to the CAT gene. 
b reference 18: NF-KB sites as in "a", but containing point mutations; reference 13: HIVI 
LTR fused to the CAT gene containing point mutations in the NF-KB binding sites, or 
containing a deletion from the 5 '  end of the LTR through the NF-icB binding sites; 
reference 10: HIV1 LTR fused to the CAT gene containing a deletion as in reference 13. 
c SV40 early promoter plus 32 nucleotides of the SV40 enhancer containing a binding site 
for transcription factor AP-1 fused to the CAT gene. 
d HBV enhancer (nucleotide positions 2351-2531) containing point mutations or a small 
deletion in the EF-C binding site (see section 1.4.3a) was fused to the SV40 early 
promoter fused to the CAT gene. 
e H-2K1' promoter containing point mutations in the NF-KB binding site and fused to the 
CAT gene. 
Abbreviations: 
enh - enhancer 
prom.- promoter 
mut. - mutant 
mur. - murine 







Transactivation Target Cells References 
HBV reuIatory sequences 
HBV core promoter HepG2 (low) 13 
HuH7 (low) 2 
HBV core promoter I enh PLC/FRFI5 14 
HuH7 2 
HepG2 6,13 
HBV preS2/S promoter I enh HepG2 6,9 
HuH7 2,9 
HBV preSi promoter / enh HepG2 6,9 
HuH7 9 
Hep3B 8a 












Adenovirus E2 promoter 
Ad2 VAI mRNA Chang liver 1 
Herpes simplex tk prom. CC113 24 
HIVI LTR HepG2 13,17,18,19,20 
Jurkat 10,11 
H938 (T-cell) 20 
Mn (T-cell) 17 
U937 11 
(T-lymphoma) 
SW480 (colon) 11 







HIV1 NF icBa HepG2 18 
Jurkat 10 
HIVI NF-KB mutantb Jurkat (low) 10 










































































SV40 early promoter NIH3T3 
SV40 early promoter / AP1C CCI13 
NIH3T3 
SV40 early promoter! BK enh Vero 
SV40 early prom. / HBV enh HepG2 
P L C/P R F/S 
Sk-Hepl 
SV40 early prom. / HBV enh 
(sEF.C) 
SV40 late prom. / HBV enh HepG2 
















HBV E site PLC/PRF/5 
HBV EP site 
HBV UE2 site 
NK-KB HepG2 
PLC/PRF/5 
Cellular promoter sequences 


















HLA-DR (MHC class II) HepG2 
HuH7 
metallothioneine CC113 (low) 
murine H2Kb(MHC class I) HepG2 
murine H-2K5 -NFicb mut.0 
c-niyc NIH3T3 
serum albumin 
















capacity to transactivate the Rous sarcoma virus (RSV) LTR in human hepatoma cells 
(HuH7), despite being able to replicate in these cells (HBxAg and GSHxAg were both 
active under these conditions). This result provides evidence against speculation that the 
DHBV genome may encode an "X-like" polypeptide within its core ORF (Feitelson and 
Miller, 1988; Feitelson et at, 1990). 
Transactivation by WHxAg and GSHxAg gives an initial indication of the sequences 
in HBxAg required for this function as the rodent antigens are missing 7 and 12 residues, 
respectively, from the carboxyl-terminus in comparison with HBxAg. Segments of HBxAg 
required for transactivating function have been analysed in several systems by deletion 
analysis (Faktor and Shaul, 1990; Levrero ci at, 1990a; Takada and Koike, 1990; Unger 
and Shaul, 1990; figure 4.1). Deletion of the first 30 amino acids of HBxAg rendered the 
product inactive (Faktor and Shaul, 1990) while removal of 11 or 12 carboxy-terminal 
residues did not affect the function of HBxAg (Levrero ci at. 1990a; Unger and Shaul, 
1990). Takada and Koike (1990) cite unpublished observations that deletion of 22 
carboxy-terminal residues, removing the carboxy-termimal conserved region, abolished its 
transactivating capacity. In contrast, Levrero ci at. (1990a) indicate that HBxAg with 37 
residues deleted from its carboxyl-terminus, removing half of the negatively charged region 
with predicted helical structure, retained the ability to transactivate. However, there are 
two reports indicating that HBxAg truncated at the same amino acid residue was non-
functional (Koike ci at, 1989; Caselmann ci at, 1990). The conflicting results may have 
arisen from different targets that were used in the transactivation assays (see figure 4.1). 
If HBxAg functions by mediating protein-protein interactions within the transcription 
complex (discussed further in section 6A.4.2) it may require alternative segments for 
interaction with different factors in the systems analysed above. 
The targets for transactivation by HBxAg are listed in table 4.1 along with the cell line 
in which the assays were carried out. HBV promoter/enhancer complexes have been 
investigated in several systems including, 1) in the context of the complete HBV genome 
itself (Colgrove ci at, 1989; Koike ci at, 1989), 2) in the context of the subgenomic 
mRNA transcription units (Rossner ci at, 1990; Zhou and Yen, 1990), 3) as isolated 
complexes linked to the CAT gene (Jameel and Siddiqui, 1986; Twu and Schloemer. 1987; 
Spandau and Lee. 1988; Wollersheim ci al., 1988; Siddiqui ci at, 1989; Faktor and Shaul, 
1990; Levrero ci at. 1990a; Unger and Shaul, 1990). and 4) with the firefly luciferase 
reporter gene inserted into the complete HBV genome (Raney ci at, 1990). Removal of 
the enhancer region from its complex with the core promoter fused to a reporter gene 
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FIGURE 4.1 Effects of deletions on the transactivating capacity of HBxAg 
Top: Representation of the complete amino acid sequence of HBxAg. Conserved 
(cons.) regions and negatively charged a-helical region (see section 1.3.4) are 
indicated. 
Below: Boxes represent the portions of HBxAg contained in deletion mutants. 
Transactivation activity (+) or lack of transactivation activity (-) are indicated 
along with the targets that were assayed. 
Abbreviations: 
HBV enh/Xp - HBV enhancer and X promoter region fused to the CAT 
gene. 
HBV E site - Three tandem copies of an oligonucleotide representing 
HBV nucleotides 2459-2484 were inserted 3'  to the CAT 
gene under control of the tk promoter. 
HIV1 or HIV2 LTR- LTR of HIV1 or HIV2 fused to the CAT gene. 
HBV genome - the truncated HBxAg polypeptide was created by a 
frameshift mutation in the X ORF contained within the 
complete HBV genome. The level of HBV-specific 
transcripts was assessed in cells transiently transfected with 
the mutant HBV genome and compared to the level 
produced by cells transientlyi tranfected with an intact 
HBV genome. 
References: 
Faktor and Shaul (1990). 
Unger and Shaul (1990). 
Levrero et at (1990a). 
Takada and Koike (1990). 
Caselmann a at (1990). 
Koike a at (1989). 
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HBV enh/Xp (a); 
HBV enh/SV40 Ep (a) 
HBV E site (b); HBV enh/Xp (b) 
HBV enhJSV40 Ep (C); HIV1 or 
HIV2 LTR (c) 
SV40 Ep/enh (d) 
SV40 Ep/enh (e); HBV genome(f) 
HBV enh/SV40 Ep (c);,HIV1 or 
HIV2 LTR (C) 
HBV E site (b): HBV enh/Xp (b) 
HBV enhJSV40 Ep (C); 1-IlV1 or 
HIV2 LTR (c 
(Spandau and Lee, 1988; Colgrove et at, 1989; Siddiqui et at, 1989 dramatically reduced 
susceptibility to transactivation by HBxAg indicating that this region serves as a target for 
transactivation within the HBV genome. Numerous transcriptional regulatory sequences 
from heterologous viruses have been reported as targets for transactivation by HBxAg-
In certain cases (for example the SV40 early promoter/enhancer in Vero cells, or the 
HIV1 LTR in HepG2 or HeLa cells) conflicting results have been obtained for the 
capacity of HBxAg to transactivate a certain regulatory sequence in a specific cell line. 
This may be due to: 1) differences in the basal activity of the reporter alone; a high basal 
activity could potentially mask transactivation, for example, in the case of the SV40 early 
promoter/enhancer in Vero cells (Twu and Schloemer, 1987); 2) variations in the HBxAg 
expressing plasmid construction used; if HBxAg was expressed at a very high level under 
control of a particular promoter the phenomenon of "squelching" (Ptashne. 1988) could 
mask transactivation (see section 4.3 for further discusion), and 3) individual variations in 
the CAT assays. 
The most detailed study of cell type specificity for HBxAg transactivation has been 
carried out by Seto and his colleagues (1989). They concluded that transactivation is cell-
line specific. Transactivation was observed in human cells of varying tissue origin and in 
mouse and monkey cells. Divergent results were obtained for a particular target in cell 
lines of similar cell-type origin, and only a subset of promoters was transactivated in any 
particular cell type (for example, the RSV LTR versus the HIV1 LTR in Jurkat, T-
lymphoma cells). The implications of these observations on the mechanism of 
transactivation by HBxAg will be discussed below. 
It has been demonstrated that several cellular regulatory sequences are targets for 
transactivation by HBxAg, and these results may explain certain physiological phenomena 
associated with HBV infection. Aberrant expression of MHC class II antigen on HBV 
infected hepatocytes (reviewed by Van den Oord, 1990) may he due to transactivation by 
HBxAg of the regulatory region of the genes that encode these antigens (Mu et at. 1990). 
The expression of MHC class II antigens by hepatocytes may have a variety of 
consequences. Hepatocytes may become antigen presenting cells to T-helper lymphocytes 
which recognise foreign antigen in association with this class of MHC antigen. T-helper 
cells secrete lymphokines to activate cytotoxic T-lymphocytes (CTLs), so activation of T-
helper cells by an infected hepatocyte could increase hepatocytolysis mediated by CTLs. 
Antigen presenting hepatocytes may also become susceptible to the direct cytolytic effects 
of a subset of T-helper cells shown to have these properties (Siliciano et at, 1988). 
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Conversely. MHC class II expression by infected hepatocytes may function to inactivate 
T-helper cells by presentation of antigen in the absence of the ability of the presenting 
cell to secrete lymphokines (reviewed by Meuller et at. 1989). thereby promoting the 
development of chronic infection. 
Transactivation of MHC class I gene expression by HBxAg may contribute to the 
elevated expression of these antigens on the surface of hepatocytes during HBV infection 
(Pignatelli a at, 1986). Zhou and his colleagues (1990) have shown that the promoter 
region of the murine MHC class I gene. H21(b. is a target for transactivation by HBxAg 
in human cells; this result is consistent with elevated production of MHC class I antigen 
by HepG2 cells stably transfected with a dimer of the HBV genome and producing virus. 
Increased MHC class I expression may augment hepatocyte necrosis mediated by CTLs. 
The susceptibility of the human n-interferon promoter to transactivation by HBxAg 
(Twu and Schloemer, 1987) is a curious result as increased serum interferon level is not 
associated with HBV infection (Hill et at, 1971). This effect of HBxAg may be blocked 
in viva by repression of the n-interferon promoter by HBcAg (Twu and Schloemer, 1989). 
Indeed, elevated 0-interferon mRNA was not detected in HepG2 cells stably transfected 
with a dimer of the HBV genome and producing virus (Zhou et al., 1990). Alternatively, 
these results may highlight the importance of chromatin environment in rendering a 
particular target promoter susceptible to transactivation. Twu and Schloemer (1987) 
observed transactivation of an episomal n-interferon promoter while the endogenous gene 
is not a target for transactivation by HBxAg expressed from an integrated HBV genome 
(Zhou a at. 1990). A similar effect has been observed for transactivation of the p-globin 
promoter in episomal configuration by adenovirus Ela protein while this result was not 
observed for the endogenous promoter (Green et at. 1983); .. 
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Increased cLmyc mRNA has been detected in mouse fibroblasts (NIH3T3) stably-
transfected with the X ORF under control of the SV40 early promoter/enhancer complex 
(Koike a al., 1989). In addition, transient assays in the same cell line revealed that the 
c-myc promoters fused to the CAT gene were susceptible to transactivation by HBxAg. 
An increase in c-myc expression could contribute to the development of HCC associated 
with HBV infection and may have implications for the mechanism of transactivation by 
HBxAg (see Chapter 6). 
- 
A striking serological feature of HBV infection is the presence of a vast quantity of 
HBsAg. High titre serum may contain 1013  particles per ml with HBsAg particles present 
in vast excess over virion (Cossart, 1971). The HBsAg particles may serve as "decoy 
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virions" to bind neutralising antibodies produced in response to infection. The work 
described in this chapter is an investigation of the effect of HBxAg on expression of 
HBsAg in transfected hepatoma cells. Expression of all three forms of H$sAg 
polypeptide is considered and preliminary studies on the segment of the HBV genome 
that serves as a target for transactivation by the X-gene product are described. 
4.2 Results 
4.2.1 Plasmid constructions 
Plasmid constructions are diagrammed in figure 4.2. Plasmid pHBV1004 contains the 
transcription units for the preS2/S mRNAs and the X mRNA and was constructed by 
Jackson (1987) as follows: HBV sequences (1005-3182/1-88) were isolated from plasmid 
pHBV130 (Gough and, Murray, 1982) by complete digestion with Bg1II followed by partial 
digestion with BarnHI. The resulting 2.3 kb fragment was ligated into the Barn HI site of 
pUCS. Plasmid pHBV1004-B contains a frameshift mutation that was introduced within 
the X-coding sequence in plasmid pHBV1004 by partial digestion with BarnHI, filling in 
cohesive ends of the site at position 2682 with DNA polymerase I (Klenow fragment), and 
ligation of the resulting blunt ends of plasmid DNA. The presence of four bp inserted 
at position 2683 was confirmed by DNA sequence determination (figure 4.3). The mutant 
X ORF contains a frameshift after the triplet coding for amino acid residue 10 (aspartate) 
in the X coding sequence resulting in the creation of a stop codon after 14 missense 
codons. To confirm that the preS2/S promoter sequences remained identical in the parent 
and mutant plasmids, DNA sequence was determined on the fragment between nucleotide 
positions 1004-1413 contained in the two plasmids. The integrity of the entire X ORF 
contained in plasmid pHBV1004 was confirmed by DNA sequence determination. 
Plasmid pSiB contains the transcription units for the preSl mRNA, the preS2/S 
mRNM, and the frameshift-mutant X mRNA and was constructed as follows: HBV 
sequences (733-1413) were isolated from plasmid pHBV130 by digestion with Bc1I and 
Xhol. Plasmid pHBV1004-B was digested with BarnHI and Xhol and the resulting 4.6 kb, 
vector-containing fragment was ligated to the 680 bp fragment isolated from plasmid 
pHBVI30. The mutant X ORF in plasmid pSiB was replaced with the wild-type X ORF 
by the following series of manipulations to create plasmid pS14. HBV sequences (2655-
3182/1-88) were isolated from plasmid pHBV1004 by digestion with Ncol and Hint/Ill. 
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FIGURE 4.2 Plasmid constructions 
Nucleotide position of ORFs in three translational reading frames (a,b,c) in the HBV 
sequence is indicated. Numbers indicate the first and last coding nucleotide. 
Transcription control regions are as follows: spi = preSl promoter, spli = preS2/S 
promoter, En/Xp = enhancer/X promoter, Cp = core promoter. Filled in arrows 
represent transcription initiation sites. A indicates HBV polyadenylation signal at 
nucleotide position 16. 
HBV sequences contained within plasmid constructions used in this study. Details of 
construction are described in the text. Restriction endonuclease cleavage sites within 
the HBV sequence and in the polylinker sequence flanking the HBV DNA insert are 
indicated. Numbers above restriction sites represent the position of the first 
nucleotide of the recognition sequence in the HBV genome. 'X f.s. indicates the site 
of the four bp insert creating a frameshift mutation in the X ORF. HBV 
polyadenylation site is indicated as in "A". 
HBxAg expression plasmid (pSV2HBX) and corresponding mutant plasmid containing 
frameshift mutation in the X ORF. Transcription in these plasmids is under control 
of the SV40 enhancer ()I early promoter () complex. 
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FIGURE 4.3 X ORF frameshift mutation 
Nucleotide sequence of plasmids pHBV1004 and pHBV1004-B showing insertion of four 
bp at the BamHI site at position 2682 in the HBV genome. Plasmids pHBV1004 and 
pHBV1004-B were digested with Sphl and Hindlll and the resulting 768 bp fragment 
(HBV nucleotide positions 2514-3182/1.88) was ligated to ml3mpl9 linearised by digestion 
with SpliT and Hindlll. Single stranded recombinant bacteriophage DNA was sequenced 
by dideoxynucleotide chain termination (Sanger et aL, 1977; section 2B.7) using the 
M13mp series -20 universal sequencing primer. The sequence of the non-coding strand 
of HBV was obtained. Numbers represent the nucleotide position in the HBV genome. 
The BamHI site (HBV nucleotide position 2682) in plasmid pHBV1004 and the "filled-in" 
BamHJ site containing the four bp insert in plasmid pHBV1004-B are indicated. 
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Plasmid pSiB was digested with Ncol and Hindlll and the resulting 4.9 kb, vector-
containing fragment was ligated to the 615 bp fragment from pHBV1004. 
Plasmid pHBV1004-BE was constructed by site directed mutagenesis resulting in 
deletion of HBV nucleotide positions 2460-2483 from plasmid pHBV1004-B (figure 4.4). 
HBV sequences contained in plasmid pHBV1004-B were isolated by digestion with EcoRI 
and Hindlil and the resulting 2.3 kb fragment was ligated to the bacteriophage vector 
m13mp19 linearised by digestion with EcoRI and Hindlll. Single stranded recombinant 
bacteriophage DNA was purified by 'large-scale" preparation (section 2B.2.4) and 
mutagenesis was carried out as described (section 213.9). 
Plasmid pSV2HBX was constructed by H. Houston to express HBxAg. Plasmid 
pSV2G (a gift from P. Southern) contains the rabbit 3-globin gene under control of the 
SV40 early promoter/enhancer complex (Gorman et al., 1982). The rabbit 3-globin 
structural sequences were excised by digestion with Hindlll, filling in cohesive ends with 
DNA polymerase I (Kienow fragment), and digestion with Bg1II. HBV sequences (2655-
3182/1-88) were isolated from plasmid pHBV 130 by digestion with Ncol, filling in cohesive 
ends with T4 DNA polymerase and digestion with Bg1II. The resulting 615 bp fragment 
was ligated to the 4.2 kb vector fragment of pSV2G. The integrity of the X ORF in 
plasmid pSV2HBX was confirmed by DNA sequence determination. Plasmid pSV2HBX-
B contains the same frameshift mutation in the X-gene as pHBV1004-B and was 
constructed by an equivalent series of reactions and confirmed by DNA sequence 
determination. 
Plasmid pspllBX contains the preS2/S promoter of HBV and was constructed as 
follows: HBV sequences (1004-1413) were isolated from plasmid pHBV1004 by digestion 
with EcoRI and Xhol and the resulting 409 bp fragment was ligated to plasmid pUC8 
linearised by digestion with EcoRI and Sail. Plasmid penHB contains the enhancerIX 
promoter region of HBV and was constructed as follows: HBV sequences (2274-2686) 
were isolated from plasmid pHBV1004 by digestion with Hincll and Barn HI and the 
resulting 412 bp fragment was ligated to plasmid pUC8 linearised by digestion with Hincll 
and Barn HI. 
Plasmids containing the human growth hormone (HGH) gene under control of the 
mouse metallothionine promoter or the herpes simplex tk promoter were obtained from 
Nichols Institute (San Juan Capistrano, California). The plasmid containing the HGH 
gene under control of the murine hypoxanthine ribosyl transferase (HPRT) promoter was 
constructed as follows: Plasmid pDWM322 (a gift from D. Melton) contains the HPRT 
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FIGURE 4.4 Nucleotide sequence of plasmids pHBV1004 and pHBV1004-BiE 
Mutant single stranded template DNA obtained by site directed mutagenesis (section 
2B.9) and parent template DNA prior to site directed mutagenesis were sequenced by 
dideoxynucleotide chain termination (Sanger et al., 1977 section 2B.7) using an 
oligonucleotide primer representing HBV nucleotides 2383-2399. The sequence of the 
coding strand was obtained. Numbers represent the nucleotide position in the HBV 
genome. The nucleotides deleted from plasmid pHBVlO04-BAE are indicated. 
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promoter (-845 to +40, relative to the transcription initiation site) inserted into plasmid 
pUC8. The HPRT promoter (-637 to +40) was isolated by digestion with BamHI and 
Bglll and was ligated into the Barnill site of plasmid pOGH containing the HGH coding 
sequence. 
Plasmid p1243 was a gift of H. Meade and contains the human serum albumin (HSA) 
gene under control of the caseine promoter. All plasmid DNA was prepared from cells 
of E. co/i strain ED8654 harbouring the plasmid as described in section 213.2.4 ("large-
scale' preparation). 
4.2.2 Transient expression of HBsAg 
In order to investigate the effect of HBxAg on surface antigen production, hepatoma 
cells (HepG2 or HuH7) were transiently transfected with both genes contained in a single 
plasmid construction (pHBV1004) which maintains the native configuration of the genes 
and their complete transcription units including all transcriptional regulatory elements. 
Differentiated hepatoma cell lines permissive for HBV replication (Sureau et at, 1986: 
Yaginuma et at, 1987b) were used to match the host and tissue tropism demonstrated by 
HBV during natural infection. The cell-lines used were devoid of integrated HBV 
sequences in order to eliminate interference in the assay by viral antigens produced from 
integrated sequences. Hepatoma cells transfected with pHBV1004 secreted HBsAg into 
the culture medium where it was detected 4-5 days post-transfection by radio-immunoassay 
(AUSRIA 11-125, Abbott Laboratories). This sensitive assay for the viral antigen 
eliminated the need for a heterologous reporter. Indeed, the HBsAg coding sequence 
itself has been used as a reporter for the activity of heterologous promoters (Marschall 
a at, 1989). 
Supercoiled plasmid DNA was used for transient transfections, as Jackson (1987) had 
shown that linearisation of the plasmid with a restriction endonuclease that detached the 
preS2/S promotet from the plasmid vector sequences did not affect HBsAg production 
upon transient transfection of mouse L cells. This indicated that the plasmid vector 
sequences did not contain a cryptic eukaryotic promoter that could direct transcription of 
the surface mRNM. Transient transfection was used in order to maintain the episomal 
nature of input DNA thus mimicking the state of HBV DNA in the hepatocyte during 
acute infection. The transfection procedure employed was a modification of the pEAE-
dextran/chloroquine method described by Luthman and Magnusson (1983) and ws 
139 
developed by Jackson (1987). The chloroquine enhancement procedure was compared 
to other enhancing treatments (Lopata et aL, 1984) and shown to be the most effective 
for both HepG2 and HUH7 cells (table 4.2). 
Table 4.2 Assessment of enhancement protocols on transfection efficiency 
P/N Values 
HepG2 HuH7 
DEAE-dextran alonea 4.7 17.9 
DEAE-dextran + chloroquine' 26.5 25.6 
DEAE-dextran + glycerolc 7.1 18.2 
DEAE-dextran + DMSOd 93 19.2 
Radio-immunoassay (AUSRIA 11-125) was carried out on medium recovered from 
cells transfected with 30 itg of pHBV1004 per plate. 
a Transfection protocol was as described in section 2B.1.2 except chloroquine was 
not added to the transfection solution. 
l? Transfection protocol was as described in section 2B.1.2 
c DEAE.dextran/DNA mixture was as described in section 2B.1.2. After 
incubation for 8 hours, transfection mixture was removed and cells were incubated 
in 4 ml of 10% (v/v) DMSO in HBS [25mM Hepes.KOH. 0.27mM 
Na2HPO4.21-120, 140mM NaCl, pH 7.11 for 4 minutes at room temperature. The 
DMSO solution was removed, and cells were washed and incubated as described. 
d As for "c' but the enhancing solution was 15% (vlv) glycerol in HBS. 
4.2.3 Frameshift mutation in the X gene reduces transient expression of HBsA 
Transfection of hepatoma cells with plasmid pHBV1004-B, containing a frameshift 
mutation in the X coding sequence, resulted in significant reduction in HBsAg synthesis 
compared to cells transfected with an equivalent amount of pHBV1004 (figure 4.5). The 
difference in HBsAg expression between the two plasmids was greatest when small 
amounts of DNA were used for transfection; HBsAg secretion by HepG2 cells transfected 
with 3 /ig of pHBV1004 was an average of fivefold (and as much as sevenfold) higher than 
by cells transfected with 3 g  of pHBV1004-B, but with 10 gg or 30 Ag of the plasmids 
the difference was two to threefold in this series of experiments. With larger amounts of 
DNA the availability of transcription factors that are not influenced by HBxAg may 
become limiting. Although it is possible it is unlikely that the stability of the transcript 
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FIGURE 4.5 Transient expression of HBxAg 
Levels of HBsAg production from cells transfected with HBsAg expression plasinids 
pHBV1004 or pHBV1004-B. HBsAg was detected by radio-immunoassay (AUSRIA 
11125) of either the cell culture medium or medium that had been concentrated 30-fold 
to bring the values within the linear range of the assay. The level of HBsAg expression 
was initially calculated as a ratio of counts per minute obtained for the sample to counts 
per minute obtained from the medium of mock transfected cells (P/N). The P/N values 
within each experiment were then normalized to the P/N value obtained for cells 
transfected with 30 jg of pHBV1004-B (relative P/N value). This allows comparison of 
the values obtained in different experiments in which the absolute level of HBsAg 
expression may differ. The average relative P/N values were calculated by weighting the 
relative P/N values in each experiment according to the number of plates used for 
transfectionwith each amount of DNA Error bars indicate the range of average values 
obtained in each experiment; A) HepG2 cells; B) HuH7 cells; (0),  cells transfected with 
pHBV1004; C$ cells transfected with pHBV1004-B. 
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been shown that even a 270 bp deletion of the HBV enhancer contained within this 
mRNA did not affect its stability in COS cells (Bulla and Siddiqui. 1988). 
Attempts to find an internal control against which to compare absolute levels of 
HBsAg produced by cells transfected with pHBV1004 or pHBV1004-B proved 
unsuccessful. Human growth hormone (HUH) is a secreted product, and it was believed 
that this reporter may provide a useful internal control, as the medium could be assayed 
in parallel for HBsAg and HUH by radio-immunoassays (AUSRIA 11-125, and Allegro 
supplied by Nichols Institute, respectively). HuH7 cells were transiently transfected with 
plasmids containing the HUH gene under transcriptional control of the mouse 
metallothionine, the herpes simplex virus tk, or the murine HPRT promoter in the 
presence (cotransfection with pSV2HBX) or absence (cotransfection with pSV2HBX-B) 
of HBxAg. A slight increase in HUH expression (1.2-1.5 fold, data not shown) was 
observed from all three plasmids in the presence of HBxAg. While these values were low, 
they were not suitable as internal controls. It had been reported that the SV40 early 
promoter devoid of the 72 bp repeat enhancer was not a target for transactivation by 
HBxAg (Siddiqui et at, 1989), however, the emergence of conflicting reports (Koike et 
aL, 1989)eliminated the suitability of this promoter in the internal control plasmid, and 
it was not used. Comparison of the absolute levels of HBsAg secretion (as reflected in 
PIN values) should be a reliable indication of the ability of each plasmid to direct 
expression of HBsAg. The transfection efficiencies achieved with the parent and mutant 
plasmids should be identical as they only differ in 4 bp inserted in pHBV1004-B, and the 
DEAE-dextran transfection procedure used in transient protocols is more reproducible 
than other procedures (Ausubel a' at. 1989). Plasmid DNAs were prepared in parallel, 
and several different preparations of the two plasmids were used throughout the course 
of these experiments. 
4.2.4 Detection of different forms of HBsAg 
Plasmid pHBV1004-B contains the transcription units for both middle- and major-S 
polypeptides. The proportion of surface antigen particles on which middle-S (preS2 
containing) polypeptides could be detected was determined by radio-immunoassay in which 
the solid phase was a polystyrene bead coated with anti-preS2 monoclonal antibody, 
Q19110 (Heerman a' al.. 1988), and the bound antigen was detected with 112511-labelled 
human anti-HBsAg serum provided with the AUSRIA 11-125 HBsAg detection kit. Table 
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4.3 shows that transfection of hepatoma cells with pHBV1004 resulted in the secretion 
of a greater number of HBsAg particles containing detectable preS2 epitopes than 
transfection with an equivalent amount of pHBV1004-B. The proportion of secreted 
HBsAg particles containing detectable preS2 epitopes was similar with both parent and 
mutant plasmids and these ratios were similar to that obtained with serum derived HBsAg 
particles. 
Table 4.3 PreS2 epitopes on HBsAg preparations 
Expt. 1a 
source of HBsAg SP preS2 
serumC 24.8 7.5 
yeasé1  N.T. N.T. 
pHBV1004e 16.8 5.7 
pHBV1004-B 5.8 1.8 
apft, values are shown from three independent experiments. 
bHBsAg  was detected with the AUSRIA 11-125 kit. (Detection of preS2 is described in 
the text). 
CHBsAg  derived from serum (20 nglml) was provided with the AUSRIA 11-125 kit as a 
Gositive control. 
HBsAg derived from yeast was purified from Saccharomyces cerevisiae harbouring 
plasmid pHING2 (Murray et aL, 1984), which contains the major-S polypeptide coding 
region under control of the yeast P1105 promoter. 
epHBv1004 and pHBV1004-B preparations are 30-fold concentrated medium from 
HepG2 cells transfected with 30 jig of the indicated plasmid. 
N.T. = not tested. 
Two procedures were employed in an effort to directly observe the different forms of 
HBsAg produced in transient assays. 1) HBsAg concentrated from cell culture medium 
by ultracentrifugation and extracts of cells transfected with pHBV1004 or pHBV1004-B 
were fractionated by SDS-PAGE and analysed by immunoblotting. 2) Cells transiently 
transfected with pHBVI004 or pHBV1004-B were metabolically labelled with [355]_ 
methionine and [35S]-cysteine, and HBsAg particles in the media and whole cell extracts 
were immunoprecipitated and fractionated by SDS-PAGE. Neither procedure revealed 
any HBsAg specific band in comparison with mock-transfected cells, most likely due to the 
low amount of HBsAg present. Thus on the assumption that the proportion of middle-S 
polypeptides on.each HBsAg particle was the same for those expressed from either the 
parent or mutant plasmid, transfection of cells with the mutant plasmid yielded reduced 
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expression of middle-S polypeptides. 
42.5 Complementation of the mutation in the X-gene 
The frameshift mutation in the X coding sequence contained in pHBV1004-B could 
be complemented by supplying HBxAg in trans. In the experiments summarised in figure 
4.6, hepatoma cells were transfected with 30 Ag of pHBV1004-B. This gave a level of 
HBsAg expression that could be readily assayed and that was about half that from the 
parent plasmid, pHBV1004. Cotransfection of HepG2 cells with pHBV1004-B and a 
plasmid carrying the X coding sequence under control of the SV40 early 
promoter/enhancer complex (pSV2HBX) restored HBsAg production to a level similar 
to that produced by cells transfected with an equivalent amount of pHBV1004 (figure 
4.6a). HBxAg was supplied in trans under control of a heterologous promoter instead of 
its own promoter/enhancer complex to avoid competition for transcription factors 
specifically interacting with the HBV enhancer contained in the HBsAg expression 
plasmids which may be important for transcription from the pre52/S promoter (see below). 
Cotransfection can give rise to a concatanated network of input DNA and thus it was 
possible that the observed effect was due to a cis effect of the SV40 transcriptional 
control signals contained in pSV2HBX. As a control, hepatoma cells were cotransfected 
with pHBV1004-B and pSV2HBX-B, which contained the same frameshift mutation in the 
X coding sequence. HBsAg expression in HepG2 cells was then equivalent to that of cells 
transfected with pHBV1004-B alone (figure 4.6a). This established that the restoration 
of HBsAg expression to wild-type levels by cotransfection with the plasmid pSV2HBX was 
due to a trans effect of HBxAg. 
In HuH7 cells, HBsAg production from plasmid pHBV1004-B was increased only 1.5 
fold upon cotransfection with 30 jzg of pSV2HBX and was not completely restored to the 
level produced by cells transfected with pHBV1004. Transactivation of HBsAg expression 
by HBxAg in HuH7 cells displayed concentration dependence; with higher amounts of 
HBxAg, transactivation was reduced or no longer observed (table 4.4). Therefore, the 
3°g of pSV2HBX used in the experiment summarised in figure 4.6a may have been 
greater than the amount needed for optimal transactivation. Concentration dependence 
for transactivation of HBsAg expression was not observed in HepG2 cells; a linear 
increase in HBsAg expression from plasmid pHBV1004-B was observed upon 
cotransfection with increasing amounts of pSV2HBX up to 100 gg (table 4.4). 
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HBsAg production. Levels of HBsAg production from cells transfected with HBsAg 
expression plasmids or cotransfected with HBsAg plasmid and HBxAg expression 
plasmid. Calculation of the Relative P/N Value is described in the legend to figure 
4.5. Except where indicated, the values presented here are an average from at least 
three experiments (* indicates values that are an average from two experiments). 
Error bars indicate the range of average values obtained in each experiment. Key to 
plasmids used for transfection: 4 = pHBV1004; B = pHBV1004-B; X = pSV2HBX; 
XB = pSV2HBX-B; "Mg  of DNA" is the amount of DNA used to transfect each plate 
of cells. 
Northern blot of RNA from cells expressing HBsAg. Total cytoplasmic RNA was 
prepared (section 28.2.3) from three plates of cells, four days post-transfection with 
A) 30 Mg  pUC8 per plate; B) 30 .tg pHBV1004; C) 30 tq pHBV1004-B; D) 30 Ag 
pHBV1004-B plus 30 tg pSV2HBX; E) 30 Mg pHBV1004-B plus 30 Mg pSV2HBX-B. 
The surface transcript probe was a 795 bp BarnHl/Pstl fragment from pHBV 1004 
representing HBV nucleotide positions 1005-1800, and film was exposed to the 
membrane for three days. The probe for HSA transcripts was a 1.8 kb BamHI 
fragment from plasmid p1243, and exposure was 30 minutes. Densitometric analysis 
of the exposed X-ray film was done on the Shimadzu Dual Wavelength Cromato 
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Table 4.4 Concentration dependence of transaçtivation by HExAg in HuH7 cells 
PIN Values 
Plasmid(s) used for transfection HepG2 HuH7 
pHBV1004 (30 btg) 7.5 18.4 
pHBV1004-B (30 tg) 3.2 7.9 
pHBV1004-B(30ag); pSV2HBX(lOpg) 6.3 12.9 
pHBV1004-B(30tg); pSV2HBX(30pg) 9.6 10.1 
pHBV1004-B(30tg); pSV2HBX( 1OOg) 22.1 6.3 
Radio-immunoassay (AUSRIA 11-125) was carried out on medium recovered from 
cells transfected with the indicated amounts of the indicated plasmid(s) per plate. 
4.2.6 HBxAp modulates the level of 12reS2IS mRNAs 
Total cytoplasmic RNA extracted from cells transfected with HBsAg expression 
plasmids and from cells cotransfected with pHBV1004-B and the FIBxAg expression 
plasmid or its corresponding frameshift mutant was fractionated by agarose gel 
electrophoresis and transferred to a nylon membrane. Hybridisation to a [32P]-labelled 
DNA probe containing sequences from the preS and surface ORFs revealed that the level 
of —2kb preS2IS mRNAs corresponded to the amount of HBsAg produced (figure 4.6b). 
This probe was stripped from the membrane, which was then rehybridied with a 
labelled DNA fragment from the plasmid p1243, a probe for HSA transcripts. The 
densitometer traces in the lo*er part of figure 4.6b showed that the samples analysed 
contained equivalent amounts of RNA; all the values lie within -13% to +18% of the 
mean, the reproducibility of individual scans of the various bands being ±• 
4.2.7 Detection of an X-specific transcript 
A nylon membrane containing fractionated RNAs identical to those described above 
was hybridised to a [32P]-labelled  DNA probe (nucleotide positions 2683-3182/1-88) 
containing sequences complementary to the 3 ' end of the preS2/S mRNAs and to the X 
mRNA. Only the transcripts that had been detected with the preS/surface-specific probe 
were detected with this probe (data not shown). No transcripts were detected from the 
X-gene under control of its own promoter (pHBV1004, pHBV1004-B) or a heterologous 
promoter (pSV2HBX, pSV2HBX-B). Some investigators have detected a —1kb transcript 
by northern blot analysis in human hepatoma cells transiently transfected with HBxAg 
under control of its own promoter in the context of the transcription unit encoding 
HBsAg (Siddiqui et aL. 1986; Bulla and Siddiqui, 1988, 1989; Koike et at, 1989) or under 
control of a heterologous promoter (Siddiqui et at, 1987; Spandau and Lee, 1988; Zahm 
et at, 1988; Koike et at, 1989). Others have not detected an X-specific transcript by 
northern blot analysis even in hepatoma cells stably transfected with the X coding 
sequence under control of its own promoter and have resorted to amplification by the 
polymerase chain reaction (PCR) to detect the X transcript (Aufiero and Schneider, 
1990). PCR could not be used to detect the X transcript in cells transfected with 
pHBVI004 or pHBV1004-B, as it is completely contained within the pre52/S mRNAs and 
could not be distinguished with oligonucleotide primers for PCR. PCR was carried out 
using as a template total cellular RNA from HepG2 cells transfected with pSV2HBX or 
pSV2HBX-B. An X-specific band was amplified in both cases (figure 4.7) indicating that 
a very low level of transcription is taking place in these cells directed by the SV40early 
promoter/enhancer complex. 
Two transcripts have been detected in hepatoma cells transiently transfected with a 
plasmid construction similar- to pSV2HBX which contains the SV40 polyadenylation site 
—800 bp downstream of the HBV polyadenylation site (Spandau and Lee, 1988; Koike 
et at, 1989). These two forms presumably arise from heterologous termination of 
transcription. The PCR primers used in this study would not distinguish between the two 
possible forms of transcript. 
An X-gene product has been detected in several transient systems in which X mRNA 
is transcribed under control of its own promoter (Chang a at, 1987) or a heterologous 
promoter (Siddiqui a at, 1987; Levrero et at. 1990b). Three procedures were employed 
unsuccessfully to detect the X-gene product expressed by plasmid pHBV1004 or 
pSV2HBX. 1) Extracts of transfected cells were fractionated by SDS.PGE and analysed 
by immunoblotting with anti-HBxAg serum. 2) Transfected cells were permeabilised and 
incubated with anti-HBxAg serum and then with secondary antibody conjugated to 
fluorescein isothiocyanate (FITC) and analysed by fluorescence microscopy. 3) 
Transfected cells were permeabilised in suspension (Schroff et at, 1984), incubated with 
anti-sera as above and analysed by fluorescence activated cell sorting. 
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FIGURE 4.7 Amplification of low abundance mRNAs by PCR 
Total cellular RNA was prepared (see section 213.2.3) from two or three plates of HepG2 
cells, four days post-transfection with 100 gg per plate of the indicated plasmid DNA 
except in the case of pHBV1004 in which 30 j.tg DNA per plate was used. "Mock" 
indicates cells subjected to the transfection procedure in the absence of input DNA. PCR 
was carried out on samples treated with DNasel or with DNase I and RNase A as 
described (section 2B.8). PCR products were fractionated by size by agarose gel 
electrophoresis, transferred to a nylon membrane and detected by hybridisation to a 
labelled DNA probe representing sequences internal to both oligonucleotide primers. 
Detection of X mRNA. Oligonucleotide primers used were SV40 nucleotides 5228-
5206 and HBV antisense strand nucleotides 3182-3163 yielding an amplified DNA 
fragment of 590 bp. The probe for amplified X transcripts was a 323 bp BamHI/Dral 
fragment from pHBV1004 representing HBV nucleotide positions 2683-3006. Key to 
plasmids used for transfection: X = pSV2HBX; XB = pSV2HBX-B. Film was 
exposed to the membrane for 48 hours. 
Detection of preSi mRNA. Oligonucleotide primers used were HBV sense strand, 
nucleotides 914-937 with eight additional nucleotides at the 5 end including a 
cleavage site for Pstl; and HBV antisense strand, nucleotides 1236-1217 with eight 
additional nucleotides at the 5 end including a cleavage site for EcoRI. The 
amplified DNA fragment was 338 bp long. The probe for amplified preSi transcripts 
was a 145 bp EcoRllBanll fragment from pHBV1004 representing HBV nucleotide 
positions 1004-1149. Key to plasmids used for transfection: 1004 = pHBV1004: S14 
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4.2.8 HBxAp activates expression of the lane-S polypeptide 
Plasmid pHBVtO04 contained only the preS2/S promoter and not the preSi promoter 
located —300 bp upstream which directs synthesis of the 2.3 kb subgenomic mRNA 
encoding the large, preSl/preS2/surface polypeptide. These two promoters in isolation 
fused to a reporter gene have similar transcriptional activities in differentiated hepatoma 
cells (Siddiqui et aL, 1986; Antonucci and Rutter, 1989: Bulla and Siddiqui, 1989; Chang 
and Ting, 1989). However the preS2/S promoter displays much higher activity in several 
systems including HBV infected liver (Cattaneo et at, 1984), the HCC cell-line, 
PLC/PRF/5 (Ou and Rutter, 1985), hepatoma cells transiently (Chang et at, 1987; 
Yaginuma et at, 1987b) or stably (Sureau et aL, 1986) transfected with the complete HBV 
genome and producing virus, and hepatoma cells transiently tranfected with a plasmid 
contruction containing a reporter gene fused to the respective promoters in the context 
of the complete viral genome (Raney et at, 1990). There is a precedent for a single viral 
polypeptide acting as both repressor and transactivator. The SV40 large T-antigen 
represses transcription from the viral early promoter and activates the late transcription 
program (reviewed by Khoury et at, 1987). Bulla and Siddiqui (1989) described a negative 
regulatory region within the preSi coding region that, when removed, greatly increased 
transcription from the preSi promoter; all of the plasmid constructions used in their study 
expressed X mRNA, and it remained to be investigated whether HBxAg played a role in 
downward modulation of transcription from the preSi promoter. 
Plasmid p514 contains the complete transcription unit for the mRNAs encoding 
HBxAg and all three forms of HBsAg. Plasmid pSiB contains the same frameshift 
mutation in the X gene as pllBV1004-B. These plasmids were used to transfect HepG2 
cells and the proportion of secreted surface antigen particles containing detectable large-S 
polypeptides was determined by radio-immunoassay in which the solid phase was a 
polystyrene bead coated with anti-preSl monoclonal antibody, MA18/7 (Heerman et at, 
1984). PreS2 epitopes and total HBsAg were detected as described above. 
Transfection of cells with plasmid pS14 or pSiB led to approximately threefold 
reduction in the total amount of HBsAg secreted compared to an equivalent amount of 
the corresponding preS2/S expressing plasmid (figure 4.8a; compare pS14 (30 g) vs. 
pHBV1004 (30 tg) and pS1B (30 tg) vs. pHBV1004-B (30 Mg)).  A corresponding 
reduction was also observed in the number of secreted HBsAg particles on which preS2 
epitopes were detected (figure 4.8b). It was possible that expression of the large-S 
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FIGURE 4.8 PreS epitopes on HBsAg preparation 
HepG2 cells were transfected with the indicated amount of the various plasmids and 
radio-immunoassays were carried out four days post-transfection on cell culture medium 
concentrated 30-fold by ultracentrifugation. HBsAg derived from serum (20 ng/ml) was 
provided with the AUSRIA 11-125 kit as a positive control. HBsAg derived from yeast 
was purified from Saccharomyces cerevisiae harbouring plasmid pHING2 (Murray et aL, 
1984), which contains the major-S polypeptide coding region under control of the yeast 
PHOS promoter. A)HBsAg was detected with the AUSRIA 11-125 kit. B,C) PreS2 and 
preSi epitopes were detected as described in the text (sections 4.2.4 and 4.2.8, 
respectively). Relative P/N values were calculated as described in the legend to figure 4.5. 
Note the differences in scale in the three histograms. N.T. = not tested. 
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polypeptides was inhibiting secretion of HBsAg particles as has been observed by several 
investigators in systems where the large-S polypeptide is overexpressed under control of 
a heterologous promoter (Laub a at. 1983; Chisari a at, 1986; Persing a aL, 1986; 
McLachlan a aL, 1987; Ou and Rutter, 1987; Molnar-Kimber a at, 1988). Soluble and 
insoluble proteins extracted by freeze-thaw lysis of transfected cells were subjected to 
radio-immunoassay in an attempt to quantify intracellular HBsAg. Very low amounts of 
HBsAg were detected (barely above the threshold for positive vs. negative determination) 
and no conclusions could be drawn from these experiments (data not shown). Procedures 
described above (section 4.2.4) for detection of different forms of HBsAg in transfected 
cells proved unsuccessful. 
Total cellular RNA was extracted from cells transfected with pS14 or pSIB or an 
equivalent amount of the corresponding preS2/S expressing plasmid. RNA was 
fractionated by agarose gel electrophoresis, transferred to a nylon membrane, and 
hybridised to a [32P]-labelled DNA probe complementary to the surface and X mRNAs. 
Transfection of cells with pS14 led to a reduction in the level of preS2/S mRNAs 
compared to that in cells transfected with an equivalent amount of pHBV1004 
corresponding to the reduction in HBsAg secreted (figure 4.9). As above, no X-specific 
mRNA was detected by this analysis. The 2.3 kb mRNA encoding the large-S polypeptide 
was not abundant enough to detect by this method but could be detected by amplification 
using PCR (figure 4.7). The low level of preSi containing mRNA compared to preS2/S 
mRNAs that was observed in this system is consistent with that observed in other systems 
described above. 
Transfection of hepatoma cells with p514 resulted in secretion of a greater number 
of HBsAg particles on which preSi polypeptides could be detected compared to 
tranfection with pSIB (figure 4.8c). Therefore, HBxAg does not repress transcription 
from the preSi promoter, but appears to transactivate it. The proportion of HBsAg 
particles on which preSl epitopes could be detected was lower in the transient expression 
system used in this study than that in human serum supplied as a positive control with the 
HBsAg detection kit. This could be due to the presence of 22 nm filaments in the human 
serum which contain a higher proportion of preSl containing polypeptides than 22 nm 
particles (Heerman a at, 1984). Analysis by electron microscopy of particulate forms 
secreted by cells transfected with HBsAg expression plasmids proved unsuccessful. 
Previous studies have revealed that transient or stable transfection of mouse or monkey 
cells with the transcription unit for the preSi mRNA or with the complete HBV genome 
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FIGURE 4,9 Northern blot of RNA from cells transfected with HBsAg expression 
plasmids 
RNA was prepared from 2 plates of cells transfected with 30 jig of the indicated plasmid 
per plate. A The surface transcript probe was a 587 bp BarnHI/Bg1JI fragment from 
pHBV130 representing HBV nucleotide positions 2683-3182/1-88. Film was exposed to 
the membrane for seven days. B) The EISA probe was as described in the legend to 
figure 4.6, and exposure was for 30 minutes. Densitometer analysis was as described in 
the legend to figure 4.6. The densitometer traces in "B" indicated that the samples 
analysed contained equivalent amounts of RNA; all values lie within -11% to +20% of 
the mean. Key to plasmids used for transfection: 4 = pHBV1004; S14 = pS14; B = 
pHBV1004-B; SiB = pSiB. "Mock" indicates cells subjected to the transfection 
procedure in the absence of input DNA. 
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yielded secretion of only 22nm HBsAg particles and not filamentous structures (Dubois 
et at, 1980; Stratowa et at, 1982; Siddiqui, 1983: Stenlund et at. 1983; Wang a at, 1983; 
Zelent et at, 1987). However, stable or transient transfection of human hepatoma cells 
with the complete HBV genome resulted in secretion of filamentous forms of HBsAg 
(Sureau a at, 1986; Chang et at, 1987; Sells et at, 1987). No reports could be found 
concerning HBsAg forms secreted by human hepatoma cells transiently transfected with 
a subgenomic fragment of HBV containing the transcription unit encoding large-S 
polypeptides. The lack of filaments produced in mouse and monkey cells could be due 
to the preference of the preSl promoter for differentiated hepatoma cells (Chang and 
Ting, 1989; Raney et at, 1990; see section 1.4.2). 
4.2.9 Investigation of the HBxAg response element of HBV 
Shaul and Ben-Levy (1987) described several regions within the HBV enhancer 
sequence that bound nuclear proteins extracted from differentiated hepatoma cells. When 
individual factor-binding regions were isolated and fused in multiple repeat downstream 
of the -globin transcription unit, one region (2459-2484, designated "F') conferred 
susceptibility to transactivation by HBxAg (Faktor and Shaul, 1990). This region was 
deleted from plasmid pHBV1004-B by site directed mutagenesis to create plasmid 
pHBV1004-BAE. The effect of this deletion on HBsAg expression was investigated in the 
X-mutant plasmid in order to eliminate as a factor any effect that the deletion might have 
on expression of HBxAg itself. Transient transfection of HuH7 cells with plasmid 
pHBV1004-BAE resulted in nearly fourfold reduction in HBsAg production compared to 
transfection with pHBV1004-B (table 4.5a). This effect was not observed in HepG2 cells. 
These results were obtained on several occasions when the two cell lines were transfected 
on the same day with the same plasmid DNA preparations. An anomaly of the results 
obtained with HepG2 cells in this series of experiments is that the amount of HBsAg 
produced by cells transfected with pHBV1004-B was lower than that observed with 
pHBV1004 to a greater extent than had been seen previously as described in section 4.2.3 
(1:6.2 compared to 1:2.2). This change in expression profile was not observed in HuH7 
cells and continued to be observed in HepG2 cells recovered from the original stock 
culture indicating that the result was not due to a change in the cells due to passaging. 
The ability of HBxAg to modulate expression of HBsAg from the E-deletion plasmid 
construction was investigated (table 4.5b). Cotransfection of HepG2 cells with 
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Table 4.5a Affect of E-deletion on secretion of HBsAg in hepatoma cells. 
Average P/N Values ± Standard Deviation 
Plasmid(s) used for transfection: 11ep62 lluH7 
pHBV1004 (30 Mg) 22.0 ± 9.9 39.3 ± 10.1 
pHBV1004-B (30 Mg) 3.5±2.1 16.1±73 
pHBV1004-BAE (30 Mg) 3.0 ± 1.4 4.1 ± 2.3 
Radio-immunoassay (AUSRIA 11-125) was carried out on 30-fold concentrated 
medium from cells transfected with the indicated amount of the indicated plasmid 
per plate. Average P/N values were calculated by weighting the P/N values 
obtained in each experiment according to the number of plates used for 
tranfection with each plasmid. 
Table 4.5b Effect of E-deletion on susceptibility to transactivation by HBxAg 
P/N Value 
Plasmid(s) used for transfection: Expt. I Expt. H 
pHBV1004 (30 Mg) 29.1 25.0 
pHBV1004-B (30 Mg) 5.9 2.4 
pHBV1004-BAE (30 Mg) 4.7 2.4 
pHBV1004-B(30xg); pSV2HBX(30g) 7.5 4.0 
pHBV1004-B(30g); pSV2HBX-B(30zg) 4.9 3.1 
pHBV1004-BAE(30g); pSV2F1BX(0jzg) 6.9 2.5 
pHBV1004-BAE(30,xg); pSV2HBX-B(301xg) 3.9 1.8 
pHBV1004-B(30g); pSV2HBX( lO0 g) 12.5 4.5 
pHBV1004-B(3Ojsg); pSV2HBX.B( 1004ag) 4.9 3.0 
pHBV1004-BAE(30j.tg); pSV2HBX( lOOtg) 8.2 3.9 
pHBV1004-BAE(30p.g); pSV2HBX.B( 100j.tg) 4.0 1.9 
Radio-immunoassay (AUSRIA 11-125) was carried out on 30-fold concentrated 
medium from HepG2 cells transfected with the indicated amount of the indicated 
plasmid per plate. Results from two independent experiments are shown. 
pHBV1004-BAE and pSV2HBX increased HBsAg expression in the same proportion as 
cotransfection of cells with its parent plasmid (pHBV1004-B) and the HBxAg expression 
plasmid. These results, however, were anomalous with those described in section 4.2.5, 
in that HBsAg production by HepG2 cells cotransfected with plasmid pHBV1004-B and 
pSV2HBX was not restored to the level observed from cells transfected with plasmid 
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pHBV1004 although a greater than twofold increase was observed. Similar results were 
obtained with preparations of pSV2HBX from E. co/i transformed with plasmid DNA 
from the original stock indicating that this result was not due to a spontaneous mutation 
in the HBxAg coding sequence in plasmid pSV2HBX. The similar response in HBsAg 
production from plasmids pHBV1004-B and pHBV1004-BE to HBxAg supplied in trans 
suggests that other regions of the HBV genome contained in these plasmids are capable 
of mediating transactivation by HBxAg. 
In order to examine a larger region of the HBV genome for an HBxAg response 
element(s), template competition experiments were carried out in vivo. The 
transcriptional control regions for HBsAg contained in plasmid pHBV1004 are the 
preS2/S promoter (HBV nucleotide positions 1069-1267; Raney et aL, 1989) and the 
enhancer (HBV nucleotide positions 2350-2550; section 1.4.3a). These regions were 
subcloned into plasmid pUC8 generating pspllBX (HBV nucleotide positions 1004-1413) 
and penHB (HBV nucleotide positions 2271-2686). 
Template competition experiments were carried out by cotransfection of HuH7 cells 
with pHBV1004-B and pSV2HBX in the presence of increasing concentrations of 
competitor plasmid. Competitor DNA should reduce the transactivating potential of 
HBxAg on HBsAg expression if HBxAg binds directly to sequences contained in the 
competitor plasmid or if the effect of HBxAg is mediated by cellular transcription factors 
present in limiting concentration that bind to those sequences. In the absence of the 
influence of the X-gene product both penilD and pspllBX could compete for factors 
necessary for transcription from the preS2/S promoter (figure 4. IN, "pHBV1004-B_(10Mg)"). 
However, when pSV2HBX was cotransfected with pHBV1004 and either competitor 
template, expression of HBsAg was increased by an equivalent amount to that in which 
no competitor was present (figure 4.10 a,b). This suggested that the effect of HBxAg 
could be mediated by sequences outwith the regions contained in the competitor template 
plasmids. 
4.3 Discussion 
The results presented in this chapter demonstrate that HBxAg can function to 
increase transient expression of HBsAg in two different human hepatoma cell lines 
transfected with a plasmid (pHBV1004) encoding the preS2/S mRNAs. A frameshift 
mutation close to the 5 end of the X coding sequence in the HBsAg expression vector 
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FIGURE 4.10 In vivo competition for transacting factors 
Hull7 cells were transfected with HBsAg expression plasmid, pHBV1004-B. in the 
absence (0 jig competitor DNA) or presence of increasing amounts of competitor plasmid 
DNA ( E ). Ag of DNA indicated in the figure refers to the amount of plasmid DNA 
per plate used for transfection. Competition for transactivation by HBxAg was assayed 
by cotransfection of pHBV1004-B with 10 tg ( 0 ) or 30 lug ( A  ) pSV2HBX in the 
absence (0 gg competitor DNA) or presence of increasing amounts of competitor plasmid 
DNA. Competitor plasmids were approximately half the size of pHBV1004-B and were 
added in four-fold (20 gg competitor DNA) or eight-fold (40 jug competitor DNA) molar 
excess relative to pHBV1004-B. Competitor plasmids contained: A) The HBV enhancer 
region (nucleotide positions 2271-2686), penHB; or B) the preS2IS promoter (nucleotide 
positions 1004-1413), pspllBX. C) The vector sequence contained in the two competitor 
plasmids (pUC8) was used as a negative control. Each point in "A" or C is the average 
P/N value obtained from two independent experiments; the actual values ranged from 
±1% to ±26 percent of the mean. Each point in "B" is the actual P/N value obtained 
from a single experiment. 
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significantly reduced the amount of HBsAg secreted into the culture medium. The 
mutation did not affect the ratio of detectable preS2 epitopes to total HBsAg secreted 
indicating that HBxAg does not affect those features of HBsAg regulation controlling this 
ratio including variable initiation of transcription under control of the preS2/S promoter 
and variable use of initiation codons in the preS2/S mRNA. The mutation in the X ORE 
in plasmid pHBV1004-B could be complemented by supplying HBxAg in trans, which is 
definitive evidence that HBxAg can modulate expression of another viral gene product. 
The levels of HBsAg expression from pHBV1004 or from its corresponding X-
frameshift mutant in the absence or presence of HBxAg supplied in trans corresponded 
to the amount of preS2/S mRNA indicating that the HBxAg does not exert its effect at 
the level of translation or secretion. This effect of HBxAg on steady state levels of 
mRNA under control of a target promoter has been observed in several systems (Seto et 
A, 1988; Zahm et at, 1988; Colgrove et at, 1989; Koike et at. 1989; Twu and Robinson 
1989; Twu et at, 1989a; Aufiero and Schneider, 1990; Faktor and Shaul. 1990; Hu et at, 
1990; Twu et at, 1990; Unger and Shaul. 1990). Analysis of transcription from preformed 
complexes extracted from nuclei has indicated that HBxAg functions at the level of 
transcription initiation and not by increasing mRNA stability (Colgrove et at, 1989; 
Siddiqui a at, 1989; Aufiero and Schneider, 1990; Hu et at. 1990; Levrero et at. 1990a). 
Transfection of HepG2 cells with a plasmid containing the transcription units for the 
preSi and preS2/S subgenomic mRNAs (p514) resulted in secretion of HBsAg on which 
preSi epitopes could be detected. The total amount of HBsAg secreted and the number 
of detectable preSi epitopes were reduced by a similar proportion by a frameshift 
mutation in the X ORE in this plasmid, indicating that HBxAg is not responsible for the 
repression of transcription from the preSl promoter, and suggesting that indeed, HBxAg 
transactivates transcription from the preSi promoter to a similar extent to that from the 
preS2/S promoter. 
The total amount of HBsAg secreted by cells transfected with pS14 or pSiB was less 
than that produced by cells transfected with an equivalent amount of corresponding 
lasmid encoding only the middle- and major-S polypeptides (pHBV1004 or pHBV1004-
B). This corresponded to a reduction in preS2/S mRNAs indicating that the reduction in 
HBsAg secretion was not due to an inhibition of secretion by the low level of large-S 
polypeptides produced. It is possible that the effect observed was due to reduced 
transfection efficiency of the slightly larger preSl expressing plasmids. Another possible 
explanation is "promoter occlusion" whereby the activity of a promoter is occluded by 
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transcription through the promoter region under control of an upstream promoter. This 
effect would be unexpected due to the very low level of transcription from the upstream, 
preSi promoter. However, there are conflicting reports as to the affect of transcription 
from an upstream promoter on internal initiation of transcription under control of the 
preS2/S promoter. Secretion of HBsAg was equivalent in COS cells transfected with a 
plasmid containing only the preS2/S promoter or one containing both the preS2/S and the. 
preSi promoter (Siddiqui et at, 1986). Although no analysis of mRNA levels was carried 
out in this study, production of HBsAg particles that contain predominantly major-S 
polypeptide reflects internal initiation of transcription as middle- and major-S polypeptides 
are not translated from the preSi mRNA (Standring a' at, 1986). Mouse L cells 
transfected with a vector containing both native HBsAg promoters produced as much 
preS2/S mRNA as cells in which transcription of the preSi mRNA was under control of 
the strong RSV LTR (Persing a' at, 1986). Further, McLachlan and his colleagues (1987) 
observed middle- and major-S polypeptides produced by NIH3T3 cells stably transfected 
with a plasmid construction in which the preSi mRNA was transcribed under control of 
a retroviral LTR indicating internal initiation even in the presence of a strong upstream 
promoter, although no comparison was made of the levels of middle- and major-S 
produced relative to cells transfected with a plasmid encoding the preS2/S mRNA under 
control of the native promoter. In contrast to the studies mentioned, stable transfection 
of Chinese hamster ovary cells with a plasmid construction expressing the preSi mRNA 
under control of the 5V40 early promoter/enhancer resulted in production of only large-S 
polypeptides indicating a block to internal initiation from the preS2/S promoter (Ou and 
Rutter, 1987). An experiment that would help elucidate the cause of decreased HBsAg 
secretion observed in this study from cells transfected with the preSi expression plasmids 
would be mutagenesis of the preSi promoter to ablate its use. Possible targets for 
mutagenesis are the binding sites for transcription factors Oct-1 and HNF-i located 
upstream of the preSi promoter 'TATA-box" (Zhou and Yen. 1991). To definitively rule 
out inhibition of secretion of HBsAg particles by the large-S polypeptide, a frameshift 
mutation could be introduced in the pEeS1 coding region of plasmids p514 and pSiB. 
There have been conflicting reports concerning the ability of HBxAg to transactivate 
the surface antigen promoters. The data were not shown in support of statements that 
the surface promoters are not targets for transactivation by HBxAg (Twu a' at. 1989a: 
Siddiqui et at, 1989). These investigations employed target promoters fused to the CAT 
reporter gene, and it is likely that the results observed were for the isolated surface 
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antigen promoters in this configuration. Zhou and Yen (1990) have recently reported 
that transcription from either surface antigen promoter contained within the complete 
preSi mRNA transcription unit is not effected by a frameshift mutation following codon 
29 of the X ORF. In contrast, there are several reports indicating that the surface 
antigen promoters are modulated by HBxAg. The luciferase reporter gene was inserted 
into the complete HBV genome downstream of the preSi promoter and up to threefold 
reduction in luciferase activity was obtained upon deletion of the start codon of the X 
ORF (Raney et al., 1990). Using the HBV mRNAs themselves as a reporter, Colgrove 
et al. (1989) showed that a mutation in the X-gene contained within the complete HBV 
genome led to a reduction in the levels of both the pregenome RNA and the preS2/S 
mRNA upon transient transfection of HuH7 cells. These results were corroborated by 
Koike et al. (1989) who noted a reduction in pregenome RNA, preSi, preS2/S, and X 
mRNM upon transient expression of an X-mutant HBV genomein HepG2 cells. 
However, in contrast to the results of Colgrove et al. (1989), Koike and his colleagues did 
not see a similar result in HuH7 cells. 
The report by Koike et al. (1989) highlights several studies noting differences in 
transcriptional regulatory properties in HepG2 and HuH7 cells. The HBV enhancer II 
(nucleotide position 2916-3084) placed downstream of the CAT gene under control of the 
preSi promoter displayed relatively high enhancer activity in HepG2 cells compared to 
HuH7 (Yuh and Ting, 1990). Aêtivation of the HIV1 LTR fused to the CAT gene by 
cotransfection with a plasmid construction expressing HBxAg under control of its own 
promoter/enhancer complex was significant in HepG2 cells but was not observed in HuH7 
cells (Twu and Robinson, 1989). 
The results presented in this chapter are consistent with those of Colgrove et al. 
(1989); HuH7 cells were capable of supporting transactivation by HBxAg expressed in its 
native configuration from within the transcription unit encoding HBsAg. However, in 
HuH7 cells complementation of the mutation in the X-gene in pHBV1004-B was 
dependent on the concentration of cotransfected plasmid expressing HBxAg, while this 
effect was not observed in HepG2 cells. The reduction in transactivating potential with 
increasing concentration of HBxAg expressing plasmid has been observed in other systems 
(Seto et al., 1990), including in HepG2 cells with respect to transactivation of the HBV 
X promoter/enhancer complex fused to the CAT gene (Faktor and Shaul, 1990). 
Concentration dependence of transactivation has been observed for other 
transactivating proteins including the yeast Ga14 protein, which turns on the genes 
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required for galactose metabolism, and the herpes simplex virus VP16 protein, which 
activates viral early gene transcription (reviewed by Ptashne, 1988). A model proposed 
to explain this phenomenon (termed "squelching") postulates that transactivators that 
display this property function by direct protein-protein interactions with cellular 
transcription factors which are in limiting concentration in the cell (Ptashne. 1988; figure 
4.11). Transactivation takes place if these interactions occur in the proper context on the 
DNA directed by a sequence specific DNA binding site on the activator protein itself or 
on another protein in the complex. Squelching occurs by overproduction of an activator 
with respect to target sites which sequesters a limiting cellular transcription factor off of 
the DNA 
A hypothesis postulating that transactivation is mediated by interaction between 
HBxAg and one or more cellular factors could explain the ability to transactivate a 
particular target sequence in one cell line but not in another. If the required cellular 
factor is present at only a !ow level or not at all in a particular cell line, it will not support 
transactivation. A variation in the concentration of a specific factor could explain why 
squelching was observed in HuH7 cells but not in HepG2 cells. Conflicting observations 
of transactivation or "squelching" of similar activator and target systems in a particular cell 
line are more difficult to reconcile but could he due to differences in concentration of 
transcription factors in particular sublines. The case of concentration-dependent 
transactivaiton observed in HepG2 cells (Faktor and Shaul, 1990) may have arisen from 
better transfection efficiency than was obtained in this study or from higher transcriptional 
activity from the RSV LTR controlling transcription of HBxAg as opposed to the SV40 
early promoter/enhancer used in this study. 
The region of the HBV genome that is responsible for responding to transactivation 
by HBxAg was investigated and resulted in observations about the effect of the HBV 
enhancer on transcription from the preS2/S promoter. Template competition experiments 
were carried out in an attempt to sequester factors present in limiting concentration 
(including possibly HBxAg itself) that may be responsible for mediating transactivation of 
transcription from the preS2/S promoter contained in plasmid pHBV1004-B. Competing 
templates used contained the preS2/S promoter itself, which displays binding sites for 
cellular proteins (Raney et at, 1989), or the HBV enhancer region, which serves as a 
target for transactivation by HBxAg in association with the HBV core promoter or X 
promoter linked to the CAT gene. (Spandau and Lee, 1988; Wo!!ersheim et at, 1988; 
Colgrove et at, 1989; Siddiqui et at, 1989). In addition, the HBV enhancer activates 
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FIGURE 4.11 A model for concentration dependence of transactivation 
The diagram depicts an activator protein. A', which does not bind DNA by itself but as 
a complex with sequence specific DNA binding protein, A- 
Protein A'  in low concentration mediates interaction of cellular transcription factor. 
A. with the cellular transcription machinery, "target protein', in the proper context on 
the DNA 
Squelching. Overproduction of activator protein A sequesters the cellular 
transcription factor that is in limiting concentration off of the DNA. 
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transcription from the preS2/S promoter linked to the CAT gene (Siddiqui et at. 1986; 
De-Medina et at, 1988: Faktor a at, 1988; Antonucci and Rutter, 1989: Bulla and 
Siddiqui, 1989; Chang and Ting, 1989; Raney a at, 1989) and increases transient 
expression of HBsAg from this promoter in hepatoma cells (Bulla and Siddiqui. 1988; 
Faktor a al., 1988). Cotransfection of competing templates in the absence of FJBxAg 
resulted in a decrease in secretion of HBsAg indicating that cellular trans-acting factors 
interacting with the preS2/S promoter and those that interact with the enhancer region 
are required for optimal activity of the promoter. These results are consistent with those 
of Karpen ci at (1988) who showed that the HBV enhancer sequence could compete for 
factors necessary for transcription of the CAT gene under control of the HBV 
enhancer/core promoter region. In contrast, Pei and Shih (1990) observed that a smaller 
region of the HBV enhancer (2321-2514, removing the X promoter) cotransfected with 
the complete HBV genome increased transcription of the pregenome RNA and 
subgenomic mRNAs. The authors provide evidence that this is due to repression of HBV 
transcription by the transcription factor CCAAT/enhancer binding protein (C/EBP), 
however, this also contradicts results obtained in this study (see below). 
C/EBP is a heat-stable protein purified from rat liver nuclei (Johnson ci at. 1987) that 
forms a dimer through interaction of repeated leucine motifs ("leucine zipper") and binds 
DNA in a sequence specific manner (Landschulz et at, 1989). C/EBP binding sites were 
initially identified as CCAAT motifs and enhancer core motifs 
(TGTGG(T/A)(T/A)(T/A)G) found in the transcriptional control regions of several 
viruses (Graves ci at, 1986; Johnson ci at, 1987). C/EBP displays binding site promiscuity 
and is capable of activating cellular genes whose product is found specifically in liver cells, 
for example, albumin (Friedman ci at, 1989) and adipose cells (Christy ci at. 1989) in 
which C/EBP is abundant (Birkenmeier et at, 1989). 
Purified, recombinant, rat-liver C/EBP binds to the HBV enhancer at at least two sites 
including the E site described above and a site upstream at nucleotides 2312-2328 
(Landschulz ci at, 1988a). At increased concentrations C/EBP binds additional sites 
immediately upstream of the E site (Dikstein et at, 1990b). The E site is highly conserved 
among all mammalian hepadnaviruses (figure 4.12), although this may be due to functional 
constraints on the coding sequence of the polymerase ORF contained in this segment. 
The E site contains the sequence GTGTTI'G which is homologous to the SV40 enhancer 
"core" sequence originally defined as a C/EBP binding site (Johnson a at, 1987). Analysis 
of native and mutant E sites by DNase I footprinting or by alteration of oligonucleotide 
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2451 2500 
HBVadyw GTCTGTGCCA AGTG=GCr GATGCI\ACCC CCACIX3GCIC CGGCflCGTC 
HBVayw GICt31ECCA AGIGTPICCT GACCCAACCC CCACIX3GCIG CGGCTICGTC 
EBVadw GWIXflCCCA A&1GTICT GACtCAACCC CCACIGGCm GGGCTThQCC 
HBVadw2 CTCIGTCCA AGTGTIGCT GACGCAACCC CCWI'GGcm, CGGCICGCC 
HBVacir GTCWICCCA AGIcTrIcCr  GACtCAACCC CCACTGGATG GGGCTICGCC 
lVadr4 GICICTGCCA AG'IGTTIfl G&XCMCCC CCWICCATG CCGCIGGCT 
HBVayr GTCIC'IGCCA AGTGTflGCT GAQ3CAACCC CCCCGGTtG GGGCICGCC 
GSHV TGGTGTr= 1GTPICCT GACXflACIC CCkCI'SGTIG GGGCATIGC 
WIN TGGIGICt  1tlCTflCCT GACGCAACCC CCPLT3GC1t GCGCATICCC 
Consensus ---T-C-- -GIGTPIGCT GA-GCAAC-C CCAC-GC-TG CCGC-T-- 
E-binding site 
Figure 4.12: Comparison of E-binding site sequence of HBV clone used in this study 
(HBVadyw) to other mammalian hepadnavirus sequences. Numbers represent nucleotide 
positions in the sequence of HBVadyw (Appendix. I). The consensus sequence and the 
position of the E-binding site defined by Shaul and Ben-Levy (1987) are indicated. 
Sequence comparison was carried out using the UWGCG "Gap' program and was 
displayed using the "Pretty" program (Devereux et at, 1984). (References: HBVadyw, 
Pugh et at, 1986; HBVayw, Galibert et at, 1979; HBVadw, Ono et at, 1983; HBVadw2, 
Valenzuela et at, 1980; HBVadr, Ono ci at, 1983; HBVadr4, Fujiyama et at, 1983; 
HBVayr, Okamota et at, 1986; GSHV. Seeger et at, 1984; WHY, Galibert ci at, 1982). 
mobility in polyacrylamide gel, provides evidence for 3 proteins binding to this region 
including C/EBP (Faktor ci at, 1990; Ben-Levy ci at, 1989; Dikstein et al., 1990a,b), and 
functional studies on a multimerised £ site inserted 3 to the -globin gene have 
implicated transcription factors AP-1/Jun and C/EBP in activation of this heterologous 
promoter in association with the E site (Ben-Levy et at, 1989; Dikstein ci at, 1990b; 
Faktor et at, 1990). - 
Deletion of the £ site from plasmid pHBV1004-B reduced HBsAg expression in 
HuH7 cells but not HepG2 cells. It is likely that the observed difference was due to the 
low level of C/EBP in HepG2 cells as determined by Western blot analysis and DNasel 
footprint analysis (Friedman et at, 1989). Dikstein et at (1990a) noted that a 4 base 
change in the E site reduced transcriptional activity under the influence of multimerised 
mutant-E sites in Hep3B, Alexander and HeLa cells but not in HepG2 cells. This 
mutation was adjacent to but not part of the enhancer "core" consensus motif, but still 
blocked C/EBP binding (Dikstein ci at, 1990b). The effect of the block to C/EBP binding 
on transcription would not be observed in HepG2 cells which express only minimal 
C/EBP. (HeLa cells have been shown to express a similar DNA binding protein (Clark 
et at, 1988)). 
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The data presented here are consistent with the hypothesis that HBsAg production 
is modulated upward by cellular factors that bind to the preS2/S promoter itself and to the 
HBV enhancer and that the C/EBP binding site within the enhancer is responsible for 
transcriptional activation of the preS2/S promoter rather than repression as observed by 
Pei and Shih (1990). The multimerised £ binding site can serve as a target for 
transactivation in association with the -globin promoter (Faktor and Shaul, 1990). 
However deletion of the F binding site from plasmid pHBV1004-B did not appear to alter 
the modulation of HBsAg expression by HBxAg supplied in trans. This suggests that 
other sites in the HBV genome may serve as HBxAg response elements. These may 
include sites outwith the HBV enhancer and the preS2/S promoter region as HBxAg 
supplied in trans was able to augment HBsAg secretion from cells transfected with plasmid 
pHBV1004-B in the presence of competing templates penHB and pspllBX. 
It is likely that the HBxAg reponse elements will be located at binding sites for 
cellular transcription factors as HBxAg itself does not show DNA binding potential 
(Faktor and Shaul, 1990; Jameel et at, 1990; Twu ci at. 1990; Unger and Shaul, 1990; Wu 
ci' at, 1990). Binding sites for cellular factors outwith the preS2/S promoter and enhancer 
include other C/EBP binding sites in the HBV genome including nucleotide positions 
2312-2328 described above and 2924-2946 in the core promoter region (Lopez-Cabrera 
et at, 1990). The latter site, however was present in the enhancerless core promoter/CAT 
constructs which were not (or only very weakly) transactivatedby HBxAg (Spandau and 
Lee, 1988; Colgrove et at, 1989; Siddiqui et at, 1989). In addition the human serum 
albumin gene has a binding site consensus for C/EBP but is not transactivated by HBxAg 
(this study; Hu et at, 1990), so it is unlikely that the effect of HBxAg is mediated through 
this cellular transcription factor. Other possible HBxAg response elements in the HBV 
genome include the glucocorticoid response element, which can mediate increased 
transcriptional activity of the SV40 early promoter in conjunction with the HBV enhancer 
in response to dexamethasone treatment (Tur-Kaspa et at, 1988). The HBV genome also 
contains a highly conserved site that binds the transcription factor NF-KB. (J. Wells, 
personal communication; figure 4.13). This factor binding site serves as an HBxAg 
response element in the HIVI LTR fused to the CAT gene (Siddiqui ci at, 1989; Twu 
et at, 1989a,b). It will be interesting to delete these regions from the HBsAg expression 
plasmid pHBV1004-B to see if this affects the response to HBxAg supplied in trans. 
The mechanism of transactivation by HBxAg and the possible role of this function in 
the development of HCC will be considered in detail in Chapter 6. An alternative 
164 
1969 2018 
HBVadyw CWETIGTICA GGTICtTA ccccrriccc CCATIC'ITIG ccrriccn 
HBVayw CPTNGTfl GICGTTCtTA CGGCITTCCC CCAC'IGTI'IG ccrnCr½G'rr 
}Vadw CATTICTfl GIccrrctTa ccccrriccc ccwmTnc ccrncrccT 
}Vadw2 CATICPfl G'ICGTTCtTA CGGCITICCC CC\CIGTI'IG GCrrICI½GCT 
HBVadr CATPIGTICA G'ICGTTCGTA GGGCrPICCC CCPJCIGTI'IG GCTflCGT 
H13Vadr4 CATflGTICA GtGTTCTA GGGCITI'CCC CCACGfl'IG GCrrflGTT 
HBVayr CATTIGTICA GGTTCGTA CGCCITTCCC CCACICTrI'G CCTITCAGCT 
GSHV ccrncncp. A'ICGTTACGA GGAATflCCC TCJCIGTYIG GCTITIGCIT 
WIN CCTIGCrI'CA AICGPTAGGP. GGAATrI'CCC ICATIGCGIG GTflTICCrr 
Consensus C-PT--Tn -ICGPT-G-A ca--priccc _cA4c._rxc G-TI'T ---- T 
NThcB site from HIV1. LTR: G GGACITICC(G/A) 
NFicB site from Igic enhancer: C ccacrricc 
Figure 4.13: Comparison of NFicB-like sequence in the IIBV clone used in this study 
(HBVadyw) with the sequence in other hepadnaviruses. Numbers represent nucleotide 
positions in HBVadyw (Appendix I). Consensus sequence and NFicB binding sites from 
the HIV1 LTR (Nabel and Baltimore, 1987) and the immunonglibin ic light chain 
enhancer (Sen and Baltimore, 1986) are shown. Methods of sequence comparison and 
references for hepadnaviral sequences are in the legend to figure 4.12. 
mechanism to the possibility of direct protein-protein interactions with cellular 
transcription factors alluded to above, is the post-translational modification of cellular 
transcription factors by phosphorylation. There are several examples of alteration of 
transcription factor activity by phosphorylation (section 6A.4.1), and this possibility along 
with the heretofore unidentified source of the HBV virion associated kinase prompted my 
investigation into a potential protein kinase activity for HBxAg. 
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A protein kinase (pk) activity has been described associated with 42 nm HBV 
particles, nucleocapsids extracted from virus particles (Albin and Robinson. 1980) and with - 
core particles purified from whole cell extracts (Albin and Robinson, 1980; Feitleson et 
at, 1982; Gerlich et at, 1982) and cytoplasmic extracts (Petit and Pillot, 1985) of HBV 
infected hepatocytes. Incubation of these preparations with [y-32P]ATP resulted in 
phosphorylation of the core polypeptide. The reaction was enhanced in the presence of 
Mg++, while inclusion of cAMP in the reaction mixture had no effect (Albin and 
Robinson, 1980). Quantitation of radioactive label incorporated into core particles 
revealed that only a small proportion of the 180 HBcAg subunits in the particle was 
phosphorylated (Gerlich ci at, 1982). In addition, treatment of labelled core particles 
with alkaline phosphatase did not remove the [32P]phospho group (Gerlich ci at, 1982) 
indicating that the phosphate acceptor site and, by inference, the protein kinase itself are 
inside of the core particle. Acid hydrolysis of labelled core particles showed major 
phosphorylation sites on serine residues (Gerlich ci at, 1982; Feitleson ci at, 1982) 
contained within three tryptic peptides (Feitleson ci at, 1982). The labelled tryptic 
peptides for HBcAg and GSHV core antigen (GSHcAg), phosphorylated through an 
equivalent set of reactions, showed identical mobility upon two-dimensional fractionation. 
Consideration of the primary sequence of these two antigens identifies three identical 
tryptic peptides containing serine (HBcAg amino acid positions 155-157,160-164,168-172) 
derived from the protamine-like carboxyl-termini of HBcAg and GSHcAg, indicating 
phosphorylation of serine 155, serine 162 and (serine 168 and/or serine 172) in the 
HBcAg amino acid sequence. 
The source of the endogenous pk activity found in HBV cores has not been identified. 
A pk activity is associated with numerous enveloped (Imblum. and Wagner, 1974; Roux 
and Kolakofsky, 1974; Howard and Buchmeier, 1983; Stevely ci at, 1985; Roby and 
Gibson, 1986) and non-enveloped (Grubman ci at, 1981; Tsuzuki and Luftig, 1985, Ratka 
a at, 1989) virus particles. In the case of herpes simplex virus type 1 and pseudorabies 
virus, the virion associated pk has the properties of casein kinase II and is most likely of 
cellular origin (Stevely ci' at, 1985). However, a viral gene encoding a virion associated 
pk has been demonstrated in two cases. In vitro pk activity has been identified for the 
large polypeptide (L) of the virion associated transcriptive complex of two negative strand 
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RNA viruses, vesicular stomatitis virus (Chattopadhyay and Banerjee, 1987) and Sendai 
virus (Einberger a aL, 1990) with viral proteins as substrate. Thus a virally encoded pk 
activity for HBV would not be without precedent. 
Endogenous polymerase activity was not required for endogenous pk activity of HBV 
core particles in vitro. Gerlich a al. (1982) showed that 'heavy' core particles, which 
contain viral DNA and display polymerase activity, had less endogenous pk activity than 
"light" cores lacking viral DNA and associated polymerase activity when these variants 
were separated by isopycnic banding. Cytoplasmic core particles devoid of DNA 
polymerase activity were isolated from HBV infected liver and were positive for 
endogenous pk activity (Petit and Pillot, 1985). A model for encapsidation of viral 
pregenome mRNA suggests that the pol-gene product is incorporated into the capsid in 
a complex with the pregenome mRNA (Bartenschlager a at. 1990). The detection of pk 
activity in core particles which have not encapsidated the viral polymerase indicates that 
the origin of the activity is-not the viral polymerase polypeptide. 
HBcAg particles purified from E. coli transformed with cloned DNA containing only 
the core ORF do not possess pk activity (Schlicht a aL, 1989a; this study) indicating that 
the core polypeptide itself is not the source of this enzymatic function. However, Serrano 
and Hirschman (1984) detected pk activity in purified HBeAg that had been secreted by 
buffalo rat liver cells stably transfected with the complete HBV genome. Despite 
employing several methods to dissociate other polypeptides from the preparation of 
HBeAg, it is possible that the material was contaminated with another polypeptide of viral 
or cellular origin accounting for pk activity. 
Purified 22 nm HBsAg particles and filaments do not harbour endogenous pk activity 
(Gerlich a at, 1982) indicating that the preS/S ORFs do not encode polypeptides with 
this enzymatic functibn. It remained to be investigated whether the X ORF encodes a 
pk activity. 
5.2 Results 
5.2.1 Plasmid constructions 
Plasmid pHBcS11 1-156 (Stahl and Murray, 1989) contains the coding sequence for 
amino acid residues 111-156 of the major-S polypeptide (HBV nucleotide positions 1767-
1905) fused through a 15 bp linker to the 3' end of the coding sequence for a fusion 
protein of -galactosidase (amino acids 1-8)/IBcAg (amino acids 3-144). The coding 
sequences in this plasmid are derived from a modification of plasmid ptacHpallR2 (Stahl 
and Murray. 1989) engineered to contain a Snial restriction site replacing the Hindlll site 
contained in the parent plasmid. Transcription of protein coding sequences in these 
plasmids is under control of the mc promoter (de Boer etal., 1983) which was constructed 
by replacing the -35 region of the IacUV5 promoter (Silverstone a aL, 1970) with the -35 
region of the stronger op promoter yielding increased transcription upon induction with 
IPTO. The HBsAg coding sequence in plasmid pFIBcS111-156 was subcloned from a 
variant of plasmid pHBVI30 (Cough and Murray. 1982) which contains a missense 
transition (HBV nucleotide 1794, C changed to T HBsAg residue 120, Pro changed to 
Set) relative to the sequence published by Pugh a al. (1986), creating a BarnHI restriction 
site. 
Plasmid pHBcX contains the complete X ORF fused to the 3' end of the coding 
sequence for a fusion protein of -gaIactosidase (amino acids 1-8)/HBcAg (amino acids 
3-144)/HBsAg (amino acids 111-120) and was constructed as follows (figure 5.1): plasmid 
pHBcS111-156 was linearised by digestion with BamHI, filling in cohesive ends with DNA 
polymerase I (Kienow fragment) and digestion with Sail. The X ORF was isolated from 
plasmid pHBV1004 by digestion with Ncol, filling in cohesive ends with DNA polymerase 
I (Klenow fragment) and digestion with Sail. The resulting 622 bp fragment was ligated 
to the 4.6 kb, vector-containing fragment from pHBcS 111-156. The integrity of the vector 
insert junctions and of the X-ORF was confirmed by DNA sequence determination (figure 
5.2a). 
Plasmid ptacX was constructed to express HBxAg fused to the carboxyl-terminus of 
-galactosidase amino acids 1-8 under control of the mc promoter (figure 5.2b). Plasmid 
pHBcX was digested with EcaRI and Ncol and cohesive ends were rendered blunt by the 
action of DNA polymerase I (Kienow fragment). The resulting 4.7 kb fragment was 
isolated and recircularised by ligation. 
5.2.2 Purification of fusion protein encoded by pHBcX 
Cells of E. cciii strain RB791 harbouring plasmid ptacX were incubated with IPTO to 
induce transcription of the iacZ/X fusion gene (section 213.10.10a). Induced cells were 
lysed by sonication, and insoluble material was removed by centrifugation. Both soluble 
and insoluble fractions were examined for HBxAg by immunoblotting which revealed a 
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FIGURE 5.1: 
Construction of pHBcX. Details of construction are provided in the text (section 
5.2.1). Thick lines represent transcriptional control regions; boxes represent the 
indicated ORFs: restriction endonuclease cleavage sites: B-BamHI, E - EcoRL N-
NwI, P-PstL S-Sall. 
Predicted amino acid sequence for HBcX. Single letter code is used for amino acids 
(aa). Numbers below boxes indicate amino acid position in the native protein. Also 
indicated are the HBV nucleotide positions of sequences contained in pHBcX. n-gal 
= D .galactosidase. 
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HBcX 317 a j-gaI EFH HBcAg tSSQFHBsAg HBxAg 
amino acid position 1 8 3 144 111 120/1 154 
in native protein 
nucleotide position in HBV 7 432 1767 1796/2656 3117 
sequence 
FIGURE 5.2: 
Nucleotide sequence of pHBcX at the junction of the 5' end of the X ORF and the 
codon for amino acid residue 120 of the surface ORF. Plasmid pHBcX was digested 
with Xbal which cuts after HBV nucleotide 345 within the core ORF and with Sail, 
and the resulting 745 bp fragment was ligated to M13mp19 linearised by digestion with 
Xbal and Sail. Single stranded, recombinant, bacteriophage DNA was sequenced by 
dideoxynucleotide chain termination (Sanger et at, 1977; section 2B.7) using the 
ml3mp series -20 universal sequencing primer. The initiation codon of the X ORF 
is boxed; restriction endonuclease cleavage sites, BamHI and Ncol, are indicated. 
Construction of ptacX. Details of construction are provided in the text (section 5.2.1). 
Thick lines represent transcriptional control regions; boxes represent the indicated 
ORFs; "sur" indicates a fragment of the surface ORF; restriction endonuclease 
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very low level of fusion protein in the insoluble fraction and none in the soluble fraction 
(data not shown). To increase the yield of HBxAg produced in E. coil it was produced 
fused to the carboxyl-terminus of a fusion protein containing HBcAg amino acid residues 
3-144. 
Expression of the HBeAg(HBxAg fusion protein (HBcX) was induced in E. coli strain 
RB791 harbouring plasmid pHBcX (section 213.10.10a). Analysis by immunoblotting of 
soluble proteins extracted from induced cells revealed a low level of fusion protein (<1% 
of total soluble protein), but a significantly higher level than had been obtained for 
expression of HBxAg encoded by plasmid ptacX (figure 5.3; lane "Cr"). The 
electrophoretic mobility of the fusion protein was slightly faster than calculated from the 
amino acid sequence (35.2 kD). This may be due to secondary structure in association 
with SDS or to disproportionate binding of SDS relative to the commercially obtained 
protein size standards. 
As a first step in purification and characterisation of HBcX, proteins in the soluble 
fraction of E. coli cell extract were fractionated by gel filtration through Sepharose CL-413. 
Fractions were assayed for the presence of fusion protein by immunodetection of proteins 
spotted onto nitrocellulose membrane (figure 5.7a), and proteins in positive fractions were 
fractionated by SDS page and analysed by immunoblotting. Figure 5.3 shows that HBcX 
was eluted in the void volume of the column indicating that it forms either particles or 
large aggregates. Insufficient fusion protein was obtained from "small-scale preparation 
to continue purification; therefore. HBcX production was induced from a ten litre culture 
of F. coli strain RB791 harbouring plasmid pHBcX (section 213.10.10b). Proceeding on 
the knowledge that HBcX formed particles or large aggregates, the purification procedure 
described by Stahl and Murray (1989) was followed initially. HBcX was sedimented from 
the soluble fraction of sonicated cell extract by ultracentrifugation. Proteins in the 
resuspended pellet were fractionated by gel filtration through Sepharose CL-413 and 
examined by SDS-PAGE (figure 5.5a). Fractions containing fusion protein were pooled 
and the product collected by ultracentrifugation. This preparation was observed by 
electron microscopy which revealed highly aggregated particles (figure 5.6). Individual 
particles were similar in appearance to HBcAg particles produced in E. co/i. 
Gallina and her colleagues (1989) showed that particles formed by HBcAg produced 
in F. coli could be dissociated by treatment with SDS or urea into dimeric form while 
particles formed by HBcAg could not be dissociated by these agents. This feature was 
exploited by Stahl and Murray (1989) to remove high molecular weight impurities from 
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FIGURE 5.3 Detection of HBcX following gel filtration through Sepharose CL-4B. 
Protein samples were fractionated by SDS-PAGE in a 12.5% acrylamide gel and 
stained with Coomassie Blue. 
Following SDS-PAGE fractionated proteins were transferred to nitrocellulose 
membrane and HBcX was detected by incubation with rabbit 98 anti-HBxAg serum 
(section 2A.5) diluted 1:2500. This antiserum had been pre-adsorbed against a lysate 
of E.coli strain RB791 (section 2B.10.7). Antibodies which bound to protein on the 
membrane were detected by incubation with goat anti-rabbit IgG serum conjugated 
to alkaline phosphatase and subsequent incubation with a colour producing substrate 
as described (section 2B.10.8). 
Lanes: 
M - Molecular weight size standards (sizes indicated in kD). 
C - 20 g  purified HBcAg. 
Cr - Soluble fraction of sonicated lysate from E. co/i strain RB791 harbouring 
plasmid pHBcX and incubated with IPTG. 
4-9 - Number of fraction eluted from gel filtration of "Cr' through Sepharose CL-
4B (30 Al of 3.3 ml fraction). 
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FIGURE 5.4 Electrophoresis of HBcX under non-reducing conditions. 
Protein samples were fractionated by SDS-PAGE in a 12.5% acrylamide gel and 
stained with Coomassie Blue. 
Immunoblot analysis carried out as described for figure 5.3b. 
Immunoblot analysis as in "B" using rabbit 87 anti-HBcAg IgG preparation (section 
2A.5) diluted 1:2500 for the primary incubation. This preparation had been pre-
adsorbed against a lysate of E. coil strain RB791 (section 2B.10.7). 
Lanes: 
M - Molecular weight size standards (sizes indicated in kD). 
C - 20 jig HBcAg. 
pBBx - Extract of E. coil straih DS410 harbouring plasmid pBBX (Pugh et 
aL, 1986) included as a positive control for rabbit 98 anti-HBxAg 
serum. The cross- reacting Acro/HBxAg fusion protein (17 kD) was 
present in panel B but was very faint and is not visible in the 
photograph. 
Cxl +DTT - HBcX following gel filtration through Sepharose CL-4B. 30 Al of 
fraction 4 (figure 5.5a, lane "4") was prepared by incubation in 1% 
(w/v) SDS, 60mM Dfl for 5 minutes at 100°C. 
CX1 - HBcX purified as above incubated in 1% (w/v) SDS for one hour at 
60°C. 
CX2+DTT - HBcX following gel filtration through Sephaciyl S-200. 30 M1  of 
fraction 4 (figure 5.5b lane "4") was prepared by incubation in 1% 
(w/v) SDS, 60mM Dfl for 5 minutes at 100°C. 
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FIGURE 5.5: "Large-scale" purification of HBcX. 
Protein samples were fractionated by SDS-PAGE in 12.5% acrylamide gels and stained 
with Coomassie Blue. 
Gel filtration through Sepharose 4B. 
Lanes: 
M - Molecular weight size standards (sizes indicated in kD). 
Cr - Soluble fraction of sonicated lysate from E. coli strain RB791 harbouring 
plasmid pHBcX and incubated with IPTG. 
P - Resuspended pellet following ultracentrifugation of "Cr". 
S _ Supernatant following ultracentrifugation of 'Cr". 
1-9 - Number of fraction eluted from gel filtration of "Pt' through Sepharose 
CL-4B (30 /Ll of 3.3 ml fraction). 
Gel filtration through Sephacryl-S200 following incubation of partially purified HBcX 
in 5M Urea 
Lanes: 
M - Molecular weight size standards (sizes indicated in kD). 
4Bp - Resuspended pellet following ultracentrifugation of HBcX purified by gel 
filtration through Sepharose CL-4B. 
4Bs - Supernatant following ultracentrifugation of HBcX purified by gel 
filtration through Sepharose CL-4B. 
1-8 - Number of fraction eluted from gel filtration of "4Bp" through Sephacryl 
S-200 (30 Al of 3.3 ml fraction). 
Anion-exchange chromatography through DEAE-Se pharose. 
Lanes: 
M - Molecular weight size standards (sizes indicated in kD). 
C - 10 Ag HBcAg. 
S2p - Resuspended pellet following ultracentrifugation of HBcX purified by gel 
filtration through Sephacryl S-200. 
S2s - Supernatant following ultracentrifugation of HBcX purified by gel 
filtration through Sephacryl S-200. 
DEAE - 1/30 of total volume of resuspended pellet from ultracentrifugation of 
HBcX positive fractions eluted from a column of DEAE-Sepharoe in a 
continuous gradient of 0 - 0.5 M NaCl. 
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FIGURE 5.6: Observation of HBcX by electron microscopy. 
Electron micrographs of HBcAg (A), HBcX following gel filtration through Sepharose 
CL-4B (B), and HBcX following anion-exchange chromatography through DEAE- 
Sepharose (C). Grids were prepared as described (section 2B.10.14). Magnification is 
80,000 x. 
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FIGURE 5.7: Immunoreactivity of HBcX 
Detection of HBcX in fractions eluted from Sepharose CL-4B column. Number of 
fraction (3.3 ml) is indicated. 50 ul of each fraction was spotted onto nitrocellulose 
membrane as described (section 2B.10.6). Membrane was incubated with rabbit 98 
anti-HBxAg serum or rabbit 87 anti-HBcAg IgG preparation (section 2A.5) diluted 
1:2500 or 1:1000 respectively. Antibodies which bound proteins on the membrane 
were detected by incubation with goat anti-rabbit IgG serum conjugated to alkaline 
phosphatase and subsequent incubation with a colour producing substrate as described 
(section 2B.10.8). Both rabbit antisera had been pre-adsorbed against a lysate of E. 
co/i strain RB791 (section 2B.10.7). 
Detection of HBcAg by antisera from rabbit inoculated with HBcX. Numbers above 
each column indicate Ag of HBcAg spotted onto nitrocellulose membrane as described 
(section 2B.10.6), "BSA" indicates 10 Ag of bovine serum albumin spotted onto the 
membrane as a negative control. Strips of membrane were incubated in the indicated 
dilution of serum withdrawn prior to inoculation with HBcX (1) or following the third 
inoculation with HBcX (2) as described in section 5.2.3. Antibodies which bound 
protein on the membrane were detected as decribed in "A". Both sera had been pre-
adsorbed as described in 'A". 
Proteins fractionated by SDS-PAGE in a 12.5% acrylamide gel were transferred to 
nitrocellulose membrane and incubated with rabbit 98 anti-HBxAg serum diluted 
1:2500 (1) or anti-HBcX serum (described in 'B") diluted 1:1000 (2). Antibodies 
which bound protein on the membrane were detected as described in "A". Both 
antisera had been pre-adsorbed as described in "A". 
Lanes: 
NFl, pEX - Extracts of E. co/i strain NFl alone (NFl), cells harbouring the 
pXA vector plasmid (pEX) encoding -galactosidase, and cells 
harbouring plasmid (pXA) encoding a -galactosidaseiI-iBxAg 
fusion protein. 
C- 20 .ig HBcAg 
CX - 30 lAg HBcX following chromatography through Sepharose CL-4B 
and concentration by ultracentrifugation. 
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fusion proteins containing HBcAg amino acid residues 3-144 by gel filtration of the 
dimeric form. When HBcX, purified by gel filtration through Sepharose CL-4B. was 
subject to SDS page under non-reducing conditions (denaturation in 1% SDS for 1 hour 
at 60°C) about 60% of fusion protein was dissociated into monomeric form, while larger 
forms and aggregated protein that did not enter the gel were also observed (figure 5.4). 
This suggested that HBcX particles might be dissociated by a chaotropic agent. 
HBcX was incubated in 5M urea pH 9.6, and proteins were fractionated through 
Sephacryl S-200. Fractions eluted from the column were assayed for the presence of 
HBcX by SDS-PAGE, which showed that particles had eluted from the column in the void 
volume and had not been dissociated (figure 5.5h). The HBcX preparation was incubated 
in 8M urea pH 7.0 for one hour at 37°C, and proteins were fractionated through 
Sephacryl S-200 equilibrated with 8M urea. Once again, the HBcX particles were not 
dissociated and eluted from the column in the void volume (data not shown). 
Two ion exchange resins were investigated for the ability to bind HBcX. The fusion 
protein was eluted in the void volume from a column of cation exchange resin, CM-
Sepharose, and the eluted sample contained the same contaminants as had been present 
prior to chromatography (data not shown). However, HBcX bound to the anion exchange 
resin, DEAE-Sepharose, and a small fraction of the protein was eluted from the column 
in approximately 0.4M NaCl within a continuous gradient of 0 to 0.5M NaCI (figure 5.5c). 
Approximately two mg of partially purified HBcX was layered onto the column as 
estimated by Lowry protein assay, while only —50 Ag was recovered as estimated by 
staining with Coomassie Blue in parallel with a known amount of purified HBcAg after 
SDS-PAGE. The eluted protein appeared to have fewer contaminants than had been 
present prior to chromatography (figure 5.5c) contaminants representing —35% of total 
protein in the starting material (estimated by densitometric analysis) were not observed 
in the eluted protein. 
HBcX was purified from a second ten litre culture of E. coil RB791 harbouring 
plasmid pHBcX by gel filtration through Sepharose CL-4B followed by anion exchange 
chromatography through DEAE-Sepharose (section 2B.10.10c). DTT (10mM) was 
present throughout the purification procedure in an effort to minimise aggregation of 
HBcX particles. As before only a small fraction of input HBcX was eluted from DEAE-
Sepharose in 0.4M NaCl. Additional protein was eluted with steps of 1M and 2M NaCl 
and with 8M urea. 
The elution of additional HBcX in each step of buffer may represent varying 
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dissociation constants for protein with the adsorbent matrix due to several different sites 
of interaction on the protein surface. In addition, the adsorbent matrix may present a 
heterologous array of binding sites (Scopes. 1987). It is also possible that protein 
precipitated at the top of the column was resolubilised to greater degrees with each 
elution step, and that this precipitate was responsible for the low yields of protein eluted 
from the column. 
5.2.3 Production of antiserum to HBcX 
HBcX purified by chromatography through Sepharose CL-4B and DEAF-Sepharose 
was used to immunise a rabbit that had been pre-immunised 3 years previously with a 
particulate form of HBeAg produced in E. co/i. HBcX (-5 g) in Freund's complete 
adjuvant was injected intramuscularly followed by a second injection of HBcX (-5 g) in 
Freund's incomplete adjuvant 30 days later. A third injection of HBcX (-5 g) in 
Freund's incomplete adjuvant was administered 140 days after the initial injection. Blood 
from the rabbit was collected from an ear-vein prior to inoculation with HBcX and one 
week after each injection. Sera collected after the second and third injection with HBcX 
were assayed for the presence of antibodies to HBxAg by immunodetection of a - 
galactosidase/HBxAg fusion protein (encoded by plasmid pXA section 3.2.1) immobilised 
on nitrocellulose membrane. No antibodies directed against HBxAg were detected, 
however an increase in the titre of antibodies specific for HBcAg was detected by 
immunoblot analysis of serial dilutions of this antigen (produced in E. co/i) spotted onto 
nitrocellulose membrane (figure 5.7b). 
5.2.4 HBcX has no kinase activity 
In vitro pk activity was assessed for HBcX at three different stages of purification: 1) 
following gel filtration through Sepharose CL-4B, 2) following elution from DEAE-
Sepharose in 0.4M NaCl, and 3) following elution from DEAE-Sepharose in salt and urea 
steps. The reaction buffer included the components described by Albin and Robinson 
(1980) for optimal activity of the endogenous pk of HBV core particles. Purified HBcAg 
produced in E. coli was used as exogenous substrate as this polypeptide is the phosphate 
acceptor for the endogenous. HBV-associated pk. The incorporation of radioactive 
phosphate into protein was determined by absorption of labelled proteins to DES  paper 
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and by autoradiography of labelled proteins fractionated by SDS-PAGE. 
The ability of HBcAg to serve as phosphate acceptor in the reaction was shown by 
incubation with the catalytic subunit of cAMP-dependent protein kinase (PKA) which 
yielded up to 100% incorporation of [y-32P]ATP into HBcAg (figure 5.8a, "C+PKA": 
figure 5.8b,c lane "CK"). HBcAg is not visible in the stain of total proteins (fig 5.8b, lane 
"CK") because the reaction mixture was diluted 300-fold before SDS-PAGE. 
Phosphorylation ot'HBcAg in the presence of [y-32P]ATP alone was not observed (figure 
5.8a, "C": figure 5.8b,c, lane "C") consistent with the result of Schlicht et ci. (1989a) that 
HBcAg produced in E. coli does not have the capacity to autophosphorylate. In 
experiment 3 (figure 5.8a: column "C't) the source of increased counts for HBcAg 
incubated with [y-32P]ATP alone is not known, because autoradiography of labelled 
proteins fractionated by SDS-PAGE showed that no radioactive phosphate has been 
covalently linked to HBcAg. 
Incubation of HBcX (-1kg) with HBcAg in the presence of [y-32P]ATP did not 
result in phosphorylation of either protein (figure 5.8a, "CX+C": figure 5.8b,c, lane 
"CXIC") indicating that the X-gene product produced in E. coli fused to part of HBcAg 
does not have pk activity for either autophosphorylation or for phosphorylation of HBcAg. 
In addition, HBcX did not serve as a substrate for PKA (figure 5.8a, "CX+PKA"; figure 
5.8 b,c, lane "CXIK"). indicating that HBcAg is phosphorylated by this enzyme on serine 
residues within the carboxy-terminal 39 amino acids of HBcAg which are missing in HBcX. 
This region of HBcAg has two serine residues (positions 168 and 176) contained in 
consensus sites available for phosphorylation by PKA (Kemp and Pearson, 1990). The 
increased Counts observed on one occasion (figure 5.8a. Experiment 3, "CX+PKA") for 
HBcX incubated with PKA in the presence of [y-32P]ATP was due to the 
phosphorylation of contaminating proteins as observed by autoradiography of reaction 
products separated by SDS-PAGE (figure 5.8c, lane CX/K). 
5.2.5 Protein kinase activity in extracts of human hepatoma cells transiently expressing 
HBxA 
In vitro pk assays were carried out on crude freeze-thaw lysates prepared from 
hepatoma cells transiently transfected with a plasmid encoding HBxAg under control of 
its own promoter/enhancer (pHBV1004) or its corresponding X ORF frameshift mutant 
(pHBV1004-B), or from cells transiently transfected with a plasmid encoding HBxAg 
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FIGURE 5.8: Kinase assays with HBcX. 
Average counts per minute (CPM) obtained from Cerenkov counting of kinase assay 
reaction mixtures absorbed in duplicate to DE81 paper and washed as described 
(section 2B.10.13) except in the case of 'A total" which was unwashed. Contents of 
reaction mixtures were as follows: 
A total 
- 
[y- P]ATP  alone in reaction buffer. 
C + PKA - 20 Ag HBcAg and 0.5 jg catalytic subunit of c-AMP dependent protein 
kinase (PKA). 
C - 20 ig HBcAg. 
CX+C - —1 Ag HBcX and 20 p.g HBcAg 
CX+PKA - —1 Ag HBcX + 0.5 gg PKA 
A - [y-32P]ATP alone in reaction buffer. 
Results from four independent experiments are shown; N.D.= not done. HBcX 
preparations were from different stages of purification: 1) following gel filtration 
through Sepharose CL-4B; 2) following anion-exchange chromatography through 
DEAE-Sepharose and elution in continuous gradient of 045M NaCl; 3) as in "2" but 
from a second large scale preparation; 4) pooled protein eluted from DEAE-
Sepharose by steps of increasing NaCl concentration and 8M Urea. 
30 jul of reaction mixture (except where indicated) was fractionated by SDS-PAGE in 
a 12.5% acrylamide gel and proteins were transferred to nitrocellulose membrane. 
Proteins on the membrane were stained with amido black. Arrow in "blank" lane 
indicates position of HBcX in lanes TX/C" and "CX/K'. 
Lanes: 
M - Molecular weight size standards (sizes indicated in kD). 
CK - HBcAg and PKA as in "C + PKA" above. 
C - HBcAg as above, reaction mixture was diluted 1:300 prior to SDS-
PAGE. 
CXJC - HBcX and HBcAg as in TX + C" above. 
CX,'K - HBcX and PKA as in TX + PKA" above. 
A 
- [y-32P]ATP as in "A" above. 
Autoradiography of nitrocellulose membrane in "B". Lane CK. 7 hour exposure of 
film to membrane; lanes C, CX/C, CX/K and A. two day exposure. 
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TABLE 5.1 Kinase assays with mammalian cell extracts. 
Expt.. 1 ExpL 2 ExpL 3 Expt. 4 
Total 1058500 511250 1102900 467205 
Background 397 733 930 362 
4 10560 7301 
B 11538 9447 
X 18398 12654 8137 
XB 19187 11884 8365 
4X 7739 4753 
BaX 9250 5692 
XaX 34843 37705 6842 
XBaX 23383 19700 4336 
XaX sup 13921 





Values obtained from four independent experiments are shown. 10 .tl of kinase reaction 
mixture (total volume. 50 il) was absorbed to each of two pieces (1 cm) of DE81 filter 
paper. Except in the case of 'total", which was unwashed, the filters were washed as 
described (section 2B.10.14) and Cerenkov counted. The value shown is the average 
value obtained for the duplicate filters. Reaction mixtures contained: "Total" and 
"Background". [y-32P]ATP alone: XaX sup and XBczX sup, soluble extract following 
immunoprecipitation as in XaX and XBaX: all others as in figure 5.9 
under control of the SV40 early promoter/enhancer (pSV2HBX) or its corresponding 
frameshift mutant (pSV2HBX-B). Approximately 30 g of total protein from the soluble 
traction of each lysate was incubated with [?- -P]ATP and HBcAg added as an exogenous 
substrate. Similar pk activities were observed in soluble extracts from cells transfected 
with plasmids encoding HBxAg and those transfected with X-mutant plasmids (table 5.1 
and figure 5.9: "4.B,X.XB"). 
Polyclonal anti-HBxAg serum was used to immunoprecipitate cross-reacting products 
from the soluble fraction of cell lysates. Protein kinase activity was determined for 
precipitated products immobilised on Sepharose beads coated with protein A. Similar 
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FIGURE 5.9: Kinase assays with mammalian cell extracts. 
30 Al of reaction mixture (section 2B.10.13) was fractionated by SDS-PAGE in a 
12.5% acrylamide gel and transferred to nitrocellulose membrane. Proteins on the 
membrane were stained with amido black. 
Lanes: 
M - Molecular weight size standards (sizes indicated in kD). 
4. B - Reaction mixture contained 30 Ag of soluble protein from a freeze-
thaw lysate of HuH7 cells transfected with 30 j.g pHBV1004 (4) or 
30 jug pHBV1004-B (B) per 90mm dish. 
X. XB - Reaction mixture contained 30 tkg of soluble protein from a freeze-
thaw lysate of HepG2 cells transfected with 100 jig pSV2HBX (X) 
or 100 p.g pSV2HBX-B (XB) per 90mm dish. 
4aX, BcX, - Reaction mixture contained washed protein A beads following 
XcX, XBaX immunoprecipitation of cross-reacting products from soluble extract 
or"XB" described above with rabbit 98 anti-HBxAg serum 
pre-adsorbed against a lysate of E. co/i strain RB791 and diluted 
1:500. 
XaC, XBaC - Reaction mixture contained washed protein A beads following 
immunoprecipitation of cross-reacting products from soluble extract 
or 'XB" described above with rabbit 87 anti-HBcAg 1gG 
preparation pre-adsorbed against a lysate of E. coli strain RB791 and 
diluted 1:500. 
XD, XBD - Soluble fractions of freeze-thaw lysates "X' or tXBI? described above 
were pre-incubated with 1% (vlv) Triton X-100. 0.5% (w/v) 
deoxycholic acid before immunoprecipitation with Rabbit 98 anti-
HBxAg serum as described above. 
Autoradiograph of nitrocellulose membrane in 'A'. Lanes 4. B, X, XB, 4czX. BctX, 
XaX, XBoX; 30 minute exposure of film to membrane. Lanes XaC and XBC. two 
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kinase activities were present in immunoprecipitates from cells transfected with 
pHBV1004 or pHBV1004-B, while greater kinase activity was detected in 
immunoprecipitates from cells transfected with plasmid pSV2HBX compared to 
pSV2HBX-B (table 5.1 and figure 5.9; 4cX, BixX, XaX, XBxX). H o w e v e r 
immunoprecipitation of greater pk activity from extracts of cells expressing HBxAg under 
control of a heterologous promoter was not specific to this gene product, as the same 
result was observed when polyclonal anti-HBcAg serum was used for immunoprecipitation 
(table 5.1 and figure 5.9, XaC, XBcC). To reduce non-specific immunoprecipitation, 
soluble fractions were pre-incubated (10 minutes at 37°C) with detergents recommended 
for use in immunoprecipitation buffer (1% (vlv) Triton X-100, 0.5% (w/v) deoxycholic 
acid; Harlow and Lane, 1988). As a control, soluble fractions without added detergent 
were pre-incubated for 10 minutes at 37°C. In the control samples, greater pk activity was 
immunopreciptated from cells transfected with pSV2HBX than with pSV2HBX-B as had 
been previously observed (table 5.1, Experiment 4, 'XaX, XBX"). However, incubation 
of soluble fractions with detergent, nearly abolished the non-specific immunoprecipitation 
of pk activity (table 5.1 and figure 5.9, "XD, XBD"). The low level of pk activity observed 
in these samples was equivalent for cells transfected with pSV2HBX or with the 
frameshift mutant. 
5.3 Discussion 
To examine if the X ORF of HBV encodes a protein kinase that could be responsible 
for the endogenous pk activity associated with HBV core particles. HBxAg was produced 
in E. coli. A very low yield of HBxAg was obtained when the antigen was fused at its 
amino terminus to the eight amino-terminal residues of -galactosidase. Several recent 
studies have shown that heterologous viral sequences fused to the 3' end of the coding 
sequence for HBcAg (up to amino acid residue 144) are produced in high yield in E. coil 
(Borisova et al., 1989; Stahl and Murray, 1989). The fusion proteins spontaneously form 
particles making them easy to purify and immunogenic, eliciting antibodies to the 
heterologous polypeptide sequence. This system was exploited for the production of 
HBxAg in F. coli fused via a fifteen residue linker to the carboxyl-end of HBcAg residues 
3-144. 
In previous reports the largest polypeptide extension accommodated in HBcAg-like 
particles was 115 amino acids (Stahl and Murray, 1989). HBcX formed HBcAg-like 
particles with an extension of 169 residues. However, unlike the fusion particles described 
by Stahl and Murray (1989). HBcX could not be dissociated by treatment with a 
chaotropic agent, although monomers were formed from a percentage of HBcX particles 
by incubation in 1% SIDS at 60°C for one hour. It appears that some HBcX monomers 
are participating in particle superstructure by disulphide bonding. 
Purified HBcX was not a substrate for PKA, while HBcAg was phosphorylated by this 
enzyme, indicating that the phosphate acceptor site in HBcAg in this reaction was located 
in the 39 carboxv-terminal residues. This is the same region phosphorylated by the 
endogenous pk activity of HBV core particles. The polypeptide sequences in HBcX do 
not contain a consensus sequence for phosphorylation by PKA and did not serve as a 
substrate for the enzyme. HBcX was not autophosphorylated in the presence of [y-
32P]ATP alone and did not phosphorylate HBcAg added as an exogenous substrate. 
It is pertinent to this discussion to consider whether the HBxAg segment contained 
in HBcX was located inside or outside of the chimeric capsid. If HBxAg was inside the 
particle, kinase activity would not have been accessible to exogenous substrates although 
nucleoside triphosphates should have been able to penetrate for assessment of 
autophosphorylation capacity. There is evidence that heterologous polypeptide sequences 
fused to HBcAg at amino acid residue 144 are presented on the surface of the particle. 
Chimeric capsids bound monoclonal antibodies directed against epitopes in the 
heterologous sequence (Borisova et al., 1989), and, when used as immunogens, chimeric 
capsids elicited antibodies to the heterologous epitopes (Borisova et al., 1989; Stahl and 
Murray, 1989). HBcX spotted onto nitrocellulose membrane cross-reacted with anti-
HBxAg serum indicating exposure of HBxAg epitopes on the particle surface. However, 
a rabbit immunised with HBcX did not produce antibodies that cross reacted with 
denatured HBxAg epitopes presented on nitrocellulose membrane after SDS-PAGE, while 
antibodies to HBcAg were elicited. This may have been the result of a deficiency in the 
immune repertoire of the individual animal or a low response due to the age of the animal 
rather than a lack of HBxAg epitopes presented on the particle surface. Aggregation of 
HBcX particles may, in part, be due to interparticle disulphide bonds. If some of the 10 
cysteine residues of HBxAg were exposed on the particle surface they may be available 
to form these bonds. 
There are numerous examples of functional mammalian protein kinases produced in 
E. coli. These include serine/threonine kinases, for example, creatine kinase (Koretsky 
and Traxler, 1989) and the catalytic subunit of PKA (Slice and Taylor, 1989); and tyrosine 
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kinases. for example, v-abl (Pritchard et al., 1989) and epidermal growth factor receptor 
(Farrow et al.. 1989). While it is thus possible for mammalian protein kinases produced 
in E. co/i to fold in proper conformation for enzymatic function, the structural constraints 
of particle formation on HBcX may result in improper folding of the HBxAg segment. 
Therefore, the pk activity of HBxAg produced in human hepatoma cells was investigated. 
Hepatoma cells were transfected with a plasmid encoding HBxAg under control of its 
native promoter/enhancer (pHBV1004) or under control of the SV40 early promoter 
enhancer (pSV2HBX) or with the corresponding X ORF frameshift mutant (pHBV1004-B 
or pSV2HBX-B). Higher pk activity was immunoprecipitated non-specifically from the 
soluble fraction of cells transfected with pSV2HBX than with pSV2HBX-B. The 
immunoprecipitation of greater pk activity from cells expressing HBxAg was abolished by 
incubation of soluble extracts with mild detergents. HBxAg was not detected by 
immunoblot analysis of extracts from cells transfected with pSV2HBX or pHBV1004. 
Indirect evidence for the presence of HBxAg in these cells is provided by detection of 
HBxAg specific mRNA in cells transfected with pSV2HBX and by the physiological 
consequence of increased HBsAg production in cells transfected with pHBV1004 
compared to the corresponding frameshift mutant (Chapter 4). No HBxAg-specific pk 
activity was detected in these studies. The source of greater pk activity 
immunoprecipitated non-specifically from cells transfected with pSV2HBX compared to 
the frameshift mutant is unknown. It is unlikely to be any of the Ca+  tdependent or 
cyclic nucleotide-dependent protein kinases as these components were not included in the 
reaction buffer. In addition to Ca+ +, protein kinase C (PKC) requires phosphatidylserine 
and an analog of diacylglycerol to function in vitro (Rodriguez-Pena and Rozengurt. 1984) 
and, therefor. would not have been active in this system. 
In this study, pk activity was not detected for HBxAg produced in mammalian cells or 
produced in E. coli fused to HBcAg. A recent report from Wu and her colleagues (1990) 
describes a pk activity for HBxAg produced in E. co/i or by transcription and translation 
in vitro. Both products had the capacity to transactivate transcription in vitro from the 
HIV1 LTR fused to the CAT gene. Incubation of purified HBxAg from both sources 
with [y-32P]ATP resulted in incorporation of radioactive phosphate into HBxAg itself or 
into histone HI added to the reaction mixture as an exogenous substrate. Zn++ was the 
only component of the reaction mixture used by Wu et al. that was not present in the 
mixture used in this study. Zn++  may be important for pk activity as has been 
demonstrated for the phosphorylation of poliovirus VP2 and VP4 by the virus-associated 
I pr.,J 
pk (Ratka et at., 1989). 
Wu et aL describe several experiments that provide evidence against contamination 
of their preparations with a protein kinase other than HBxAg. A preparation of purified 
HBxAg derived from E. coli was fractionated by SDS-PAGE and the 16.5kd protein was 
eluted from the gel and renatured. The authors note that the pk activity observed with 
HBxAg purified in this manner was not observed using the same purification method for 
lysates of bacteria harbouring the vector plasmid without HBxAg coding sequences. They 
do not indicate, however, whether this negative result was obtained in the presence or 
absence of exogenous substrate. If one was not added, it is possible that the 16.5 kD X 
polypeptide served as substrate for a cellular kinase fractionated at the same place in the 
gel. Phosphorylation of the 16.5 kD purified protein was obtained following SDS-PAGE 
and transfer to nitrocellulose supporting the observation of an autophosphorylating kinase 
activity for HBxAg. The physiological significance of in vitro autophosphorylation of 
HBxAg is unkown. HBxAg produced in mammalian cells in culture does not appear to 
be phosporylated. When human embryonic cells, transiently transfected with a plasmid 
encoding HBxAg, were incubated in radioactive orthophosphate, only unlabelled p17 was 
immunoprecipitated from cell lysate with anti-HBxAg serum (Levrero et at., 1990b). 
In the study by Wu et at. HBxAg bound the ATP analog. p-fluorosulphonylberizoyl 5-
adenosine (FSBA); ATP binding would be necessary for pk activity, and both in vitro 
phosphorylation of HBxAg and in vitro transactivation of the HIV1 LTR were blocked 
by preincubation with FSBA, implicating pk activity in transactivating function. The 
authors indicate that these functions were also abolished by denaturation of HBxAg in 6M 
guanidine chloride followed by removal of the denaturing agent. This is a curious result 
in light of the fact that HBxAg was initially purified from the insoluble fraction of E. coli 
extract by solubilisation in 7M urea and subsequent renaturation. 
Wu et al. describe immunoprecipitation of radioactively labelled HBxAg from a 
preparation of 42 nm HBV particles, which were denatured following incubation in [y-
32P]ATP. Unlabelled viral HBxAg could also bind FSBA. Acid hydrolysis of 
phosphorylated HBxAg from virus particles, or produced in E. coli or in vitro revealed 
incorporation of phosphate on serine and threonine residues. Complete tryptic digests 
of HBxAg from all three sources yielded identical labelled peptide maps. Eight tryptic 
peptides were labelled, i.e. every tryptic peptide of HBxAg (translated from the nucleotide 
sequence of the HBV subtype used in their study, adw2) containing serine or threonine 
(assuming complete digestion). Kinetic studies indicated that five molecules of phosphate 
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were transferred to each molecule of HBxAg during in vitro phosphorylation. Therefore, 
the phosphorylation of HBxAg observed by Wu et al. was non-specific with different 
residues phosphorylated in each HBxAg molecule. 
Eukaryotic protein kinases constitute a large and diverse family of enzymes differing 
in cellular and subcellular distribution, regulatory control and substrate specitcity, yet they 
show extensive sequence similarities throughout a catalytic core domain (Hanks et al., 
1988). In considering the amino acid sequence of HBxAg, Wu et al. conclude that it must 
be a novel protein serine/threonine kinase, as it is half the size of the catalytic domains 
of most protein kinases (300 amino acids or more) and does not contain consensus motifs 
conserved in eukaryotic protein serine/threonine kinases (Hanks et aL, 1988). Highly 
conserved features include the ATP-binding site comprising Gly-X-Gly-X-X-Gly followed 
by an invariant Lys 15-30 residues downstream, which appears to be directly involved in 
the phosphotransfer reaction. Protein serine/threonine kinases contain another conserved 
Lys —100 residues further downstream which is diagnostic for this activity (tyrosine kinases 
have Arg or Ala at the equivalent position). Continuing —10 residues downstream, the 
triplet Asp-Phe-Gly has been implicated in ATP binding, while —20 residues further along, 
the triplet Ala-Pro-Glu lies near the catalytic site. A function has not been proposed for 
the conserved motif —10 residues further downstream, Asp-X-Trp-X-X-Gly. HBxAg does 
not contain sequences that resemble any of these motifs and it is impossible to speculate 
at this point as to a mechanism for the proposed catalytic function. The cellular codon 
usage of HBxAg relative to the other HBV antigens (Miller and Robinson, 1986) suggests 
that it may have been acquired from the host genome. The primary structures of all 
eukaryotic protein serine/threonine kinases identified thus far show significant homologies 
to the conserved motifs in their catalytic domains and may have diverged from a single 
progenitor (Hunter, 1987). A eukaryotic kinase lacking these motifs must have diverged 
significantly or else be a completely novel sequence with convergent function. The latter 
suggestion is not inconceivable as prokaryotic protein kinases have evolved with a 
different primary structure, for example. E. coli isocitrate dehydrogenase 
kinase/phosphatase (Cortay et al., 1988). 
As well as not addressing the kinase activity of HBxAg produced in mammalian cells. 
Wu et al. do not address the ability of the HBxAg pk to phosphorylate HBcAg. which is 
known to serve as a substrate for the core particle associated pk. Whether HBcAg is 
phosphorylated by the capsid associated kinase in vivo is not known. The core antigen 
of both HBV (Roossinck and Siddiqui. 1987) and DHBV (Schlicht etal.. 1989a) produced 
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in human hepatoma cells in culture was phosphorylated in the protamine-like region of 
the carboxyl-terminus. During natural infection, phosphorylation of DHBcAg was 
associated with immature core particles isolated from the cytoplasm of DHBV infected 
hepatocytes, while nucleocapsids purified form DHBV virion were not phosphorylated 
(Pugh et at, 1989). Phosphate groups on DHBV cytoplasmic core particles were removed 
by treatment with alkaline phosphatase. The susceptibility to alkaline phosphatase of 
HBcAg phosphorylated in vivo was not determined (Roossinck and Siddiqui, 1987). 
Phosphorylation of both DHBcAg (Pugh et at, 1989) and HBcAg by the core particle 
associated pk is resistant to alkaline phosphatase indicating that in vivo and in vitro 
phosphorylating activities may be distinct. The presence of endogenous pk activity in 
DHBcAg particles argues against this activity being encoded by the X-gene product, as the 
DHBV genome lacks a homologous ORF. 
Phosphorylation of proteins is a covalent means of regulating their activity, and the 
capsid proteins of numerous viruses are modified in this way in viva Phosphorylation of 
the poliovirus capsid proteins VPO, VP2, and VP4 may serve to destabilise the capsid for 
uncoating of the virus (Ratka et at, 1989), while cleavage of p65gag polyprotein of 
Rauscher murine leukaemia virus and subsequent maturation of the virion maybe related 
to phosphorylation (Naso nat, 1979). Increased viral transcription was associated with 
phosphorylation of the influenza NP protein (Kamata and Watanabe, 1977), while 
phosphorylation of pl2gag of Rauscher murine leukaemia virus was inversely proportional 
to RNA binding (Sen et at. 1977). What physiological role might phosphorylation of 
HBcAg play? • 
Birnbaum and Nassal (1990) speculate that phosphorylation of HBcAg by the 
endogenous pk activity might release the viral genome from the capsid upon infection. 
Eckhardt et at (1991) suggest that removal of the phospho group attached in vivo may 
play a role in nuclear localisation of HBcAg. In the duck model system mature core 
particles are not phosphorylated. In the absence of envelope synthesis, mature capsids 
localise to the nucleus resulting in amplification of covalently closed circular DHBV DNA 
(Summers et at, 1990). During HBV infection immature (phophorylated?) nucleocapsids 
containing pregenome RNA and minus-strand DNA are localised to the cytoplasm 
(Gowans et at, 1985; Miller a' at, 1984). Phosphorylation of HBcAg could regulate its 
transcriptional regulatory properties. While the effect of HBcAg on transcription of the 
HBV genome has not been investigated, this polypeptide can regulate transcription from 
the n-interferon promoter (Twu et at, 1988; Twu and Schloemer, 1989). 
ME 
In this study no pk activity was detected for I-IBxAg while a pk activity with unusual 
features has been described by Wu et at (1990). The viral associated kinase responsible 
for endogenous activity has not yet been identified. A consideration of the implication 
of the proposed pk activity on a mechanism for transactivation by HBxAg will be 
considered in the next chapter. 
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in the Aetiology of HCC 
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6A Mechanism of Transactivation by HExAg 
6A.1 Some features of transcriptional control in eukarvotes 
Initiation of transcription in eukarvotes is regulated by promoter sequences which 
contain clusters of short, defined DNA sequence motifs for binding specific protein 
factors. These transcription factors comprise two broad categories; general factors that 
are part of the RNA polymerase complex (the basal transcription apparatus) and are 
required for setting the transcription start site and for achieving a basal level of 
transcription, and regulatory factors that influence the efficiency of formation of active 
transcription complexes. The latter function can be modulated by a distant cluster of 
regulatory factor binding sites, an enhancer, which can operate in an orientation 
independent manner and was originally defined as a cis-acting regulatory sequence. 
Recently, evidence has been provided to show that a cis-linkage is not required for 
enhancer function; only a physical association between enhancer and promoter is 
necessary for interaction (Dunaway and Droge, 1989: Muller et at, 1989). This 
observation supports the model that regulatory factors contact the basal transcription 
apparatus by looping out of the intervening DNA (reviewed by Atchison, 1988). Binding 
sites for a particular regulatory factor can be part of a promoter or an enhancer, and the 
consequences of factor binding may be positive or negative. 
Regulatory factors can be composed of a polypeptide (or polypeptide homo-dimer) 
bearing both a DNA binding domain and a distinct activation domain required for 
transactivating or transrepressing function presumably by mediating protein-protein 
interactions. Examples of this type of factor include the yeast activator GAL4 or the 
mammalian transcription factors C/EBP and CREB (cAMP response element binding 
protein). Alternatively, activation- and DNA binding domains may be provided by a 
complex of heterologous polypeptides (Ptashne and Gann, 1990; see below for examples). 
Using the. SV40 enhancer as a model system, it has been shown that there are distinct 
levels of organisation among regulatory factor binding motifs (Ondek et at, 1988). In this 
system, enhancer 'elements" are composed of two factor binding motifs (enhansons). The 
activity of enhansons within an element is sensitive to changes in spacing suggesting 
interactions between regulatory factors binding to adjacent sites, while elements within an 
enhancer are insensitive to spacing changes and may function in either orientation (Zenke 
et at, 1986) suggesting participation in more distant protein-protein interactions. 
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Differential patterns of gene expression characteristic of distinct developmental stages 
or of different tissues may be attributed to variations in the level or activity of particular 
regulatory factors. This level, in turn, may be regulated by the transduction pathways for 
extracellular signals (see below). The complexity of transcriptional regulation in 
eukaryotic systems is manifest by the fact that transcriptional control regions may contain 
more than one binding sequence for a particular regulatory factor and/or the binding 
sequences for more than one type of factor. This modularity could allow regulation of 
transcription in response to diverse intracellular conditions (Dynan 1989). Additional 
complexity arises from identification of particular sequence motifs that can be bound by 
more than one type of transcription factor, for example, the sequence CCAAT and the 
octamer motif, and individual factors have been identified that bind divergent sequences, 
for example, C/EBP (reviewed by Johnson and McKnight. 1989). Therefore, multiple 
factors can influence transcription of a gene containing a particular binding motif in its 
regulatory region(s), and a single factor may evoke responses from genes with regulatory 
regions bearing different binding motifs. The level of transcription of a particular gene 
will be determined by an integrated association of regulatory factors within promoter and 
enhancer regions and the interaction of these factors with the basal transcription 
apparatus. 
6A.2 Cellular factors mediate transactivation by HBxAg 
The identification of many cellular transcription factors has occurred through 
investigation of viral transcriptional control regions. With the exception of pox viruses, 
all vertebrate DNA viruses and retroviruses rely on the cellular transcription machinery, 
and they have evolved regulatory sequences capable of recruiting cellular transcription 
factors. In addition, the genomes of most, if not all, DNA viruses encode regulatory 
proteins involved in the control of transcription of the viral genes. Two categories of viral 
transactivator proteins can be discerned based on whether.they exhibit sequence-specific 
DNA binding (reviewed by flint and Shenk, 1989). Those  activators that bind directly to 
specific DNA sequences include the herpes simplex: virus (HSV) ICP4 protein, the SV40 
and polyoma virus larg&T antigens Sand the. Epstein-Barr virus BZLF1 protein. In 
contrast, the human T lymphotropic virus type 1. (HTLV1) p4O'. protein, HSV VP 16, 
adenovirus Ela and pseudorabies virus immediate early protein do not bind DNA directly. 
The evidence available for HBxAg indicates that it falls into the second category àf 
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viral transactivator. In vitro binding assays indicate that HBxAg produced in E. coli or by 
in vitro transcription and translation does not bind directly to DNA sequences that are 
targets for transactivation (Jameel et at. 1990; Twu a at, 1990, Wu et at, 1990). There 
are several examples of viral or cellular transactivators that do not bind DNA themselves 
but as a complex with another polypeptide: VP16 exerts its effect at a specific octamer 
binding motif in a complex with the cellular Oct-1 protein (Triezenberg et at, 1988); the 
proto-oncogene product c-Myc, interacts with a specific DNA sequence in a complex with 
the Max protein (Blac7k'wood and Eisenman, 1991); and the 65 kD subunit of transcription 
factor NF-KB does nqt bind DNA itself but is part of the active sequence-specific factor 
in a complex with the 50 kD, DNA-binding subunit. Wu et at (1990) cite unpublished 
data indicating that purified HBxAg derived from E. coli, when added to a nuclear extract 
from HepG2 cells, did not cause formation of any protein-DNA complexes with altered 
mobility inacrylamide.gel  compared to those formed using unsupplemented extract. This 
method has been used to demonstrate the ability of VP16 to form a sequence-specific 
DNA complex in association with Oct-1 (Preston et at, 1988). The study by Wu et at 
(1990) was limited to the HIV1 LTR and indicated that HBxAg does not form a strong 
complex with this sequence in the presence of cellular factors. However, it does not rule 
out a more subtle interaction between HBxAg and factors bound to DNA. 
In vitro DNA binding studies indicate that HBxAg does not provide an integral part 
of a particular sequence specific transcription factor. This observation is supported by the 
diversity of targets susceptible to transactivation by HBxAg suggesting a less specific 
interaction. The recruitment of cellular factors by viral transcriptional control regions 
predicts that, if the function of a viral transactivator is mediated by cellular factors, it will 
have the capacity for transactivation of heterologous viral sequences as well as modulation 
of transcription of certain cellular genes. HBxAg displays this promiscuous capacity. 
Evidence for the involvement of regulatory (as opposed to general) cellular factors in the 
transactivation of genes transcribed by RNA polymerase II is provided by the observation 
that not all cell lines support transactivation of a particular target by HBxAg and not all 
known targets are transactivated in a particular cell line (Seto et at, 1989; see table 4.1). 
6A.3 Identification of factor binding sites that mediate transactivation by HBxAg 
Investigation of the DNA sequences susceptible to transactivation by HBxAg suggests 
that its effect is mediated by more than one cellular factor, as no single recognition 
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sequence is found in all of the targets. It has been reported that HBxAg can transactivate 
the RNA polymerase III promoters of the adenovirus VA1 RNA or the tRNAaIa  gene 
contained in recombinant plasmid DNA (Aufiero and Schneider, 1990). Extracts of cells 
expressing HBxAg were shown to contain higher levels of active TFIIIC, a general factor 
in the RNA polymerase III transcription complex. This result would predict 
transactivation by HBxAg of cellular genes transcribed by RNA polymerase III which has 
not been thoroughly investigated. 
Studies on the mechanism of transactivation of RNA polymerase II promoters by 
HBxAg have focused on deletion or mutation of individual regulatory factor binding sites 
from target promoters as well as on the generation of synthetic target promoters from 
cloned or synthesized factor binding sites. The HIV1 LTR fused to the CAT gene is a 
target for transactivation by HBxAg upon cotransfection of Jurkat T-lymphoma cells (Seto 
et at, 1988. 1989). Several transcriptional regulatory regions have been defined within the 
HIV1 LTR including: the transacting response element (TAR) (nucleotide position -17 
to +80 relative to the transcriptional start site) which is the target for transactivation by 
the HIV1 tat protein (Fisher et at, 1986); binding sites for transcription factor Spi (-77 
to -45) shown to bind the factor and to be important for activation of transcription (Jones 
et at, 1986); the enhancer region (.104 to .81) consisting of two sequences with strong 
homology to the binding site for NF-xB in the immunoglobulin ic enhancer (this site 
confers inducibility of transcription from the HIVI LTR by phorbol ester (Dinter et al., 
1987; see below) and purified NF-icB binds to and stimulates transcription from the HIV1 
LTR in vitro (Kawakami et at, 1988)); and a region homologous to the interleukin-2 (IL-
2) distal and proximal control elements (-303 to -246) (figure 6.1a). Seto et al. (1988) 
showed that deletion from the 5 end of the LTR, removing the region homologous to 
the IL-2 promoter, reduced the level of transactivation by HBxAg, while a further deletion 
of the NF-icB binding sites, leaving Spi sites and TAR intact, further reduced 
transactivation by HBxAg but still did not completely abolish it. Deletion of the LTR 
from the 3 'end (to +41), removing about half of TAR abolished transactivation by 
HBxAg. The isolated NF-KB binding sites fused to the tk promoter and fused to the 
CAT gene were susceptible to transactivation by HBxAg but to a much lower level than 
the intact LTR. The authors conclude that multiple cis-acting sites within the HIV1 LTR 
are needed for HBxAg to exert its full effect. 
The ability of HBxAg to function through multiple sites as described by Seto ci at 
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FIGURE 6.1 
Transcriptional regulatory regions defined within the 1-IlVi LTR. Plus signs 
denote 100 bp increments upstream and downstream of the transcription start site 
(+1). Individual regions are described in the text. 
Transcription factor binding sites in the SV40 enhancer (one 72 bp repeat). 
Adapted from Seto et al. (1990). 
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adenovirus E2 and E3 genes, which can be mediated by any of several promoter elements 
(reviewed by Hint and Shenk, 1989). However, the similarity in the mechanisms for 
transactivation by HBxAg and Ela is called into question by the observation that a 
replication defective adenovirus mutant, which does not express the viral Ela gene, could 
not replicate in hepatoma cells expressing HBxAg, indicating ihat HBxAg could not 
compensate for the loss of Eta activity (Aufiero and Schneider, 1990). Furthermore, Twu 
a al. (1989a,b) and Siddiqui a a?. (1989) have obtained conflicting results to those 
obtained by Seto et al. (1988) in examining transactivation of the HIV1 LTR fused to the 
CAT gene in HepG2 cells. Deletion of the NF-KB binding sites, leaving the Spi sites and 
TAR intact, completely abolished transactivation by HBxAg as did point mutations in the 
NF-KB binding sites within the complete LTR. In this system, the isolated NF-KB binding 
sites fused to the tk promoter fused to the CAT gene served as a target for transactivation 
by HBxAg that was nearly as efficient as the intact LTR (Twu a al., 1989a). In addition, 
synthetic, multimeric NF-KB binding sites in association with the -globin promoter (Twu 
a al., 1989a) or fused to the SV40 early promoter (Faktor and Shaul, 1990) served as 
targets for transactivation of transcription of the CAT gene by HBxAg. The discrepancy 
in results could be due to the presence of different cellular factors (or factors in varying 
concentrations) in different cell lines. 
NF-icB was originally detected as a nuclear protein that could bind a specific 10 bp 
sequence in the immunoglobulin x light chain enhancer, and was present in B-cells only 
at the appropriate developmental stage for light chain expression (reviewed by Lenardo 
and Baltimore, 1989; Gilmore, 1990). Further investigation revealed that NF-KB is 
present in the cytoplasm of all non-B-cells tested as an inactive complex with an inhibitor 
protein, ItB. Treatment of cells with various agents such as phorbol esters results in the 
release of active NF-KB from its inhibitor and subsequent translocation of the active 
factor to the nucleus. Phorbol esters, such as phorbol 12-myristate 13-acetate (PMA), are 
stable analogs of diacyglycerol (DAG). DAG is a catabolic product of inositol phosphate 
metabolism induced by ligand binding to cell-surface receptors, and it is responsible for 
activation of protein kinase C (PKC). Hence, NF-KB is not only developmentally 
regulated, as in B-cells, but is also involved in inducible gene expression through 
phosphorylation of IicB by PKC (Ghosh and Baltimore, 1990). 
It is unclear whether HBxAg is affecting the PKC inducible pathway of NF-icB. In 
HepG2 cells, the HIV1 LTR was transactivated by HBxAg to the same extent in the 
presence or absence of PMA suggesting that they function through the same pathway 
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which is stimulated to its full extent by HBxAg (Twu et al., 1989a). In contrast, treatment 
of Jurkat cells with PMA in the presence of HBxAg gave multiplicative induction of 
transcription from the HIV1 LTR relative to that observed with either activator alone 
indicating distinct pathways for induction of NF-icB by PMA and HBxAg (Seto et aL, 
1990). While other pathways for activation of NF-KB have been observed, for example. 
the PKC-independent induction of NF-KB activity by tumour necrosis factor a (Meichle 
et aL, 1990), it seems unlikely that a single activator, HBxAg, would exert its effect on a 
single factor through different pathways even in different cell lines. 
Many of the transcriptional regulatory regions that are targets for transactivation by 
HBxAg contain binding sites for NF-KB. These include the SV40 enhancer (Sen and 
Baltimore, 1986; Chiu et aL, 1987), the HIVI LTR (Kawakami et aL, 1988), the 0-
interferon promoter (Lenardo et all, 1989), and the MHC class I promoter (Baldwin and 
Sharp, 1988). Other targets, however do not contain NF-icB binding sites, notably the 
HBV enhancer (personal observation), the HTLV1 LTR (Dingwall, 1991), the promoter 
of MHC class II gene HLA-DR (Hu et aL, 1990) and the c-myc promoters (Wingender, 
1988), indicating that HBxAg can exert its effect through other cellular factors. 
Mutational analysis was carried out on the 5V40 enhancer (one of the 72 bp repeats. 
figure 6.1b) fused to the human metallothionein promoter fused to the CAT gene and 
transiently expressed in CVI monkey kidney cells (Seto et al., 1990). Mutations in the 
binding sites for transcription factors AP-1 or AP-2 reduced basal transcriptional activity 
as well as the extent of transactivation of transcription by HBxAg while not abolishing this 
effect. When both sites were mutated, transactivation was reduced further. Mutations 
in the binding site for octamer binding factors or NF-icB/AP-3 reduced basal transcription 
but did not affect the extent of transactivation by HBxAg. Multimers of synthetic AP-1 
or AP-2 binding sites fused to the human metallothionein promoter fused to the CAT 
gene were susceptible to transactivation by HBxAg, while a multimeric. mutant AP-2 site 
showed a reduced response. Further evidence for the mediation of transactivation 
through the cellular factor AP-2 was provided by transfection of the plasmid construction 
bearing multimeric AP-2-binding sites into Drosophila Schneider cells which are devoid 
of AP-2 activity. Cotransfection with an HBxAg expression plasmid did not yield 
transactivation while cotransfection with HBxAg and AP-2 expression plasmids gave a 
significant response. AP-2 binding sites are located in the c-myc promoter (Wingender, 
1988) and consensus sequences for AP-2 binding are located in the promoters of MHC 
class II genes including HLA-DR (Benoist et aL, 1990). 
Support for the involvement of AP-2 in mediating transactivation by HBxAg may be 
inferred from the results of Spandau and Lee (1988) who observed that transactivation 
of the SV40 early promoter/enhancer complex in Cvi cells could be blocked by 
cotransfection with a plasmid expressing SV40 large T-antigen (Tag) or by carrying out 
transactivation assays in COS cells which express Tag from integrated SV40 DNA. 
Mitchel et at (1987) have shown that, through direct protein-protein interaction, Tag 
inhibits the ability of AP-2 to bind DNA. Tag did not block transactivation of the RSV 
LTR (Spandau and Lee, 1988) which lacks AP-2 binding sites (Wingender, 1988), 
implicating AP-2 in mediating transactivation of the SV40 early promoter/enhancer and 
indicating, once again, that the function of HBxAg can be mediated by more than one 
cellular factor. 
The HIV1 LTR contains a sequence motif which resembles an AP-2 binding site (-95 
to -88), however, no transactivation was observed in HepG2 cells of deletion mutants in 
which this site remained intact. (Twu et at, 1989b; Siddiqui et at, 1989). Multimers of this 
site in association with the -globin promoter did not serve as a target for transactivation 
by HBxAg in HepG2 cells (Twu et at 1989a). In apparent contrast, SV40 Tag inhibited 
transactivation of the HIV1 LTR by HBxAg in monkey kidney cells (Seto et at, 1989). 
Perhaps the block to transactivation of the HIV1 LTR by Tag could be accomplished by 
a mechanism other than inactivation of AP-2. It is possible that Tag also interacts with 
and inactivates NF-KB although this has not been reported. 
Support for the involvement of AP-1 in mediating transactivation by HBxAg may be 
inferred from the results of Faktor and Shaul (1990) who showed that multimers of the 
HBV enhancer E binding sites can serve as a target. This site was defined by its ability 
to bind C/EBP, but as described above (section 4.3), the presence of C/EBP binding sites 
does not confer susceptibility to transactivation by HBxAg. The sequence of the E site 
also contains homology to the consensus sequence for an AP-1 binding site. As with NF-
KB, the activity of APi is modulated by phorbol esters (Jones et at, 1988). Transcription 
from a plasmid bearing multimeric E binding sites was activated by phorbol ester 
implicating APi in interaction with this site where it may also function to mediate 
transactivation by HBxAg. 
The HBV E site contains sequence homology to the HTLV1 p4otax response element 
(taxRE) which consists of three repeats of 21 bp in the viral LTR). p4Otax does not bind 
to taxRE but stimulates transcription from this site as well as from the heterologous HBV 
E site (Faktor and Shaul, 1990). Additional similarity between HBxAg and p40 is 
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indicated by the ability of p40" to stimulate transcription from promoters containing NF-
KB binding sites including the HIV1 LTR (reviewed by Dingwall, 1991). Unlike HBxAg, 
however, p4otax  is exclusively a nuclear protein, and it could not transactivate the HTLV1 
LTR in which the enhancer fragment (-350 to -55) was in reverse orientation (Rosen et 
at, 1985). This modified LTR sequence, as well as the intact HTLV1 LTR, served as 
targets for transactivation by HBxAg (Wollersheim et at, 1988; Zahm et at, 1988; Siddiqui 
a at, 1989). 
Goodarzi a at (1990) examined a large segment of the HBV enhancer for its ability 
to mediate transactivation by HBxAg in association with the SV40 early promoter. 
Consistent with the results presented in Chapter 4, mutations in the E site did not alter 
the ability of this enhancer/promoter complex to serve as a target for transactivation by 
HBxAg, while mutations in the EP site (see figure 1.7) reduced stimulation of 
transcription by HBxAg. This region of the HBV enhancer can compete with the 
polyoma virus enhancer for binding of a factor termed EF-C. Therefor, it appears that 
this factor may also mediate transactivation by HBxAg. 
6A.4 Mechanisms for alteration of the activity of cellular transcription factors 
TFIIIC, NF-KB, AP-1, AP-2 and EF-C have all been reported as having potential to 
mediate transactivation by HBxAg, and it is probable that this list is not exhaustive. A 
variety of mechanisms can be envisioned to explain the increase in transcriptional activity 
mediated by a cellular factor in the presence of HBxAg. HBxAg could simply stimulate 
the gene(s) encoding particular factors, thereby increasing their concentration in the cell. 
If a factor was in limiting concentration before HBxAg was present, increasing its 
abundance would stimulate promoters containing the corresponding binding site. This 
proposed mechanism does not answer the question of how HBxAg transactivates but 
merely shifts the question to a different target promoter. It is unlikely that HBxAg 
functions in this manner as it would require de flOVO protein synthesis, and transactivation 
by HBxAg produced in E. coli or in human hepatoma cells has been observed in vitro 
(Aufiero and Schneider, 1990; Wu et at, 1990). 
Two of the ways in which a transactivator might increase the activity of a particular 
transcription factor are by enhancing its ability to bind DNA or by improving its ability to 
interact with other regulatory factors or with the basal transcription apparatus. Either of 
these modulations could be achieved by, a) post-translational modification of the 
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transcription factor, or b) direct interaction between the activator protein and the 
transcription factor (figure 6.2). Any proposed mechanism for the function of HBxAg 
must seek a common pathway whereby several distinct cellular factors are regulated 
coordinately. In case "a" HBxAg must activate a modification pathway that alters the 
function of several different factors, while in case "b', HBxAg itself must be able to 
interact with different cellular factors. 
6A.4.1 Post-translational modification 
A 
Phosphorylation of transcription factors has been shown to regulate their DNA-
binding activity or to modulate their ability to activate transcription without affecting their 
DNA-binding capacity. Phosphorylation of c-Jun (a component of transcription factor 
AP-1) inhibits DNA binding while the binding activities of factors E2F and E417, which 
are induced by adenovirus Ela, are increased by phosphorylation (Boyle et aL, 1991; and 
references therein). Phosphorylation of 1KB releases NF-KB from a cystolic complex of 
the two pn3teirsl and allows NF-KB to enter the nucleus and bind DNA (reviewed by 
Lenardo and Baltimore, 1989). The DNA-binding activity of CREB (Gonzalez and 
Montminy. 1989) and yeast heat shock factor (Sorger and Pelham, 1988) is not affected 
by phosphorylation, however, their activity is increased by this modification which may be 
attributed to enhanced interaction with other elements of the transcription apparatus. In 
the case of CREB, this effect is not simply due to the increase in negative charge by 
phosphorylation as replacement of the phosphorylated serine residue with an aspartate 
or a glutamate residue created an inactive polypeptide (Gonzalez and Montminy, 1989). 
It has been claimed that HBxAg itself possesses a protein serine/threonine kinase 
activity resulting in autophosphorylation of serine residues (Wu et aL, 1990; section 5.3), 
although no such activity could be detected in this study. In the experiments of Wu et aL, 
HBxAg derived from E. coli could transactivate the HIV1 LTR in vitro when added to the 
template in the presence of HepG2 cell nuclear extract. This effect could be abolished 
by pre-treatment of purified HBxAg with an analog of ATP known to block pk activity. 
Transactivation in vitro could not be mediated by NF-KB as the factor would not be 
present in a nuclear extract of HepG2 cells. The capacity of HBxAg to transactivate in 
vitro appears to contradict previous results reported by the same investigators indicating 
that de novo protein synthesis was required for transactivation of the HP/I LTR in a 
cell line treated with E. co/i derived HBxAg by protoplast fusion (Twu et aL, 1990). 
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FIGURE 6.2 Mechanisms of transactivation 
Schematic diagram depicting alternative models for the mechanism of transactivation by 
HBxAg. In each case, two transcriptional control regions are depicted in the presence 
(+) or absence (-) of HBxAg. The arrow denotes transcriptional activation in the 
presence of HBxAg.  
Post-translational modification in the presence of HBxAg (left) or direct 
interaction with HBxAg (right) enhances DNA binding by a cellular regulatory 
factor. 
Post-translational modification in the presence of HBxAg (left) or direct. 
interaction with HBxAg (right) does not alter the DNA-binding capacity of a 
cellular regulatory factor but enhances its ability to interact with other components 
of the transcription complex. 
Adapted from Nevins (1989). 
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However, if transactivation in vivo were being mediated by NF-KB, de novo protein 
synthesis may have been needed over the time course of the experiment to maintain the 
concentration of this factor. Hohmann et ci. (1991) have shown that activated NF-KB 
(released from IicB) has a very short half-life and needs to be replaced by de nOvo protein 
synthesis in order to maintain the activated state. Active NF-ICB in cells pre-treated with 
PMA was completely degraded within 2.5 hours of treatment with cycloheximide. The 
experiment by Twu et ci (1990) involved treatment of cells with cycloheximide for 48 
hours. 
Wu et at (1990) note that protein complexes with the HIV1 LTR DNA were formed 
more efficiently after incubation of the LTR DNA fragment in HepG2 cell nuclear extract 
supplemented with HBxAg derived from E. coli than after incubation in unsupplemented 
extract. This effect, too, was abolished by pretreatment of HBxAg with the ATP analog 
suggesting that the pk activity of HBxAg enhances the binding of cellular transcription 
factors (other than NF-icB) with the HIV1 LTR. 
If the HBxAg kinase itself is responsible for mediating transactivation of transcription, 
its substrates must include all of the cellular factors shown to be involved in this function. 
To date, the only cellular substrate described for HBxAg pk activity is histone HI (Wu 
et at. 1990). Alternatively, the HBxAg kinase may activate a single cellular protein kinase 
for which the transcription factors are substrates. One candidate cellular kinase would be 
PKC. The activity of AP-1. AP-2 (reviewed by Jones et at, 1988). and NF-KB (reviewed 
by Gilmore, 1990) is activated by phosphorylation following induction of signal 
transduction pathways activating PKC. TEIIIC is activated by phosphorylation in the 
presence of adenovirus Ela protein (Hoeffler et at, 1988), although the source of kinase 
activity is yet to be determined. The modification of EF-C by phosphorylation has not 
been reported. In order to investigate the effect of PKC on HBV transcription and its 
involvement in transactivation by HBxAg, cells transfected with HBsAg expression 
plasmids (with or without an intact X-ORF) could be treated with phorbol esters to 
induce PKC or, alternatively, treated with specific inhibitors of PKC. 
While the post-translational modification of cellular transcription factors remains a 
possibility, the balance of evidence currently favours a model postulating that HBxAg 
regulates transeription through protein-protein interactions. 
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6A.4.2 Protein-protein interactions 
The concentration dependence observed for transactivation by HBxAg suggests that 
it functions by direct protein-protein interactions with cellular transcription factors 
(section 4.3). This hypothesis is supported by the construction of sequence-specific 
transcriptional regulatory factors by fusing HBxAg to the DNA-binding domain of a 
transcriptional control protein. Fusion of HBxAg to the DNA-binding domain of the 
bacterial repressor protein, LexA, conferred upon HBxAg the ability to activate 
transcription from a reporter plasmid bearing a lexA operator sequence fused to the 
human metallothionein promoter fused to the CAT gene (Seto et aL, 1990). Fusion of 
amino acid residues 1-143 of HBxAg to the DNA binding domain of transcription factor 
CIEBP from rat liver, significantly improved the ability of HBxAg to activate transcription 
from a construct bearing the HBV E site (CiEBP binding site) in association with the D-
globin promoter and the tk promoter (Unger and Shaul, 1990). These results indicate 
that HBxAg has a transcriptional activation domain which is brought into the transcription 
complex by association with DNA-binding cellular factors. The activation domain of 
HBxAg was localised to amino acid residues 110-143, as a protein containing only amino 
acid residues 1-109 of HBxAg fused to the DNA-binding domain of CIEBP showed greatly 
reduced activation of transcription from the reporter plasmid bearing C/EBP binding sites 
(Unger and Shaul, 1990). 
How might HBxAg function in the RNA polymerase II transcription complex? The 
interaction of the activation domains of cellular regulatory factors with the basal 
transcription apparatus may occur through different mechanisms (reviewed by Sawadogo 
and Sentenac, 1990). TFIID is a general transcription factor which binds to the "TATA 
box present in most eukaryotic promoters and directs assembly of the basal transcription 
apparatus. Some factors (for example, CREB) bind DNA cooperatively with TFIID 
suggesting direct protein-protein interactions, while others (Sp I, NFl) do not. TFIID may 
not be relevant in the transactivation of transcription directed by the preS2/S promoter 
of FIBV, as this promoter does not contain a "TATA box', and it remains to be shown 
whether promoters of this type utilise TFJTD. However, the interaction of transcription 
factors with TFIID provides an interesting model for connections between regulatory 
factors and the basal transcription apparatus. It is becoming increasingly clear that there 
are adaptor proteins that can mediate this function (reviewed by Lewin, 1990; Ptashne and 
Gann, 1990), and HBxAg may serve as one of these adaptor molecules with an ability to 
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interact with several regulatory factors. 
Fusion proteins directing a transcriptional activation domain to a particular DNA 
sequence (as described above for HBxAg) provide useful tools to investigate whether viral 
transactivators that do not bind DNA serve as a direct or indirect link with the basal 
transcription apparatus. VP16 is thought to provide the activation domain as part of a 
complex with the cellular DNA-binding protein Oct-1 and there is now evidence that an 
adaptor is required to link this complex to the basal transcription apparatus. Ga14-VPI6 
consisting of the DNA-binding domain of yeast Ga14 protein fused to the activation 
domain of VP16 activates transcription in vitro from a template containing a Ga14 binding 
site. Activation can be abolished by further purification of one of the yeast nuclear 
fractions comprising the extract for in vitro transcription without affecting the level of 
basal transcription. The potential of Gal4-VP16 to transactivate can be restored by 
addition of a distinct fraction of yeast nuclear extract which has no effect on basal 
transcription (Flanagan et al., 1991). The requirement for an adaptor protein for 
interaction with the basal transcription apparatus has also been described for transcription 
factor Spi which binds a specific DNA sequence and contains an activation domain (Pugh 
and Tjian, 1990). It is becoming clear that the activation domains described for many 
regulatory transcription factors do not necessarily contact the basal transcription apparatus 
but may contact an adaptor protein. 
Flanagan et all (1991) site unpublished work indicating that an assay has been 
developed identifying an adaptor required for activity of NF-xB. It would be interesting 
to see if HBxAg could serve this function. Adaptor function would require two domains 
involved in protein-protein interaction, one contacting the regulatory factor and the other 
contacting the basal transcription apparatus. The latter of these regions may be the 
activation domain described by Unger and Shaul (1990). If this model is correct a 
truncated HBxAg polypeptide (amino acid residue 1-109) may interfere with the function 
of wild type HBxAg by sequestering cellular factors in the absence of the capacity to 
interact with the basal transcription apparatus. Experiments of this type have not yet 
been reported. 
205 
6B-Potential Mechanisms for the involvement of HBxAg in the Development of HCC 
The potential for HBxAg to contribute to the development of liver-cell neoplasia has 
been discussed above (section 1.6). In this section, the mechanism whereby HBxAg or a 
form of HBxAg altered by fusion to cellular sequences may cause neoplastic growth is 
considered. The biochemical functions that have been identified for known proto-
oncogenes (the cellular homologs of viral transforming genes) fall into three categories 
(reviewed by Bishop, 1991): 1) GTPases involved in transduction of signals at the plasma 
membrane (for example, Ras); 2) protein kinases that are activated to phosphorylate 
substrates in response to extracellular or intracellular signals; 3) transcription factors 
regulating gene expression. Deregulation of any of these functions, for example, by 
introduction of a viral gene product into the cell, may lead to neoplasia. HBxAg has the 
potential to contribute to the development of HCC in its proposed capacity as protein 
serine/threonine kinase or as a transcriptional activator (figure 6.3a). 
There are two known proto-oncogene products (Raf and Mos) with protein 
serine/threonine kinase activity whose expression is associated with cellular proliferation. 
The c-mos product may be responsible for phosphorylation of the cell cycle control 
protein, MPF (maturation promoting factor) (O'keefe et at, 1989). Mitogenic stimulation 
of cells yields an increase in phosphorylation of the c-raf product and an associated 
increase in pk activity (Morrison et at, 1988). The viral raf product can induce 
transcription of the c-fos oncogene most likely by phosphorylating a factor that regulates 
transcription of this gene (Jamal and Ziff, 1990). The components of the transcription 
factor AP-1 (c-fos and c-jun products) may serve as substrates for Raf pk activity (Wasylyk 
nat, 1989). 
Activation of PKC is associated with treatment of cells with tumour promoting agents 
(see section 6A.3), and, as discussed above (section 6A.4.1), transcription factors serve as 
substrates for PKC. It is becoming evident that activation of cellular transcription factors 
is an important step in cellular proliferation leading to neoplasia, and HBxAg may 
participate in the development of HCC by activation of transcription through either 
mechanism described above (section 6A.4). 
The identification of proto-oncogene products that are transcriptional regulatory 
factors, for example, c-Fos, c-Jun, c-Rel (reviewed by Lewin, 1991) and c-Ets (Wasylyk 
et at, 1990), indicates that aberrant expression of these factors themselves can cause 
neoplasia. Increased expression of a transcription factor, or alteration of the factor itself 
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FIGURE 6.3 Potential mechanisms for the involvement of HBxAg in hepatocyte 
transformation 
HBxAg may contribute to the development of HCC in its proposed capacity as a 
protein kinase or as a transcriptional activator. A kinase may modulate the activity 
of a cell-cycle control protein directly by phosphorylation or indirectly by 
phosphorylating a trancription factor and altering its activity. Trancription factor "A" 
may modulate the concentration a cell-cyle control protein directly by acting on its 
promoter or indirectly by acting on the promoter of transcription factor "B". 
A specific mutation in p53 may confer the ability to interact with HBxAg thereby 
inactivating the tumour suppressor protein. 
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to increase its activity, or enhanced activity of a factor due to the presence of  viral 
transactivator could directly activate a cellular gene encoding a cell-cycle control protein 
or could activate transcription of another transcription factor which in turn activates a 
mitogenic gene (figure 6.3a). An example of the former type of target may be the IL-2 
receptor gene whose transcription is activated by p4OUC  (Cross et at, 1987). An example 
of the latter type of target may be the c-myc gene whose transcription is activated by 
HBxAg (Koike et at, 1989) in the same HBxAg expression cell line which forms tumours 
when introduced into nude mice (Shirakata et at, 1989). Unger and Shaul (1990) 
speculate that fusion of HBxAg coding sequence and host cellular sequence at the 
junction of integrated HBV DNA could affix a DNA binding domain to HBxAg creating 
a potent transcriptional activator. 
While activation of cellular transcription factors could account for the potential role 
of HBxAg in development of HCC, the transformation of cells by adenovirus and SV40 
provides an example of another possible mechanism. The adenovirus Ela protein is a 
viral transactivator capable of activating transcription of cellular genes, and it promotes 
oncogenic transformation. However, these two functions appear to be separable and 
distinct activities of the protein (reviewed by Flint and Shenk, 1989). A model for the 
transforming ability of Ela indicates that this function is mediated, at least in part, by it's 
ability to bind and functionally inactivate the retinoblastoma susceptibility gene product 
(Rb) (reviewed by Cooper and Whyte, 1989). The normal function of Rb is to negatively 
regulate retinoblast proliferation: both alleles of the Rb-gene are deleted or mutated in 
most retinoblastomas, and mutations in Ela that reduce its ability to bind Rb diminish its 
transforming activity. Recently, this sort of "anti-oncogene" function has been assigned 
to the p53 protein which was originally identified in mutant form at high levels in many 
tumours and tumour cell lines. Interaction of SV40 Tag with wild type p53 may be part 
of the mechanism by which cells are transformed upon infection with the virus (reviewed 
by Lane and Benchimol, 1990). 
Very recently, two reports have emerged describing a mutational hotspot in p53 
genes isolated from HCC tissues. In one study (Hsu a at, 1991), 10/16 HCC tissue 
samples contained a mutant p53 gene; 50% of these mutations resulted in a specific amino 
acid change (residue 249; arginine to serine) present in either hemizygous or heterozygous 
configuration. In the other study (Bressac et at, 1991) mutations in the p53 gene were 
detected in 5/10 HCC tissues examined. All of the p53 mutations were found in tumours 
from patients with current or earlier HBV infection. 60% of these mutations resulted in 
M. 
the same amino acid change observed by Hsu et aL Bressac et at note that 2/6 HCC-
derived cell lines, including PLC/PRF/5, harboured the identical p53 mutation, while 
tumours of other cell types showed a range of p53-gene mutations none of which affected 
amino acid residue 249. Therefore, the mutation at 249 appears to be HCC specific and 
may, in association with HBV infection, be involved in progression of HCC. 
The appearance of the specific mutation argues against this mutation being loss of 
function and implies a gain in function (Harris, 1991). One possible gain in function 
would be the ability to interact with an HBV encoded protein, perhaps HBxAg, which 
could functionally inactivate the mutant p53 molecule (figure 6.3b). Affinity purification 
of mutant p53 expressed in PLC/PRF/5 cells, known to express HBxAg (Moriarty et at, 
1985), would begin to provide insight into this possibility. 
6C Concluding Remarks 
The function of HBxAg as an activator of HBV surface antigen expression has been 
established in this study and is consistent with reports of concurrent investigations. This 
effect may be relevant to the very high levels of HBsAg secreted from naturally infected 
cells. Other roles for HBxAg transactivation in the progression of liver disease in 
individuals infected with HBV are under intensive investigation. The effect of HBxAg on 
viral and cellular transcription appears to be mediated through cellular factors, although 
the mechanism of this interaction remains to be elucidated. Investigation of this and 
other viral transcriptional regulatory mechanisms will provide insight into general features 
of eukaryotic gene expression. 
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Appendix I: Nucleotide sequence of HBV subtype adyw 
The nucleotide sequence of HBV subtype adyw contained in plasmid pHBV130 (Pasek 
a al., 1979: Gough and Murray, 1982: Pugh et aL, 1986) is shown. Both strands of the 
complete genome (3182 nucleotides) are shown with the sense strand on top. Numbering 
is by the convention of Pasek et aL (1979), which sets number 1 at the start of the core 
ORF. Restriction endonuclease cleavage sites are indicated at the first nucleotide of the 
recognition sequence. The amino acid sequence of the viral ORFs is shown in their 
respective translational frames. 
ORFs 
preC 3096-3182 frame c 
core 1-549 frame a 
polymerase 407-2903 frame b 
preSi 948-1271 frame c 
preS2 1272-1436 frame c 
surface 1437-2114 frame c 
X 2656-3117 frame a 
Recognition sites of restriction endonucleases used in these studies 
Avail 246, 461, 1421, 1464, 1791, 2854 
Barn HI 1004, 2682 
Ban II 1145, 2759 
Bc1I 732 
Bg1II 84, 499, 523 
DraI 2113, 3004 






















151 ---------+---------+---------+---------+---------+ 200 
G1GTA'IACUIGAG'ICCGTIUnAAGAAACtACCCCWIGAATTACIG 
a: HisHisThrA1aLeuArgG1nA1aI leLeuCysTrpGlyAspLeuMetThr 
Avail 
TAGCTACCGG'ICGGTACTAAaTTAGAAGATCCCCATh'TACCGACC 






251 ---------+---------+---------+---------+---------+ 300 
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351 ---------+---------+---------+---------+---------+ 400 
CATAAACCACAGAAAACCICACACCTAAGcGTAGGACG!ICGAATAWIG 
a: TyrLeuValserPheGlyvalTrpl lePxgTbrProProAlaTyrArgPro 
CACCAAGCCCCrATCCTATCAACACCGGAGACTACIGnY3nAGA 
401 ---------+---------+---------+---------+---------+ 450 
GTCGTflACtGCGAT1½QGATAGTMIAAGGCCICIGA1GACAACAAWT 
proAsnAlaProl 1eLeuSetThrLeuPr1uThrThrVa1Va1Arg 
po1ynrase : roLeuSetTyrG1nHisPheArgArgL.euLeuLeuLeuAsp 
Avail 




agi I I 
AWmAATCGCGCAGAIGArCAAWICGGAATCICAMGTT 
501 ---------+---------+---------+---------+---------+ 550 
TAGAGTMGCCCCtCAGCGTCTIaAGAGTTAGAGCCCnAGAGTTACAA 
SerGlnserProArgArgArgArgserclnserArgGluSerGlnCysEnd : core end 
LeuasnArgArgvalAiaGluAspLeuAsnleuGlyAsnLeuAsnVal 
AGTA1tCCflCGACICATAACGICCGAAAaTITACICCGCITTATIt'flt 



































His ThrLeuTrpLysAl aGlyVa iLeuT'rLysArgVa is erThrHis Ser 
pz1 
CGCCTCAa'lTamCGGTCZkCCATAflCTIGGGAACAAGAGCTACAGCAm 































































































MetproHisLeuLeuVa 1G lyse rS erclyLeu S erArg'I'rVa lAla 
















1851 ---------+---------+---------+---------+---------+ 1900 
ACATGTTTICGPAGCCTACCPI'IGACtTCGACTAAQGGTACCGThGTAG 
a: 
LeuT'rLysThrPheG1yTrpLysLeu1-flsLeuT'rSerHisProI lel le 
CysTbrLysProSerAsp31yAsnCysThrCys I leProl leProserser 
CICGGCFICCGAAAATTCCTATCGAffICGCCCICAGCCCGTTICCT 








































































































































a: phePheTbrserAlaEnd : X end 
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Modulation of expression of the hepatitis B virus 
surface antigen gene by the viral X-gene product 
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Department of Molecular Biology, University of Edinburgh, King's Buildings, Mayfield Road, Edinburgh EH9 MR, 
Scotland, U.K. 
SUMMARY 
Human hepatoma cells (HepG2 and HUH7) transfected with a plasmid (pHBV1004) containing the 
transcription units for the major surface antigen (5) mRNA and the X mRNA of hepatitis B virus (HBV) 
secreted surface antigen (HBsAg) into the culture medium. A frameshift mutation in the X gene carried 
by pHBV1004 greatly reduced HBsAg production by cells transfected with an equivalent amount of the 
mutant (pHBV1004-B). The mutation could be complemented by cotransfection with a plasmid 
(pSV2HBX) containing the X structural gene under control of the SV40 early promoter. HBsAg 
production by cells cotransfected with pHBVI004-B and pSf72HBX was equivalent to that in cells 
transfected with the parent plasmid (pHBV1004) alone. Levels of HBsAg production were directly related 
to the amount of S mRNA produced, showing that the X-gene product (HBxAg) can modulate expression 
of the S gene. 
I. INTRODUCTION 
Hepatitis B virus (HBV) has a partially double stranded 
DNA genome of 3.2 kilobases (kb) that carries four 
open reading frames (oRrs) including the S gene 
encoding the surface antigen and the C gene encoding 
the core antigen. The size of a third oRF and amino 
acid sequence similarities between its translation 
product and retroviral reverse transcriptases indicate 
that it encodes the viral polymerase. The Ibuth ORF 
encodes a protein of 154 amino acids and has been 
termed X because the function of its product in the 
viral life-cycle is not established. 
There is strong evidence that the X-gene product 
(HBxAg) is expressed during viral infection and is 
immunogenic. Expression of an X-specific mRNA was 
demonstrated in mammalian cells transfected with HBV 
DNA (Gough 1983; Saito ci at. 1986; Siddiqui ci al. 
1986; Simonsen & Levinson 1983). Direct evidence 
that the X gene encodes a protein was provided by its 
expression as a fusion protein in both prokaryotic and 
eukaryotic systems to yield an immunogenic product 
(Elfassi ci at. 1986; Kay et at. 1985; Meyers ci at. 1986; 
Moriarty ci at. 1985; Pugh ci at. 1986; Siddiqui ci at. 
1987). The X antigen, synthesized as a fusion protein in 
Escherichia colt, served as a reagent to detect antibodies 
to HBxAg in the sera of HBV infected individuals 
(Weber ci at. 1988), and antisera raised against X-
fusion proteins or against synthetic peptides repre-
senting segments of HBxAg were used to detect cross-
reacting proteins in liver biopsies from HBV infected 
patients, in human hepatoma cells containing inte-
grated nv DNA (Moriarty ci at. 1985), and in cells 
Present address: CSIRO Division of Wildlife and Ecology, 
P0 Box 84, Lynehani, ACt 2602, Australia. 
transfected with the complete }SBV genome (Chang 
ci at. 1987; Pugh ci at. 1986). 
The X ORF is conserved in all mammalian hepadna-
viruses and amino acid sequence comparisons show 
two strong regions of similarity in all species (Colgrove 
ci at. 1989) suggesting a conserved function for the X-
gene products. A model for repliction of the HBV 
genome requires reverse transcription of an RNA 
intermediate in a manner analogous to retroviral 
genome replication (Summers & Mason 1982). All 
human retroviruses characterized to date encode 
polypeptides that activate transcription from the viral 
long terminal repeat (LTR) suggesting that one of the 
HBV oRFs may encode a transcriptional transactivator. 
Several studies have shown that HBxAg can indeed 
exert a transactivating function that appears to be 
quite promiscuous with many different targets for 
transactivation (Auflero & Schneider 1990; Colgrove 
ci at. 1989; Seto ci at. 1988; Seto ci at. 1990; Siddiqui 
ci at. 1989; Spandau & Lee 1988: Two & Robinson 
1989; Two & Schloemer 1987; Wollersheim & 
Hofschneider 1988; Zahm ci at. 1988). Here we show 
that HBxAg can elevate expression of HBsAg in 
transfected hepatoma cells and suggest that corres-
ponding activity in vivo may contribute to the high 
level of HBsAg expression observed in the course of 
natural infection (Cossart 1971). 
2. MATERIALS AND METHODS 
Cloning reagents and techniques 
Manipulation of plasmid DNA was done essentially 
as described by Maniatis ci at. (1982). Restriction 
enzymes, DNA polymerase preparations and DNA 
ligase were purchased from Boehringer Mannheim. 
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Plasmid constructions 
Plasmid pHB 171004 containing the transcription units 
for the major surface mRNA and the X mRNA, was 
constructed as follows: HBV sequences (1004-3182/I-
84, in the numbering system of Pasek et at. (1979)) were 
removed from the pl asmid pHB 17130 (Cough & Murray 
1982) by complete digestion with Bgill followed by 
partial digestion with BamHT. The resulting 2.3 kb 
fragment was ligated into the Barn/Il site of pUC8. 
Plasmid pHB 17/004-B contains a frameshifi mutation 
that was introduced within the X coding sequence in 
pHB 171004 by partial digestion with BamHI followed by 
filling in the cohesive ends of the site at position 2682 
with DNA polymerase I (Klenow fragment). To 
confirm that the major surface promoter sequences 
remained identical in the parent and mutant plasmids, 
DNA sequencing was done on the HBV sequences from 
positions 1004-1409 contained in the two plasmids 
with the dideoxy-nucleotide chain termination method 
(Sanger et al. 1977). 
Plasmid pSJ'2HBX was constructed to express 
HBxAg. Plasmid pSV2/3C (a gift from P. Southern) 
contains the rabbit fi-globin gene under control of the 
5V40 early promoter/enhancer complex. The rabbit 
/3-globin structural sequences were removed by 
digesting with Hindlll, filling in the cohesive ends with 
DNA polymerase I (Klenow fragment) and digesting 
with Bgt!I. The Xgene (2654-3182/1-84) was cleaved 
from p1-fBI/I30 by digesting with Need, filling in the 
cohesive ends with T4 DNA polymerase and digesting 
with Bglll. The resulting 12 base pair (b.p.) 
fragment was ligated to the 4.2 kb vector fragment of 
p8172/IC. Plasmid pSV2HBX-B contains the same 
frameshift mutation in the X gene as pHB 171004-B, and 
was constructed by an equivalent series of reactions. 
Plasmid DNA was prepared from cells (E. coli strain 
ED8654) harbouring the plasmid by lysis in alkaline-
SDS (Maniatis et at. 1982), followed by several rounds 
of phenol extraction. 
Cell culture 
Human hepatoma cells devoid of integrated HBV 
sequences, HepG2 (Knowles et at. 1980) and HUH7 
(Nakabayashi et at. 1982), were grown in Glasgow's 
modification of Eagles Medium (GMEM) supple-
mented with I mm sodium pyruvate, 2 MM L-glutamine, 
non-essential amino acids and 10% (by volume) fbetal 
calf serum (FCS) at 37°C in 6 0/. CO2 . 
Trans,fiction of hepatoma cells 
Hepatoma cells were transfected with . expression 
vectors by using the DEAE-Dextrats/chloroquine 
method (Luthman & Magnusson 1983). Briefly, 
4 x 10" cells were seeded onto 100 nun diameter plates 
I (lay before transfection. Plasmid DNA was added in 
5 ml of a solution of serum-free GMEM containing 
200 fig mL° DEAE-Dextran (molecular mass 5 x 10° ; 
Sigma), 50 mint Tris-HCl pH 7.3. DNA was adsorbed 
for 5 It (HUH7 cells) or 6 h (HepG2 cells) at 37 °C at 
which time chloroquine diphosphate (Sigma) was 
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added to 100 lIM. Cells were incubated for a further 
2 h (HepG2) or 3 Is (HUH7) afterwhich the transfection 
solution was removed, cells were washed in PBS and 
incubated in GMEM supplemented with 10% (by 
volume) FCS for 3-4 days. 
Detection of HBsAg 
HBsAg was detected by radioimmunoassay of the 
cell culture medium with the AUSRIAII-125 kit 
(Abbot Laboratories) according to the manufacturer's 
instructions. In some cases HBsAg was concentrated 
from the culture medium by ultracentrifugation 
(150000 g for 16 h) and resuspension in 1/30th volume 
of PBS for assay. For detection of HBsAg particles 
containing middle S (preS2/S) polypeptides, poly-
styrene heads were incubated in a solution of 0.2 M 
NaHCOq, pH 9.2, containing 60g  ml-' anti-preS2 
monoclonal antibody Q 19/10 (Heerman etat. 1988) at 
room temperature for at least 4 h. Beads were dried on 
absorbent paper and stored at 4°C. 
RNA extraction from transfected cells 
RNA was extracted by a modification of the hot 
phenol method. Harvested cells were resuspended in 
10 cell-volumes of 10 mrvr Tris-HCI, pH 7.4, 150 mini, 
NaCI, 3 mini MgCl2, 1 mm EDTA, (pH 8.0). NP40 was 
added to 0.5% (by volume), cells were vortexed for 
30 s and the lysate cleared by centrifugation (1600 g, 
15 mm) SDS was added to 0.5% (w/v) and the lysate 
was extracted with an equal volume of phenol at 60 °C. 
RNA was precipitated with ethanol. 
Analysis of mRNA by hybridization 
RNA preparations were treated with DNase and 
fractionated according to size by electrophoresis in I % 
agarose gels containing 0.27 M formaldehyde. RNA 
was transferred to nylon filters (Hybond-N, Amer-
sham) by strandard blotting methods (Maniatis et at. 
1982) and was hybridized to [°2P1-labelled  probes 
prepared by the random priming method (Feinberg & 
Vogelstein 1983). Hybridized filters were washed 
2 x 15 min in 2 x SSC, 0.1% SDS at room temperature 
and I bin 0.1 x SSC, 0.1% SDS at 65 °C. Hybridizing 
RNAs were detected by au5oradidgraphy at —70 °C 
with an intensifying screen. 
3. RESULTS 
Pia,cmds carrying the coding sequences for HBxAg and 
HBsAg 
l-Iepatitis-B-virus sequences used in this study were 
derived from plasmid p1-lB 17130 (Gough & Murray 
1982), which contains a complete copy of the HBV 
genome subtype adyw (figure Ia). Plasmid pHB 171004 
was constructed to contain the transcription units for 
the major surface mRNA and A' mRNA under control 
of their own expression elements (figure I h): Plasmid 
/'HBVtOOI-B contains a frameshif.i mutation that was 
introduced following the triplet coding for amino acid 
residue 10 (asp) within the X coding sequence in 
pHBVJOOI. Plasmid p8V2HBX was constructed to 
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Figure 1. (a) Genomic organization of HBV subtype odyw used in this study. Open reading frames are represented by 
arrows. Boxes represent transcriptional control regions. Restriction sites used in this study are indicated. (b) The 
plasmids used in transfection experiments. Numbers in parentheses indicate the positions of the restriction sites in 
the Hay genome. Transcripts are represented by arrows inside the circles. The heavy arrows outside the circles 
indicate the site of the frameshift mutation in the X gene in pHBV1001-B and ps V2HBX-B. Key to boxes: (•), Hay 
DNA insert; (n), preS2/S promoter; (u), pre-32 oRF; (n), S oar; (n), enhancer/X promoter; (n). X. ORF. 
(Construction of the plasmids is described in Materials and methods.) 
express HBxAg under control of the 5V40 early 
promoter and enhancer, and plasmid pSV2HBX-B 
contains the same frameshift mutation in the Xgene as 
pHB 171004-B (figure lb). 
Frameshiji mutation in the X gene reduces transient 
expression of HBsAg 
• Hepatoma cells (HepG2 or HUH7) transfected with 
pHBVI004 secreted HBsAg into the culture medium 
where it was detected 4-5 days post- transfection by 
radio-immunoassay. Transfection with an equivalent 
amount of pHB 171004-B resulted in significant 
reduction in HBsAg synthesis (figure 2). The difference 
in HBsAg expression between the two plasmids was 
Proc. R. Soc. Lord. B (1990)  
greatest when small amounts of DNA were used for 
transfection; HBsAg secretion by HepG2 cells trans-
fected with 3 'g  ofpHBV1004 was an average of fivefold 
(and as much as sevenfold) higher than by cells 
transfected with 3 jig of pHB 171004-B, but with 10 .tg Or 
30 ig of the plasmids the difference was two-threefold. 
With the larger amounts of DNA the availability of 
transcription factors other than HBxAg may become 
limiting. Although it is possible, it is unlikely that the 
stability of the S mRNA was affected by the 4 b.p. 
insertion in the X coding sequence, for it has been 
shown that even a 270 h.p. deletion of the HBV 
enhancer contained within the S transcript did not 
affect mRNA stability in COS cells (Bulla & Siddiqui 
1988). 






log [DNA] log [DNA] 
Figure 2. HBsAg production. Levels of HBsAg production from cells transfected with HBsAg expression plasmids. 
HBsAg was detected by radio-immunoassay of either the cell culture medium or medium that had been concentrated 
30-fold to bring the values within the linear range of the assay. The level of HBsAg expression was initially calculated 
as a ratio of counts per minute obtained for the sample to counts per minute obtained from the medium of mock 
transfected cells (P/N). The P/N values within each experiment were then normalized to the P/N value obtained 
for cells transfected with 30 jig ofpHBVIOO4-B (relative P/N value). This allows comparison of the values obtained 
in different experiments in which the absolute level of HBsAg expression may differ. The average relative P/N values 
were calculated by weighting the relative P/N values in each experiment according to the number of plates used for 
translèction with each amount of DNA. Error bars indicate the range of average values obtained in each experiment; 
(a) HepG2 cells; (b) HUFI7 cells; (a), cells transferred with pHBVI004; (a), cells transfected with pHBVlO04-/3. 
Table 1. PreS2 epitopes on HBsAg preparations 
source of HBgAg 
P/N values' 
AUSRIA-11125 preS2 
serumb 24.2 ILl 
24.8 7.5 
yeast' 25.9 1.2 
24.9 1.1 
HepG2 cells transfected with 16.8 5.7 
pHBVJ0040 20.5 _. 5.3 
HèpG2 cells transfected with 5.8 1.8 
pHBV1004-J3 6.4 1.3 
'Values are shown from two independent experiments. 
'HBsAg derived from serum (20 ng ml-') was provided with 
the AIJSRJA-I1125 kit as a positive control. 
HBsAg derived from yeast was purified from Sacchatomyces 
cerenz.czae harbouring plasmid pHING2 (Murray et al. 1984), 
which contains the S coding region under control of the yeast 
PH05 promoter. 
'pHBVIOOl and pHBV1004-B preparations are 1:30-fold 
concentrated medium from FIepG2 cells transfected with 
30 fig of the indicated plasmid. 
The number of surface antigen particles containing 
middle S (preS2/S) polypeptides was detected by 
radio-immunoassay in which the solid phase was a 
polystyrene bead coated with anti-preS2 mpnoclonal 
antibody Q 19/10 (Heerman ci al. 1987) and the 
bounded antigen was detected with [1251]-labelled 
human anti-S serum provided with the AUSRTA 11-125 
HBsAg detection kit. Table 1 shows that transfection of 
hepatoma cells with pHE 11OO4 resulted in the secretion 
of a greater number of HBsAg particles containing, 
detectable pre52 epitopes than transfection with an 
equivalent amount of pHB 171004-B. The proportion of 
secreted HBsAg particles containing detectable pre52 
epitopes was similar with both the parent and mutant 
plasmids. Assuming that the proportion of middle S 
polypeptides on each HBsAg particle was the same for 
those expressed from either the parent or mutant 
plasmid, transfection of cells with the mutant plasmid 
gave reduced expression of middle S polypeptides. 
Complementation of the mutation in the X gene 
The frameshift mutation in the X coding sequence 
contained in pHB 171004-B could be complemented by 
supplying HBxAg in trans. In these experiments, 
hepatonia cells were transfected with 30 pig of 
p1-lB 171004-B. This gave a level of HBsAg expression 
Figure 3. (a) HBsAg production. Levels of HBsAg production from cells transfected with HBsAg expression plasmids 
or cotransfected with HBsAg plasmid and HBxAg expression plasmid. Calculation of the Relative P/N Value is 
described in figure 2 legend. Except where indicated, the values presented here are an average from at least three 
experiments (* indicates values that are an average from two experiments). Error bars indicate the range of average 
values obtained in each experiment. Key to plasmids: 4 =pHBV1004; B =pHB 171004-B; X =pSV2HBX; 
XB = p5 V2HBX-B; pig of DNA' is the amount of DNA used to transfect each plate of cells. (b) Northern blot of RNA 
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Surface mRNA 
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I HLL  
.4- HSAmRNA 
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from cells expressing 1-IBsAg. RNA was prepared from three plates of cells, four days post-transfection with (a) 
30 p of pUCS per plate; (b) 30 Vg of pHBV1004; (e) 30 p of pHB171004-B; (d) 30 ag of pHBVIOOI-B plus 30 a of 
pSV2HBX; (e) 30 p of p1-/B V1004-13 plus 30 a of pS V2HBX-B. the surface transcript probe was a 796 b.p. BainHl/PsT 
fragment from pHBV1004 representing HBV DNA positions 1004-1800. The  probe for the LISA gene was a 1.8 kb 
BamH1 fragment from the plasmid p1243, which contains the HSA gene under control of the caseine promoter. 
Densitometric analysis of the exposed X-ray film was done on the Shimadzu Dual Wavelength Cromato Scanner, 
Model CS-930. The numbers under the curves represent the area under each peak. 
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that could readily be assayed and that was about half 
that from the parent plasmid, p1-lB V1004. Cotrans-
fection of HepG2 cells with pHB 171004-B and a plasmid 
carrying the X coding sequence under control of the 
5V40 early promoter and enhancer (pSV2HBX) 
restored HBsAg production to a level similar to that 
produced by cells transfected with an equivalent 
amount of pHBVI004 (figure 3a). In HUH7 cells, 
HBsAg production from plasmid pHBV1004-B was 
increased 1.5-fold upon cotransfection with pSV2HBX. 
This may reflect a greater susceptibility to toxic effects 
of expression of HBxAg from a heterologous promoter 
that have been observed in CHO cells (J. Barsoum, 
personal communication). 
Co-transfection can give rise to a concatanated 
network of input DNA molecules, and thus it was 
possible that the observed effect was due to a cis effect 
of the 5V40 transcriptional control signals contained in 
pSV2HBX. As a control, hepatoma cells were co-
transfected with pHBV1004-B and pSV2HBX-B, which 
contained the same frameshift mutation in the X 
coding sequence. HBsAg expression was then equiva-
lent to that of cells transfected with pHBV1004-B alone 
(figure 3a). This established that the restoration of 
HBsAg expression to wild-type levels by co-transfection 
with the plasmid pSV2HBX was due to a trans effect of 
HBxAg. 
1JBxAg modulates the level of S mRNA 
Total cellular RNA from cells transfected with 
HBsAg expression plasmids and from cells co-trans-
fected with pHBV1004-B and the X expression plasmid 
or its corresponding frameshift mutant was fractionated 
by agarose gel electrophoresis and blotted to a nylon 
filter. Hybridization to a DNA probe containing 
sequences complementary to the S transcript revealed 
that the level of 2 kb S mRNA corresponded to the 
amount of HBsAg produced (figure 31'). The S 
transcript probe was stripped from the filter, which was 
then rehybridized with a [32 P]-labelled fragment from 
the plasmid p1243, a probe for human serum albumin 
(HSA) transcripts. The densitometer traces in the 
lower part of figure 31' showed that the samples 
analysed contained equivalent amounts of mRNA; all 
the values lie within - 13 % to + 18 % of the mean, the 
reproducibility of individual scans of the various bands 
being ±7%. 
4. DISCUSSION 
We have shown that HBxAg can function to increase 
transient expression of HBsAg in two different human 
hepatoma cell lines. A frameshift mutation close to the 
5' end of the X coding sequence in the HBsAg 
expression vector reduced the amount of HBsAg 
secreted into the culture medium to as little as 14% of 
that with the parent plasmid. This mutation could be 
complemented by supplying HBxAg in trans, which is 
definitive evidence that HBxAg can modulate expres-
sion of another viral gene product. 
The level of HBsAg expression corresponded to the 
amount of S mRNA (figure 3) indicating that HBxAg 
Proc. R. Sec. Laid. B (1990) 
does not exert its effect at the level of translation or 
secretion. This effect is unlikely to be post-transcrip-
tional as the S mRNA is not spliced and thus HBxAg 
cannot function like the rev protein of HLv in diverting 
transcripts from splicing (Felber ci at. 1989; Malim ci 
at. 1989). Furthermore, with the bacterial chlorarn-
phenicol acetyl transferase (CAT) gene as a reporter 
for promoter activity, HBxAg has been shown to affect 
transcription, but not mRNA stability (Siddiqui ci at. 
1989). Our results are also consistent with the recent 
demonstration that a mutation in the Xgene contained 
within the complete HBV genome led to a reduction in 
the levels of both the pregenomic RNA and the S 
mRNA upon transient expression in HUH7 cells 
(Colgrove ci at. 1989). 
Several other transcriptional regulatory sequences, 
including rctroviral LTRs, the SV40 early promoter/ 
enhancer complex, the 0-interferon promoter and the 
RNA polymerase III promoter of the Adenovirus2 
VA1 RNA are targets for transactivation by HBxAg 
(Aufiero & Schneider 1990; Colgrove et al. 1989; Seto 
el al. 1988; Siddiqui el al. 1989; Spandau & Lee 1988; 
Two & Schloemer 1987; Two & Robinson 1989; 
Wollersheim & Hofschneider 1988; Zahm ci at. 1988). 
The function of HBxAg therefore may be mediated 
through a common cellular transcription factor either 
by increasing its rate of expression or by interacting 
with the factor itself; in Drosophila cells, HBxAg can 
interact with human AP2 transcription factor to 
increase transcription from a reporter plasmid carrying 
multiple AP2 sites in the target promoter (Seto ci at. 
1990). 
Four distinct cellular factors interacting with the 
!IBV enhancer region are present in several cell types 
(Ben-Levy ci at. 1989). This enhancer is a target for 
transactivation by HBxAg in association with the HBV 
core promoter or X promoter linked to CAT (Colgrove 
et al. 1989; Siddiqui et al. 1989; Spandau & Lee 1988). 
The HBV enhancer also activates transcription from the 
major, preS2/S promoter linked to CAT (Antonucci & 
Rutter 1989; Chang & Ting 1989; De-medina ci at. 
1988; Faktor et at. 1988; Siddiqui ci at. 1986), and 
increases the transient expression of HBsAg from this 
promoter in HepG2 cells (Bulls & Siqqiqui 1988). This 
is similar to the requirement of the 5V40 enhancer for 
efficient transcription from the SV40 major late 
promoter (Ernoult-Lange ci at. 1984). The effect of 
HBxAg on the transient expression of HBsAg may thus 
be mediated through. the HBV enhancer. 
The HBsAg expression vector used in this study 
contained only The preS2/S promoter and not the 
TATA-like, preSl promoter, which is located 300 b.p. 
upstream and directs synthesis of the 2.4 kb mRNA 
encoding the large preSl/preS2/S polypeptide. 
Although the two promoters in isolation have similar 
transcriptional activities (Antonucci & Rutter 1989; 
Siddiqui et at. 1986), the preS2/S promoter accounts 
for 98% of surface gene transcription in infected liver 
(On & Rutter 1985). Bulla & Siddiqui (1989) have 
described a negative regulatory region within the 
preS 1 oRr that, when removed, greatly increases 
transcription from the preS 1 promoter; all of the 
constructs used in their study expressed X mRNA, 
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however, and the role of HBxAg in this regulation is 
therefore unclear. Preliminary studies in this lab-
oratory (M. T. Rossner & K. Murray, unpublished 
observations) indicate that HBxAg effectively trans-
activates the preS 1 promoter and does not appear to be 
involved in the negative regulation described by Bulla 
& Siddiqui (1989). 
The role of HBxAg in the viral life-cycle is still under 
intensive investigation. The effect reported here on 
liBsAg production may be relevant to the very high 
levels of UBsAg secretion from naturally infected 
hepatocytes. The secreted forms are predominantly 
22 vIm empty viral envelopes that may serve as 'decoy 
virions' to bind neutralizing antibodies produced in 
response to infection. 
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